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Abstract 
Febrile neutropenia is the commonest life-threatening complication of treatment for children 
with cancer. Though the majority of children have no significant complications associated with its 
occurrence, current management includes intravenous antibiotics and in-patient care. Reduced 
therapy regimes for children at low risk of complications may have benefits for families and the 
National Health Service.  
This thesis aimed to answer two main questions: In children and young people with low risk 
febrile neutropenia, are reduced therapy regimes safe, effective and acceptable to key 
stakeholders? What factors are involved in decision-making about acceptability of early discharge 
regimes?  
Given the complexity of the research problem, the work utilised a mixed methods approach, 
selecting appropriate methodologies for each aspect of the problem and then combining results 
to provide a nuanced consideration of this multifaceted topic. Three sequential phases were 
performed, each informing and developing the next, whilst simultaneously allowing deeper 
interpretation of findings in earlier phases.  Phase one, a quantitative systematic review, provided 
safety and treatment failure rates relating to reduced therapy regimes, whilst phase two, a 
qualitative synthesis, presented an interpretive account of experiences of early discharge. Phase 
three involved a focus group study exploring experiences and perceptions of key stakeholders 
involved in febrile neutropenia care in the United Kingdom.  
Following mixing of phases in both design and interpretation stages, the thesis found that 
reductions in therapy are associated with increased readmission rates, but not increased risk of 
serious adverse events. It exposed the previously underestimated harms of febrile neutropenia 
admissions and the paternalistic nature of decision making.  
Increasing shared decision making through discussing risks, developing mutual trust and 
negotiating control is necessary to achieve individualised treatment and improve experiences for 
stakeholders. The thesis outlines aspirations for future care of these children and young people 
and proposes various actions to achieve these goals. 
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Chapter 1: Febrile neutropenia: history, current research priorities 
and overview of thesis 
Febrile neutropenia is the commonest complication of therapy in children with cancer.(1) Its 
current treatment involves hospital admission and antibiotic administration, with considerable 
associated burden to patients, families and the healthcare service. For children at low risk of 
serious complications of their febrile neutropenia, it has been suggested that reducing treatment 
to allow children to be at home may be an appropriate course of action that results in significant 
physical, social, psychological and financial benefits. However, many steps towards achieving this 
goal have yet to be clarified, including the time at which discharge should occur and the 
acceptability of these approaches to patients, families and healthcare professionals. This thesis 
intends to synthesise existing evidence and provide additional primary data to explore these 
issues, so as to inform the design of future services for children with cancer in the UK.    
This chapter serves as an introduction to the thesis. I present some of the key concepts relating to 
febrile neutropenia, provide a brief history of the research within this area and outline the current 
issues surrounding the management of febrile neutropenia in children and young people with 
cancer in the UK. I then clearly define the research problem and describe the overarching 
methodology for this thesis. I provide both a written and pictorial representation of the structure 
of the thesis and outline how the research problem will be addressed.  
What is febrile neutropenia? 
To begin this chapter, it is important to understand what febrile neutropenia is and its clinical 
impact in childhood cancer. Neutrophils are the most common type of white blood cells. They 
play a vital part in cell-mediated immunity by engulfing and destroying infecting micro-organisms.   
Neutropenia describes a reduced number of neutrophils in the blood. The precise definition of 
neutropenia is varied, with some definitions giving a value of greater than two standard 
deviations below the population mean, whilst others, including current National Institute for 
Health and Care Excellence (NICE) guidelines, use a level of 0.5x109 cells per millilitre.(2) 
Neutropenia can occur for many reasons, including congenital conditions, aplastic anaemia, 
autoimmune disease, viral infections and medications (see Box 1). In patients with cancer, 
neutropenia occurs for two main reasons. First, the infiltration of bone marrow with disease 
results in insufficient production of cells and hence low levels of circulating neutrophils. Secondly, 
the treatment of malignancy, including chemotherapy and radiotherapy, can have a 
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myelosuppressive effect. Indeed, neutropenia occurs most commonly in cancer patients following 
chemotherapeutic interventions. 
Patients with neutropenia are at risk of infection with bacteria, viruses and fungi, each of which 
pose a different risk to the patient. Children with cancer are often already at increased risk of 
infections due to other effects of their disease or treatment. There may be inadequate skin and 
mucosal barrier protection due to mucositis and the presence of indwelling medical devices, 
particularly central venous access catheters or ‘lines’. Normal body flora is disrupted by the 
frequent administration of antimicrobial agents. The malignancy and its treatment may also affect 
other aspects of the immune system, causing hypogammoglobulinaemia and impaired immune 
cellular function, resulting in decreased cell numbers and reduced activity.(3,4)  
 
Febrile neutropenia, which is seen in all causes of neutropenia (see Box 1), describes the presence 
of a fever in a person with a low neutrophil count. Fever may occur in a neutropenic patient for 
many reasons, including administration of certain medications (particularly chemotherapeutics), 
blood products, allergic or inflammatory reactions and due to the malignancy itself. However the 
most concerning reason for raised temperature is the presence of an infection, and therefore 
febrile neutropenia is usually considered to be due to infection unless proven otherwise.  For the 
remainder of this work, the phrase ‘febrile neutropenia’ will be used to describe this condition 
Box 1  Causes of Neutropenia (2) 
Isolated:  
 Congenital: Kostmann’s syndrome 
 Acquired: Drug-related (Anti-inflammatory drugs, antibiotics, anticonvulsants, 
antithyroids, hypoglycaemics, phenothiazines, psychotropics, antidepressants, 
miscellaneous) 
 Benign: racial or familial 
 Cyclical 
 Immune: autoimmune, Systemic Lupus Erythematosus, Felty’s syndrome, 
Hypersensitivity, Anaphylaxis 
 Large granular lymphocytic leukaemia 
 Infections: viral, fulminant bacterial 
General Pancytopenia 
 Bone marrow aplasia (congenital, idiopathic acquired, ionizing radiation, chemical-
induced, drug-related, viral) 
 Acute leukaemia, myelodysplasia, myeloma 
 Infiltration with tumour 
 Megaloblastic anaemia 
 Paroxysmal nocturnal haemoglobinuria 
 Myelofibrosis 
 Splenomegaly  
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exclusively in patients receiving treatment for haematological and oncological disorders, the 
patients who most commonly present with febrile neutropenia.  
Febrile neutropenia is the commonest life-threatening complication of treatment of children with 
cancer.(1) It occurs in around a third of episodes of neutropenia, at a rate of 0.75 episodes per 30 
days of neutropenia and 0.15 per month of chemotherapy exposure time.(5,6) Certain groups of 
children are at greater risk of developing febrile neutropenia, depending on their disease and its 
treatment. Around 3% of children with cancer will die of an infection during their treatment.(1,7) 
Other potential septic complications of a febrile neutropenic episode include bacteraemia, 
significant bacterial infections, and medical complications (such as hypotension, altered mental 
state, and renal dysfunction). It can also require intensive care input and lead to delays in further 
treatment of the child’s malignancy.(8,9) However, many episodes of febrile neutropenia in 
children have no significant sequelae, and up to 50% of episodes have no clinically or 
microbiologically defined infection.(9,10) 
History of febrile neutropenia 
Febrile neutropenia was first recognised as a significant medical problem in the 1950s, when the 
initial treatments for leukaemia were being developed.(11) In those early years of chemotherapy, 
febrile neutropenia posed a significant risk to the patients being treated, with up to 70% of deaths 
of children with cancer being due to infections.(12) However, as penicillins were introduced to 
practice in the early 1960s, outcomes improved.  
In 1966, Bodey et al noted that the risk of infection, and indeed infection-related mortality, in 
cancer patients was related to the degree of neutropenia.(13) At around the same time, Curtin 
and Marshall recognised the importance of rapid recognition of febrile neutropenia and initiation 
of early antimicrobial therapy in improving patient outcomes.(14) Over the next ten years, 
protocols were developed for early empirical1 treatment with antibiotics in febrile neutropenia. 
These protocols involved prolonged inpatient stays for intravenous antibiotics whilst fever and 
neutropenia persisted, but resulted in a significant reduction in mortality related to neutropenic 
sepsis.(11) 
The next period of febrile neutropenia history focused on development of improved antibiotic 
schedules, with cover for the bacteria Pseudomonas resulting in a further significant decline in 
                                                             
1 Empirical treatment, in this setting, refers to the use of antibiotics before a specific organism has been 
identified, thus the antimicrobial selected is chosen for its ability to cover the most frequent and most 
serious infections seen in this population. 
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mortality. Furthermore, prophylaxis against certain infections, including Pneumocystis jiroveci 
(previously Pneumocystis carinii), was recommended for selected patients.(15)  
In the early days of managing febrile neutropenia, patients were kept in hospital on intravenous 
antibiotics for the duration of both their fever and their neutropenia.(16,17) Over time, it was 
recognised that it was safe to discontinue antibiotics and discharge patients if they were afebrile, 
with no other signs of infection, despite ongoing neutropenia.(9,17,18) In current practice, the 
majority of children with febrile neutropenia will be discharged without resolution of their 
neutropenia, the only significant exceptions to this are those children with certain haematological 
malignancies for whom the risk following discharge is particularly high. These include children 
with Acute Myeloid Leukaemia (AML) and Infant Acute Lymphoblastic Leukaemia (ALL). 
This work into improving the clinical management of febrile neutropenia, has continued such that 
the risk of death from infection in children with cancer has fallen from the original 70% to around 
3%.(1,7,12) Given this significant improvement in mortality, febrile neutropenia research has 
developed in various directions.  
I will now explore the two main current areas of research that are relevant to this thesis: (i) risk 
stratification and (ii) the reduction of therapy for patients at low risk of septic complications of 
their febrile neutropenia.  
Risk stratification in febrile neutropenia 
Risk stratification is the process of categorising patients according to their risk of developing a 
disease or complication of treatment. Clinicians can then adjust their management based on 
these categories and provide more personalised care, by instigating more intensive monitoring, 
investigation and treatment for high risk patients, and reducing therapy, with its associated side 
effects, in low risk patients. In haematology and oncology services, risk stratification was first 
considered following the observation that a large number of patients with febrile neutropenia 
have no significant sequelae of the condition, whilst a much smaller number are at high risk of 
medical complications including organ failure and death.  
Various risk stratification models have been developed in adult haematology and oncology. The 
first model created by Talcott in 1988 defined as low risk those who presented as outpatients, 
with no co-morbidities and with controlled cancer.(19) In 2000, the Multinational Association for 
Supportive Care in Cancer (MASCC) developed a scoring system that reduced the misclassification 
rate and had increased sensitivity compared to the Talcott score, although this came at the 
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expense of reduced specificity2 (Table 1).(20) The MASCC score has been validated on a number of 
occasions and has been recommended as the most appropriate risk index score for adults with 
febrile neutropenia.(21) 
Table 1 - The MASCC score (score ≥21 identifies low risk patients) (20) 
Characteristic Weight 
Burden of illness: no or mild symptoms 5 
No hypotension 5 
No Chronic Obstructive Pulmonary Disease 4 
Solid tumour or no previous fungal infection 4 
No dehydration 3 
Burden of illness: moderate symptoms 3 
Outpatient status 3 
Age <60 years 2 
 
Unfortunately, these adult risk scores cannot be applied to paediatric, teenage and young adult 
patients.(22) The spectrum of malignancy seen in paediatric and young adult practice is different 
to that seen in older adults and children often have fewer co-morbidities than their adult 
counterparts. Therefore, they receive different therapeutic regimes for their cancer, often 
including more intensive myelosuppressive agents. Consequently, children tend to have more 
prolonged and profound periods of neutropenia, with the accompanying increased risk of 
infection. Furthermore, the spectrum of infections that children are susceptible to is different to 
the adult population, with children being more likely to develop streptococcal illnesses and 
affected less frequently by staphylococcal infections.(23) Finally, children have a different 
physiological response to infection, being more prone to high temperatures (above 39°C) and 
experience hypotension as a much later sign of circulatory abnormalities. In addition to this, some 
of the specific criteria in the MASCC score are not helpful in differentiating children with febrile 
                                                             
2 Sensitivity refers to the ability of a test (or risk stratification tool) to accurately detect people with the 
disease, in this case high risk febrile neutropenia. Specificity describes the test’s ability to accurately identify 
those people without the disease, in this case those who do not have high risk febrile neutropenia - those 
with low risk disease. 
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neutropenia. Age stratification to under or over 60 years of age is not relevant, whilst Chronic 
Obstructive Pulmonary Disease (COPD) is not seen in children and young people.  
Given the inapplicability of adult risk scores, attempts have been made to create risk stratification 
tools specifically for use in paediatrics.(24–27) Over 23 different paediatric risk stratification tools 
have been described in the literature.(10) Each of these rules is defined by different criteria of 
fever and neutropenia, and is designed for different patient groups, for example outpatient only 
compared with all patients, and no stem cell therapies compared with all patients. In various 
combinations, they have used criteria such as the underlying diagnosis, the intensity 
of recent chemotherapy, profound neutropenia (<0.1 x109/L), thrombocytopenia (platelet count 
<50g/L), comorbidities and expected duration of neutropenia to identify those at the highest risk 
of adverse events.   
The utility of these tools has been investigated in a systematic review and meta-analysis carried 
out by Phillips et al  in 2010 and updated in 2012.(8,10)  Validation studies for each of the six tools 
evaluated were found to have higher misclassification rates than the studies initially introducing 
the tools. This is to be expected given that the rule has been created from a particular cohort with 
individual characteristics, some of which are different in the validation population and reduce the 
tool’s accuracy. Almost all tools will be less accurate in a validation population compared to the 
groups they were developed on. The important issue is the degree of difference and whether the 
use of the tool in different populations still provides clinically meaningful information. 
Particular challenges in the development of Clinical Decision Rules include having sufficient 
sensitivity to identify those patients at high risk of significant complications, alongside appropriate 
specificity to identify enough patients as low risk to enable clinically important numbers of 
patients to be treated on a reduced therapy protocol. Furthermore, Clinical Decision Rules need 
to be simple, quick and easy to apply regularly to patients in day-to-day clinical work. They need 
to be applicable to the specific population they serve, such that different rules may be need for 
different geographical areas.  On-going work by the Predicting Infectious Complications of 
Neutropenic sepsis In Children with Cancer (PICNICC) collaboration, using Individual Patient Data 
meta-analysis to develop a more accurate Risk Prediction Rule, aims to resolve some of the 
challenges mentioned above and to provide clinicians with further guidance.(28) So far, this 
collaboration has designed a risk prediction model including malignancy type, temperature, a 
clinical assessment as ‘severely unwell’, haemoglobin, white cell count and absolute monocyte 
count which appears accurate but requires further investigation to confirm its use in the clinical 
environment.(29)  
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Reduced therapy regimens 
As mortality from febrile neutropenia continues to fall and risk stratification tools become more 
reliable, researchers have begun to focus on the safe reduction of treatment for patients who are 
believed to be at low risk of developing septic complications of febrile neutropenia.(1) 
Approaches to reducing treatment focus on either reducing the duration of hospitalisation or 
reducing the duration of intravenous antibiotic administration. Studies focusing on location of 
treatment can be split into those that aim for early discharge, wherein the child or young person 
spends some time as an inpatient before being discharged at a point earlier in the treatment 
course than for standard treatment, and those that aim for entirely outpatient therapy, where the 
child spends no time in hospital following the initial assessment and diagnosis of febrile 
neutropenia. Similarly, studies tackling the route of administration may either give a period of 
intravenous antibiotics that is shorter than standard treatment (sometimes followed by a period 
of oral antibiotics) or aim to treat the episode of febrile neutropenia entirely with oral antibiotics, 
thus completely avoiding intravenous administration. As yet, there has been no assessment of the 
most appropriate time to reduce therapy, either through early discharge or switching from IV to 
oral antibiotics. Very few studies have investigated a strategy in which patients identified as low 
risk are observed without any antimicrobials given.(30) 
Reducing treatment for low-risk febrile neutropenia has a number of potential benefits. Firstly, 
patients and their families may prefer to be at home during treatment for chronic conditions.(31) 
This is reflected in national policy documents that advocate care as close to home as possible for 
children and young people wherever this is safe and achievable.(32,33) Within the realms of 
febrile neutropenia care, adult studies have found that outpatient treatment protocols results in 
improved quality of life.(25)  
Interestingly however, paediatric studies have found that healthcare professionals tend to assess 
child and parents’ quality of life during inpatient stays as worse than the parents do, and also 
overestimate the improvement in quality of life associated with going home.(35) Indeed, parents 
have been found to predict that their own quality of life would not improve if given oral 
antibiotics for their child to have at home instead of an inpatient stay.(35) Therefore, care needs 
to be taken before assuming that reduced therapy options are what patients and their families 
would prefer. Attitudes to reductions in therapy are further explored later within this chapter and 
are a key focus of the thesis as a whole.  
A further suggested benefit of alternative strategies for managing febrile neutropenia is that 
there is a theoretical reduction in the risk of hospital acquired infections as a result of reduced 
contact with the healthcare environment. Indeed, a recent Children’s Oncology Group review of 
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infections in children with Acute Myeloid Leukaemia found that hospitalisation of neutropenic 
children did not reduce their risk of infection related mortality but did increase their risk of 
Clostridium difficile infection.(36) 
Finally, from a health service point of view, reductions in hospital stay significantly reduce the 
costs of providing care. This reduction has been reported to be between £3500 and £7000 per 
episode of febrile neutropenia, depending on the regimes used for comparison and the country in 
which the research was performed.(37,38) However, there is some evidence that this reduction in 
costs to the service is partially transferred to the patient.(39) For families, having a child at home 
receiving treatment for febrile neutropenia, may result in additional costs, including time away 
from work and transport to and from the hospital for frequent reviews of progress.  
The NICE Guidelines 
In 2010 the National Institute for Clinical Excellence (NICE) set up a guideline development group 
for febrile neutropenia. They were tasked to develop a guideline for the prevention 
and management of febrile neutropenia, to include all adult and paediatric patients with febrile 
neutropenia related to treatment for cancer.   
NICE Clinical Guideline 151 “Neutropenic sepsis: prevention and management of neutropenic 
sepsis in cancer patients”, published in 2012, was the results of the development group’s work. It 
clearly defines febrile neutropenia (for which the term “neutropenic sepsis” is used throughout 
the guideline) as a neutrophil count of <0.5x109/L with either a temperature >38°C or symptoms 
or signs consistent with clinically significant sepsis. The guidance advises that patients should be 
risk stratified within the first day of hospital admission using a validated risk scoring system. For 
paediatric patients, the modified Alexander rule is advised (see Box 2).  Treatment should then be 
tailored according to this risk assessment. The following recommendation is particularly relevant 
to this thesis: 
“Consider outpatient antibiotic therapy for patients with confirmed neutropenic sepsis 
and a low risk of developing septic complications, taking into account the patient’s 
social and clinical circumstances and discussing with them the need to return to hospital 
promptly if a problem develops.”(21)  
The guideline proved to be controversial in the paediatric oncology community for a number of 
reasons.(21) These can be split into two main areas. The first is the argument that ‘children are 
not little adults’ and therefore should not be included within the same guidelines as adult 
patients.  However, this concern can be contended by the fact that although only around 1.2% of 
patients with cancer within the UK are diagnosed under the age of 24 years, around 50% of the 
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evidence for the NICE guideline comes from this age group. Thus paediatric and young adult 
patients are significantly overrepresented within CG151 and the evidence that is provided in 
children is generally consistent with adult data.(21) Having said this, the numbers of children 
included in the analyses is still relatively small and so some experts have been cautious about the 
guideline recommendations.  
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The second main cause of controversy within the NICE guidelines is that, although the majority of 
the guidelines are consistent with current adult practices, they do not reflect practice in most 
Box 2 - Modified Alexander Rule 
Risk factors excluding from low risk protocol: 
Admission and 48 h assessment 
 Age 
o <1 year 
 Associated medical conditions requiring hospitalisation 
o Shock or compensated shock 
o Haemorrhage 
o Dehydration 
o Metabolic instability 
o Altered mental status 
o Pneumonitis 
o Mucositis (unable to tolerate oral fluids or requiring IV analgesia) 
o Respiratory distress/compromise 
o Perirectal or other soft tissue abscess 
o Rigors 
o Irritability/meningism 
o Organ failure 
 Cancer associated co-morbidities 
o ALL at diagnosis/relapse <28 d 
o ALL not in remission >28 d 
o AML 
o Infant ALL 
o Intensive B-NHL protocols 
o Haemopoietic stem cell transplant 
o Sequential high dose chemotherapy with PBSC rescue 
 History 
o Intensive care admission during last FN episode 
o Non adherence (social concerns or patient) 
o Inability to tolerate oral antibiotics 
48 h Assessment only 
 Positive blood culture result at 48 h 
 ANC < 0.1 × 109/L at 48 h 
 Child not clinically well at 48 h (clinician judgement) 
ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; B-NHL, B cell non-
Hodgkins lymphoma; BMT, bone marrow transplant; PBSC, peripheral blood stem cells; and 
ANC, absolute neutrophil count. 
 
 22 
 
paediatric haematology and oncology centres.(39–41) This juxtaposition of current practice with 
the new guidelines has induced a degree of concern.   
UK service structure and current management for paediatric febrile 
neutropenia 
In the UK, children and young people with cancer are treated within highly specialised 
multidisciplinary teams. Upon diagnosis, children are transferred to one of the Principal 
Treatment Centres (PTCs) where further investigations are performed and their initial treatment 
is commenced (see Figure 1). Some children receive all their treatment in their PTC, whilst others 
may be managed using shared care between the PTC and a Paediatric Oncology Shared Cared Unit 
(POSCU) located closer to the child’s home. The role of shared care centres and the services they 
provide varies depending on regional design.  
Due to the absence of national or international Clinical Practice Guidelines for febrile neutropenia 
until recently, the management varies widely across the UK.(40,42) A national audit of febrile 
neutropenia practices was performed in 2012, prior to the introduction of NICE guidelines, and 
again in 2015, three years after the guidelines were published, to establish current management 
and to describe areas where the guidelines were not adhered to.(31,32) The initial survey 
included 21 centres and the follow-up included 45 (of which 14 were principal treatment centres). 
In 2015, only 49% of centres used the NICE guideline definition of febrile neutropenia 
(temperature ≥38°C on one occasion and neutrophil count of <0.5x109/L).(21) 
In each audit, just 42% of centres routinely risk stratified patients, and thus many children at low 
risk of septic complications of their febrile neutropenia are managed similarly to those at high risk 
of septic shock, intensive care admission or death. Those centres using risk stratification generally 
used the modified Alexander rule outlined in the NICE guidelines (see Box 2). In the 2012 audit, all 
UK centres managed children and young people with at least 48 hours of inpatient care and used 
intravenous antibiotics for the empirical treatment of febrile neutropenia.(40) The duration of 
admission was not clearly documented within the 2015 audit but intravenous antibiotics were 
used throughout.  
From these data, it can be seen that UK practice does not currently comply with the NICE 
guidelines. Some of the potential reasons for this have been explored above but others will be 
expanded in the following subsections about attitudes to reductions in therapy and change 
management.  
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Figure 1 - Location of UK Principal Treatment Centres for Paediatric Haematology and Oncology 
(43) 
A systematic review into why physicians do not follow guidelines suggested that the main barriers 
were related to physician knowledge, attitudes and behaviour.(44) When related to the current 
NICE guidelines, the main barriers may be attitudinal, such that physicians are concerned about 
the potential risks of this strategy and its applicability to children and young adults. There may 
also be concerns regarding the practicalities of providing such a service and the challenges in 
establishing this given current NHS financial difficulties. 
Attitudes to reductions in therapy 
Ever since reduction in the intensity of febrile neutropenia therapy was suggested, studies have 
been performed to assess the attitudes of healthcare users and providers to this approach. The 
research has been illuminating to those in the field. In adult febrile neutropenia, where the 
practice of outpatient treatment or early discharge with oral antibiotics has been commonplace 
for some time,(45) these strategies are acceptable to most adult cancer patients and seem to 
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improve health-related quality of life, although attitudes obviously vary between individual 
patients.(46) 
However, in paediatric haematology and oncology, the findings have been somewhat different. 
Whilst it might be expected that families would prefer to be together in their own homes  with 
more control over their surroundings, the work so far has varied in its findings. Some studies 
whose main intentions were to establish the efficacy of alternative treatment strategies also 
examined patient preferences and almost universally report high satisfaction with these 
approaches.(47,48)  
However, in a more specific attitudinal study Cheng et al found that only around a half of families 
would take up a reduced therapy option, and inpatient therapy is often preferred.(46) 
Furthermore, work by Sung et al established that this preference persisted even when the risk of 
significant deterioration (death or intensive care admission) was equal between the groups 
treated at home or in hospital.(35) This was despite an increase in the anticipated Health Related 
Quality of Life with outpatient therapy including initial admission followed by early discharge.(46) 
More recently, Sung et al have aimed to identify what aspects of an outpatient therapy schedule 
might be most acceptable to families and found that a requirement for frequent clinic attendance 
and a high probability of readmission was likely to be a barrier to early discharge approaches.(49) 
This body of research has found a degree of disparity between groups regarding acceptance of 
outpatient regimes. Parents seem less keen for their children to be treated at home than the 
healthcare professionals involved in providing care. Children and young people also appear to be 
more keen to be out of hospital than their parents and are willing to accept a higher frequency of 
clinic visits and higher readmission risk in order to achieve this.(49)  
Current evidence has identified certain characteristics that make families more likely to prefer 
outpatient care. These include less fear or anxiety about febrile neutropenia, parents with higher 
income and higher education, and those who assessed their child as having higher current Health 
Related Quality of Life.(35,46) However, it should be recognised that all of this research into the 
attitudes of children, families and healthcare professionals has been performed by a single 
research group, within a single centre in Toronto, Canada. Thus further information is required 
from other centres and settings, to explore whether these results apply to other populations, and 
also to identify other features that might influence the attitudes of key stakeholders. 
The negative attitudes of families towards reductions in therapy could be reflected in poor 
recruitment to trials of early outpatient therapy. For example, in the Swiss Paediatric Oncology 
Group (SPOG) 2003 FN study a third of patients who were eligible to take part refused consent, 
although the reasons for this were not fully explored.(17) Rates of consent to paediatric 
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haematology and oncology trials are usually very high and thus this rate of refusal is 
noteworthy.(53) Whether low recruitment rates are particularly prevalent in reduced therapy 
trials for febrile neutropenia has not been investigated.  
The issue of non-participation in cancer trials in general has been explored by Cox and McGarry, 
who found a variety of reasons why patients do not participate in trials.(50) In particular, they 
identified that patients may not be offered trial participation by their doctors, despite being 
eligible for entry; they may find the burden of participation too demanding; or they may distrust 
the idea of participating in medical research. These reasons may also be relevant to febrile 
neutropenia studies. However, there may be additional or different concepts that are relevant to 
any poor recruitment to reduced therapy febrile neutropenia trials. I will further explore the 
issues of choice and decision-making that relate to this thesis, within chapter 2.  
The problem addressed by this thesis 
Febrile neutropenia is a common problem within paediatric haematology and oncology. Reduced 
therapy regimens may provide benefits to both patients (including increased quality of life and 
reductions in hospital acquired infections) and the health service (including cost savings and 
reduced bed pressures), when there is a low risk of septic complications. As outlined in the earlier 
sections of this chapter, further information is required about the safety and efficacy of these 
regimens, and specifically, how these change according to the timing of reductions. There also 
remain a number of unresolved issues regarding attitudes towards early discharge in patients with 
low risk febrile neutropenia, particularly in identifying barriers and facilitators to acceptance of 
early discharge as a treatment strategy. The factors used in this decision making process need to 
be considered and the methods people use to balance the benefits and challenges of early 
discharge explored. Furthermore, investigation of any differences in acceptance between young 
people, their parents and the professionals caring for them, and how these might be aligned, is 
needed so as to provide an acceptable service for all. 
Aims of the thesis 
The main aim of this thesis is to further investigate the issues surrounding the reduction in 
Box 3 – Main research questions for thesis  
In children and young people with low risk febrile neutropenia, are reduced therapy regimes 
(particularly early discharge) safe, effective and acceptable to key stakeholders?  
What factors are involved in decision-making about acceptability of early discharge 
regimes? 
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therapy for children and young people with low risk febrile neutropenia (see Box 3 for main 
research questions). In particular, it will aim to establish the safety, adequacy and treatment 
failure rates of various reduced therapy strategies in the face of new research evidence. It focuses 
specifically on the issue of the timing of reductions in therapy, that is the point in the care 
pathway at which the child or young person moves from inpatient to outpatient care or from 
intravenous to oral antibiotic administration. These data are essential to inform decisions about 
care strategies and aim to allow discussions which are based on the best current available 
evidence when designing and providing care.  
The work then investigates the attitudes of those involved in strategies involving early patient 
discharge in various hospital settings. This aims to provide wide-ranging information about the 
experiences of early discharge and potential barriers and facilitators to the provision of these 
services for children and young people. Finally the views of key stakeholders, specifically about 
early discharge in paediatric febrile neutropenia, have been sought. These provide a nuanced 
account of the perceptions of various strategies proposed for this group of patients. It conveys 
the voice of patients, parents and healthcare professionals from multiple institutions in the UK, in 
order to provide health care service providers and policy makers with information on how best to 
address these issues, and how to structure future services for children and young people with 
febrile neutropenia.  
Mixed methods applied to this research 
The complexity of the research problem, rooted in clinical practice, that this thesis addresses and 
the varied nature of its component aims, required a mixed methods approach. I drew on both 
quantitative and qualitative research paradigms  selecting of the most appropriate methodologies 
for each aspect of the research problem, and then combining these results to achieve a more 
nuanced consideration and deeper understanding of this multifaceted topic. Mixed methods 
research is a relatively new concept, which allows for the exploration of complex problems by 
examining them using different perspectives, and thus providing a more holistic study of the 
various interacting aspects of the situation.(51) The triangulation of results constructs a detailed 
account of the subject of the research, in this case reduced therapy in paediatric febrile 
neutropenia. Using this methodology enables the inclusion of both quantitative and qualitative 
data, methods and modes of thought, so as to provide a deeper, clearer and more nuanced 
understanding of the research problem and its potential solutions. This is particularly applicable in 
areas where there are both quantitative and qualitative facets to the research problem – as in 
paediatric low risk febrile neutropenia, where there are questions about risks of certain outcomes 
alongside those about experiences, perceptions and attitudes.(52) Using a mixed methods 
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approach and selecting the most appropriate methodology for each of these components should 
ensure that the research problem is extensively explored and the research questions are 
answered, whilst overcoming some of the limitations of each of the individual included 
methodologies.(53) 
However, challenges arise in mixed methods research when the underlying epistemological and 
ontological beliefs of these quantitative and qualitative paradigms are in opposition.(53) The 
resolution of these potential disagreements occurs when focus is placed on the problem to be 
addressed and the strengths and weakness of each methodology used are acknowledged. The 
results may then be combined to best utilise each methodology and the conclusions outlined 
while explicitly recognising these issues.(54) Mixed methods research is particularly suited to a 
pragmatic philosophy, as is often seen in health sciences, and for this project allows for the most 
appropriate exploration of the research problem with the intention of providing a clinically 
informative and practically useful outcome for all involved in paediatric haematology and 
oncology services.(53,55,56)   
The following section of the chapter details the way in which the thesis has been structured and 
how the methodology has been applied to the research problem.  
Structure of thesis 
The work undertaken for this thesis was carried out as three sequential research phases. Each 
addressed different aspects of the research problem and used appropriate methods to tackle 
specific research questions.. The earlier phases provided data and theory to inform and develop 
the design of later phases, the contribution of which is discussed at the beginning of each of the 
relevant chapters. The later phases then helped to expand and explore issues identified at earlier 
points, allowing deeper interpretation of findings in earlier phases. This is discussed further within 
relevant chapters reporting these phases, and the translating of works together is further 
described within the conclusions in Chapter 9.  Phases 1 and 2 are both systematic reviews of the 
earlier literature, seeking to combine pre-existing research evidence and generate new 
knowledge within the findings. Phase 3 is an exploratory piece of primary research that seeks to 
build on the two syntheses and to generate further data to expand upon the earlier work and to 
provide new insight to the research problem. The phases were performed chronologically in 
sequence with some overlap between phases 1 and 2, such that the final analysis of phase 1 
occurred at the same time as the design and searching for phase 2. The analyses of both phases 1 
and 2 were completed before the design of phase 3, which was informed by both pieces as 
outlined in Chapter 4. The three phases of the thesis are outlined narratively below and pictorially 
in Figure 2.  
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Phase 1 - Systematic review of reduced therapy regimens for children with low-
risk febrile neutropenia 
This phase involved the synthesis of quantitative data within the existing literature to define the 
safety, adequacy and treatment failure rates of oral antibiotics and outpatient management for 
low-risk paediatric febrile neutropenia. Standard systematic review and meta-analysis 
methodologies were applied, with thorough searching of the literature, screening of identified 
references, and data extraction and quality assessment of included studies. Data were combined 
in meta-analyses and subgroup and sensitivity analyses undertaken. The results provide detailed 
information regarding the outcomes of various treatment strategies for febrile neutropenia and, 
in particular, explore the effect of timing of reductions in therapy on the rates of treatment failure 
in paediatric febrile neutropenia, which has not previously been examined. Furthermore, this 
review specifically collected data on rates of refusal to consent to studies of reduced therapy for 
children with low risk febrile neutropenia so as to begin to explore the issues surrounding 
acceptance of reduced therapies. The findings of this phase, particularly the refusal to consent 
data, contribute to the design of both the qualitative synthesis and primary study, as discussed in 
Chapters 3 and 5. The safety and treatment failure rates also formed part of the topic guide for 
discussion within the qualitative study in phase 3.  
Phase 2 - Experiences of early discharge, with a focus on paediatric febrile 
neutropenia: a meta-ethnography 
The second phase of the study was a systematic review of the qualitative literature describing 
experiences of early discharge, aiming to explore concerns raised in Phase 1 that reductions in 
therapy might not be acceptable to key stakeholders. This was an original approach to considering 
this research problem and uses a relatively new methodology to explore the issues in a unique 
way. It used structured searching of literature, with screening of all identified references to obtain 
evidence in the area of paediatric febrile neutropenia. As that evidence was sparse, it also drew 
on experiences of early discharge in adults with febrile neutropenia and children with other 
chronic conditions. The quality of data was assessed and used to inform the analysis which 
followed an adapted version of Noblit and Hare’s phases of meta-ethnography.(57) The work 
aimed to triangulate experiences from patients with those of their parents or carers, and their 
healthcare professionals. It considered the process of decision making and the factors influencing 
the choices made, as well as features of early discharge strategies that could improve the 
experiences of participants. The synthesis allowed the development of higher level themes and 
the identification of potentially relevant theories, as well as the description of significant gaps in 
current knowledge. These were then explored and expanded through Phase 3, where the 
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qualitative study findings were translated back into the qualitative synthesis results within 
Chapter 8.  
Throughout the thesis, this phase of the work is referred to as the qualitative synthesis so as to 
provide clarity and to help distinguish between this phase and that of the quantitative systematic 
review already described. It should be noted that both pieces of research use standardised 
systematic review methodology and rigorous scientific methods; the differences in terminology 
simply aim to reduce confusion over the pieces of work being referred to. Thus “systematic 
review” will be used to refer to phase 1 of the work and “qualitative synthesis” to phase 2. 
Phase 3 – A multi-centre focus group study of experiences and perceptions of 
early discharge in paediatric low-risk febrile neutropenia involving patients, 
parents and healthcare professionals 
The final phase of the work used a qualitative study designed to further investigate the 
experience and perceptions of early discharge strategies within the UK, and provide original data 
relevant to this area of paediatric supportive care. In particular, the views of patients, parents and 
healthcare professionals were sought in an exploration of the triadic nature of this problem. For 
each stakeholder group, focus groups discussions allowed the examination of how decisions are 
made and the identification of barriers and facilitators to acceptance of outpatient care. Using 
multiple centres enabled the recognition of the influence of the centre’s structure, culture and 
current treatment strategy on the perceptions of different models of care. This study drew on the 
knowledge gained from, and the safety and treatment failure rates quantified in, Phase 1 to 
inform participants of risk and benefits of various treatment strategies. It also aimed to scrutinise 
and develop the theory created in Phase 2 of the project. A detailed account of how the findings 
of phases 1 and 2 were incorporated into the qualitative study is provided in chapter 5. This phase 
then provides further interpretation to the earlier findings of phase 1 and 2, as described in 
Chapters 8 and 9.  
The final conclusions section of this thesis further translates the findings from all three phases of 
the work in order to address holistically the original problem and to explore possible explanations 
for findings. The original contributions of this thesis to the field are clearly outlined and I reflect 
on the process of performing the work, with a particular focus on how this influences the 
application of the results.  The potential implications for current policy and practice are also 
detailed and various options for further development within the field of paediatric low risk febrile 
neutropenia are presented with the aim of further progressing service design and improving 
experience for these children and young people.  
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Summary  
Within this chapter, I have introduced the concept of febrile neutropenia, as a common 
complication of treatment for childhood cancer. I have explored the history of its management 
within the UK and how this has now resulted in standard care for paediatric patients being a 48 
hour inpatient admission for intravenous antibiotics. Two broad areas of current research have 
been introduced – the risk stratification of episodes of febrile neutropenia in children, and the 
potential for reduced therapy regimes in children at low risk of septic complications. This second 
area of research is supported by current NICE guidelines which suggest that outpatient treatment 
should be considered for low risk episodes, but the safety and efficacy of these approaches in 
children and the attitudes of key stakeholders in this area have yet to be fully explored.(21) This 
thesis therefore addresses the issues of safety and efficacy in relation to the timing of reduced 
therapy in children, and explores the experiences and perceptions of early discharge in febrile 
neutropenia from the perspectives of patients, parents and healthcare professionals. I have 
decided to use a mixed methods approach in recognition of the multi-faceted nature of the 
research and its pragmatic aims. I have outlined the three phases of the thesis and provided a 
brief summary of what each of these involve, including the original findings that they contribute 
to the field. The following chapter introduces many of the concepts lying behind the qualitative 
work and further sets the scene for the work within this thesis.  
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Figure 2 - Overview of Thesis (Research questions for each Phase outlined within each box),  upper arrows indicate mixing at design phase whilst lower 
arrows demonstrate  mixing in interpretation.
Phase 1: Systematic Review
• In children with low-risk 
Febrile Neutropenia:
• Are oral antibiotics safe 
and efficacious with low 
rates of treatment failure?
• Is early discharge safe and 
efficacious with low rates 
of treatment failure?
• Is there a time of 
discharge where the 
safety, efficacy and rates 
of treatment failure 
change?
• How frequently do 
participants refuse to 
consent to trials of 
reduced therapy for 
febrile neutropenia?
Phase 2: Meta-ethnography
• What are the experiences 
of patients, parents and 
healthcare professionals 
of early discharge in 
paediatric febrile 
neutropenia, adult febrile 
neutropenia and other 
paediatric chronic 
conditions with 
potentially life-
threatening 
consequences?
• What are the barriers and 
facilitators to acceptance 
of early discharge in these 
populations?
• How do the perspectives 
in these situations differ 
and how does this impact 
on the process of early 
discharge?
Phase 3: Focus group study
• What are the factors 
involved in decision 
making about outpatient 
therapy in low-risk febrile 
neutropenia?
• What are the barriers and 
facilitators to acceptance 
of an outpatient therapy 
strategy from the point of 
view of patients, parents 
and healthcare 
professionals?
• What are the similarities 
and differences in 
acceptance between 
young people, their 
parents and the 
professionals caring for 
them?
• How might these factors 
be aligned so as to 
provide an acceptable 
service for all?
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Chapter 2: Choice and decision making in paediatric practice 
Introduction 
This chapter aims to provide an overview of some of the issues involved in exploring attitudes 
towards early discharge that  are relevant to all phases of the thesis. It is a contextual discussion 
of some of the surrounding literature, providing further background to the thesis, and to the 
debates that will be discussed in later chapters. It also outlines many of the underlying tenets of 
the thesis, particularly in relation to the value of young people’s voices and the challenges of 
healthcare decision making in this population. Leading on from these general discussion points, I 
will then perform a more conventional and focused qualitative synthesis, scoping the primary 
literature surrounding early discharge in Chapter 4. 
This chapter first covers the areas of child and young person choice and participation in 
healthcare decisions and in research, specifically outlining the importance of allowing children 
and young people their own voice within these areas. This forms the basis of the rationale for 
including the views of young people in the following sections of this thesis. It then moves on to 
cover the challenges of triadic consultations and therefore decision making when children, young 
people, parents and healthcare professionals are making choices together about care. This 
informs the approach to the focus group discussions, including the analysis of this work. It also 
underpins the discussion of how the findings of this thesis may apply to clinical practice and to 
areas of future research.  
Finally this chapter discusses decision making processes in general and in relation to clinical trials. 
Consideration is given to the fact that giving or obtaining consent is part of a decision making 
process about specific treatment options, whether as part of standard medical care or within the 
structure of a trial. By introducing relevant concepts and theories, it aims to explore the use of 
consent rates to trials in the systematic review as a proxy marker for attitudes to reduced therapy 
regimes and begins to examine areas relevant to following chapters. This is consistent with the 
overarching objective of the thesis to explore wide-ranging issues surrounding the acceptance of 
early discharge in paediatric febrile neutropenia and to identify potential barriers and facilitators 
to the provision of these services for children and young people. 
Children and young people’s choice and participation 
The issue of patient choice is much discussed and politicised, and is at risk of becoming a 
tokenistic catch-phrase used for political impact, but divorced from service provision. There is 
argument about whether patients truly can make choices about healthcare in the same way as 
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they would when making consumer choices. The experience of healthcare, and particularly 
children’s cancer, is somewhat different to a classical consumer choice.(58) Families often have 
little experience of the options being offered, the potential benefits and associated risks are 
considerably greater, the uncertainty more difficult to understand and there may not be repeated 
opportunities to get it ‘right’. Furthermore, there is generally no option to defer or avoid making a 
choice, as may occur in consumer situations. Even when doctors become patients, the challenges 
in making these ‘choices’ are great.  
Acknowledging these issues and constraints, but recognising the importance of allowing 
autonomy, national and international guidance states that healthcare professionals should 
endeavour to involve patients, and their relatives, in their care; be this in small choices such as 
where an intravenous cannula should be placed, in the greater decisions of their individual care 
(for example, when to stop treatment with curative intent) or in how services are designed and 
delivered:  
‘You must listen to patients, take account of their views, and respond honestly to their 
questions.’(59) 
Historically, these concepts applied only to adults with capacity, but over time as the social 
construction of childhood has changed, children have been given a greater voice in their own 
care. Healthcare providers are guided by Article 12 of the United Nations Convention on the 
Rights of the Child: 
‘States Parties shall assure to the child who is capable of forming his or her own views 
the right to express those views freely in all matters affecting the child, the views of the 
child being given due weight in accordance with the age and maturity of the child.’(60) 
In agreement with this, Professor Terence Stephenson, previous president of the Royal College of 
Paediatrics and Child Health, succinctly captured the professional dedication to seek the opinions 
of paediatric patients: 
‘We do a great injustice to children and young people when, as a society, we fail to 
listen to their views, take on board their perspectives and value their contribution in 
shaping child health services.’(61) 
However, there are a number of challenges to allowing children to be heard. Firstly, the opinions 
of children are often obtained from a proxy; that is the opinions of the parents are sought as a 
reflection of their child’s and taken to be a true representation of that child’s thoughts. There is 
now a considerable body of evidence that this approach does not capture the views of children 
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accurately.(62) Furthermore, there is a distinct risk of double silencing, in that the views of the 
child are not heard directly, and the parent fails to express their own views through trying to 
represent the child.(63) Thus neither voice is clearly heard. 
Secondly, there may be a paternalistic view of the abilities of children to participate in making 
choices, with both parents and healthcare professionals feeling that children and young people 
lack cognitive and emotional skills to contribute, particularly to choices that are more complex or 
those with greater consequences.(105,107–109) Thus children may be listened to but restricted 
from making overt choices about their care. 
Despite these challenges and despite later in this chapter questioning the extent to which people 
can exercise choice, it is imperative that society maintains a commitment to hearing children’s 
voices and involving them in their healthcare as far as possible. All healthcare decisions ought to 
be made in partnership between a healthcare professional and the patient, or in the case of 
paediatrics, between the child or young person, their parents and the healthcare professional, 
wherever the patient has the capacity to participate in the decision. Interestingly, alongside this 
moral imperative to include all stakeholders in decision making, there is also evidence that 
decisions made by groups are generally better than those taken by individuals:  
 ‘…on average, groups outperform individuals on such tasks [making important 
decisions], although group decisions frequently do not measure up either to the 
decisions made by their most capable individual members or to statistical aggregates of 
individual decisions… In other words, while groups tend to make better decisions than 
individuals, on average those decisions are often are not as good as they theoretically 
might be.’ (67) 
In the case of low risk febrile neutropenia, there are distinct power differentials within this group. 
Healthcare professionals may be seen to hold the most intrinsic power in this situation – they 
hold responsibility for the inpatient beds and therefore can theoretically decline a patient stay in 
hospital. Furthermore, they hold social power in which society confers greater control over 
decision making to professionals than to their clients. At the same time, decision making about 
children and young people almost exclusively takes place within families, and their surrounding 
communities, such that parents hold considerable power over their children, even as they 
become young adults with a degree of their own autonomy. Thus the child or young person might 
feel that their own contributions to these decisions are minimised or even completely excluded. 
Parental impact, and that of wider society, on young people’s choices should not be ignored, as 
choices are rarely exercised in isolation. Parents play a key role in supporting young people to 
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develop the skills required to make competent decisions.(68) This is discussed further in the 
following section of this chapter. 
Further research is needed into how healthcare decisions for children and young people can be 
best supported so as to allow contributions from all stakeholders to be heard and valued. 
Healthcare professionals may make efforts to share information and knowledge with young 
people and their families so as to reduce the power differential and allow for decisions to be more 
equally shared. This concept of shared decision making will be discussed further later in this 
chapter and in Chapters 8 and 9. Linked with these considerations about involving young people 
in healthcare choices, this chapter now considers the triadic nature of paediatric consultations 
and the challenges of communication and decision making within this structure.  
Triadic consultations 
In paediatric practice, the issue of shared decision making is complicated by the three-way 
consultations involved, in which young people, their parents and the health care team may all 
have different views, values and choices when it comes to a healthcare decision. It is essential to 
consider how these triadic relationships function and how differences are negotiated, in order to 
be able to understand how they might influence the issue of reduced therapy in paediatric low 
risk febrile neutropenia, helping to both explain the findings of previous research and to inform 
the analysis and interpretation of the primary research performed within this thesis. 
The dynamics of these complex triadic consultations have been explored by Tates and 
Meeuwesen.(65) Perhaps most interesting from a professional’s point of view is the finding that 
the child’s contribution to a consultation was mostly controlled by the parent, with large 
proportions of questions that had been directed to the child being interrupted and answered by 
the parent. Although these issues may have improved over time as society has become less 
paternalistic, other strategies could also improve the child’s participation in discussions, including 
their own determination to contribute and the persistence of the professional in directing 
discussion towards the child.(65,69) It is worth noting that for some children this may be because 
they prefer to use their parents to indirectly communicate with the professionals and this 
preference should be accepted provided it is the patient’s choice.(70)  
When considering the involvement of children and young people in health care discussions, it is 
also worth noting the different conversational styles that professionals tend to use when 
addressing them compared to their parents.  Doctors have a tendency to be more effective when 
conversing with children, using softer tones and limiting discussions to obtaining information.(65) 
Although the communication skills used with children and young people must be adapted to 
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enable them to engage in the consultation, it is essential that this change in consultation style 
does not diminish the value of the opinions of the child or young person nor limit their ability to 
participate in decision making as far as they are able. Close attention to the developmental stage 
of the child or young person may facilitate the greatest degree of involvement possible.  
The challenges of maintaining a balanced triadic consultation are perhaps even greater in the 
setting of paediatric oncology than those settings where the majority of this work has been 
completed. Parents of children with cancer have significant levels of health anxiety and this 
degree of concern may create an emotional or psychological need to control more of the 
discussions, and also decisions regarding care. Parents may wish to protect their child from the 
more distressing aspects of a diagnosis or a decision to be made and thus choose not to involve 
them in the information sharing discussions about their disease.(71) Furthermore, the complexity 
and potential consequences of the choices to be made may cause both parents and professionals 
to limit the involvement of children and young people in decision making, for fear of them making 
a ‘wrong’ decision.  
Despite this, it is important to note that conflicts within triadic decision making are relatively 
uncommon.(72) Generally, decisions can be reached which all parties are happy with. There may 
be many reasons for this frequency in consensus. The first is that young people tend to learn their 
decision making processes from their parents. They observe the attribution of weight to various 
factors, along with the attitudes of their parents towards risk.(68) Young people also tend to have 
similar health knowledge and beliefs to their parents. As such, they are likely to come to similar 
decisions to their parents as this is the model of decision making they are most exposed to. 
Secondly, young people develop their confidence and perceived self-efficacy in healthcare 
decision making from the observation of their parents and through the feedback given to them by 
their parents and healthcare professionals. They may seek the approval of parents and healthcare 
professionals when making decisions as they are still negotiating this relatively new task. It is not 
surprising then that they chose similar decisions to the more dominant adults within the 
consultation. Thirdly, parents, young people and healthcare professionals frequently herald from 
similar cultures. Thus the influence of the predominant culture on each factor within the decision 
making process is likely to be similar and therefore result in more unified conclusions. The 
normative values and assumptions of the culture result in an unspoken pressure to reach a certain 
decision - for example to prioritise a child’s physical health over the psychological and social 
wellbeing of other family members.(73)  
The infrequency of conflict within triadic decision making means that when this does occur it is a 
particularly difficult scenario. The challenges of reconciling these differences are familiar to 
healthcare professionals dealing with this age-group. However, although communication training 
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and conflict resolution skills are increasingly being taught within both undergraduate and 
postgraduate healthcare professional training, the particular challenges related to adolescent 
decision making (including the various stages of adolescent cognitive development) and methods 
for supporting shared decision making within triadic consultants are rarely covered. Professionals 
may struggle to harmonise decisions in the absence of specific guidance and within the often 
high-pressure and time-critical setting of many healthcare decisions in paediatric haematology 
and oncology services.  
Having considered the challenging nature of triadic consultations and of decision making within 
them, this chapter now moves to more of the psychological and sociological theories surrounding 
healthcare decision making, aiming to highlight features that are specifically relevant to decisions 
surrounding early discharge in paediatric low risk febrile neutropenia. 
Decision making theories  
An understanding of healthcare decision making theories enables the exploration of attitudes 
surrounding reductions in therapy for low risk febrile neutropenia. Alongside identifying the 
attitudes stakeholders have towards different strategies, it is vital to understand how patients, 
families and healthcare professionals come to the decisions that they make in this area. 
Furthermore, exploring how these decisions differ between family members, and between 
families and healthcare professionals, might enable further understanding of the specific reasons 
for agreeing to or declining reduced therapy options and thus help to address the research 
problem outlined in Chapter 1.  This section of the chapter considers how people negotiate 
decisions, within their own decision making processes, within family relationships and within 
healthcare consultations.  
One of the earliest works about healthcare decision making is found in the Health Belief Model 
(Error! Reference source not found.).(74) First described in the 1950s by social psychologists R
osenstock, Hochbaum and Kegels, the Health Belief Model describes how a person’s health care 
decisions, and actions, are influenced by four main perceptions. (74) These are their perceived 
susceptibility to the specific condition, the perceived severity of the condition (both physical and 
social), the perceived benefits of a decision or behaviour, and the perceived barriers to that 
decision or behaviour. Furthermore, a ‘cue to action’ or prompt is required to stimulate the 
person to make the decision or action. All of these factors may be influenced by demographic and 
sociological variables.  
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The Health Belief Model is a simplified way of considering health care decision making, focusing 
mainly on screening or disease prevention actions, although it can be transferred to almost any 
decision making situation. The importance of perceptions in the model is key. Most healthcare 
decisions are made in situations of uncertainty, where although events may occur with a 
predictable probability, it is not possible to know whether, for this particular person in this 
situation, the event will occur. (67) Decision making may therefore be influenced by the 
communication of this uncertainty between members of the consultation, and attitudes towards 
risk within the decision making person or group.  
Similarly, consideration must be given to the ways in which different stakeholders may view 
health conditions. Specifically, research has found that those who have experience of a health 
condition, for example those who have previously experienced cancer, often consider the quality 
of life in this condition to be higher than those who have no experience of it. (67) Healthcare 
professionals will generally assign a value between these two groups. This may be particularly 
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social class, peer and 
reference group pressures, 
etc.)  
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of preventive action 
Minus 
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Advice from others 
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or dentist 
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Figure 3 The Health Belief Model 
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important for low risk febrile neutropenia – patients with no experience of low risk febrile 
neutropenia may be less likely to opt for an early discharge option than those who have been 
admitted for previous episodes, particularly if those episodes have not resulted in serious adverse 
events. Furthermore, patients who have experienced an early discharge strategy may be more 
likely to value this option again and thus have a more positive perception of this course of action. 
Healthcare professionals may have a more moderate view, influenced by both their experience of 
poor outcomes in febrile neutropenia and by their day-to-day contact with patients who suffer no 
significant septic complications. 
The Health Belief Model, although a useful way to consider the basics of decision making, is 
perhaps overly reductive as a theory. Decisions are rarely made in such a rationalist and 
autonomous fashion, and may be shaped by inaccurate perceptions, social factors, and normative 
values and assumptions.  
Consideration of challenges to accurate perceptions is vital when exploring the process of 
decision making and considering the Health Belief Model. Cognitive biases describe the influences 
of various heuristics that result in systematic deviations from rational reasoning.(75) In the setting 
of febrile neutropenia, both professionals and families may be contending with multiple cognitive 
biases, including availability bias (where frequency assessments are based on ease of recall of 
their occurrence), loss aversion (where losses hold more weight within decision making than 
equivalent gains), status quo bias (where people prefer the current situation over changes), and 
anchoring (where there is persistence in thinking dependent upon the initial information 
available).(75,76) Perhaps most significant in terms of reductions in therapy is that of omission 
bias, whereby any harm (eg intensive care admission) that occurs to a child from committing to 
change to an early discharge strategy is felt more keenly than harms that occur due to omitting to 
change.(76) Healthcare professionals have been found to be at particular risk of employing biases 
and heuristics, due to the benefits in speed and accuracy that these cognitive strategies often 
bestow.(76) 
The Health Belief Model also fails to recognise that healthcare decisions are invariably made 
within the confines of social, economic, cultural and historical contexts, such that the choice is 
constrained by various factors acting upon the patient and those around them.(77,78) The 
influences of gender, race, power, family structure, social views on age on both patient and 
healthcare professional decision making have been clearly described in the literature, but are not 
acknowledged by the Health Belief Model.(62,68,77,79) 
Working alongside these social influences, normative values and assumptions about appropriate 
responses to health challenges may greatly impact on the choices offered and made. For parents 
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who are making healthcare decisions about their children, a key influence in the decision making 
process is often the concept of doing what a ‘good parent’ would do. The ‘good parent’ in the 
literature is represented in a similar way across varied populations and appears to be socially 
defined.(73,80) Three key features within this literature that are particularly relevant to health 
care decision making are that the ‘good parent’ makes “informed, unselfish decisions in the child’s 
best interest”, “tries to prevent suffering and protect health” and “teaches the child to make good 
choices…”.(80) The decisions made by parents are therefore constrained by the societal pressures 
to be a ‘good parent’.  
In the case of healthcare professional decision making, staff are governed by various 
professionally enshrined ethical principles. The four pillars of medical ethics described by 
Beauchamp and Childress of beneficence, non-maleficence, justice and autonomy are taught 
explicitly within professional curricula and also implicitly during the apprenticeship of new 
colleagues into the healthcare service. (81)  Beneficence describes the importance of working for 
the benefit of the patient and non-maleficence compels clinicians to work to minimise the harms 
to patients of treatment.  
Meanwhile, the importance of allowing patients to make their own decisions, within their own 
beliefs, even if these contrast with those of their healthcare team is captured in the ethical pillar 
of autonomy. The role of autonomy for children and young people, where they have the capacity 
to contribute to decisions about their own healthcare, has already been discussed within this 
chapter. Those involved in service design must consider that families might choose different 
options to healthcare professionals and service providers. The extent to which practitioners 
should encourage patients to take particular options and therefore limit autonomy is debateable. 
Within the classical model of informed decision making, the patient is given information regarding 
the various options available to them, and is then the primary decision maker. However, within a 
shared decision making model, the healthcare professional and patient might share the 
information about various options, along with their values and preferences, so as to come to a 
decision together. From this concept stems the GMC advice: 
“The doctor may recommend a particular option which they believe to be best for the 
patient, but they must not put pressure on the patient to accept their advice.”(82) 
The issues surrounding shared decision making will be discussed further later in this thesis. 
Finally, when contemplating the normative values within healthcare professional decision making, 
the fairness of healthcare decisions, also known as justice, should be considered. Patients are 
considered to have a ‘right’ to receive similar care to other patients in their situation, regardless 
of cost, and consideration should be given to the distribution of healthcare through the 
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community. This feature of medical decision making is focused less on the direct care of the 
individual patient and so may not feature so strongly in the choices made by families. However, 
clinicians making decisions are often also thinking about the impact of their decisions at a societal 
level. They may be making decisions for whole groups of patients, based on the costs of various 
treatment options, the potential outcomes and resource constraints within the specific 
department and within the health service as a whole; decisions about individual patients take 
place against a backdrop of wider healthcare decisions.  
For low risk febrile neutropenia, physicians may be thinking about how a patient in hospital may 
be located in a bed space that could be needed for another child who is also the clinician’s patient 
or may be receiving nursing and medical staff time which might otherwise be used differently. 
Balancing these health care service costs and benefits alongside the advantages and 
disadvantages for the individual patient makes the decision about whether to implement an early 
discharge even more complex. This may, in part, account for differences in the choices made by 
healthcare professionals compared with patients and families when it comes to the issues 
surrounding early discharge for paediatric low risk febrile neutropenia.  
When people choose to let a healthcare professional make a choice for them, it ought to be noted 
that this should also be considered an active decision.  It requires a degree of trust in the 
professional involved, and as such professionals have a responsibility to obtain as much 
information about the patient’s preferences, goals and values as possible and to communicate 
their rationale for the chosen course. This feature of decision making has been eloquently 
captured by Atul Gawande, who writes: 
“The new orthodoxy about patient autonomy has a hard time acknowledging an 
awkward truth: patients frequently don’t want the freedom that we’ve given them. That 
is, they’re glad to have their autonomy respected, but the exercise of that autonomy 
means being able to relinquish it.”(19) 
Younger patients and those with higher educational levels are more likely to want to be involved 
in medical decision making, whilst gender also plays a role. (67)  Female patients are more likely 
to wish to be involved in the decision making process. Furthermore, patients tend to prefer to 
make simpler medical decisions, with a tendency to relinquish the decision to professionals if it 
requires a higher degree of medical proficiency. (67) Thus, families may not wish to be involved in 
decisions about which chemotherapeutic agents to use for their child’s primary diagnosis, but 
may want to contribute to the decision surrounding treatment of low risk febrile neutropenia. The 
desire to be involved in some decisions, and not others, requires frequent checking and 
negotiation by healthcare professionals.(83,84) This reflects the dynamic nature of medical 
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decision making, in which conditions may change frequently, and where individuals may feel more 
or less willing to participate in decision making based on their physical, psychological or social 
situation.  
Finally, relating to the theories of decision making, it is important to consider the issue of ‘option 
setting’ in which practitioners make choices about what options they offer to patients, whether 
this is treatment options or an invitation to participate in trials. This process precedes that of 
decision making and may limit the ability to participate in decisions by reducing the choices 
offered to patients. The range of options offered may be influenced by local policy, the 
professional’s knowledge of the various options, organisational constraints, the professional’s 
sense of duty and responsibility and assumptions made on the behalf of the patient about their 
values and preferences.(85) Importantly, the judgements made about interest and capability may 
exclude participants from disadvantaged social groups, including the very young or very old and 
those from ethnic minority and lower social economic backgrounds from participation in 
treatment options or research studies which they might otherwise have chosen. (85–87) 
 
Assessment of decision making 
Having explored these theories and the various influences on decision making, two main areas 
need discussion. First, how can ‘good’ decision making be defined and identified, and second, how 
should research assess decision making in healthcare.  
The assessment of decision making in clinical practice traditionally takes an individualistic 
approach, assessing only the patient themselves. Within this context, healthcare professionals are 
encouraged to assess the process of the patient’s decision making, through the assessment of 
capacity, rather than assessing the option chosen or the outcome related to that choice. Thus a 
patient may chose an option that the healthcare professional may not feel is the ‘best’ option, but 
provided the patient can show that they understand the relevant information, can retain it long 
enough to make the decision, can weigh the information and communicate their decision then 
that decision is considered to be medically ‘good’.(88) 
Again this traditional approach may seem overly simplistic. Defining a good decision as informed 
decision making alone, or autonomous choice, neglects the psychological and social complexities 
of decision making as discussed earlier in this chapter. Furthermore, the opinions of various 
stakeholders about whether a decision was ‘good’ may vary over time. Thus a decision that was 
‘good’ when first diagnosed with a chronic condition may no longer be a ‘good’ decision later in 
the course of that disease. Within the context of termination of pregnancy, the strength of feeling 
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about whether a decision was ‘good’ or not has been shown to reduce over time, suggesting that 
the emotional intensity of decision making diminishes with distance from the event.(89)  
Practically, there are two main methodologies used to assess decision making in healthcare 
research. The first, sited within the quantitative paradigm, uses utility assessments to provide 
numerical assessments of decisions and the worth that participants place on various effects. 
These methods include discrete choice experiments, threshold techniques or utility analyses 
(using visual analogue scales, willingness to pay or time trade off methods). (46,90) They aim to 
define the features of a decision, which, if changed in a certain way, might alter the choices made. 
Participants may be asked to assign a worth to a feature in terms of time or of money. These 
methods have been used in numerous studies to explore many important aspects of attitudes to 
reductions in therapy for febrile neutropenia and present them in a quantitative manner that fits 
with the current medical paradigm.(35,46,49) For example, Sung et al determined that 
requirements for significant outpatient attendance (more often than thrice weekly) or a 
readmission rate of greater than 7.5% would be a barrier to most families eligible for such care. 
(49)   
However, there are some limitations to this approach, particularly in the fact that it limits the 
participants to the options provided by the researchers and that it provides a relatively superficial 
account of the features involved in a decision. In particular, probability trade-off methods have 
not been proven to be an accurate method for assessing group decision making or in service 
development issues, whilst utility assessment is difficult in transient states such as febrile 
neutropenia where the worth given maybe less varied than for more chronic conditions. (67)  
Finally, utility assessment and trade-off methodologies can be quite cognitively demanding and 
require a level of development which may be challenging to comprehend for children and young 
people who have yet to acquire skills in abstract thinking. 
In the second main methodology for assessing decision making, qualitative techniques may 
complement these utility based assessments by helping to answer other difficult clinical questions 
about the decision making process. Thick qualitative material may provide details about the 
process of weighing up decisions and balancing the various risks and benefits involved in a 
decision. They can provide depth to quantitative methodologies by expanding on the rationale for 
certain choices in specific situations, allowing for a more comprehensive understanding of the 
social and cultural contextual influences on a decision. Qualitative methods may also allow the 
assessment of the negotiations between various members in decisions made by groups and may 
address the influence of additional social and cultural factors through these observations of 
decision making process.  
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Decision making in clinical trials  
Having identified and reviewed various theoretical aspects of medical decision making as well as 
considering how to assess the choices made, this section now explores two main aspects of 
decision making in clinical trials. As discussed briefly in Chapter 1, there are a number of reasons 
why participants may choose not to participate in clinical trials, this section aims to discuss these 
more broadly. This is important to the thesis  given that the rates of consent to studies of reduced 
therapy regimens for febrile neutropenia are explored in Chapter 3 as a proxy marker for 
attitudes to early discharge regimes. However, rates of consent  may be  partly due to factors 
which are specific to decision making in clinical trials, rather than a reflection of a particular 
treatment approach. Thus this section of this chapter will consider the issue of decision making in 
clinical trials separate to that used in other clinical decisions, and will highlight issues which are 
particularly relevant when considering consent to clinical trials. It adds to the thesis both by 
informing these explorations in Chapter 3, but also through providing discussions of aspects of 
consent relevant to the qualitative study in phase 3 and to the research implications discussed in 
Chapter 9. The first aspect of decision making I will explore in this section is the legal and ethical 
aspects of informed decision making in clinical trials, particularly those involving children, and the 
second is the factors involved when individuals choose to be part of a clinical trial. 
The main legal process involved in decision making for clinical trials is that of consent. The 
majority of clinical trials will require a written record signed by the participant confirming they are 
happy to participate in the study. Often this signature is referred to as ‘consent’. However, the 
term actually refers to making a decision to allow the researchers to perform the study on the 
participant. It is not a ‘one-off’ event, at which the participant puts pen to paper; instead it is a 
process, involving a two-way flow of information about the study, the requirements, the patient’s 
role and the effects on them, as well as their own thoughts and considerations about the 
research.  The importance of this as an ethical construct is outlined clearly by the General Medical 
Council and  in Good Clinical Practice principles, which are underpinned by the Declaration of 
Helsinki, the Nuremberg Code and other laws and directives.(26–29) 
The process of consent is somewhat different when considering children, and becomes 
particularly complex when dealing with adolescents and young adults. For very young children, 
who are unable to contribute to discussions, their parents, or legal guardians, are responsible for 
making decisions relating to their care. For medical decisions, the age of capacity is set at 16 
years.(88) Once you have turned sixteen, you are considered competent and able to make your 
own decisions in any medical or research setting, supported by your family and healthcare 
professionals.  
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For children who are able to voice an opinion about a decision but who are younger than sixteen, 
the guidance surrounding consent differs between clinical decision making and that involved in 
trial participation. In the clinical setting, if a patient is younger than sixteen, they may be 
considered able to consent if they show capacity, that is they can understand the treatments 
offered, including the risks and benefits, retain this information, weigh up their options and then 
communicate that decision.(88,95) This ‘Gillick competence’ is decision and situation specific. For 
example, a relatively young child may be able to decide whether they want anaesthetic cream or 
cryogesic spray to help with the pain of venepuncture, but is unlikely to be able to make a 
decision about chemotherapy options. It should be noted that decisions by Gillick competent 
young people to refuse treatment may be overruled by the consent of a parent. Furthermore, 
clinicians can struggle to apply the guidance regarding the assessment of Gillick, being influenced 
by their own opinions and by the complexity of this judgement: 
“In practice, judgements of competency go beyond semantics or straightforward 
applications of legal rules; such judgements reflect social considerations and societal 
biases as much as they reflect matters of law and medicine.”(95,96) 
In contrast to this, the rules regarding consent to participation in clinical trials are somewhat 
different. In general, parental consent would be considered to be required for the involvement of 
all young people under the age of sixteen, even if the child is competent to make their own 
decisions.(91) Furthermore, in the case of research, the young person’s refusal to assent to 
participate is given more weight, and is less likely to be overruled than within decisions about 
standard medical practice. 
Choosing to be part of a clinical trial can be a difficult decision for patients. They often have the 
choice of standard treatment, for which the risks and benefits have been more clearly defined and 
the healthcare professionals caring for them often have more experience with, or a new 
treatment, which may, or may not, have better benefits or fewer risks than the conventional 
option. The challenge of dealing with uncertainty, both in the effects of a new treatment and in 
the process of randomisation to treatment, compounds the dilemma, which is often posed at a 
time when patients are already trying to absorb news of a diagnosis or adjust to deterioration in 
their condition. 
Alongside this, research has found that patients and families can find consenting to trials of 
reduced therapy even more difficult than randomisation of intensification or substitution trials. 
Tulstrup et al found that parents of adolescents were more likely to consent to reductions in 
therapy compared with parents of younger children, and this may reflect the involvement of 
young people in these decisions.(97) This suggests that parents find it harder to consent to 
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reductions in therapy than adolescents do and is worthy of consideration within the later phases 
of this thesis. This is further supported by evidence that parents chose to take less risks for their 
children than competent adults or adolescents would chose for themselves.(49) 
Summary 
This chapter has highlighted some of the issues surrounding involving young people in choices 
within healthcare and research settings as well as the challenges of triadic consultations. Relevant 
concepts and theories, including the Health Belief Model and cognitive biases in decision making, 
have been explored. Some of the complexities of medical decision making and how this may be 
assessed have been discussed, particularly in relation to involving children and young people in 
healthcare decision making.  This background research further contextualises and provides the 
grounding for the thesis, particularly the qualitative synthesis of experiences of early discharge 
and the subsequent focus group discussion study. Many of the concepts outlined in this chapter 
will be referred to again, where relevant, in the following phases of the work. 
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Chapter 3: Systematic review and meta-analysis of reduced therapy 
regimens for children with low risk febrile neutropenia 
Introduction and rationale 
In this first empirical chapter of the thesis, I report the systematic review of reduced therapy 
regimens, including early discharge, outpatient care and oral antibiotics, for children with low risk 
febrile neutropenia. I aim to address the safety, efficacy and rates of treatment failure for each 
regimen, whilst considering the role of timing of treatment change upon each of these outcomes. 
This provides a robust and up-to-date synthesis of current quantitative evidence in the field, so as 
to inform key stakeholders about the different options for care, whilst also providing the data for 
discussion within the focus group study performed in Phase 3 of the thesis. This chapter also 
provides initial data about the issue of attitudes to reduced therapy regimens as consideration of 
the rates of consent to studies included within the systematic review provides a crude measure of 
perceptions of early discharge and oral antibiotics. This will be assessed further in phases two and 
three of the thesis, through the synthesis of current qualitative evidence and the performance of 
the focus group discussion study. 
As discussed in Chapter 1, reduced therapy regimens for managing children and young people 
with low risk febrile neutropenia may provide benefits to both patients (including increased 
quality of life and reductions in hospital acquired infections) and the health service (including cost 
savings and reduced pressure on hospital beds).(34,36–38) However, any reduction in therapy 
must be both safe and effective to justify a change from current practice. 
A previous systematic review conducted by Manji et al considered two aspects of the reduction of 
therapy.(98) It compared outpatient treatment with inpatient treatment, and oral antibiotics with 
intra-venous (IV) therapy. They included only low-risk patients as defined by individual study 
protocols, recognising that this is a heterogeneous group.  
The review found that treatment failure, defined as persistence, recurrence or worsening of 
fever/infecting organisms, new infections, any modification of antibiotics, readmission, or death 
during study drug treatment, was as likely to occur in inpatients compared with outpatients and 
that inpatients were more likely to have alterations made to their antibiotic regimens. Within the 
included studies, two low risk patients died – they had both been treated as inpatients. The 
authors found no increase in medical complications with oral therapy. In particular, there were no 
deaths, and no increase in readmission to hospital or in treatment failure, including the need to 
modify the antibiotic regime, for patients receiving oral therapy.  
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Although this review provided essential information about the broad concepts of outpatient and 
oral therapy for febrile neutropenia, it involved combining data from very different groups and 
thus lost some of the more nuanced information from the original trials. This is particularly 
important when considering timing of discharge as further information is required to know 
precisely when discharge should be advised. 
Meanwhile, a recent Cochrane review focused mainly on adults with febrile neutropenia and 
found that oral therapy was an acceptable alternative to intravenous antibiotics.(99) A subgroup 
analysis of paediatric studies found no difference in treatment failure rates within this population, 
although this included exclusively randomised controlled trials, of which there were only 8 
identified in children. Furthermore, it examined the impact of oral antibiotics alone, without 
consideration of the role of location of treatment.  
Finally, neither review included non-English studies despite the presence of very active research 
groups in this field based in South America. In addition to these limitations, I was aware that 
important further work had since emerged in this area. In particular, one trial had looked 
specifically at early step-down from intravenous antibiotics given as an inpatient to oral 
outpatient treatment within 22 hours of presentation with febrile neutropenia.(17) 
Given all of these issues and the high likelihood of identifying other new and relevant studies, I 
decided that a new systematic review should be performed. This review had more focused aims 
than previous reviews, particularly in defining the most appropriate time of discharge in these 
patients, and had a new and more thorough search strategy. It also included studies using 
observational methods, and aimed to provide further depth and clarity to the findings of prior 
works. 
Methodology 
Systematic review is an established methodology used to identify, evaluate and summarise the 
research evidence in a specific area. It involves a structured, pre-planned and considered 
approach to identify relevant research studies. In systematic reviews of effectiveness, as 
described in this phase of the thesis, attempts are made to identify as many relevant studies as 
possible, to critically assess them and combine their results in a way that is informative to the 
intended audience.(100) This method aims to reduce the biases inherent in a narrative review 
through consideration of all available research evidence relevant to the research question.(101) 
Where appropriate, meta-analysis of quantitative results provides a more precise estimate of an 
intervention’s effectiveness, given the power provided by increased events.(100,101) 
Furthermore, by exploring differences between subgroups of studies, further research questions 
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can be answered beyond the original studies’ objectives. For this systematic review, the use of 
meta-analysis provides estimates of the safety, efficacy and treatment failure rates of the various 
treatment regimens for febrile neutropenia. As these estimates are more specific, robust and 
precise than those previously available, they inform both the subsequent chapters of this thesis 
and future clinical decision making. 
Aims and objectives 
This systematic review aimed to provide an up-to-date and robust assessment of the role of the 
route of antibiotic administration and the location of treatment in the management of low-risk 
febrile neutropenia in children being treated for cancer. It aimed to define the overall success (or 
failure) of each treatment regime in resolving an episode of febrile neutropenia without 
complications. Furthermore, I aimed to explore both safety and efficacy for each potential regime.  
In particular, I investigated the timing of discharge (before 24 hours, 24-48 hours or after 48 
hours), including the role of entirely outpatient treatment.  
Finally, considering that there may be concern regarding reduction of therapy from patients, their 
parents and the healthcare professionals caring for them, this systematic review collected data on 
rates of declined consent, where this was reported, as a way of gaining insight to the potential 
acceptability of these approaches. The precise research questions for this review are outlined in 
Box 4.  
  
Methods 
A protocol for this review was developed, registered on PROSPERO (CRD 42014005817) and 
published, prior to commencing the work.(102) This chapter is presented in accordance with 
PRISMA guidelines.(103) 
Box 4 - Research Questions  
In children with low risk febrile neutropenia: 
1. Are oral antibiotics safe and efficacious with low rates of treatment failure? 
2. Is early discharge safe and efficacious with low rates of treatment failure? 
3. Is there a time where the safety, efficacy and rates of treatment failure change? 
4. How frequently do participants refuse to consent to trials of reduced therapy for febrile 
neutropenia? 
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Searches 
Electronic searches of MEDLINE, MEDLINE in-Process & Other non-Indexed Citations, EMBASE, 
Cochrane Database of Systematic Reviews (CDSR), Cochrane Central Register of Controlled Trials 
(CENTRAL via the Cochrane Library), Literature Latinoamericana y del Caribe en Ciencias de la 
Salud (LILACS), Health Technology Assessment Database (HTA) and Database of Abstracts of 
Reviews of Effects (DARE) were performed. The search strategy focused on febrile neutropenia 
and the interventions of antibiotics and early discharge, whilst using a paediatric filter. Published 
and unpublished studies were sought and no date or language filters were applied. The latter is 
important given I suspected that there would be a number of studies that had been performed in 
Spain, Portugal and South America as these areas have been active in research into paediatric 
supportive care. The full database search strategy is provided in Appendix 3.1.  
Conference proceedings of the RCPCH (Royal College of Paediatrics and Child Health), SIOP 
(International Society of Paediatric Oncology), ASPHO (American Society of Paediatric 
Haematology/Oncology), ASCO (American Society of Clinical Oncology) and ICAAC (Interscience 
Conference on Antimicrobial Agents and Chemotherapy) meetings were searched for relevant 
abstracts. Reference lists of included articles and relevant systematic reviews were also reviewed. 
Authors of relevant studies and prominent clinicians within the field were contacted seeking 
further studies.  
Study selection  
I screened the title and abstract of all studies for inclusion. A second reviewer (JC) independently 
screened a sample of 1000 of the titles and abstracts. The kappa statistic for agreement was 
calculated and showed good agreement between reviewers (k = 0.69, 95% confidence interval 
0.59-0.79). Full text was obtained for all potential articles of interest.  All full texts were assessed 
for eligibility by two reviewers (myself and JC). Disagreements were resolved by consensus, or 
referred to a third reviewer (RSP, 5 studies referred).  
Inclusion and Exclusion criteria 
Studies were included if they met the criteria shown in Box 5. 
Study design:  
I anticipated, given the previous reviews, that the number of RCTs in this area would be small. I 
believe there is clinical value in knowing the absolute numbers of patients experiencing failures in 
safety and adequacy. Therefore, I derived information from both prospective observational 
cohorts and the separate arms of RCTs to determine these estimates, and to provide observations 
on different treatment groups within a range of studies. Quasi-randomised trials would have been 
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eligible for inclusion provided the methods of allocation to treatment groups were clearly 
described.    
Retrospective studies were excluded, as were studies that enrolled participants ≥24 hours after 
initial empiric treatment. 
  
Population:  
Children or young adults (aged less than 18 years) who attended paediatric services with fever 
and neutropenia secondary to treatment for cancer and who were assessed to be at low risk of 
medical complications.  
Studies that enrolled only children and studies in which the majority (defined as > 80%) of 
patients were less than 18 years old, even if those patients are not reported separately were 
included. This reflects the fact that some paediatric studies may include a small number of young 
adults who have malignancies and physiology similar to the paediatric cohort being investigated 
and who are therefore treated within Teenage and Young Adult services by paediatricians. Such 
Box 5 - Inclusion criteria 
Study Design: Randomised Controlled Trials, Quasi-Randomised Controlled Trials and 
prospective observational cohorts 
Population: Aged <18 years with low-risk fever and neutropenia secondary to treatment for 
cancer, or results available for this subgroup 
Interventions: one or more of 
 Location of treatment – inpatient, outpatient, or initial inpatient with early discharge to 
outpatient 
 Route of antibiotic administration – intravenous, oral or intravenous with switch to oral 
(IVOST) 
Outcomes: one or more of 
 Treatment failure at 30 days- persistence, worsening or recurrence of fever/infecting 
organisms, modification of antibiotics, new infections, re-admission, admission to critical 
care services or death during treatment. 
 Safety - medical complications, defined as admission to critical care services or death. 
 Adequacy - resolution of the episode without change in antibiotic or location of the 
patient. 
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studies designed for the paediatric group that have recruited small numbers of young adults do 
not generally recruit from the older adult population, in which the causes and outcomes of febrile 
neutropenia are likely to be different. Studies of adults which report data for patients less than 18 
years old were included, if outcome data for children were reported separately. Studies which 
included > 20% of adult populations and those which included mixed age populations with no 
details on age distribution were excluded.  
There were no eligibility restrictions concerning the definitions of fever and neutropenia or the 
stratification rule used. Studies of multiple risk groups were included, if data for low risk patients 
(as defined by study protocols) could be extracted separately.  
Interventions and comparators: 
I was aware that studies had included a variety of treatment regimens, including inpatient IV 
therapy, outpatient IV therapy and oral outpatient therapy.(98) This created a challenge as there 
are two components to the comparison – the route of administration of the antibiotics (IV or oral) 
and the location of the patient’s treatment (outpatient or inpatient) – which could be correlated 
in individual studies. In particular, oral antibiotics and outpatient treatment are likely to be used 
together and I appreciated that it might be difficult to establish whether any differences in 
outcome are related to the route, the location of treatment, or both. The considerable 
intermeshing of these two issues within the literature justified the use of a single review to 
attempt to address the various options in reduction of therapy to these patients.  
To be included a study had to have investigated the location of treatment or route of 
administration of antibiotics. Prospective single arm studies had to examine these features of the 
regime as the primary aim of the study. Studies examining different antibiotics given by the same 
route and in the same location were excluded. 
For the purpose of this review, outpatient care was defined as discharge within 8 hours of 
presentation. Justification for using an eight-hour cut-off is a practical one. The time taken to 
review a patient, ensure they are eligible for outpatient treatment and then prescribe and obtain 
any medications to take home may be up to eight hours. Any period longer than this could 
reasonably be called admission to hospital.  The timing of discharge was grouped into outpatient 
(admission of less than 8 hours), <24 hours, 24-48hrs, >48 hours and entirely inpatient treatment. 
Early discharge is used to refer to all categories except entirely inpatient treatment, unless 
otherwise specified. 
Where patients received a single dose of IV antibiotics followed by a course of oral antibiotics, this 
was considered to be an entirely oral course. This was to allow for studies in which IV antibiotics 
are administered whilst awaiting the results of blood tests to confirm low risk status, but once the 
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patient was identified as low risk, they were started on oral antibiotics. The timing of switch to 
oral antibiotics was grouped into entirely oral (as described above), <24 hours, 24-48hrs, >48 
hours and entirely intravenous treatment. The phrase ‘any oral therapy regimen’ is used to refer 
to all categories except entirely intravenous treatment, unless otherwise specified. 
Outcomes:  
For the purpose of this review, the three primary outcomes were treatment failure, safety and 
adequacy. The definitions of these outcomes are given in Box 5. These outcomes were used 
because they are likely to provide the information that patients and clinicians combine when 
making decisions about choice of care, thus they are the most clinically relevant outcomes for 
those involved in planning and delivering paediatric haematology and oncology services. 
Multinational guidelines have recommended that the primary outcome of studies into febrile 
neutropenia should be a composite measure, hence the use of treatment failure (persistence, 
worsening or recurrence of fever/infecting organisms, antibiotic modification, new infections, re-
admission, admission to critical care or death) as an outcome.(104) Meanwhile, knowledge about 
the safety of a strategy is essential to be able to consider its use at all, whilst information about 
adequacy would allow services to plan appropriately for potential re-admissions or changes in 
treatment associated with changing to a new low risk strategy. 
To be included a study had to have recorded and provided data for one or more of the primary 
outcomes.  
Data extraction and Quality assessment 
Data were extracted by myself and independently checked by a second researcher (JC). This 
included information related to the aims, design, inclusion and exclusion criteria, and definitions 
used by the study, as well as the participants, interventions and all outcomes described by the 
study and included in the pre-defined outcomes of the systematic review (Appendix 3.2). This was 
performed using Microsoft Word forms and then exported into Excel before being converted into 
CSV files for use in the R environment. Risk of bias was assessed using the Cochrane risk of bias 
tool for controlled trials and the NICE prognostic studies tool for observational cohorts.(101,105) 
Analysis 
The study characteristics and quality assessments were described narratively and represented in 
tabular form. For each outcome, study level data were combined with a random-effects model 
using the DerSimonian & Laird estimator using metafor within the R programming 
environment.(106) Comparative analyses of randomised controlled trials were performed and 
expressed in odds ratios. Safety and adequacy outcomes were explored using data derived from 
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single arm studies and from the individual arms of comparative studies. Weighted averages are 
presented for each outcome.  
Subgroup analyses related to timing of discharge, risk stratification tool used and timing of risk 
assessment were planned to assess the role of these features in relation to the safety, efficacy 
and failure rates of the various treatment regimens. Sensitivity analyses were used to explore 
potential areas of heterogeneity. For the purpose of sensitivity analyses, as the studies used a 
variety of methods of risk stratification, the risk tools were grouped into more or less stringent 
tools. The more stringent tools generally required a period of observation after presentation, and 
excluded very young patients, patients following bone marrow transplant (BMT) or with 
leukaemia (except ALL on maintenance), those with a neutrophil count <0.1x109/L and patients 
with respiratory symptoms. Less stringent rules all had only two or three exclusion criteria that 
were not restrictive. For example, a less stringent rule might exclude patients with signs of sepsis 
and those with social concerns such as no reliable caregiver, but allow the inclusion of all other 
patients, regardless of age, underlying diagnosis and neutrophil count.   
Heterogeneity was examined using χ2 tests, the I2 and tau2 statistics and by visual inspection of 
forest plots. I2 represents a quantitative assessment of the degree of statistical heterogeneity 
beyond that expected by chance. Meanwhile tau2 provides an estimate of the between-study 
variance. The risk of publication bias was explored using contour-enhanced funnel plots and 
Harbord and Peters tests.  
Results  
A flow diagram for study selection is provided in  Figure 4. 2370 titles and abstracts were assessed 
and 112 full text articles retrieved. 80 full text articles were excluded as they failed to meet the 
inclusion criteria. (Appendix 3.3.) Five conference abstracts were identified through searching 
proceedings and a further study through reference searching of included articles.  
Of the 37 included studies, 12 are RCTs, including a total of 1291 episodes of febrile 
neutropenia.(17,107–118) 
 One further RCT was identified, but was not included in the RCT analyses as it compared early 
discharge on oral antibiotics with early discharge on an oral placebo. However, the individual 
arms of this trial have been included in the analyses of the observational cohorts. No quasi-
randomised trials were identified by the searches. The demographics of included studies are given 
in Table 2 and the study interventions and definitions are outlined in Table 3. 
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Figure 4 - Flow diagram for study selection 
2370 references identified by 
database searches (after 
removal of duplicates) 
80 Excluded after review of Full text 
 21 Not studies 
 29 Adult studies/mixed 
populations 
 3 Not low risk 
 12 Retrospective 
 7 Not intervention of interest 
 1 Not outcome of interest 
 2 Duplicate publication 
 5 Full text not available  
37 Included in review 
112 Full text articles retrieved  
2258 Excluded after review of Title 
and Abstract 
5 Identified from review of conference 
proceedings and reference searches 
 
 
 
 
  
Table 2 - Demographics of included studies 
Study Design Language Country Number of 
episodes 
(patients) 
Age 
Mean ± SD (years) 
Gender 
(M:F) 
Diseases Bacter-
aemias 
Notes 
Randomised Controlled Trials 
Brack et al, 
2012(17) 
RCT English Switzerland 61 (52) Experimental group 
4 <4yo, 9 age 4-7.99 
yrs, 8 age 8-11.99yrs, 
6 ≥12yo; Standard 
group 9 <4yo, 10 age 
4-7.99 yrs, 6 age 8-
11.99yrs, 9 ≥12yo  
26:35 31 leukaemia, 7 brain 
tumours, 23 solid tumours 
5  
Cagol et al, 
2009(107) 
RCT Portuguese Brazil  91 (58)  
7.74±4.55 
57:34 7 leukaemia, 1 lymphoma, 50 
solid tumours 
8  
Gupta et al, 
2009(108) 
RCT English India 119 (82) not given (1.4-19.0)* 67:21 41 leukaemia, 82 non-
leukaemia 
5 Diseases include 
4 episodes 
excluded from 
analysis 
Mullen et al, 
1999(110) 
RCT English USA 73 (41) 9.7±4.3 Not given 22 leukaemia, 51 non-
leukaemia 
4  
  
Table 2 - Demographics of included studies 
Orme et al, 
2014(111) 
RCT English Australia 37 (27) 6.38 +/-3.87  17:20 22 ALL, 15 solid tumours 3  
Paganini et 
al, 2000 
(114) 
RCT English Argentina 154 (128) 5.13 (0.67-16.67)† 68:86  
80 leukaemia, 8 lymphoma, 66 
solid tumours 
0  
Paganini et 
al, 2001 
(113) 
RCT English Argentina 93 (87) Not given (0.92-
15.83)* 
50:43 38 leukaemia, 4 lymphoma, 51 
solid tumours 
1  
Paganini et 
al, 2003 
(112) 
RCT English Argentina 177 (135) 7.5 (1.6-15.8)* Not given 104 leukaemia, 8 lymphoma, 
65 solid tumours 
Unclear  
Petrilli et al, 
2000 (115) 
RCT English Brazil 116 (70)  9.8(3-20)† 45:25 6 lymphoma, 132 solid 
tumours 
1 Diseases include 
22 episodes 
excluded from 
analysis  
Santolaya et 
al, 
2004(116) 
RCT English Chile 149 (107) 5.02±0.66 69:80 67 leukaemia/lymphoma, 82 
solid tumour 
3  
Shenep et al, 
2001(117) 
RCT English USA 200 (156) Not given (1.3-19.0)* 94:106 124 leukaemia, 76 solid 
tumours 
NR  
  
Table 2 - Demographics of included studies 
Varan et al, 
2005(118) 
RCT English Turkey 21(18) 9(3.5-17)* Not given lymphoma and solid tumours 
only 
Not 
given 
Conference 
Abstract 
Prospective Observational Cohorts 
Abbas et al, 
2003 (119) 
POC English Saudi Arabia 68 (64) 4.7±3.2 33:35  All ALL 12  
Aquino et al, 
2000(120) 
POC English USA 45 (32) 6.5 (2-20)† 24:21 31 leukaemia/lymphoma, 14 
solid tumours 
2  
Bash et al, 
1994  
Group A(18) 
POC English USA 70 (NA) Not given Not given 52 haematological 
malignancy, 22 solid tumours  
NR Diseases include 
patients later 
excluded from 
analysis 
Bash et al, 
1994  
Group B(18) 
POC English USA 8 (NA) Not given Not given 52 haematological 
malignancy, 22 solid tumours 
NR Diseases include 
patients later 
excluded from 
analysis 
Dommett et 
al, 2009 
Group A(121) 
POC English UK 143 (NA) 5.58 (0.08-17.5)* Not given  
Not given 
NR age at first 
recorded FN 
admission 
 
 
  
Table 2 - Demographics of included studies 
Dommett et 
al, 2009 
Group B(121) 
POC English UK 18 (NA) 5.58 (0.08-17.5)* Not given Not given NR age at first 
recorded FN 
admission 
Doyle et al, 
1996(122) 
POC English Canada 79(NA) Not given Not given Not given NR Conference 
Abstract 
Fernandez et 
al, 2012(123) 
POC English Spain 5(5) 9.58 (not given)* Not given Not given Not 
given 
Conference 
Abstract 
Kaplinsky et 
al, 1994(124) 
POC English Israel 50 (NA) Not given Not given 16 leukaemia, 9 lymphoma, 20 
solid tumours 
2  
Karthaus et al, 
2000(125) 
POC English Germany 75 (NA) Not given (0.5-15)* 45:29 (1 no 
data) 
39 leukaemia, 3 lymphoma, 33 
solid tumours 
19  
Klaassen et al, 
2000 
Group A (109) 
RCT English Canada 37 (NA) 4.9 (not given)* 16:21 24 leukaemia, 2 lymphoma, 11 
solid tumours  
NR (antibiotic arm) 
Klaassen et al, 
2000  
Group B (109) 
RCT English Canada 36 (NA) 4.3 (not given)* 14:22 24 leukaemia, 3 lymphoma, 9 
solid tumours 
NR (placebo arm) 
Lau et al, 
1994(126) 
POC English Canada 23 (21) 6.81 ± 5.17  Not given 8 leukaemia, 3 lymphoma, 12 
solid tumours 
NR  
 
  
Table 2 - Demographics of included studies 
Malik, 
1997(127) 
POC English Pakistan 91 (75) 9.2±4.3 49:42 19 leukaemia, 25 NHL, 47 
other solid tumours 
0  
Miedema et 
al, 2012(128) 
POC English The 
Netherlands 
47 (NA) Not given Not given Not given 3 Conference 
Abstract 
Mustafa et al, 
1996 (37) 
POC English USA 19 (19) 7.5 (2-15)† 12:7 13 leukaemia/lymphoma, 6 
solid tumour 
0  
Paganini et al, 
2001(129) 
POC Spanish Argentina 247 (215) 5.33 (0.67-16.67)* 118:129 118 leukaemia, 12 lymphoma, 
117 solid tumours 
Not 
given 
 
Paganini, 
2000(130) 
POC Spanish Argentina 101 (91) 5.42 (0.75-18.33)* 60:41  53 leukaemia, 6 lymphoma 42 
solid tumours 
Not 
given 
 
Paganini, 
2003(131) 
POC Spanish Argentina 127 (90) 6.2 (0.58-17.92)* 64:26 62 leukaemia, 8 lymphoma, 57 
solid tumours 
Not 
given 
 
Park et al, 
2003(132) 
POC English USA 30 (26) 8.2 ±3.5  17:13 19 leukaemia, 4 lymphoma, 3 
solid tumours 
NR  
Petrilli et al, 
2007(133) 
POC English Brazil 201 (108) 10.8 (3-21)† 70:38 12 leukaemia, 12 lymphoma, 
84 solid tumours 
4  
Phillips et al, 
2006(134) 
POC English UK 281(NA) Not given Not given Not given NR Conference 
Abstract 
Preis et al, 
1993(135) 
POC English Germany 64 (42) 9 (1-22)* 21:21 29 systemic disease, 13 solid 
tumours 
0  
  
Table 2 - Demographics of included studies 
Quezada et al, 
2007(136) 
POC English USA 59 (NA) 9.4 (2-21)† Not given 80 non-haematological 
malignancies. 25 hematologic 
malignancies. 
4 Demographics 
include patients 
later excluded 
from protocol 
Sari et al, 
2007(137) 
POC English Turkey 44(19) Not given Not given All solid tumours 1 Conference 
Abstract 
Shrestha et al, 
2009(138) 
POC English Nepal 54 (54) 7.2 (2-14)† 22:32 40 haematological, 14 solid 
tumours 
Not 
given 
 
Tordecilla et 
al, 1998 (139) 
POC Spanish Chile NA (77) Not given Not given Not given NR  
Wiernikowski 
et al, 1991 
(140) 
POC English Canada 22 (13) Not given Not given Not given 10  
Key: *median (range), †mean (range), ‡ - Italicised data has been calculated by combining data from two arms. NR - bacteraemia was exclusion criteria for study 
therefore not relevant, 
 
  
Table 3 - Study interventions and definitions 
Study Location(s) Timing of 
discharge 
Route(s) Timing of 
antibiotic 
change 
Antibiotics Risk Tool Fever 
definition 
Neutropenia 
definition 
Randomised Controlled Trials 
Brack et al, 2012 (17) Early discharge 
Inpatient 
9-24 hours 
NA 
Oral 
IV 
NA 
NA 
ciprofloxacin + amoxicillin 
not given 
More 
stringent 
Compound <0.5 x109/L 
Cagol et al, 2009 (107) Inpatient 
 
Inpatient 
NA 
 
NA 
Oral 
 
IV 
NA 
 
NA 
ciprofloxacin,  co-amoxiclav +oral/IV 
placebos 
cefipime + oral placebo 
Less 
stringent 
Low-grade 
Compound 
<1.0 x109/L 
Gupta et al, 2009 (108) Outpatient 
Outpatient 
NA 
NA 
Oral 
IV 
NA 
NA 
ofloxacin-clavulanate 
ceftriaxone 
More 
stringent 
Compound <0.5 x109/L 
Mullen et al, 1999 (110) Early discharge 
Early discharge 
3-16hours 
3-16 hours 
IV 
Oral 
NA 
NA 
ceftazidime 
ceftriaxone 
More 
stringent 
Compound <0.5 x109/L 
or falling 
Orme et al, 2014 (111) Inpatient 
Outpatient 
NA 
4 hours 
IV 
IV 
NA 
NA 
cefipime 
cefipime 
Less 
stringent 
Compound <0.5 x109/L 
Paganini et al, 2003 (112) Outpatient 
 
Outpatient 
NA 
 
NA 
IVOST 
 
IV 
24 hours 
 
NA 
ceftriaxone + amikacin, then 
ciprofloxacin 
ceftriaxone + amikacin 
More 
stringent 
Compound <0.5 x109/L 
or falling 
 
  
Table 4 - Study interventions and definitions 
Paganini et al, 2001 (113) Early discharge 
 
Early discharge 
72 hours 
 
72 hours 
IVOST 
 
IVOST 
24 hours 
 
72 hours 
ceftriaxone+ amikacin, then 
ciprofloxacin 
ceftriaxone + amikacin, then cefixime 
More 
stringent 
Compound <0.5 x109/L 
or falling 
Paganini et al, 2000 (114) Early discharge 
Early discharge 
72 hours 
72 hours 
IVOST 
IV 
72 hours 
NA 
ceftriaxone + amikacin, then cefixime  
ceftriaxone + amikacin 
More 
stringent 
Compound <0.5 x109/L 
or falling 
Petrilli et al, 2000 (115) Outpatient 
Outpatient 
NA 
NA 
IV 
Oral 
NA 
NA 
ceftriaxone 
ciprofloxacin 
More 
stringent 
Low-grade 
Compound 
<0.5 x109/L 
or falling 
Santolaya et al, 2004 
(116) 
Outpatient 
 
Inpatient 
NA 
 
NA 
 
IVOST 
 
IVOST 
72 hours 
 
72 hours 
 
ceftriaxone + teicoplanin, then 
cefuroxime 
ceftriaxone +teicoplanin, then 
cefuroxime 
More 
stringent 
Compound <0.5 x109/L 
Shenep et al, 2001 (117) Inpatient 
 
Inpatient 
NA 
 
NA 
 
IVOST 
 
IV 
48 hours 
 
NA 
 
vancomycin + tobramycin/ticarcillin or 
ceftazidime, then cefixime 
vancomycin + tobramycin/ticarcillin or 
ceftazidime 
More 
stringent 
Compound <0.5 x109/L 
Varan et al, 2005 (118) Early discharge 
Early discharge 
48 hours 
48 hours 
 
IVOST 
IVOST 
48 hours 
48 hours 
 
cefepime then cefixime 
cefepime then ciprofloxacin + co-
amoxiclav 
Not given Not given Not given 
 
  
Table 5 - Study interventions and definitions 
Prospective Observational cohorts 
Abbas et al, 2003 (119) Outpatient NA IV NA ceftriaxone +amikacin Less 
stringent 
Compound <0.25-1.0 
x109/L 
Aquino et al, 2000 (120) Outpatient NA Oral NA ciprofloxacin More 
stringent 
Compound <0.5 x109/L 
Bash et al, 1994 
Group A (18) 
Early discharge 48 hours IV then 
stop 
48 hours ceftazidime, then oral abx if indicated  More 
stringent 
Compound <0.5 x109/L 
Bash et al, 1994  
Group B (18) 
Early discharge 48 hours IV then 
stop 
48 hours ceftazidime, then oral abx if indicated  More 
stringent 
Compound <0.5 x109/L 
Dommett et al, 2009 
Group A (121) 
Early discharge 48 hours IVOST 48 hours piperacillin/tazobactam + gentamycin, 
then co-amoxiclav 
More 
stringent 
Compound <1.0 x109/L 
Dommett et al, 2009 
Group B (121) 
Early discharge 48 hours IVOST 48 hours piperacillin/tazobactam + gentamycin, 
then co-amoxiclav 
More 
stringent 
Compound <1.0 x109/L 
Doyle et al, 1996 (122) Early discharge 24 hours IVOST 24 hours IV regime not given, then cefixime and 
flucloxacillin 
More 
stringent 
>38°C Not given 
Fernandez et al, 2012 
(123) 
Early discharge 48 hours IVOST 48 hours Not given More 
stringent 
Not given Not given 
Kaplinsky et al, 1994 
(124) 
Outpatient NA IV NA ceftriaxone Less 
stringent 
Compound <0.5 x109/L 
  
Table 6 - Study interventions and definitions 
Karthaus et al, 2000 (125) Outpatient NA IV NA ceftriaxone Less 
stringent 
≥38.5°C <0.5 x109/L 
or falling 
Klaassen et al, 2000 
Group A (109) 
Early discharge 48 hours IVOST 48 hours piperacillin + gentamycin then 
cloxacillin + cefixime 
More 
stringent 
Compound <0.5 x109/L 
Klaassen et al, 2000  
Group B (109) 
Early discharge 48 hours IV then 
stop 
48 hours piperacillin + gentamycin, then placebo More 
stringent 
Compound <0.5 x109/L 
Lau et al, 1994 (126) 12 inpatient, 11 
outpatient 
72 hours IVOST 72 hours ticarcillin + gentamycin, then cefixime + 
cloxacillin 
Not given ? Not given 
Malik, 1997 (127) Outpatient  NA Oral NA ofloxacin Less 
stringent 
Compound <0.5 x109/L 
or falling 
Miedema et al, 2012 
(128) 
Early discharge 12 hours Nil NA NA Less 
stringent 
? Not given 
Mustafa et al, 1996 (37) Outpatient NA IV NA ceftriaxone Less 
stringent 
? <0.5 x109/L 
Paganini et al, 2001 (129) Early discharge  72 hours IVOST 72 hours ceftriaxone + amikacin, then cefixime More 
stringent 
>38°C <0.5 x109/L 
Paganini, 2000 (130) Outpatient NA IVOST 24 hours ceftriaxone then ciprofloxacin More 
stringent 
>38°C <0.5 x109/L 
 
  
Table 7 - Study interventions and definitions 
Paganini, 2003 (131) Early discharge 24 hours IVOST 24 hours ceftriaxone + amikacin, then cefixime or 
ciprofloxacin 
More 
stringent 
>38°C <0.5 x109/L 
Park et al, 2003 (132) Early discharge 48 hours IVOST 48 hours ceftazidime then ciprofloxacin 
+amoxicillin 
More 
stringent 
Compound <0.2 x109/L 
Petrilli et al, 2007 (133) Outpatient NA Oral NA gatifloxacin More 
stringent 
Low-grade 
Compound 
<0.5 x109/L 
or falling 
Phillips et al, 2006 (134) Early discharge 48 hours IVOST 48 hours piperacillin/tazobactam + tobramycin, 
then ciprofloxacin 
Not given Compound <1.0 x109/L 
Preis et al, 1993 (135) Outpatient NA IV NA ceftriaxone More 
stringent 
>38.5°C <1.0 x109/L 
Quezada et al, 2007 (136) Early discharge  24 hours IVOST 24 hours cefepime then ciprofloxacin + 
azithromycin 
More 
stringent 
Compound <0.5 x109/L 
or falling 
Sari et al, 2007 (137) Mostly inpatient NA IVOST 48 hours cefepime or cefaperazone/sulbactam 
then co-amoxiclav + ciprofloxacin 
Not given Not given Not given 
Shrestha et al, 2009 (138) Inpatient NA Oral  NA ofloxacin/amoxy-clav More 
stringent 
Compound <0.25-1.0 
x109/L 
Tordecilla et al, 1998 
(139) 
Early discharge 96 hours IVOST 96 hours cloxacillin, amikacin, cefoperazone More 
stringent 
Compound <0.5 x109/L 
 
  
Table 8 - Study interventions and definitions 
Wiernikowski et al, 1991 
(140) 
Early discharge 48 hours IV NA multiple More 
stringent 
? Not given 
Key: IV- Intravenous, IVOST – Intravenous to Oral Switch of Therapy, NA – not applicable, ? - definition unclear or not given,  
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Twenty-four observational cohorts are included, describing 26 separate treatment cohorts, including 
a total of 1914 episodes of febrile neutropenia. (37,119–141) Two of these cohorts have been split 
into two arms, as in each case the patients they describe form two distinct risk or treatment groups.  
In total, this review describes 3205 episodes of paediatric low risk febrile neutropenia. 
Six of the included studies (one randomised controlled trial, five prospective single arm studies) 
were identified as conference abstracts only. 
Within the RCTs, three directly compared different locations of treatment and eight examined the 
route of administration of antibiotics. Twenty three observational cohorts examined outpatient 
treatment or early discharge and 18 explored oral antibiotics or IVOST regimes. 
Multiple different risk stratification tools were used by the included studies; the majority of which 
were unnamed and un-validated. The tools were grouped as described within the Methods section. 
Twenty-five studies used more stringent tools and eight used less stringent tools. Four studies did 
not describe their risk stratification tool in enough detail to allow classification of the tool. 
Risk of bias 
All but one of the RCTs showed a moderate risk of bias as participants and outcome assessors were 
not blinded to the intervention received. It is worth noting that it is not possible to blind participants 
to the location of their treatment. Furthermore, some of the outcomes included in this review are 
unlikely to be affected by this lack of blinding, including admission to critical care services or death. 
Other outcomes, particularly treatment failure, have been specifically selected to examine pragmatic 
issues, which are as closely related to standard clinical practices as possible, and hence the 
outcomes of unblinded studies are informative in these situations. Other than the issue of blinding, 
the RCTs were generally at low risk of bias, as were the prospective observational cohorts (see 
Appendix 3.4). 
Adequacy 
No studies explored the concept of adequacy outwith the definition of treatment failure. The timing 
of the final aspect of risk stratification universally matched the timing of discharge and hence 
planned subgroup analyses of the timing of risk stratification were not performed. 
Safety 
There were two deaths within the data from the RCTs (12 studies, 1291 episodes).(14–26) One child 
died of an adenovirus infection on day 10 of treatment. The second died of a Pseudomonas 
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aeruginosa infection after an acute deterioration on day 3 (notably, this child was well until day 3 
and had negative blood cultures on admission).  Both patients were treated entirely with 
intravenous inpatient therapy. A further two safety events were identified in the observational 
cohorts (total 2663 episodes, 42 arms). (3,14–33,35–37,39–44,46–50) These two patients were 
admitted to intensive care; one with pneumonia and one with diarrhoea causing hypotension. 
Neither patient died. Both had been treated with oral therapy as outpatients from presentation. 
Therefore, the proportion of low risk episodes which resulted in intensive care or death was 0.1% 
(95% confidence interval (95%CI) 0.03-0.3%). 
Treatment failure 
Three RCTs (including 247 episodes of febrile neutropenia) compared the risk of treatment failure 
between inpatient and outpatient treatment, including discharge up to 48 hours after admission. 
(17,111,116) The odds ratio for failure with outpatient treatment was 0.98 (95% CI 0.44-2.19, I2=0%, 
tau2=0, Figure 5), providing no clear evidence of a difference in failure rates between these 
treatment settings. There were insufficient trials for subgroup analyses.  
 
Figure 5 - Forest plot of odds ratios for treatment failure in studies comparing inpatient versus 
outpatient treatment for paediatric low risk febrile neutropenia 
Eight RCTs (including 930 episodes of febrile neutropenia) compared the risk of treatment failure 
between intravenous and oral therapies, including change to oral medications up to 48 hours after 
presentation. (14–16,18,20,22,23,25) The odds ratio for failure with oral treatment was 1.05 (95% CI 
0.74-1.48 I2=0%, tau2=0, Figure 6), which also provides no clear evidence of difference between the 
two approaches. Again, there were insufficient trials for subgroup analyses. 
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Figure 6 - Forest plot of odds ratios for treatment failure in studies comparing intravenous versus 
oral antibiotics for paediatric low risk febrile neutropenia 
The RCT data for reduced therapy options suggests that the odds of treatment failure are similar for 
both reduced therapy and conventional regimes. However, the confidence intervals are wide, 
suggesting uncertainty about this issue. I therefore went on to explore the rates of treatment failure 
for data derived from the observational cohorts combined with the individual arms of the RCTs.  
Within these data, 42 prospective arms (including 2619 episodes of febrile neutropenia) in which 
patients were treated on any outpatient or early discharge regimen were included. (3,14,16–24,26–
37,39–43,46,49,50) 
The estimated rate of failure using these approaches was 11.2% (95% CI 9.7-12.8%, I2 = 77 %) and 
included patients treated on any outpatient or early discharge regimen. Given the significant clinical 
and statistical heterogeneity in this group, this combined estimate suggests there are features of an 
early discharge strategy which will alter the risk of treatment failure. I therefore proceeded to 
analyse these as subgroups split by timing of discharge. Upon further investigation of the timing of 
discharge, for studies of patients treated entirely as outpatients, the treatment failure rate was 14% 
(95% CI 9.7% -19%, I2 = 82%, 
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Figure 7a). The rate of treatment failure for studies including patients receiving early discharge after 
48 hours was 2.2% (95% CI 1.2-4.1%, I2 = 0%, 
 97 
 
 
Figure 7b).  
34 cohorts (from observational cohort studies and the individual arms of the RCTs, including 2251 
episodes of febrile neutropenia) were included in the assessment of treatment failures following any 
oral therapy regimen. (14–26,28–32,35,36,39–43,46–49) The estimated rate of failure using this 
approach was 10.5% (95% CI 8.9-12.3%, I2 = 78%). Due to high heterogeneity in this composite 
analysis, we again proceeded to subgroup analysis based on timing of change to oral antibiotics. The 
rate of failure for those receiving oral antibiotics after 48 hours of intravenous administration was 
3.4% (95% CI 2-5.7%, I2 = 11%) and for patients treated entirely with oral antibiotics the rates of 
treatment failure were 17% (95% CI 12-25%, I2 = 75%). 
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Figure 7 - Forest plots of rates of treatment failure in a) patients treated entirely as outpatients 
and b) patients discharged early after at least 48 hours of inpatient care 
Re-admission 
The examination of readmission data within the RCTs comparing location is not possible, given that 
one arm of each trial were kept as inpatients and therefore were unable to be readmitted. For the 
RCTs related to route of administration of antibiotics, two studies treated all patients as inpatients 
and therefore do not provide readmission data. One study treated one arm as inpatients and one as 
 97 
 
outpatients and therefore was also not included in the readmission data. This left 5 studies 
(including 578 episodes of febrile neutropenia) comparing the effect of route of antibiotic 
administration on the rates of readmission. The odds ratio for readmission with oral treatment was 
1.65 (95% 0.76-3.58, I2= 0%, tau2=0, Figure 8), which also provides evidence of no clear difference 
between the two approaches. There were insufficient trials for subgroup analyses.  
 
Figure 8 - Forest plot of odds ratios for readmission in studies comparing intravenous versus oral 
antibiotics for paediatric low risk febrile neutropenia 
43 observational cohorts were included in the assessment of re-admissions following outpatient 
treatment or early discharge. The estimate of risk of re-admission in studies using this approach was 
8.8% (confidence interval 7.4-10.3%, I2 = 85%). The rate of re-admission for trials of patients treated 
entirely as outpatients it was 8.6% (confidence interval 5.4% -14%, I2 = 85%,  
Figure 9a) and for those of patients receiving early discharge after 48 hours was 2% (confidence 
interval 1-3.8%, I2 = 0%,  
Figure 9b).  
30 observational cohorts were included in the assessment of re-admissions following oral therapy 
regimens. The estimate of risk of re-admission in studies using this approach was 7.4% (95% CI 6.2-
8.8%, I2 = 80%). For studies of patients treated entirely with oral antibiotics the rate of re-admission 
was 10% (95% CI  7% -14%, I2 = 26%).The rate of re-admission for studies of patients receiving oral 
antibiotics after 48 hours of intravenous administration was 2.8% (95% CI 1.5-4.9%, I2 = 0%).  
Sensitivity analyses 
The rates of the outcome measures were unaffected by the use of full text articles alone, fixed effect 
meta-analysis or location of the study. Given the similarities in risk of bias between studies, it was 
not possible to assess whether the quality of study affected rates of the outcome measures. There is 
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Figure 9 - Forest plots of rates of readmission in a) patients treated entirely as outpatients and b) 
patients discharged early after at least 48 hours of inpatient care 
a suggestion that using a more stringent risk stratification tool reduces the rates of treatment 
failure, as might be expected given the features used in risk tools. When considering location of 
treatment, studies using the most stringent risk tools report failure rates of 7% (95% CI 4.7-10.3%, I2 
= 82%) compared with failure rates of 19.1% (95% CI 11.7-29.6%, I2 = 77%) in studies with the least 
stringent risk tools. Similarly, regarding the route of administration of antibiotics, studies using the 
most stringent risk tools reported failure rates of 7.8% (95% CI 5.2-11.6%, I2 = 85%). There were only 
two studies exploring the route of administration of antibiotics and using less stringent tool. These 
found a failure rate between 8.8% and 51%.  
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Publication bias 
As the meta-analyses that provided the estimates of rates of treatment failure included the largest 
numbers of studies, I assessed publication bias primarily using these studies. When examining the 
studies which reported patients receiving early discharge or outpatient care, Peters test did not 
reveal evidence of heterogeneity (p=0.21) whilst Harbord’s test suggested that publication bias 
might be present (p<0.001). Examination of the contour enhanced funnel plot (Figure 9a) reveals 
that there is a wide spread of proportion of failures in studies with small standard error, but that in 
studies with a larger standard error, few evidenced high levels of treatment failure. This pattern 
does not differ between RCTs and observational cohorts. In the arms relating to oral antibiotic 
regimens, both Harbord and Peters tests suggest publication bias (p= 0.06 and 0.004 respectively), 
whilst the funnel plot (Figure 10b) presents a similar picture to that of location. 
a)  b)  
Figure 10 Contour-enhanced funnel plots3 for treatment failure in a) early discharge or entirely 
outpatient treatment and b) any oral antibiotic regimens. Solid dots represent data from RCTs, 
open dots represent data from prospective observational cohorts 
Refusal to consent 
10 studies provided data on refusals to participate (see Table 
4).(17,110,111,116,117,122,126,132,136,140)  The data provided were very heterogeneous and thus 
                                                             
3 Contour-enhanced funnel plots provide a visual means for assessing the risk of small study bias.(100,101) This 
scatter graph of the standard error, a close proxy for the size of the study, against the outcome of interest, 
allows the examination of any areas where studies would be expected to exist but are not present within the 
identified literature. The underlying premise is that by chance 95% of relevant studies, if all published, should 
lie within contours plotted on the graph and studies with a smaller standard error will generally lie closer to 
the estimate effect than those with a larger standard error. If particular sections of the scatter graph do not 
include any studies, it may be suspected that studies which have found results in this area have not been 
published, either through researcher choice or due to bias within the publication system. These are generally 
smaller studies and so researchers should also consider whether the scatter seen is actually due to differences 
in effect between smaller and larger studies in the area of interest. 
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not amenable to meta-analysis. However the data can be conceptually grouped into the issues of 
refusal to enrol in a study and refusal to confirm consent following enrolment (in study designs when 
enrolment takes place prior to episodes of febrile neutropenia with further consent sought at the 
time of presentation with an episode). 
Study Concept 
described 
Number of 
instances 
where 
parents 
refused 
consent  
Number of 
instances 
where 
physicians 
refused 
consent 
Total 
number 
of 
eligible 
patients  
Notes 
Brack et al, 2012 (17) Enrolment 25 NA 93  
Doyle et al, 1996 (122) Enrolment 5 NA 84  
Lau et al, 1994 (126) Enrolment 5 NA 29  
Mullen et al, 1999 
(110) 
Enrolment 12 13 66  
Park et al, 2003 (132) Enrolment 9 NA 39 Includes 
inability to take 
oral antibiotics 
Quezada et al, 2007 
(136) 
Enrolment 3 9 34 First year of 
study only 
Santolaya et al, 2004 
(116) 
Enrolment 2 NA 151  
Shenep et al, 2001 
(117) 
Enrolment 86 NA 286  
Orme et al, 2014 (111) Confirmation 
following 
enrolment 
6 7 50  
Quezada et al, 2007 
(136) 
Confirmation 
following 
enrolment 
8 Included with 
parental 
refusal 
67  
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Table 9 - Refusal to consent data 
Eight studies looked at failure to consent to enrolment in the study. They found that 147 of 760 
patients (19.3%, range 1.3-30.1%) who were eligible for enrolment refused to participate. Two of 
these studies also included data on episodes that were not enrolled as the physician was 
uninterested or not willing for the patient to take part. These found that in 19.6-26.5% of otherwise 
eligible episodes the treating physician chose not to enrol the patient in the study.  
Three studies provided data on confirmation of consent following enrolment. One looked at 
physicians’ attitudes and found that in 7 (14%) of 50 otherwise eligible episodes, the oncologist 
decided not to include the patient in the study. Two studies examined parental confirmation and 
found refusal of 8.3-12% of eligible episodes. Finally, one study did not separate parental and 
physician refusal to confirm consent, but found that 8 (12%) of 67 episodes in enrolled patients were 
not included due to the preference of the physician or family. 
Discussion  
Outpatient therapy and oral antibiotics are safe treatment options for paediatric low risk febrile 
neutropenia. The episodes included in this review had a very low risk of death or admission to 
critical care services. Furthermore, for the few adverse events observed, there was no obvious 
association between their occurrence and the route or location of treatment. Remaining as an 
inpatient receiving intravenous antibiotics did not prevent all deaths within this group. This 
illustrates the importance of recognising that low risk febrile neutropenia is not ‘no risk febrile 
neutropenia’.  
The overall rates of treatment failure are also low. Studies that moved patients from a more 
intensive regimen to a reduced therapy option at 24 or 48 hours had lower rates of treatment failure 
than those who were treated entirely on reduced regimes. Although these data are from separate 
observational cohorts and therefore it is not appropriate to statistically compare groups, the trend 
would seem clinically plausible. The results of this study indicate that outcomes are different for 
those treated as outpatients to those discharged at 48 hours. I therefore suggest that the combined 
estimate of treatment failure rates is not a clinically useful figure as it describes a very 
heterogeneous group, and that instead rates for each group be used separately to inform the design 
of future services. It should be noted, however, that all treatment regimens achieved a high success 
Wiernikowski et al, 
1991(140) 
Confirmation 
following 
enrolment 
2 NA 24  
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rate (over 83%) and therefore the rates of treatment failure may be considered acceptable in any 
group.   
For some studies, the reasons for re-admission, and therefore treatment failure, were clearly 
reported. In others, they were unclear or not documented. Where provided, the indications were 
variable, such that failure rate recorded within studies is driven by the components of the definition 
of treatment failure. For example, in some studies, a single repeated fever after reduction in therapy 
would be defined and counted as a treatment failure. This does not necessarily describe an unwell 
child and may not be of concern to either parents or clinicians. Additionally, where a child is on a 
reduced regime, there may be a tendency for physicians to increase therapy more rapidly than for 
children where standard, more familiar, treatment is already ongoing. Thus, the estimates of 
treatment failures within this review may be higher than the rates of clinically meaningful 
deterioration for children on reduced therapy regimens, and this effect is likely to be more strongly 
accentuated in those who receive reduced therapy regimens earlier in their episode of febrile 
neutropenia. 
In the exploration of treatment failure in relation to the timing of discharge, it should also be noted 
that a substantial proportion of the data is from one group (Paganini et al). Most data about 
discharge after at least 48 hours of inpatient care are provided by this group. Along with this, the 
studies examining patients treated entirely as outpatients seem to be grouped within the forest plot 
into two distinct areas. Studies with smaller numbers of episodes have more variable failure rates 
compared to those with more episodes. Interestingly, the treatment failure rates in larger studies 
seem to be lower than for smaller studies, however, again the Paganini group provide much of these 
data. Therefore, it is unclear whether these differences are due to variations in treatment failure at 
the various time points or whether they are instead due to the impact of this group’s definitions and 
approaches.  
This review has shown a small study effect in the literature regarding paediatric low risk febrile 
neutropenia. A small study effect could be reasonably expected in this area. Small studies are likely 
to be produced by groups for whom the process of treating children with oral antibiotics or as on an 
outpatient basis is a new concept. These teams may be more concerned about the introduction of 
these techniques and therefore be more cautious about re-admission and changes in antibiotics. 
This would result in higher rates of treatment failure. Meanwhile, groups who have become more 
comfortable with these regimens may attempt studies including larger number of febrile 
neutropenic episodes. Simultaneously, they are more likely to be tolerant of minor changes in a 
child’s condition without recommending a change in treatment approach. Thus, familiarity with a 
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regimen results in reduced treatment failure and the conduct of larger trials to evidence this. If this 
mechanism were to be correct, it could also be potentially reassuring for those considering 
introducing reduced therapy regimens to their services. It could be predicted that there would be an 
initial high rate of treatment failure followed by a gradual reduction in failures as clinicians and 
families become familiar with the new service. 
Another issue which must be discussed is that of the influence of risk stratification tools. There was 
significant heterogeneity between the tools used to assess whether participants were low risk. 
However, there was a suggestion within the sensitivity analyses that the stringency of the risk tool 
affects the likelihood of treatment failure. This is unsurprising given that some of the most stringent 
tools required a child to have a blood culture which was negative at 48 hours and at least 24 hours 
without a fever before they were eligible to be low risk. This therefore excluded the use of an 
immediate reduced therapy regimen, and thus avoided many of the issues surrounding treatment 
failure that I have previously discussed. Thus the finding that a more stringent risk stratification tool 
results in low rates of treatment failure may actually represent the fact that a longer time to 
discharge leads to less treatment failure. It should be noted however that the four safety events 
occurred in studies that used relatively stringent risk tools. 
The sheer variety in the antibiotics used for paediatric febrile neutropenia adds complexity to this 
review. Both the previous work by Manji et al and the recent NICE guideline found numerous 
different antibiotic regimes studied, in both adult and paediatric protocols.(21,98) It is worth noting 
however that although the specific antibiotics used are varied, the microbiological coverage of these 
antibiotics is certainly less so. Thus, differences between regimes are more likely to be related to the 
route of administration, including absorption and dosing, than the specific antibiotic used.  
When considered alongside the results of the two previous reviews by the Cochrane group and 
Manji et al, the work in this phase of the thesis reinforces the conclusion that reduced therapy can 
be safely achieved in children with low risk febrile neutropenia.(98,99) However, these treatment 
failure rates contrast with those of Manji et al.(98) The previous review had found that treatment 
failure was more likely in patients treated as inpatients than those who received outpatient care. 
This review has found that the rate of treatment failure was higher in the group who were treated as 
outpatients earlier in their course. This difference in results is likely to be due to the differences in 
inclusion criteria for the two reviews, resulting in the comparison of different inpatient regimens. In 
particular Manji chose to examine all initial treatment regimens for febrile neutropenia, and thus 
included RCTs comparing inpatient IV treatment regimens with other inpatient IV treatment 
regimens. These studies are likely to be designed to be more sensitive at detecting certain treatment 
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failures, such as changes in antibiotics, and therefore may detect a greater number of failures that 
the trials that I have included in this review. This may account for the differences of findings 
between the reviews. Meanwhile, the Cochrane review by Vidal et al found similar rates of failure 
for intravenous and oral regimens as this review.(99) 
There are high rates of refusal to participate in trials of these regimens, which relate to both families 
and physicians. In many areas of research, a refusal to consent rate of up to 30% may not be 
considered problematic. However, in the context of children’s cancer where high recruitment rates 
are generally seen, this rate of refusal is noteworthy.(143) Refusal to consent to enrolment was 
generally greater than refusal to confirm consent following enrolment. This may be due to the fact 
that participants who have committed to the study by consenting to enrol are already likely to have 
considered many aspects of the research and have decided that these are acceptable prior to 
presenting with febrile neutropenia. They are prepared for the possibility of randomisation when 
attending the hospital and so are less likely to decline. In addition to this, once committed to a 
decision, people tend not to change their minds due to a sunk-cost effect, where the effort put into 
considering and agreeing to the study means they are more likely to continue with their original 
decision to prevent ‘wastage’ of their invested effort. 
In studies that examined the number of refusals by physicians, these were similar to or greater than 
the refusals by parents. This may reflect physician refusal as a proxy for parents, or alternatively may 
represent uncertainty amongst physicians about the safety or efficacy of reduced therapy. No 
studies provided data on why families and physicians refused to participate, but two discussed 
potential issues. They used anecdotal evidence to describe practical issues as a potential barrier to 
participation for families, whilst a perceived lack of safety may be an issue for both families and 
physicians considering reduced therapy options.  
Strengths and limitations 
The main strength of this work is in the examination of a large amount of data. The RCTs are few, 
and although they suggest that reduced therapy regimens are safe, the additional consideration of 
observational cohort data provides further support for these strategies. The inclusion of a large 
number of episodes also allows the consideration of the issue of timing in early discharge so as to 
inform service development in this area. 
The main limitation within this work is its inability to completely define the features of a low risk 
strategy that result in the lowest rates of treatment failure. This is mostly due to the considerable 
heterogeneity within the literature, with regards to the inclusion criteria and interventions used. In 
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particular, I was unable to fully explore the influence of various risk stratification tools, as a large 
number of tools were used by the studies and thus sensitivity analysis could only be performed using 
broad groups. 
Summary 
This systematic review has shown that reduced therapy regimens for paediatric low risk febrile 
neutropenia are safe and have low rates of treatment failure. The adverse events observed seem to 
occur regardless of the route or location of treatment. The risk of treatment failure seemed to be 
higher when reduced intensity therapies were used immediately after assessment, with lower rates 
observed when these were introduced after 48 hours. However, both rates might be considered 
acceptable given the potential benefits of early discharge. The high rates of refusal to participate in 
trials of these regimens, by both families and physicians, suggest that key stakeholders may be 
uncertain about adopting these regimens and this requires further investigation. In the next phase of 
the thesis, the qualitative synthesis (Chapter 4) will explore the existing qualitative literature 
surrounding early discharge, drawing on evidence from relevant fields, so as to begin to understand 
the possible reasons for these low rates of consent and to identify barriers and facilitators to 
implementation of these strategies in the futures.  
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Chapter 4: Experiences of early discharge, with a focus on paediatric 
febrile neutropenia: a meta-ethnography 
Introduction and rationale 
The systematic review in Chapter 3 raised concerns that reduced therapy, particularly outpatient 
treatment, may not be acceptable to patients, their parents or the health care professionals 
providing for them.(144) Within this chapter of the thesis, I now report the qualitative synthesis of 
experiences of early discharge, focused on paediatric febrile neutropenia, which forms the second 
phase of the thesis.  
Performing a qualitative synthesis alongside the systematic review of effectiveness draws on one of 
the key strengths of this methodology, which is its ability to contextualise the results of quantitative 
reviews.(145–147) Thus the qualitative synthesis provides analytical depth and further nuanced 
interpretations to the consent rates found in the studies in the systematic review recounted in 
Chapter 3. It also provides an extensive exploration of the qualitative literature surrounding 
paediatric low risk febrile neutropenia, in a structured systematic way, to inform and prepare for the 
primary qualitative study performed in phase three.  
This synthesis of primary qualitative work provides an in depth narrative of the different 
perspectives of those involved in early discharge services, focusing specifically on paediatric febrile 
neutropenia. The thorough exploration of the existing literature outlines the issues that may act as 
barriers or facilitators to acceptance of outpatient therapy for different groups. The resultant 
account provides sufficient insight to allow the development of a subsequent overarching theory 
outlining the factors influencing the acceptance of early discharge in febrile neutropenia, and the 
features of services that might make them more successful from the perspectives of different 
stakeholders. Thus, the findings from the qualitative synthesis complement the findings from the 
systematic review of effectiveness and help to inform those designing commissioning and 
implementing services.  
The qualitative synthesis aimed to explore perceived experiences and understanding of early 
discharge, with a focus on paediatric febrile neutropenia and from the viewpoint of patients, their 
family carers and healthcare professionals. I anticipated, and the preliminary literature searches 
confirmed, that the subject-specific qualitative material available would not be of sufficient volume 
to perform an in-depth exploration of potential barriers and facilitators, or the differences in 
perspectives between patients, their parents and their healthcare professionals.  
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To account for this, I expanded the review to consider other qualitative material that might 
reasonably inform theories about the experience of early discharge in paediatric febrile neutropenia. 
I, therefore, explored the literature surrounding experiences of early discharge in two additional 
areas (Figure 11). The first area of exploration was adult febrile neutropenia, where many of the 
concerns related to complications of febrile neutropenia and experiences of oncological services 
might be similar. For example, patients, their carers and healthcare professionals may feel 
particularly anxious about early discharge with febrile neutropenia because of previous bad 
experiences with severe infections, or because of education about the potential severity of an 
episode of febrile neutropenia. The second area of exploration was other paediatric chronic 
conditions with life-threatening consequences, where there may be similar social implications of 
early discharge strategies. For example, parents may struggle with the practicalities of taking a child 
home, including giving medications or attending frequent follow-up appointments, or feel anxious 
about the responsibility of caring for their child during an acute exacerbation of illness. 
 
Figure 11 - Interactions of different topic areas for synthesis 
Paediatric 
Febrile 
Neutropenia
Adult Febrile 
Neutropenia
Paediatric 
Chronic 
Disease
Oncology setting 
Diagnostic similarities 
Paediatric setting 
Social similarities 
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Aims and objectives 
This synthesis aimed to explore perceived experiences and understanding of early discharge, with a 
focus on paediatric febrile neutropenia. I aimed to explore how these concepts differ between 
groups and how they form barriers and facilitators to acceptance of early discharge. In particular, I 
focused on the views of patients, their carers, and the healthcare professionals providing services to 
them. The specific research questions for this qualitative synthesis are outlined in Box 6. Following 
the assessment of this broad and more contextual literature, I aimed to develop higher level theory 
about the experience of early discharge in paediatric febrile neutropenia and the factors which 
influence the acceptance of this as a management strategy. This synthesis seeks to contextualise 
some of the findings from the systematic review in Chapter 3 and has fed into the qualitative study 
described in Chapters 5-8. 
 
Methods 
A protocol for this synthesis was developed and registered prior to commencing this work 
(PROSPERO CRD 42014013084). This chapter is reported in accordance with ENTREQ (Enhancing 
transparency in reporting the synthesis of qualitative research) guidelines.(148) 
Methodology 
Although quantitative synthesis in the form of systematic reviews, with meta-analyses as a 
significant subgroup, has become an established concept for those involved in health research, 
similar methodology in the qualitative paradigm has only been developed more recently. (145–147) 
When considered, qualitative synthesis clearly has great potential to benefit the health sciences, not 
just through increasing the numbers of patients involved thus giving more confidence in the 
Box 6 - Research Questions  
1. What are the experiences and perceptions of patients, parents and healthcare 
professionals of early discharge in paediatric febrile neutropenia? 
2. What are the experiences and perceptions of patients, carers and healthcare 
professionals of early discharge in adult febrile neutropenia? 
3. What are the experiences and perceptions of patients, parents and healthcare 
professionals of early discharge in other paediatric chronic conditions with potentially 
life-threatening consequences? 
4. What are the barriers and facilitators to acceptance of early discharge in these 
populations? 
5. How do the perspectives in these situations differ and how does this impact on the 
process of early discharge? 
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conclusions drawn (as for quantitative synthesis), but also in allowing the development of higher 
level theories and further analysis of complex constructs. Finally, just as in quantitative synthesis, it 
can be used to identify key gaps in the literature so as to guide future research endeavours.  
Selecting the most appropriate method for qualitative synthesis is challenging and depends on a 
number of components, including the research question, its intended output (to inform theory, 
practice or policy), the underlying epistemological beliefs of the researchers carrying out the 
synthesis, and those of the studies which are to be included within the review. 
I considered using a number of different approaches.(147) A thematic analysis would perhaps be the 
most recognisable to a clinical audience, and might provide results which are most accessible to an 
audience already versed in quantitative systematic reviews. Thematic analysis provides a clear 
description of the evidence available and allows assessment of current gaps in the literature. 
However, this methodology may not provide as much depth as more interpretive approaches and 
has less use when integrating more varied forms of qualitative research, as I anticipated would be 
present in this review.  
At the more interpretative end of the spectrum of qualitative synthesis methodologies, critical 
interpretative synthesis provides an inductive process of adding studies where necessary, intending 
primarily to create new theory. I decided this was not the most appropriate methodology for this 
research, given the intention to both describe the current literature base and to create new 
theoretical considerations. Furthermore, I aimed to combine and compare the results with the 
quantitative systematic review, which would be less straight-forward with critical interpretative 
synthesis. This methodology is also less accessible to clinicians and therefore less likely to have an 
impact on the intended audience.  
Ultimately, I chose to use meta-ethnography to perform this qualitative synthesis. This methodology 
was first described by Noblit and Hare in 1988.(146) Although initially used to combine only 
ethnographic studies, it is now used to synthesise many different theoretical and methodological 
approaches. This pragmatic approach sits well with the overarching philosophy of this thesis, and 
was likely to yield the highest volume of included studies when there may be minimal good quality 
literature. Furthermore, the mixing of different theoretical and methodological approaches is 
especially consistent with the mixed methods nature of the thesis, which performs a similar 
technique with the different phases of the work.  
Another benefit of meta-ethnography is that although it aims to describe the various themes in the 
studies included, it also aims to translate those concepts into each other and thus create higher-level 
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theory, which may be more generalizable. It was this balance between descriptive and interpretative 
approaches that was my primary reason for selecting a meta-ethnographic approach. The constant 
comparison of the similarities and differences in studies and their findings is particularly applicable 
to my work, as the literature selected provides both overarching themes and interesting contrasts in 
perceptions of early discharge in different contexts. By using this interpretive approach, I aimed to 
inductively produce a model of experiences and understanding of early discharge. 
Searches 
Electronic searches of MEDLINE, CINAHL, EMBASE, British Nursing Index and PsychInfo were 
performed. A full search strategy is provided in Appendix 4.1. As eligible studies were likely to be 
poorly indexed and I was searching particularly for theoretical richness, I used a CLUSTER approach 
to searching.(8) This involved using key reports as nodes from which to explore the literature, in a 
systematic and explicit way. The CLUSTER searches are outlined in Appendix 4.3. The reference lists 
of all included and relevant excluded papers were also searched. All authors were contacted to 
request details of any other work that they were aware of in this area. 
Study selection 
I screened the title and abstract of all studies for inclusion. A second reviewer (JC) independently 
screened a sample of 1000 of the titles and abstracts. The kappa statistic for agreement was 
calculated and showed acceptable agreement (k = 0.44, confidence interval 0.04-0.85). Full texts 
were obtained for all potential articles of interest and assessed for eligibility by two reviewers 
(myself and JC) using a standardised study eligibility form. Disagreements were resolved by 
consensus or referred to a third reviewer (KA). 
Inclusion and exclusion criteria 
Studies were eligible for inclusion if they met all of the following criteria:  
Study design 
All studies using qualitative methodology were eligible for inclusion, including but not limited to 
ethnography, phenomenology, and grounded theory. Studies that used qualitative methods but 
which did state an explicit methodology were also eligible to be included, provided that they 
presented qualitative data. This included, but was not limited to, studies using focus group 
discussions, interview studies and observational studies. Similarly, mixed methods studies were 
eligible for inclusion if they provided sufficient qualitative data. 
Study Participants 
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Patients, their parents/carers, healthcare professionals, commissioners and/or policy makers. 
Topic of Interest 
Early discharge from hospital, defined by the study. There had to be details of the difference 
between early discharge and routine care, although routine care could be described with reference 
to a historical group. 
Context (any of) 
a) Paediatric febrile neutropenia 
b) Adult febrile neutropenia 
c) Other paediatric chronic conditions with life-threatening consequences. This could include, 
but was not limited to, asthma, diabetes mellitus, inborn errors of metabolism and 
neurodegenerative conditions at risk of respiratory exacerbations. 
Outcome of Interest 
Experiences or perceptions (where early discharge had not been experienced). 
Exclusions 
i) Studies of early discharge in the neonatal period of healthy term newborns or babies following 
admission to neonatal critical care services were not included. 
These studies were excluded as they describe a very different context to that of febrile neutropenia. 
New parents are likely to describe different experiences and concerns compared to those with a 
previously well child who is now suffering from a life-threatening illness. Furthermore, the design of 
services in neonatal care is unique, particularly in relation to community-based follow-up and 
therefore is not comparable to that of febrile neutropenia. 
ii) Studies of early discharge from psychiatric services were excluded. 
Again, these studies describe a different service to that provided for paediatric haematology and 
oncology patients. Psychiatric services are more likely to used phased discharge processes and have 
ongoing community care. Furthermore, the disease processes described, although life threatening, 
have few other similarities to paediatric febrile neutropenia and, as such, are likely to result in very 
different experiences for patients, parents and healthcare professionals. 
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iii) Studies exclusively using methods to quantitatively define preferences were excluded. These 
could have used Visual Analogue Scores, Time Trade Off analyses, Willingness-to-Pay or other 
methods. Studies that used one or more of these methods but also provided qualitative data were 
eligible for inclusion in the review.  
iv) Studies using a survey design were not included, unless they also provided qualitative data using 
another method. 
Language 
Studies were limited to those written in the English language for three reasons. Firstly, these were 
most likely to reflect the cultural experiences of the group in which I planned to apply the results, 
that is paediatric haematology and oncology patients with febrile neutropenia in the UK. Secondly, 
the benefit of qualitative research is to allow participants to express their experiences and 
perceptions, the clarity of which could be lost through translation and thus the results of the 
synthesis may less accurately capture the views of participants. And finally, I speak only English and 
therefore the decision to exclude non-English papers also represented a pragmatic approach. 
Data extraction and quality assessment 
General study data was extracted using a standardised data extraction form. Data extraction was 
performed by myself and checked by JC. All studies were assessed for quality using the Qualitative 
Assessment and Review Instrument (QARI) tool, a 10 point critical appraisal tool developed by the 
Joanna Briggs Institute for use in qualitative syntheses.(149) The criteria assessed by the QARI tool 
are demonstrated in Appendix 4.4.  
Analysis 
The analysis followed an adapted version of Noblit and Hare’s phases of meta-ethnography using 
ATLAS.ti software (Error! Reference source not found.).(57) The adaptation, developed by Flemming e
t al, is a simplification of the methodology described by Noblit and Hare that removes three stages 
originally described (Getting started, Deciding what is relevant to the initial interest, and Expressing 
the synthesis).(57,146) This adapted version also provides a more concise description of the phases. 
In practice, this adapted version is of little difference from the originally described methodology. The 
review was an iterative process, driven by the studies identified through the systematic searches. 
Qualitative data from the reports were transferred to ATLAS.ti software and read repeatedly to 
ensure full understanding. The context was fully explored and study content thematically coded for  
key findings. Review by supervisors ensured accuracy of coding (Phase 1 of meta-ethnography). 
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Codes were compared, grouped and translated to provide the initial level of synthesis and reviewed 
at meetings with supervisors.(Phases 2-3) This process confirmed that the codes and findings 
showed little evidence of stark contradiction between studies, meaning a refutational synthesis was 
not appropriate. However, the studies were not completely similar, showing differences between 
different social and clinical settings, rendering a reciprocal approach  inappropriate. Instead I used a 
‘line of argument’ synthesis, drawing on both the similarities and differences between studies to 
form the overarching synthesis. (Phases 2-4)The resulting account was then further explored and 
compared to identify a small number of higher theoretical constructs and to create the lines of 
argument (Phase 4). 
An example of this process can be seen in the discussion of resources as an influence on decision 
making. Repeated reading of the studies identified their key findings, noting specifics such as social 
support from grandparents, finances and parental abilities to provide care (phase 1). Comparing 
these across studies identified the similarities and differences between groups in different studies 
that are discussed in detail in pages 105-6 (phase 2). In Phase 3 these ideas were then brought 
together within the reduced concept of resources, and in Phase 4 this concept was recognised to sit 
within the overarching theme of Complexities of decision making and influences on this.  
 
Box 7- Phases of meta-ethnography (10) 
Phase 1: Reading the studies 
o Studies are read to develop an understanding of their position and context before being 
compared with others. Repeated re-reading of studies to identify key findings. 
Phase 2: Determining how studies are related 
o Determining the relationships between individual studies by compiling a list of the key 
findings in each study and comparing them with those from other studies. If findings are 
oppositional, a refutational synthesis should be undertaken. 
Phase 3: Translating the studies into one another 
o Determining the similarities and differences of key findings in one study with those in other 
studies and translating them into one another. The translations represent a reduced 
account of all studies. (First level of synthesis) 
Phase 4: Synthesizing translations 
o Identification of translations developed in phase 3, which encompass each other and can 
be further synthesized. Expressed as ‘line of argument’. (Second level of synthesis) 
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I aimed to explore the broader context and implications of each study. I considered the role of 
health service design and how this might influence the experience of early discharge, as well as 
social, cultural and economic structures and patient factors that could contribute to certain themes. 
I looked for patterning of the data for themes that suggested how different groups of participants 
might perceive similar experiences and how these perceptions could influence acceptance of 
services. 
Specifically, the broader literature was explored for themes that might provide concepts and theory 
that can be translated to the context of paediatric febrile neutropenia. In reports of studies of adult 
febrile neutropenia, I expressly looked for themes related to aspects of the febrile neutropenia 
diagnosis and the experiences of oncological services that might influence perceptions of early 
discharge. Meanwhile, in studies of experiences in chronic childhood conditions, I explicitly 
examined the data for the influences of social circumstances and care in the paediatric setting as 
potentially transferrable concepts.  
The conceptual contribution of each report was explored in relation to the final theory, so as to 
more explicitly demonstrate the similarities and differences between studies. Furthermore, I 
considered the complex issue of quality within qualitative research, and aimed to integrate the 
findings of the quality assessment within the analysis. In particular, I evaluated whether studies 
which appeared to be of higher quality contributed concepts to the final theory that were not 
evident within poorer quality studies and whether specific quality attributes explained any 
differences.  This is consistent with the iterative and reflexive approach which characterises 
qualitative methodologies. 
I also examined the literature base to establish how it is conceptually organised and to identify any 
particular dominance in regards to geography, professional interest and theoretical standpoints. 
Furthermore, I sought to identify areas where the body of research is incomplete, with a view to 
indicating potential future areas for exploration. The strengths and limitations of the synthesis 
process were explicitly explored adding reflexivity to the review. 
Results 
Study details 
A flow diagram for study selection is provided in Figure 12. 4275 titles and abstracts were assessed 
and 50 full text articles retrieved. 46 full text articles were excluded as they failed to meet the 
inclusion criteria. Appendix 4.2 outlines the reasons for exclusion for each study. Thus four studies 
were included from the database searches. One further study was included from the reference list of 
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an excluded paper that was relevant to the topic of interest.  Three studies were included from 
searching the reference lists of included papers. No further studies were identified by contacting 
authors of the included papers. CLUSTER searching of three key papers identified 538 records of 
which one paper was included in the synthesis (see Appendix 4.3).  
In total, nine papers were included in the synthesis (see Most studies included parents or caregivers 
within the participant group. Three studies explicitly explored the views of children, with another 
briefly discussing a single child’s comment. A total of twenty-six children had been interviewed 
across the studies. Where the age of children was given, the majority were aged 5-12 years, with one 
13 year old and one 14 year old also interviewed. All studies involving children used interviews, 
some augmented with drawing techniques. Notably, the literature included very few teenagers or 
young adults, and no focus group discussions with children or young people.  One study researched 
the views of adult patients. Three of the studies involved healthcare professionals in some manner, 
mostly nursing staff and general practitioners.  No studies considered the views of commissioners or 
policy makers in this area.  
Generally the studies gave few details of the social and environmental surroundings of the 
participants (including housing, local amenities, income banding, ethnicity, socio-economic status, 
and educational level). Tatman et al, however, gave in depth details of the context within which their 
participants lived, including ethnicity, employment status, housing situation and family structure and 
support. (150) 
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Table 10 for included study details). These were published between 1977 and 2011. Two thirds were 
performed within the United Kingdom, with the remaining from North America. Those who 
described the funding provided had received academic support only.  
 
4275 references identified by 
database searches (after 
removal of duplicates) 
46 Excluded after review of Full text 
 17 Not studies 
 11 Not qualitative 
 1 Not primary research 
 11 Not patient group of 
interest 
 4 Not early discharge 
 2 Full text not available 
4 Included from database 
searches 
50 Full text articles retrieved  
4225 Excluded after review of Title 
and Abstract 
 
 
 
Figure 12 - Flow diagram for study selection 
 
9 Included in synthesis 
1 Included after reference searches of 
excluded studies 
  
3 Included after reference searches of 
included studies 
1 Included after CLUSTER searches 
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Within the included reports, one study was specific to the area of paediatric febrile neutropenia. 
One study did not specify the context, although the paper refers to ‘caregivers’ which suggests an 
adult setting. The remainder of the studies focused on children with conditions other than febrile 
neutropenia, although one did include patients undergoing haematopoietic stem cell 
transplantation. Therefore, the majority of the literature relates to paediatric patients and their 
parents, as such, the findings rely mostly upon studies with participants from this background. The 
main methodology used was of semi-structured interviews, sometimes alongside other 
methodologies as part of an overarching research project. One study reported observational 
ethnographic methods and one used focus group discussions.  
Most studies included parents or caregivers within the participant group. Three studies explicitly 
explored the views of children, with another briefly discussing a single child’s comment. A total of 
twenty-six children had been interviewed across the studies. Where the age of children was given, 
the majority were aged 5-12 years, with one 13 year old and one 14 year old also interviewed. All 
studies involving children used interviews, some augmented with drawing techniques. Notably, the 
literature included very few teenagers or young adults, and no focus group discussions with children 
or young people.  One study researched the views of adult patients. Three of the studies involved 
healthcare professionals in some manner, mostly nursing staff and general practitioners.  No studies 
considered the views of commissioners or policy makers in this area.  
Generally the studies gave few details of the social and environmental surroundings of the 
participants (including housing, local amenities, income banding, ethnicity, socio-economic status, 
and educational level). Tatman et al, however, gave in depth details of the context within which their 
participants lived, including ethnicity, employment status, housing situation and family structure and 
support. (150) 
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Table 10 - Included study details 
Study Country 
of 
origin 
Methods Phenomenon of interest Setting Population Methods of 
Analysis 
Diorio et al, 
2011 (151) 
Canada Interview Parent preferences for treatment of febrile 
neutropenia and the key drivers of parental 
decision making 
Paediatric 
Febrile 
Neutropenia 
155 parents Thematic analysis 
Freund and 
Siegel, 1986 
(152) 
USA Observations 
through 
practice 
Global issues of readjustment that may occur 
in any family with a child undergoing the 
transplant procedure. Notably also – the 
psychosocial concerns faced by the patient 
and the family in the transition from the 
hospital to the home environment 
Paediatric Bone 
Marrow 
Transplantation 
83 patients, of whom 56  
had leukaemia, 13 had 
aplastic anaemia and 14 
had SCID 
Thematic analysis 
Fuji et al, 
2013 (153) 
USA Focus Group 
Discussions 
Perceptions of care transitions, their role 
within the process, barriers to effective care 
transitions, and strategies to overcome these 
barriers 
Unclear 18 patients and/or 
caregivers, 13 hospital-
based providers, 7 non-
physician community 
providers 
Content analysis 
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Table 5 - Included study details 
Hally et al, 
1977 (154) 
UK Multi-
methods – 
quantitative 
data, 
interviews, 
questionnaires 
Describe a home nursing scheme Paediatric home 
nursing scheme  
53 (of 61 eligible) 
families, 18 GPs from six 
practices and number of 
nurses unclear (?4) 
Descriptive 
Sartain et 
al, 2000 
(155) 
UK Semi-
structured 
interviews, 
augmented 
with drawing 
techniques for 
children 
To explore children’s parents’ and health 
professionals’ experience of childhood chronic 
illness 
Other paediatric 
chronic 
condition with 
potentially life-
threatening 
exacerbations 
6 children, 10 parents, 
and one healthcare 
professional associated 
with each family 
Grounded theory 
Sartain et 
al, 2001 
(156) 
UK Structured 
and semi-
structured 
interviews. 
Experiences of hospital and home care 
 
Hospital at 
home service 
11 children age 5-12 (6 
hospital care, 5 hospital 
at home). Parents – 20 
in hospital care, 20 in 
hospital at home.  
Content analysis 
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Table 5 - Included study details 
Smith and 
Daughtrey, 
2000 (157) 
UK Semi-
structured 
interviews 
To identify any gaps in nursing services for 
acutely sick children and their families 
following discharge, and to suggest ways to 
improve integration and communication 
between hospital and primary care to 
facilitate a `seamless web of care' for families. 
Children’s ward 
in medium sized 
DGH with both 
medical and 
surgical patients  
20 parents who had 
needed help/support 
from a health care 
professional in the first 
48 hours following 
discharge 
‘Burnard’s (1991) 
method for 
analysing 
interview 
transcripts in 
qualitative 
research’ 
Tatman et 
al, 1992 
(150) 
UK Semi-
structured 
interviews and 
questionnaires 
Views of parents and GPs of a paediatric home 
care service 
Other paediatric 
chronic 
condition with 
potentially life-
threatening 
exacerbations 
46 parents of 47 
children. In depth detail 
of the families’ social 
context given within 
paper. 
Descriptive 
analysis 
While, 1992 
(158) 
UK Semi-
structured 
interviews 
Experiences of hospitalization and home care Other paediatric 
chronic 
condition with 
potentially life-
threatening 
exacerbations 
9 children, number of 
adults unclear- 
suggestion of 40 but not 
clearly stated 
Content analysis 
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Quality assessments 
When assessed using the QARI tool, the quality of the included studies was variable (see Appendix 
4.4). The theoretical premises on which the studies were based were rarely described, nor was 
their impact on the methodologies used acknowledged. Indeed only Sartain et al gave a clear 
theoretical basis to their work, which then obviously flowed from this starting point.(155) The 
remaining studies were largely descriptive in nature. Another clear omission through all the 
included papers was the lack of reflexive consideration of the influence of the researchers’ own 
values and attitudes on the work they were performing. However, generally the methods of data 
collection, analysis and interpretation seemed appropriate to the research problem posed and the 
participants’ voice seemed to be communicated well through this process. The overall conclusions 
drawn by most of the papers seemed to be clearly demonstrated within the data and its analysis, 
with obvious lines of argument seen through the reports.  
Analysis 
During my work on this meta-ethnography, it became apparent that the overarching experience 
of early discharge is that the decision making involved is complex and difficult. This experience 
may be influenced by various common factors, including fear, timing and resources. From this 
challenging background, I identified two clear and distinct themes. First, participants struggled 
with some of the practical aspects of their treatment regimens, namely those of childcare, 
finances and attendance at follow-up.  Second, I explored the social and emotional issues raised 
during early discharge, particularly those of social benefits and isolation, although relational and 
environmental issues were also raised. Linking these two themes, participants noted the 
importance of continuity of care and the need for information if they accepted early discharge 
strategies. This theme represents the opinions of participants within the included studies who 
expressed possible changes to strategies that would circumvent some of the practical challenges 
they faced and alleviate some of the feelings of isolation experienced.  
This overarching theory of the meta-ethnography is represented in Error! Reference source not f
ound., whilst supporting evidence for all themes is given in Table 11. 
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Table 11 - Themes and Subthemes with supporting evidence 
Themes and Subthemes Sample Evidence 
Practical Logistics 
 Child care 
 
 
“The more kids you have the harder it is to be 
in  
hospital.”(151) 
“It [home nursing] also avoided special 
arrangements for other siblings and the 
disruption entailed in visiting the 
hospital.”(154) 
 Finances 
 
“six parents (30%) commented on the 
financial cost of staying in hospital with their 
children. Extra expenditure included meals for 
parents, telephone calls, and buying things 
(such as 
toys and magazines) to keep their child 
preoccupied”(156) 
“…we saved a fortune, when you’re in hospital 
you spend more money than you ever dream 
you will, so we didn’t have all that expense, 
which was good again.” (156) 
“The respondents also felt that time and 
money had been saved and, in particular, they 
referred to savings as regards travelling to 
hospital.”(158) 
“Parents reported that the cost of fuel, 
parking, and meals necessary during clinic 
visits were higher than the cost of staying in 
hospital for several days” (151) 
 Follow-up “The nurse comes once a day but we have to 
come back three times a week. That’s not 
good.” (151) 
“Forget it, I’ll just stay in the hospital if I have 
to be here every day.”(151) 
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Table 12 - Themes and Subthemes with supporting evidence 
 
Social and Emotional Issues 
 Social benefits and isolation 
 
 
See Table 16 
 Normal social relationships 
 
“…I missed going to school and playing with 
my friends...”(155) 
“I don't get to see half of my friends because 
I was in hospital. I miss out on loads of stuff 
at school” (155) 
“Just over half of the children interviewed said 
that it was nice to remain at home with the 
family…”(158) 
 Environmental influences 
 
“there was a lot of things that I missed from 
home that I had, so the things at home that I 
can play with and amuse myself but I haven't 
got at the hospital”(155) 
“Stephen tried to minimize the disruption 
actively by taking his own duvet into hospital 
and by setting up his computer games in 
hospital” (155) 
“you may as well be at home where you’ve got 
your creature comforts, you’ve got your own 
bed…”(156) 
“We would have definitely preferred to have 
been at home, and I think when you’re in your 
own surroundings, it’s far better, it makes a 
difference.” (156) 
“I can still look after him at home and in your 
own environment really, and plus for X he’s in 
his own surroundings, he doesn’t like change, 
he’s got his own toys around, he’s got his own 
bed and things like that, so it’s benefited him 
and it’s also benefited us” (156) 
“one parent (parent 21) stated that home 
care allowed the child to have 'decent' meals  
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Table 13 - Themes and Subthemes with supporting evidence 
 and enabled him to do what he wanted with 
all his toys available for play…”(158) 
 Staff experiences “Separation anxiety and a reluctance to give 
up the care of the child are frequent 
manifestations experienced by staff during 
the period the family is preparing to take the 
child home.”(152) 
“it is important for them to learn that the 
child is home, well cared for, and recovering 
satisfactorily” (152) 
“The staff must be assisted to acknowledge  
feelings of loss and to resolve them so as not 
to complicate the process of transition for the 
patient and family” (152) 
 
Continuity of care 
 
“it might be a nice thing if the hospitals 
would call to ask, ‘How is everything going? . 
. . Do you  
have any questions?”(153) 
“The feelings of anxiety and isolation 
following discharge were exacerbated if 
parents did not have a named person to 
contact when they needed reassurance and 
specific advice.”(157) 
“I would have felt happier if I had had a point 
of contact at the hospital because obviously 
they were familiar with him. They knew what 
had been wrong with him” (157) 
“The nurses who visit are never just "in and 
out"; they have always had time to stop and 
talk and have always been incredibly 
supportive.”(158) 
 
Need for information 
 
“While definitive answers may not be 
possible, the provision of at least a tentative  
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Table 14 - Themes and Subthemes with supporting evidence 
 timetable would provide patients and families 
with a framework that enables them to begin 
to plan for the future.”(152) 
“Nurses described needing notice for advance 
planning to evaluate and reinforce medication 
and aftercare education, reconcile 
medications for discharge with pharmacists 
and physicians, complete and verify 
understanding of patient discharge teaching, 
and provide transfer information to staff at 
the receiving agency.”(153) 
“Patients described the need for additional 
education and follow-up post-
discharge.”(153) 
“I would have just liked them to talk to me a 
bit more and explain what to do if she has 
another fit, because I still don't know what to 
do.” (157) 
“… the general practitioner wrote: "The home 
care team largely communicated fairly well, 
but as I had little information from the 
hospital as to 
the overall plan I found dealing with arising 
problems difficult.”(150) 
 
Complex decision making and influences on 
this 
 Fear 
 
 
“[It’s a] hard [decision] because my child likes 
being home but as a parent I feel scared [at 
home].”(151) 
“Parents were also concerned about children 
contracting infections either from other 
children at home or from other children 
during clinic visits, while they are neutropenic. 
Interestingly,  
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Table 15 - Themes and Subthemes with supporting evidence 
 very few parents mentioned concerns about 
nosocomial infections during hospital 
admissions” (151) 
“The child too may feel anxious about the 
parents' capacity to keep the child "well" at 
home”(152) 
“Resuming total responsibility for their 
recovering child once at home produced 
inordinate amounts of stress and anxiety to 
the interviewed parents, not least because 
they felt isolated from any professional 
support.”(157) 
 Timing 
 
“Part of me wants early discharge, but I 
remember the last time ending up in 
ICU.”(151) 
“You’ve caught me at a good time, when my 
son’s health is good ... if it was a worse time 
maybe my answers would have been 
different.” (151) 
 Resources “Two years ago, hospital is the only one I 
would have considered, but we’ve become 
much more confident in our ability to 
administer medication.”(151) 
“The more you can do in hospital, the more 
you want to do at home”(158) 
“…we had to disrupt other people to help us, 
get like his parents to help us get there and 
bring things for me, money for food and that.” 
(156) 
Key: black – words of report author(s), blue – words of parents, red – words of children 
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Figure 13 - Overarching model of qualitative synthesis of experiences of early discharge. Blue: 
overarching theme, Red: influences upon decision making, Purple: major themes (factors 
considered), Green: subthemes, Orange: potential positive aspects of future strategies 
Complexities of decision making and influences on this 
Throughout the included literature, it is clear that the process of decision making about early 
discharge is complex. It became apparent early in the analysis of the data that the factors 
influencing this decision could not be simply split into barriers and facilitators, as I had initially 
presumed. Instead, certain aspects could at times help families to accept an early discharge 
regime and at others prevent this without the factor itself changing. Instead, it appears that 
combinations of features work in various ways to influence a decision, and perhaps instead of 
focussing on particular aspects of a regime, services should instead aim to facilitate acceptance 
through creating a milieu that best supports positive decisions for families. 
Fear 
Timing 
Resources 
Childcare 
Finances 
Follow-up 
Social benefits 
and isolation 
Normal social 
relationships 
Environmental 
influences 
Continuity of care 
Need for information 
Practical 
logistics 
Social and 
emotional 
issues 
Complex decision making 
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Participants acknowledged the challenges of conflicting feelings about outpatient care. For them, 
it appears that there is a delicate balance between what is good about an early discharge option 
and what is not.  There were obvious difficulties in assigning importance to different aspects of 
the decision making, and, for parents, in balancing what is best for the child physically and 
emotionally, whilst simultaneously considering the needs of different family members. Parents 
also discussed the challenge of seeking reassurance about their concerns without feeling they 
were placing excessive demands on the healthcare service.(157) Furthermore, the dilemma of 
incongruent patient, family and healthcare worker priorities was also acknowledged. (153)  
Various factors impacted on the decisions made by participants. One overarching influence was 
that of fear, particularly related to potential deterioration in the outpatient environment. This 
was occasionally explicitly stated but can also be seen in parental requests for more information 
about what to do in the case of such eventualities. Indeed, the idea of patient safety, including 
the specific safety issues of a regime, was only discussed within the context of fearful situations. 
The literature did not discuss the patient safety risks of remaining in hospital.   
Another clear influence is that of timing. Diorio et al describe how prior experiences influenced 
decisions made by parents of children with febrile neutropenia, as did the health status of the 
child at the time of the episode.(151) This introduces the concept of biographical time, such that 
the impact of an episode of illness may have different meaning and disruption dependent on the 
current internal ‘biography’ of a child or family.(159) Relevant to febrile neutropenia, parents 
reported feeling more confident in their own abilities to care for their child and to identify any 
deterioration in their condition as they became ‘experts’ in this field. Meanwhile, previous events 
such as an admission to intensive care could influence a decision for early discharge in a negative 
way. Thus families’ ongoing interpretation of the biographical experience of having a child with 
cancer may be as important as the chronological time, the child’s age or the specific stage of 
treatment. Dealing with the various contingencies of a paediatric cancer diagnosis, therefore, 
could be an important part of the process of resilience that is discussed further in the discussion 
section of this synthesis.   
A further influence on decision making about early discharge is that of resources - physical, social 
and psychological. Participants in various studies alluded to the importance of physical resources 
on their ability to manage successfully within a regime. For parents, having the practical skills to 
care for their child and the confidence to use these skills facilitated acceptance of an outpatient 
regimen. Similarly, having the economic resources to deal with the financial demands of a 
regimen was discussed by many participants. This is expanded further with the theme of practical 
logistics.  
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Meanwhile, participants in Sartain et al’s study commented on how social resources were needed 
to support their inpatient regimens, whilst a participant in Hally et al’s work had struggled with an 
outpatient regimen because of a lack of social resources.(154,156) The main social resources 
mentioned were other family members, including grandparents, who were nearby and willing to 
help with some of the practical aspects of a regimen such as transportation to and from hospital. 
However, a close network of friends could also fulfil this resource need. The need for certain 
social resources seemed closely linked to the family structure, particularly whether there were 
other children within the household, for whom childcare would be required during an inpatient 
stay.  
Finally psychological resources, although not explicitly mentioned in any of the reports, became 
apparent as a clear influence when the literature was reviewed as a whole. These resources 
include optimism, confidence, and a sense of control. Optimism in particular helps to overcome 
some of the negative feelings associated with treatment regimes, whilst simultaneously allowing 
easier identification and use of available practical and social resources.(160)  Families who 
responded to a regimen by accepting and adapting to the stressful situation seemed to tolerate 
any regimen more easily. This was seen in comments such as: 
"You slot it in - it becomes a way of life."(150) 
Meanwhile a lack of these psychological resources was evidenced in those who felt an increased 
sense of disruption or anxiety with certain regimens: 
 “…the other parents visited…. one because she had anxiety attacks in hospital.” (150) 
 “[Clinic visits] are very disruptive to family life.”(151) 
Practical logistics 
When it comes to logistical issues related to outpatient care, the included studies outlined three 
main challenges for patients and their families. The first surrounds the care of other children 
within the household. Parents with other children often stated that outpatient treatment was 
preferable as it avoided the need for additional childcare arrangements.  
The second logistical issue is that of the financial costs of a regime. These can be described as 
including additional costs and lost income, and occur in both the inpatient and the outpatient 
setting. Families treated as inpatients spoke of the challenges of paying for food and television 
cards whilst in hospital, whilst outpatient families incurred costs from travelling to and from 
clinics. Parents in both locations mentioned parking costs at the hospital as a logistical issue.  
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The final logistical challenge for patients and families is in attendance at follow-up.  Parents 
whose children were treated as outpatients and were required to visit the clinic regularly found 
this to be a particularly negative aspect of treatment and sometimes preferred to stay as 
inpatients. Meanwhile, in other reports, where frequent clinic attendance was not required, 
participants seemed to prefer the outpatient management option. 
Social and emotional issues 
Social and emotional factors also featured greatly in the experiences of outpatient treatment. It is 
important to note that although none of the included studies explicitly used ethnographic 
methods and few gave details on the social, cultural and economic situation of their participants. 
Nonetheless, the data frequently shows that these are of great influence on the experience of 
care. Families who were economically less well-off reported more of the practical challenges 
related to finances. Depending on their social organisation, families had different experiences of 
the practical challenges of childcare, the social benefits and isolation of various regimes and had 
different social resources to call upon during the episode of illness. Meanwhile, Tatman et al 
described the challenges for Bangladeshi families in meeting their need for information when 
interpreting services were limited.(150) 
The literature reveals multiple mentions of the importance of social interaction at all points within 
treatment. The concepts of both social benefit and social isolation are used by recipients of both 
inpatient and outpatient care (see Table 16).  In particular, the feelings of being isolated and alone 
are raised in both hospital and home settings. Participants receiving hospital care felt that staff 
were too busy to be available to them, and that staff did not enquire about deeper feelings 
regarding early discharge. Meanwhile, parents at home reported that there was a lack of follow-
up, where they would have appreciated knowing who to call with a problem, or if staff contacted 
them at home to enquire about the child. Notably some children and young people also stated 
that they experienced a feeling of abandonment and social isolation in hospital. However, other 
children described social benefits from being in hospital and some preferred this to being at 
home.  
Table 16 - Themes of social benefits and isolation/abandonment expressed by various 
participants receiving both inpatient and outpatient care 
 Inpatient care Outpatient care/early discharge 
Social benefits “… and you can meet loads of 
friends as well here, like I met 
Laura last Monday when I came 
in, I met her and then I’ve 
“They [parents] perceived HAH 
[Hospital at Home] as causing 
less social disruption…”(156) 
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known her every time I come in 
I’m always in the bed next to 
her.”  (155) 
“they [the children] had the 
opportunity to make friends and 
play.”(158) 
“Two children made 
friends”(156) 
“If you’re staying with your child 
you may as well be at home… 
you’ve got family 
around….”(156) 
“Just over half of the children 
interviewed said it was nice to 
remain at home with the 
family..” (156) 
Isolation/abandonment “ I don’t get to see half of my 
friends because I was in 
hospital” (155)   
“I missed going to school and 
playing with my friends…”(155) 
“…you know when you’re in 
hospital…., you’re sort of 
isolated in a sense…..”(156) 
“like it being in hospital 
because, it’s like dead boring 
here [at home] and you’ve got 
people to play with you [at the 
hospital]… and I meet people…” 
(155) 
Key: black – words of report author(s), blue – words of parents, red – words of children 
The fact that isolation is discussed in both locations needs further consideration. Participants may 
be describing two forms of isolation – ‘isolation from their normal social life’ and ‘isolation from 
medical support’. This idea could explain the identification of similar feelings within both 
locations, but is refuted by the description of the first form of isolation within patients who are at 
home. Therefore, I concluded that isolation is a complex but singular concept.  Secondly, it is 
difficult to assess whether the participants’ responses about isolation are a result of objective 
increases or decreases in social contact, or whether they instead reflect altered perceptions due 
to a change in need for social input during the increased stress of an illness. However, the 
responses do appear dependent upon both the individual themselves and the situation within 
which they find themselves. 
The issue of isolation should be considered to be potentially important in the setting of febrile 
neutropenia as many inpatients are placed in ‘source isolation’ to prevent the spread of infection 
to other patients within the hospital. Source isolation restricts the child to a single room with en-
suite bathroom facilities. Parents are allowed to leave the room but will usually spend most of 
their time with their child. This situation may exacerbate the feelings of social isolation as families 
are much less likely to interact with other inpatients and thus experience less of the social 
benefits available on a paediatric ward.  
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Other social and emotional issues discussed within the literature relate to the interruption of 
normal social relationships for children. These include relationships with siblings, school friends 
and playmates. In this area, the process of early discharge appears to provide a more favourable 
environment for the maintenance of these relationships. Furthermore, the importance of familiar 
surroundings, toys and meals to the emotional wellbeing of children was also strongly emphasized 
by participants. These environmental factors were mentioned by both teenagers and the parents 
of younger children. 
Despite this being a main theme within the studies involving patients and families, the social and 
emotional issues of early discharge experienced by staff were discussed in only one paper. It is 
unclear whether the remaining projects found no social and emotional issues for staff, or whether 
this aspect of experience was not explored.  Freund and Siegel considered the feelings of staff on 
early discharge of a child from a bone marrow transplantation unit.(152) Here the close and long-
term relationship between staff and patients was recognised and the challenges for staff were 
acknowledged. In particular, staff were seen to worry about the safety of children discharged 
early and were keen to follow-up with children after discharge. Furthermore, this concern was 
recognised as potentially causing complications to the process of early discharge. These issues are 
relevant to febrile neutropenia, where staff also tend to know the children very well due to 
ongoing contact with the service. Furthermore, staff might also have concerns about safety at 
home, particularly during the early phases of the introduction of a new outpatient treatment 
regimen. 
Continuity of care and need for information 
Linked to the theme of social isolation, participants within the literature described wanting 
ongoing care after discharge. In particular, they highlighted the importance of ensuring that 
teams in the community and the hospital communicate and that someone contacts the family 
following discharge to find out how they are getting on. It seems that families did not want to 
come into the hospital for this contact but would have preferred for it to happen at home. There 
was praise of nurses coming out from ‘hospital at home’ schemes with a clear dislike of coming 
into clinic on a regular basis. Parents stated that they would prefer contact from professionals 
that they already knew, particularly those at the hospital who had already been involved in this 
episode of care.(157) 
Almost contiguous with the desire for continued care in the community was the message that 
families felt a need for more information during the process of early discharge. Comments about 
information transfer appear through roughly half the reports. Families report feeling that they 
needed more information about the problems that their child currently had and how they could 
expect that condition to change over the time following discharge. They would have liked to have 
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information regarding what to do if something went wrong following discharge (for example a 
further seizure or fever) and who to contact if they were concerned. One report told of a feeling 
of inconsistency of information from the healthcare team and how this influenced the parent's 
perception of early discharge. Indeed, the provision of information (or lack of it) seemed to 
influence the feeling of emotional wellbeing for parents. 
For staff, the need for continuous care with good transfer of information was also felt to be 
particularly important. Communication between teams was mentioned as a challenge, by both 
the discharging inpatient team and the receiving outpatient team across a number of the included 
reports.  
It seems particularly interesting that staff would like the opportunity to follow up on the progress 
of children following discharge and parents report that they would appreciate such a service; 
however this ongoing continuity does not appear to be present within these studies. It is unclear 
why from the literature with the review. However, potential barriers to the follow-up of patients 
include time and resource constraints for healthcare workers and a culture within services of not 
contacting patients who have been recently discharged – instead families must travel to the clinic. 
Further consideration needs to be given to the fact that families may resent returning for 
frequent clinic appointments but would like more contact following discharge. Services should 
reflect on whether some of these appointments could be replaced with more timely contact via 
telephone alongside or as an alternative to hospital at home visits. 
Contributions to the synthesis 
Within the review of the literature, I identified that there was a small amount of material 
surrounding early discharge in paediatric situations, albeit not febrile neutropenia. This allowed 
consideration of the social issues experienced by paediatric patients as I had intended to do at the 
outset of this review (see Figure 11). However, there was minimal data about either adult or 
paediatric experiences with febrile neutropenia, and this has limited the opportunities for analysis 
of disease specific themes.  
The study by Diorio et al was most closely linked with the area of interest for this synthesis.(151) 
This did provide some helpful subject-specific information, including the practical challenges of a 
paediatric haematology and oncology service, particularly frequent clinic follow-up for outpatient 
management of febrile neutropenia. However, the study was limited to a single centre and to the 
perspectives of parents, without input from patients or health care professionals who are also key 
stakeholders with this situation.  
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Interestingly, the Diorio et al report did not allude to the concept of social isolation or 
abandonment. There are a number of reasons why this might be the case. This could have been 
mentioned within the interviews of this study, but not felt to be a clear theme within the authors’ 
scheme and thus not have been reported. If it was not discussed this may be due to the brevity of 
an episode of febrile neutropenia and thus minimal impact on the family’s social environment.  
Alternatively, the fact that a degree of social change has previously happened within the child’s 
illness may mean that families are more adaptable to current changes in their social support 
structure. Finally, long-term relationships with staff and other families within a paediatric 
haematology and oncology service may mean that there is considerable social support both 
within and outside the hospital environment: “….the known nursing staff [that] made the child 
feel very comfortable in hospital.”(151) 
However, despite lacking this negative theme, the participants of the Diorio study appeared to be 
less positive about outpatient care than the other studies, where early discharge options were 
generally preferred. It is difficult to ascertain exactly why this is the case. The main considerations 
are whether this is a study specific phenomenon, which is dependent on the centre and 
participants involved, or whether this is a disease specific issue, where other families at risk of 
febrile neutropenia might have similar attitudes to these regimens.  
The most notably different report within this synthesis is that of Fuji et al. (153) This study, 
including adult patient participants, described many similar themes to that of the paediatric 
studies. In particular concerns about abandonment and continuity of care persisted and 
participants were emphatic about their need for more information when they were discharged 
early. This study also contributed valuable data about staff experiences, which were not so 
apparent elsewhere within the literature. Practical issues were not raised by Fuji et al. This may 
be because the demands of childcare and attendance at follow-up were less for this group 
compared with the paediatric population, and thus justifies the approach of including both adult 
febrile neutropenia and childhood chronic conditions to ensure different aspects were considered 
in this synthesis (Figure 11). 
When considering whether the quality of a study influenced the themes it contributed to the 
synthesis, there were no obvious differences between higher and lower quality studies. Indeed, 
the lower quality studies contributed similar themes, in similar quantities and with similar depth 
to the higher quality studies. However, it should be noted that the studies scored similarly on the 
assessment of their quality, and the aspects missing were comparable across the included works. 
There was no apparent difference in the studies from the UK compared to North America, or from 
any particular professional or theoretical interest.  
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Reflexivity  
Consistent with qualitative tradition, I feel it is important to be reflexive about my own influences 
on this review. Reflexivity with qualitative research is discussed extensively within Phase three of 
this thesis and forms a key tenet within the qualitative paradigm. It enables consideration of the 
inherent influences and biases of researchers, methods and societal norms and values on the 
findings of a study. As such, it can be seen as of benefit to consider these issues in the reporting of 
a qualitative synthesis, which holds many similar challenges to a piece of primary qualitative work.  
As a health care professional with experience in both general paediatrics and paediatric 
haematology and oncology, I acknowledge that role undoubtedly influences my opinions and 
interpretations. However, other members of my supervisory team are non-clinician researchers 
who have provided different perspectives and ensured that other views have been considered. 
Furthermore, through reflection on my own experiences and those of other supervisors within 
this population, I consider the model to be credible to those working within this environment, 
whilst recognising that some areas require further in-depth exploration and validation. 
Discussion 
This meta-ethnography has found that decisions about early discharge are complex and difficult. 
Some of the main influences on these decisions are fear, resources and timing. Practical logistics 
and social and emotional issues are some of the key factors considered in the decision. 
Participants described a need for increased continuity of care and a desire for more information if 
they are to consider early discharge. These key themes are represented visually in Error! R
eference source not found..  
Possible mechanisms/explanations 
The concepts of trust and confidence offer an overarching theoretical explanation for my findings. 
Participants need to trust both their healthcare professionals and themselves when accepting an 
early discharge programme and require confidence in their own caring skills as well as feeling 
confident that healthcare professionals are contactable and would give appropriate advice once 
they are discharged.  
The issues of trust and confidence appear to be interdependent with the resources available to 
families – both facilities are required in order to be able to manage an early discharge regime. 
Trust and confidence enable families to recognise the resources available to them and to be able 
to mobilise those resources. Meanwhile, families who might otherwise have the trust and 
confidence to thrive in an early discharge situation also need resources to be available to them so 
as to make it possible for them to fully achieve the potential for outpatient care.   
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This suggests that socially informed resilience is particularly relevant to early discharge strategies. 
Resilience has been defined in many ways, but the overarching themes are that resilience 
describes a process (rather than a personality trait) in which individuals, families and communities 
respond to adversity in an adaptive way that enables them to continue to function adequately. 
(161) Resilience is a spectrum of time and situation dependent responses  - a person may have 
resilience within their work life but meanwhile not be functioning well in their personal life.  
Resilience takes into account psychological influences, in this case trust and confidence, alongside 
the social context in which they have to be realised, such as physical and social resources. 
Interestingly, resilience is a common response to adversity.(162) 
In order to consider resilience, it is important to define adversity, which ranges from prolonged 
exposure to personal adversity, such as chronic disease, to single catastrophic events, including 
natural disasters. An episode of febrile neutropenia might be considered as a single acute event 
which occurs on the background of prolonged  adversity experienced by the family of a child with 
cancer. It is important to consider whether individuals regard an episode of febrile neutropenia as 
an adverse event and, if they do, what they perceive its severity to be. These perceptions may be 
vital in defining the need to employ resilient processes and the extent to which resources may 
need to be accessed. These perceptions of adversity are likely also to be time, situation and 
context dependent, just as resilience is.  
Research describes various predictors of resilience, including biological, psychological and social 
influences. Gender and age both affect responses to adversity.(162) Ethnicity may also play a role 
in resilience, however the social and cultural influences are more difficult to control for when 
assessing this factor.(162) High levels of perceived social support can foster resilience, whilst  
multiple life stressors may reduce resilience.(162) Positive family relationships, flexibility and 
adaptability within adverse situations are known attributes of family resilience, as are positive 
relationships with health-care professionals.(163)  
It is also important to consider the impact of financial resources on resilience - any loss of income 
may result in a less resilient response, independent of the initial or final income.(162) This may be 
of particular importance in the paediatric haematology and oncology population where the 
additional costs of caring for a child with cancer average £367 per month.(164) Furthermore, 
families often experience a loss of income at diagnosis as parents often are unable to work as 
much as they had prior to diagnosis. Families of children with cancer may therefore be less able to 
demonstrate resilience during an episode of febrile neutropenia. 
Resilience can be supported through encouraging developmental resilience, strengthening family 
and social relationships, increasing the availability of resources and ensuring that services are 
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designed to promote resilience.(161,162) In relation to febrile neutropenia, this might include 
fostering relationships of trust and honesty and encouraging families to identify the resources 
already available to them, whilst providing additional resources of pre-discharge information, 
practical home nursing support, accessible advice in the community and achievable follow-up 
regimes.  
Finally, the desire to improve resilience to disadvantage should not take place without also aiming 
to deal with that disadvantage. This may include improving practical assistance, such as free 
parking, transport or parental meals in hospital, and considering the structure of an outpatient 
strategy to reduce the burden on families by reducing clinic visits where possible and ensuring 
easy access to professional advice. By providing services are more accessible and appropriate for 
patients, the amount of resilience needed to deal with episodes of febrile neutropenia and the 
resultant treatment may be reduced.  
Strengths and limitations of synthesis 
A specific strength of this synthesis is in its structured scientific methodology and transparent 
approach, which allows readers to make their own judgement as to its credibility. I performed 
thorough, systematic searching of the literature using predefined inclusion and exclusion criteria. I 
note that CLUSTER searching added little data to the review beyond reference searching and 
contacting the authors. The use of a wide breadth of literature to inform this unique clinical 
problem has enabled me to formulate an initial theoretical construct and will enable the shaping 
of future qualitative research. 
The key limitation of this work is that it has not been possible to clarify some of the issues of 
concern, because of the restricted data available. In particular, the voices of participants are 
potentially skewed as key stakeholder perspectives are missing or minimal represented. 
Furthermore, there is insufficient disease-specific data to allow complete confidence in the 
conclusions about the experience within paediatric febrile neutropenia without further replication 
of primary studies 
The lack of social information within the included studies also limits the scope of this synthesis. 
The impact of family structure could play a particularly important role in the experiences of 
patients and families, for example lone parents may struggle with practical logistics more than 
nuclear families, whilst families including other children with health problems may feel more 
confident using care skills in the home, but it is not possible to assess these hypotheses within the 
current literature base. Meanwhile, the impact of inequalities and cultural diversity is also muted 
within the accounts but could be further explored if future primary research provides relevant 
 115 
 
data. Similar to this, the role of healthcare service design could not be fully explored through this 
review because of the limited information given by the included studies.  
Emerging Research Problems 
Overall, this review provides a preliminary theoretical framework for considering early discharge 
for children and young people with febrile neutropenia. It describes the logistic, socio-economic 
and psychobehavioural factors involved from various perspectives, providing detail to this 
essential and yet often poorly understood and underestimated aspect of healthcare. 
Following on from this work, further research was clearly required to explore the disease-specific 
challenges for patients with febrile neutropenia who are being offered early discharge strategies. I 
use this section of the chapter to explore the issues still to be addressed and thus highlight some 
of the reasons for the design and execution of the study described in phase three of this thesis. 
The study aimed to identify whether the negative attitudes found by Diorio et al are also present 
in other populations and to explore the reasons behind any barriers to acceptance in this group.  
It also aimed to collect more detailed contextual information from participants, so as to be able to 
investigate the influence of social, cultural and environmental factors on the perceptions of 
participants. 
It is appropriate to aim to represent the voices of young people and healthcare professionals, 
particularly hospital-based physicians, involved in early discharge regimens for febrile 
neutropenia. Further, it is necessary to expand on the experiences of parents as individuals, as the 
current literature has a risk of ‘double silencing’.(63) This is where parents report on their 
perceptions of their child’s experience. This results in silencing of the child’s voice as they are not 
directly asked about their experiences, but also silencing of the parent’s voice as their own 
experiences, independent of their child, are not explored. To avoid double silencing, participants 
should be encouraged to speak about their own experiences and the perceptions of both children 
and their parents should be sought. This is the rationale of holding separate focus groups for 
parents and young people in the following phase of the thesis. 
In particular, it has been difficult to fully explore the issue of resilience because of the descriptive, 
rather than explanatory nature of the literature base.  The future work aimed to confirm whether 
resilience is an important process in the acceptance of early discharge, and if so, the features 
which make some families more resilient than others in this situation and the influence of family 
structure on resilience.  
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Summary 
This synthesis has begun to explore some of the issues raised within the systematic review of 
effectiveness. In particular, I have established the previously identified challenges to the 
acceptance of studies that offer early discharge or reduced therapy. This meta-ethnography 
confirms the assumption from the studies included in the quantitative systematic review that 
practical aspects of a regime can act as potential barriers to participation. However, although the 
systematic review suggested that there may be a perceived lack of safety of outpatient regimes, 
this theme was not particularly prominent within the qualitative synthesis.  
Overall, the synthesis has found that decisions about early discharge are complex and influenced 
by fear, resources and timing. Practical logistics and social and emotional issues are key factors 
considered in the decision. There is a clear need for increased continuity of care and a desire for 
more information for families considering early discharge approaches. Socially informed resilience 
provides theoretical explanations for the experiences and perceptions found within this meta-
ethnography. The ways in which resilience is fostered and negotiated may mediate the ability and 
inclination of families to care for their children within their home during episodes of febrile 
neutropenia. Services should consider how to recognise and encourage action to enhance 
resilience within the communities they serve. 
Many of the future research issues suggested from this meta-ethnography are addressed in the 
qualitative study that forms phase three of the thesis. This aims to explore the disease-specific 
issues relating to early discharge in febrile neutropenia along with inclusion of the voices of young 
people and healthcare professionals, alongside those of parents. It will also investigate whether 
resilience is confirmed as an important feature in this setting and will evaluate the overarching 
theory of this meta-ethnography. 
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Chapter 5: Early discharge in paediatric febrile neutropenia: 
experiences and perceptions of young people, parents and 
healthcare professionals 
Introduction 
Following on from, and drawing together the results of, the systematic review in Chapter 3 and 
the qualitative synthesis in Chapter 4, this chapter provides a description of the methods used in 
the qualitative study. It explores the methodological choices made and the potential impact of 
these on the study findings. It outlines the aims and objectives for the work and then provides the 
rationale for the use of the chosen methods. I explain the process of study site identification and 
the practicalities of patient recruitment. There is then an outline and justification of the focus 
group discussions, including explanations for each segment of the topic guide. The details of data 
management and maintenance of confidentiality are given before a discussion of the analytical 
process along with examples of how the data were brought together to provide the findings 
chapters of this thesis. I close the chapter with a reflexive account of the challenges relating to the 
planning and procedure of performing this study and a consideration of the additional ethical and 
governance issues related to this work.  
Consistent with the traditions of presenting qualitative research, I weave the theoretical 
background and rationale with empirical material which demonstrates the application of this 
theory to the research.(56) As such, there are times when I refer to the findings of the study 
within this methodology chapter so as to illustrate the decisions made in the performance of the 
work. 
Background and rationale 
Given the limitations of the qualitative synthesis described in Chapter 4, I aimed to conduct a 
primary research study to obtain further data to build understanding about perceptions of early 
discharge for paediatric febrile neutropenia so as to inform future policy and practice. I felt it was 
particularly important to further explore the disease specific features of low risk febrile 
neutropenia that may have a role in the acceptance of early discharge strategies, given that only 
one of the previous studies had considered this.(151) I also wanted to explore the contextual 
features that might influence the experience of individual patients and families undergoing 
treatment for an episode of febrile neutropenia, such as socioeconomic situation and family 
structure, and the role of different features within healthcare service designs that then impact on 
the experiences of key stakeholders. Furthermore, it is important that the voices of children and 
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young people are listened to when planning services that affect this age group as discussed in 
Chapter 2. Given that these have so far been under-recorded in this area, I chose to include this 
group within the study. I discuss the rationale behind this decision and the evidence for including 
children and young people in research within the other ethical issues surrounding the research 
section of this chapter. As the literature of healthcare professionals’ experiences and perceptions 
is also limited, I aimed to collect data that could provide depth to our understanding of the 
challenges of providing care for children with low risk febrile neutropenia. This would allow 
triangulation with patient and parent accounts, such that service design issues could be 
considered from all three perspectives. This is explored later in this chapter when considering 
methods used to enhance the credibility of the research performed. The benefits gained from 
including various groups and centres are further expanded on and discussed later in the chapter.  
By beginning to understand these issues and the resultant decision making process, this study 
may then inform the development of future services.  
Research Governance and funding 
This study was presented to the University of York Health Sciences Research Governance 
Committee and received positive feedback and approval. It was then submitted to the NHS 
Research Ethics Committee and was approved (REC reference: 15/YH/0208, see Appendix 5.8 for 
all REC Approvals). Minor amendments were made to the original protocol to accommodate the 
recommendations of the Research Ethics Committee that a time limit be set for withdrawal from 
the study, that there need be no delay in consenting participants once they had expressed a wish 
to take part and that an assistant moderator be present at each focus group discussion.  
Two substantial amendments were made to the original protocol, which are discussed further 
later in this chapter. The first substantial amendment was made prior to the study opening in any 
site. The second major amendment was made following the challenges in recruitment to parent 
and young person focus groups. This amendment was approved by REC on 14th December 2015 
and was implemented at the involved sites within 7 days of this amendment. 
At each site within the study, local Research and Development approval was obtained prior to the 
site opening and for each amendment. Site specific collaborators were identified to act as links 
with myself as Chief Investigator and to take on the role of identifying and approaching eligible 
participants. They were also responsible for highlighting the study to healthcare professionals 
within their centre, encouraging the recruitment of this group to the research. They identified a 
lead research nurse for each project, who carried out much of the site specific collaborators’ work 
and who were my main contact with each site during the conduct of the study.  
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Aims and objectives 
This study aimed to explore experiences and perceptions of outpatient management of paediatric 
low risk febrile neutropenia. It examined decision making about these strategies, specifically 
aiming to identify the factors involved in decision making and the context in which people make 
these choices. It sought the perspectives of patients, parents and health care professionals within 
paediatric haematology and oncology services in the UK. This study investigated the similarities 
and differences between the various groups, and considered how these might be aligned so as to 
provide an acceptable service for all. The main aims and objectives of the study were as outlined 
in Box 8. Balancing the various attitudes and opinions to provide maximal benefits for key 
stakeholders was identified as a potential challenge early in the research process. The decisions 
made in combining preferences or in negotiating tensions surrounding key aspects of the service 
design and the rationale behind these decisions are discussed later in the thesis as part of Chapter 
8.  
Methodology 
To achieve its applied health research aims, this study used a pragmatic approach intending to 
solve particular problems in the care of children with febrile neutropenia, and to identify barriers 
and facilitators to acceptance of reduced therapy regimes. The methods used and discussions of 
findings are theoretically informed so as to provide high quality research with the ability to impact 
on healthcare policy and practice.  
Qualitative methods are an excellent pairing with the quantitative methods used earlier in the 
thesis as they will provide a deeper understanding of why we have seen the results identified in 
Chapter 3 in relation to the low rates of consent to reduced therapy regimes. This combination of 
techniques also allows methodological and theoretical triangulation to identify the problems 
Box 8- Research Questions 
1. What factors influence decision making about outpatient therapy in paediatric low-risk 
febrile neutropenia? 
2. What are the barriers and facilitators to acceptance of an outpatient therapy strategy from 
the point of view of patients, parents and healthcare professionals? 
3. What are the similarities and differences in acceptance between young people, their 
parents and the professionals caring for them? 
4. How can service provision best reflect the views of different stakeholders? 
 120 
 
surrounding the potential implementation of outpatient care of febrile neutropenia in children 
and thus provides credibility to the overarching thesis.  
Qualitative methods allow consideration of the experiences, perceptions and interpretations of 
participants in a detailed manner. As such, they help to expand upon, illuminate and contextualise 
the quantitative findings. They enable participants to talk about the issues relevant and important 
to them; a distinct benefit over quantitative or survey based approaches in which participants are 
provided with a selection of options and asked to select the most significant. The iterative process 
in qualitative methods ensures new and individualised responses can be raised by participants 
and the interactions between factors can be discussed and explored beyond a simple ranking of 
importance. Thus, the use of qualitative methods encourages the expression of uncertainty and 
the complex challenges of dealing with it, which is likely to be particularly important within this 
setting.   
I selected focus group discussions as the method for data collection within this study for six 
reasons: 
First, focus group discussions provide an opportunity to explore normative values and 
assumptions within groups of participants. This allows an understanding of what the group 
processes are when coming to an opinion, through identifying the unspoken knowledge about 
societal norms.(165) Through exploring these, often implicit, aspects of community culture and 
thinking, it becomes clearer why certain choices might be made in preference to others. For 
example, by exploring professional discussions of their concerns about early discharge it became 
more apparent that the normative value is that children within paediatric oncology services are 
considered different to general paediatric populations even when the risks to them are 
statistically similar, and that this is rarely articulated in discussions about service design. Thus 
through the focus group discussion process, participants are encouraged to participate in 
‘retrospective introspection’ in an attempt to identify their own assumptions and to identify the 
nuances in each of them. In my analysis, I further explore these issues and consider the influence 
of the social, cultural and environmental context upon them.  
Second, and leading on from this, focus groups allow for discussions of uncertainty about the 
conflicting normative values and assumptions of different groups within society, particularly given 
that participants often have multiple group identities (such as parent, care-giver, accountant and 
young woman) and these subtly influence their normative beliefs.(165) Thus a focus group may 
provide a space for the identification of value conflicts and for a closer inspection of why these 
occur and how they might be resolved. For example, junior clinicians who have previously had 
general training but now enter the subspecialty and must acknowledge the differences in 
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normative values and assumptions of their new colleagues and then negotiate how they will 
adapt their own views.  
Third, the use of focus group discussions was particularly appropriate in this situation as the 
subject matter is potentially contentious, with multiple possible conflicting viewpoints. Some 
groups may feel that early discharge is an unsafe or unnecessary change to current practice which 
places undue stress upon parents to monitor and treat their child at home. Others might argue 
that the benefits of improved quality of life and reduced service pressures outweigh these 
concerns. Through in-depth focus group discussions, I aimed to provide a clearer understanding of 
these various viewpoints to ensure that the nuances of the debate can be taken into account 
when making changes in care pathways. 
Fourth, given the potential differences of opinion over the role of early discharge in low risk 
febrile neutropenia, focus group discussions also enabled me to examine how social interaction 
may change opinions about the different service design options. The process through which 
participants present their own views, but also how they change or modify their views following 
interaction with others in the discussion, is a particular advantage of using the focus group 
method.(56) The “sharing and comparing” of experiences and opinions can be seen to be a key 
strength of focus group work, and may also reflect the ways in which groups interact outside of 
the research environment through the use of “structured eavesdropping”.(56,166) For example, 
in this research, reflecting how patients and families might share experiences and discuss service 
changes whilst sitting in a clinic waiting room or whilst making a meal in the ward kitchen.  
Fifth, outpatient treatment of low-risk febrile neutropenia was likely to be a treatment strategy 
that some participants had not fully considered. By bringing together groups of people, rather 
than conducting individual interviews, a greater depth of discussion can be achieved as different 
aspects of the problem were considered by different members.(166) Furthermore, focus groups 
can make the expression of dissatisfaction with services easier than within the confines of an 
individual interview, particularly considering that I, the moderator, am a healthcare 
professional.(167) Thus focus groups provided an environment in which the process of reflecting 
on the issue and debating the potential barriers and facilitators could be observed and analysed. 
(168)  
Finally, focus groups have been found to be particularly useful for obtaining qualitative data from 
young people, who may feel intimidated in the one-to-one environment of semi-structured 
interviews.(169) Given that this group have been traditionally under-researched, both in this field 
and elsewhere, I was particularly keen to develop a study which was accessible to them and in 
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which they felt comfortable participating. Thus the decision to use a focus group method was also 
strongly influenced by the desire to hear the ‘voice’ of teenage participants.  
In summary, these six factors combined meant that focus group discussions were felt to be the 
most appropriate method for this study, given its aims and objectives. Although interviews were 
also considered, they would not allow for such thorough exploration of the social context in which 
decisions about the management of febrile neutropenia are most likely to be made.  
Incorporation of the systematic review and qualitative synthesis 
The results of the systematic review and qualitative synthesis are used throughout this qualitative 
study to inform the study design, the focus group topic guides and the analysis of the data, 
consistent with the overarching mixed methods approach to the thesis. Within this section I 
describe how the systematic review and qualitative synthesis impacted upon the design, 
performance, analysis and interpretation of the qualitative study, showing mixing at many levels 
through the work. The systematic review of effectiveness provides evidence that is appropriate to 
perform such a qualitative study. Had the systematic review found that early discharge regimens 
were either unsafe or had particularly high rates of treatment failure, then it would have been 
inappropriate to discuss reduced therapy regimens any further. It also provided the data about 
reduced rates of consent to these regimes and therefore stimulated further research into the 
perceptions of early discharge regimens. The systematic review then provided stimulus 
information for the focus group topic guides, initially by allowing the description of various service 
design options, and then using the results of the meta-analysis to outline the particular safety and 
treatment failure rates for participants to discuss. Thus, the qualitative study did not only address 
generalised opinions of inpatient versus outpatient care but also specifically discussed whether 
the known risks of outpatient treatment influenced the decisions of participants, thus providing 
information which allows the interpretation and application of the systematic review in a way 
which is consistent with the views of key stakeholders. Furthermore, the qualitative study allows 
observation and assessment of the way in which the statistical results of the systematic review 
are viewed by key audiences, thereby informing the findings of the original phase.  
The qualitative synthesis reported in Chapter 4 contributed to the design of this study by 
identifying the current gaps in the primary literature. I was therefore able to focus on participants 
whose perceptions had not yet been explored and could develop aims to complement the existing 
literature. Furthermore, the qualitative synthesis delineated themes that could be identified 
within the discussion and which also made me more aware when participants began to discuss 
new themes that have not been explored elsewhere. Thus, I could probe further into these 
aspects of the conversation so that deeper and more insightful data could be obtained. The 
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synthesis of qualitative studies has also informed the analysis of this research by identifying the 
issues that are specific to febrile neutropenia, compared with those that are more generally 
associated with early-discharge regimens.  
Study site identification and recruitment 
This first stage of this work involved the identification of study sites. The aim of a sampling plan 
should be to enable the collection of material to inform the research question.(167) This can start 
with choosing larger “units” within which participants are grouped.(170) For this study, it was 
appropriate to select multiple study sites within the different Primary Treatment Centres of the 
UK from which to then sample the individual participants.  
I decided to use multiple study locations within the UK to enable investigation of the role of 
various centre-level factors.  Data from a recently published survey were obtained from the 
authors and used to identify centres with different approaches to risk stratification (and tool 
used), low risk protocol (particularly in relation to current timing of discharge), shared care 
services and geographical spread of patients.(40) These features were selected because they were 
thought likely to influence the experiences of participants. For examples, centres which do not 
currently use a risk stratification tool will treat all patients as if at high risk of septic complications 
of their febrile neutropenia and are thus likely to keep low risk patients in hospital for a longer 
duration than those centres where risk stratification is performed. Early discharge may then feel 
like a substantial change from their current practice and there may be more concerns about the 
safety and practicalities of these regimens than for other centres where low risk patients are 
already treated on reduced therapy regimens compared with higher risk patients. Meanwhile, 
centres with a large geographical spread might mean participants are less keen on early discharge 
strategies because of the distance to travel if a child deteriorates in an outpatient setting, or 
because of the challenges of attending clinic for follow-up on a regular basis. Having a large 
shared-care network may ameliorate some of these issues, thus resulting in a more positive 
attitude from participants in these centres. The design of acceptable early discharge services is 
likely to need to take into account these nuances and thus provide different care dependant on 
these factors. 
Four main centres were purposively selected based on the design of their service.  I then 
approached the appropriate centres through known contacts within the paediatric haematology 
and oncology community. I had already created good relationships with the centres through 
professional groups such as the Children’s Cancer and Leukaemia Group (CCLG), and the clinicians 
at these centres had voiced an interest in potentially being involved in this research when the 
plans had been discussed at national meetings. This personal approach allowed centre staff to ask 
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questions about the study before agreeing to participate. At two centres I also gave presentations 
to the healthcare professionals’ at their regular meetings to ensure as many people as possible 
were engaged with the research. The work for the study then involved creating greater links with 
each centre to ensure that key collaborators were identified, Research and Development 
approvals were obtained, recruitment processes were established and practical arrangements 
made for each focus group. 
There was one particular challenge during the recruitment of centres. Although three centres 
were keen to participate when approached, finding a fourth proved challenging. I had originally 
hoped to include a centre where the current treatment of febrile neutropenia involves a length of 
stay of greater than 48 hours. I approached both of the centres that responded to the survey 
stating that this was their practice. Unfortunately, both centres were unable to commit to 
participation in the study, owing to challenges related to workload, their current personnel 
resources, and internal political issues. As no other site within the UK fulfilled these criteria, it was 
not possible to recruit a fourth centre to the study. No other UK centre could be considered a 
reasonable replacement. The study, therefore, does not include centres with long current 
admissions.  
Three centres were therefore involved in the study. Centre 1 has around 25 inpatient beds at the 
Primary Treatment Centre and sees 100-150 new cases of childhood cancer per year. There is 
minimal care of febrile neutropenia in its shared care centres. Centre 2 also sees between 100 and 
150 new cases of childhood cancer per year and has around 25 inpatient beds. Centre 2 has some 
shared care services but the majority of cases of febrile neutropenia are managed in the Primary 
Treatment Centres. The service is in the process of reviewing its febrile neutropenia policy and 
there have been open discussions about how to reduce the burden of treatment for young people 
at low risk of septic complications. The final centre, Centre 3, treats over 160 new children per 
year in their unit, which has more than 30 beds. They have a strong shared care network involving 
multiple Paediatric Oncology Shared Care Units (POSCUs) and the majority of episodes of low risk 
febrile neutropenia are managed outside of the Primary Treatment Centre. This is consistent with 
three other centres within the UK.   
The study opened in July 2015 in one centre and in October 2015 in the other two centres. Focus 
group discussions generally took place within 2 weeks of recruiting the final participant, 
dependent upon finding a date that was convenient for all. In all centres, the healthcare 
professional groups recruited most easily and were performed between 9 and 16 weeks from the 
study site opening. Focus groups for parents of children under the age of 13 years took place 17 
to 29 weeks after study site opening. The groups for young people and parents of children over 
the age of 13 took place 38 weeks after opening in Centre 1. As discussed in detail later in this 
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chapter, recruitment young people and parents of children over the age of 13 in centres two and 
three was difficult, and hence focus groups were not formed.  
Analysis of protocols 
In order to prepare for the focus group discussions and inform the analysis of the discussions 
observed, the febrile neutropenia protocol for each centre was obtained. These were reviewed 
and compared with the NICE guidelines for neutropenic sepsis.(21) As Table 17 demonstrates, the 
NICE guidance was generally followed, though certain deviations were present and will be 
highlighted within this section. All centres use the NICE definition of neutropenia and centres 1 
and 3 also use the NICE definition of fever, with centre 2 choosing a slightly higher threshold for 
diagnosis.  
Table 17 - Summary of febrile neutropenia protocols from each centre alongside NICE guidance 
 NICE CG151 Centre 1 Centre 2 Centre 3 
Definition of 
fever 
Higher than 
38°C 
≥38°C >38.5°C on one occasion 
or >38°C on two or 
more occasions 
recorded at least 1 hour 
apart 
≥38°C 
Definition of 
neutropenia 
≤0.5x109/L ≤0.5x109/L <0.5x109/L ≤0.5x109/L 
Risk 
stratification 
Advised 
Suggests 
modified 
Alexander rule 
Yes  
Modified 
Alexander 
rule 
Yes  
SPOG 2003 rule (Note: 
currently not used to 
discharge patients) 
Yes 
Modified 
Alexander rule 
First line 
antibiotics  
IV Piperacillin 
with 
tazobactam 
unless there 
are patient-
specific or local 
microbiological 
indications 
IV Piperacillin 
with 
tazobactam 
IV Piperacillin with 
tazobactam for 
standard risk patients, 
Oral ciprofloxacin and 
co-amoxiclav for low 
risk patients (not 
currently in use). 
IV Piperacillin/ 
tazobactam and IV 
Gentamicin 
(except patients 
with bone 
tumours) 
Timing of 
discharge for 
Consider 
outpatient care 
Step down to 
oral 
According to risk tool, at 
8-22 hours but not yet 
48 hours with oral 
co-amoxiclav 
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low risk 
patients 
for low risk 
patients 
ciprofloxacin 
and co-
amoxiclav at 
24 hours then 
discharge 
from 48 hours 
approved, therefore 
treated as per standard 
risk patients and eligible 
for discharge at 36-48 
hours 
 
Centres 1 and 3 follow protocols which closely match the NICE guideline, with the addition of 
gentamicin to the standard antibiotic regime in Centre 3 being due to local microbiological 
indications. Centre 2 appears to be the most different in terms of their management of febrile 
neutropenia. This is a centre in the process of transitioning between management strategies. 
Therefore, although the protocol describes the SPOG rule and then risk stratified treatments 
including oral antibiotics with early discharge for children with low risk febrile neutropenia, there 
are clear notes within the document advising staff that these changes are not to be implemented 
and that currently all patients should follow the standard risk protocol, which involves a 48 hour 
admission for intravenous antibiotics. Therefore, all included centres currently follow a protocol 
that involves a roughly 48 hour admission with administration of intravenous antibiotics for at 
least 24 hours in low risk patients.  
This exploration of the written protocols gives a contextual grounding to the focus group 
discussions.  It allows consideration of the extent to which these protocols have been translated 
into the clinical practice described by participants. Areas where participants describe different 
behaviour to the protocols are explored later in the thesis, and the influence of the centre culture 
is examined so as to give greater understanding of the issues surrounding a move to outpatient 
care of paediatric low risk febrile neutropenia. 
Identification, recruitment and consent of participants 
Four focus group discussions were planned in each of the three study sites (i.e. 12 focus groups, 
see Table 18).  Separate focus groups were offered for each of the following categories of 
participant: 
 Patients (age 13-18 yrs) 
 Parents of teenagers (13-18 yrs) 
 Parents of younger children (under 13 yrs) 
 Healthcare professionals 
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For the purpose of this study, patients and their parents/caregivers were only invited to 
participate if the patient was considered to be at risk of low risk febrile neutropenia, or within 6 
months following being at risk. This was assessed using the modified Alexander rule (121), as this 
is the tool advised by the NICE guidelines, and was defined as requiring all of: 
1. Current age >1 year 
2. Currently receiving myelosuppressive chemotherapy or radiotherapy, or within 6 months 
following completion of final course 
3. NOT any of:  
a. All leukaemia except Acute Lymphoblastic Leukaemia (ALL) on maintenance 
chemotherapy for at least one month 
b. B Cell Non-Hodgkin's lymphoma  
c. Any high dose chemotherapy regimen requiring stem cell support within the last 
90 days 
d. Allogeneic bone marrow transplant recipient within the last year 
4. NOT receiving palliative care alone   
I chose to exclude both high risk patients and patients receiving palliative care alone, as the 
perceptions of these groups were likely to be substantially different to those of patients who may 
potentially have episodes of low risk febrile neutropenia. Given that the main aims of the study 
relate to understanding perceptions of management and providing key features of an acceptable 
service design for children with low risk febrile neutropenia, I worked to ensure that the study 
included participants who were most likely to fall within this group. Although I recognise that it is 
the episode of febrile neutropenia that is ultimately risk stratified, I aimed to include those 
patients who might be eligible for an outpatient regimen and thus excluded patients on highly 
intensive courses of treatment. Patients receiving palliative care alone are generally managed 
according to patient choice and as such are unlikely to be treated strictly according to such 
protocols, even if instituted.  
Participants in the young people’s focus group discussions were between 13 and 18 years old. This 
age range was selected as this group of patients are generally treated in Teenage and Young Adult 
Services, compared to paediatric services for those under 13 years old, and hence this is a 
clinically meaningful age cut-off in the design of services. Each of the Teenage and Young Adult 
services involved is situated within the same centre, and provided predominantly by the same 
team, as the paediatric services included. However, teenage patients tend to be managed in 
slightly different environments (separate wards or beds specifically for teenage patients within 
the Primary Treatment Centre) and therefore may have a different experience of care.  
I recognise that the age range for the teenage group is rather broad and that participants aged 13 
and 18 may actually be very different developmentally and socially. This could mean that the 
focus group discussions for this group of participants would be more difficult to moderate.  
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However, there were two main reasons for choosing to accept this potential difference. The first 
is a very pragmatic reason, in that there are very few teenagers diagnosed with a malignancy 
between the ages of 13 and 18 each year in the UK. When the patients with non-Hodgkin’s 
lymphoma, most haematological malignancies and those who receive high dose therapies are 
excluded, the number of potential participants are even smaller. Given that this age group are 
known to often be quite difficult to recruit to research studies, having a broader age range was 
felt to beneficial in increasing the rates of recruitment. The second reason for accepting a broad 
age range for the TYA groups was that the main area of interest for the study is the experiences 
and perceptions of patients with low risk febrile neutropenia. Therefore, as all participants would 
be able to contribute to a discussion of this area, these groups were actually relatively 
homogenous, and differences in age, opinions or social structures were only likely to be as 
relevant to this group as they were to the parental or healthcare professional groups, where 
similar diversity in age or social positioning was likely to occur. The experiences of recruiting to 
and moderating of teenage focus groups are discussed later in this chapter.  
Participants were invited with a view to obtaining maximal diversity based on age, gender, 
ethnicity, socioeconomic/educational group, diagnosis, family structure, number of siblings, 
distance from home to hospital, likely location of treatment of febrile neutropenia (Paediatric 
Oncology Shared Care Unit/Primary Treatment Centre) and previous febrile neutropenia 
experience (including both high risk and low risk episodes). (171) The successes in achieving this, 
the challenges I faced, the reasons for these difficulties and the impact upon the findings are all 
discussed in the following sections of the chapter. 
Parents and caregivers of selected children were also invited to take part in one of the focus 
groups. Parents and caregivers of children under the age of 13 were eligible to take part in a 
separate focus group, provided the index patient met the low risk criteria given. Separate focus 
groups for parents of children aged under 13 and over 13 were performed as it was anticipated 
that these groups would have different opinions about the services to be provided for their 
children. Both of a patient’s parents were eligible to be involved if they were interested. This 
occurred twice within the groups. For the young people over the age of 13, it was not a 
requirement that both patient and parents/caregivers take part in the study. However, in most 
cases, this did occur as both parties shared similar views about the research. Parent couples and 
parent-child dyads were not explicitly recruited nor were they excluded, but I took note when this 
occurred and used this data to inform the findings. 
Health care professionals from the teams looking after these children were invited, also in a 
purposive way, to give maximal diversity around the areas of age, gender, ethnicity, professional 
background (only doctors and nurses working actively with children and young people with low 
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risk febrile neutropenia), and level of experience. Table 18 shows the focus groups performed at 
each centre. 
Table 18 - Summary of focus group discussions 
 Healthcare 
Professionals 
Parents of 
patients aged 
under 13 years 
Parents of 
patients aged 
over 13 years 
Young People 
aged 13-18 
years  
Centre 1     
Centre 2     
Centre 3     
Key: Green – focus group performed, Red – focus group desired but precluded by poor 
recruitment 
Participants had to be able to participate in focus group discussions in English. This reflected the 
practicalities of being an English speaking researcher but was also justified as the majority of 
people from an ethnic minority have English as their first or second language and thus the study 
was likely to obtain breadth and depth of concepts without the need for interpretation. There are 
a number of potential difficulties facing participants who do not have English as a first language, 
particularly in understanding the frequently rapid flow of focus group discussions, or in 
understanding the idioms which are often used by those for whom English is the first language. I 
closely observed participants within the focus group for signs that they did not understand the 
language used and aimed to provide further explanation when complex issues were raised.  
The choice to include only English language speakers does mean that some participants who do 
not speak English might be excluded. This group of participants may face particular challenges 
when a child is diagnosed with cancer and may have additional concerns about reduced therapy 
regimes, which relate to both language and cultural differences. These may differ across cultural 
groups and would therefore require a particularly large study to explore. The challenges of 
interpretation, recruitment and analysis are beyond the scope of this study and therefore, readers 
must take into account that this group have not been approached. The clinical application of the 
findings therefore may not be appropriate for this group, and particular care should be taken 
when reduced therapy regimes are being offered to those for whom English is not their first 
language and thus reporting problems and re-accessing care may be more problematic. 
Patients and caregivers were identified and invited by their local team to participate in the study, 
and were provided with appropriate participant information sheets. In the case of healthcare 
professionals, participants were invited to take part through announcements at local team 
meetings and through emails sent by the site specific collaborator (see Appendix 5.2).  
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There were five different participant information sheets for this study, so as to cover the five main 
groups who needed to be informed about the work (see Appendix 5.1). These were: 
 Young people aged 13-16 years, who were asked to give assent for their own 
participation 
 Parents of young people aged 13-18 years, who were asked to give consent for 
their children to participate  
 Adult patient participants aged 16-18 years, who were asked to give consent for 
their own participation 
 Parent participants (parents of children/young people at risk of low risk febrile 
neutropenia), who were asked to give consent for their own participation 
 Healthcare professionals, who were asked to give consent for their own 
participation 
Prior to the submission of the study for ethical review, draft participant information sheets were 
reviewed by young people, parents and healthcare professionals. The young people were of 
varying ages from 11 to 18 years and were being treated within paediatric haematology and 
oncology services. I specifically asked younger people to review the information sheet than would 
be eligible to take part, to ensure that they were comprehensible to those with a younger reading 
age. I checked with all young people that they understood the terminology used, in particular the 
phrase ‘febrile neutropenia’ and all were very clear that this was familiar to them and did not 
need to be changed. Parents of children of all ages were also asked to review the information 
sheets and stated similar agreement with the young people, that the sheets were understandable, 
clear and covered all their questions. I approached only patients and parents who would not be 
eligible to take part in the study to review the participant information sheets so as not to reduce 
the pool of potential participants for the study. However, all those who reviewed the participant 
information sheets stated that, based on the information sheet, they would have been keen to 
take part if they had been eligible. All feedback about changes to the information sheets was 
taken on board and incorporated into the versions submitted to the ethics committee. 
When potential participants had read the patient information sheets, they were asked by the local 
team if they were interested in taking part in the study, and if so, verbal consent was obtained to 
share their name, address and telephone number with the study team. After this verbal consent 
had been given, the study team then contacted the potential participants to obtain consent for 
the study and to determine their availability for the focus groups. In the case of participants under 
the age of 16, consent was sought from someone with parental responsibility, but the assent of 
the participant was also essential for entry into the study.(172)   
 131 
 
Participants were made aware that they could withdraw from the study at any point up to two 
weeks following the focus group discussion and that a decision to withdraw would not impact on 
clinical care. They were made aware that should they withdraw, all personal data that they had 
provided up to that point would be removed from the study. Their quotations from the focus 
groups would not be used in the analysis or any reports and publications. However, the rest of the 
data from their focus group (which related to other participants’ quotations) would continue to 
be used.  
The time limitation in the right to withdraw from the study was advised by the Research Ethics 
Committee. It reflects the challenges of analysis within qualitative research should a participant 
withdraw from the study at a point when the key themes and arguments have been identified and 
the thesis is on the verge of submission. Furthermore, it was felt that participants who had not 
felt the need to withdraw after this ‘cooling-off’ period following the focus group, were unlikely to 
wish to do so at a later point. The participants within the study were comfortable with this aspect 
of the research process and no participant chose to withdraw from the study following their 
participation in a focus group.  
Patient participants were also asked for permission to inform their GP about their participation in 
the study. (See Appendix 5.6.) The GPs of parent or healthcare professional participants were not 
informed. 
Immediately prior to the focus group, the patient/caregiver participants were asked to complete a 
basic data collection form providing: 
1. Name, age, gender, ethnicity 
2. Address (to obtain distance from hospital) 
3. Family structure 
4. Data on socio-economic level – to include occupation of parent(s), parents’ highest 
educational level and the family’s housing situation 
5. GP (to inform about participation in the study)  
Young people were encouraged to involve their parent(s)/caregiver(s) in this process to ensure 
that as much detail as possible was provided. 
After the focus group in which written consent had been obtained, the local team were asked to 
provide the following data for each index patient: 
1. Diagnosis (and date of diagnosis) and treatment regimen (including current/most recent 
course) 
2. Dates of previous episodes of febrile neutropenia, whether each episode was low or high 
risk, location of treatment (POSCU/PTC), treatment received, duration of admission, 
complications arising. 
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Healthcare professionals were asked to provide their name, age, gender, ethnicity, profession, 
grade, time spent at current grade, and time spent at current centre. All basic data collection 
forms are provided in Appendix 5.4. This information was used to inform trends within the data 
and to further understanding about the influences on perceptions of early discharge. 
Focus Group Participants 
The participants in the study are described within this section. As mentioned earlier in this 
chapter, the study faced substantial challenges related to the recruitment of participants, which 
will be discussed further in this section and the one that follows. The aim is to consider the 
representativeness of the sample and how this impacts upon the findings of the study. This 
process complements the reflexive nature of the study as a whole and is included within this 
methodology chapter because it explores many of the methodological issues surrounding 
recruitment and then informs the later chapters on the conceptual findings of the work. 
Whilst the healthcare professionals groups recruited well at all centres, parents and young people 
were less easy to recruit. Potential participants reported various different reasons for declining to 
take part, including difficulties with childcare during focus groups, distance of travel and a 
preference not to come to the hospital on days when they did not have treatment. Some of these 
problems were difficult to solve, but I did realise that there was a need to recognise the time 
commitment of participants. I therefore applied for further funding and submitted a substantial 
amendment to the Research Ethics Committee to provide parent and young person participants 
with a £20 Amazon voucher. Following implementation of this amendment the recruitment rates 
to the study appeared to increase; the rates of acceptance of the Amazon vouchers were high, 
whilst travel expenses claims were minimal. 
In addition to these changes, various steps were taken to reduce the rates of non-attendance at 
focus groups.  However, the majority of groups experienced at least one non-attender. For one 
group, the number of non-attenders was sufficient to mean that the discussion could not take 
place on that occasion and hence was rearranged for another time. The reasons for the majority 
of the non-attendances were unknown as participants did not contact any member of the 
research team before or after the group to explain. In situations where the reasons for non-
attendance were given, child-care issues predominated for parents and clinical pressures for 
healthcare professionals. No withdrawals occurred following the performance of any focus group 
discussion. 
The composition of each of the focus groups is outlined in Table 19. In total, 13 healthcare 
professionals participated in the discussions, of whom six were medical and seven nursing staff 
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who were evenly distributed through the groups. Participants of various professional grades had 
been purposively recruited. There was a wide range of experience within the specialty of 
paediatric haematology and oncology, and within each centre. The majority of healthcare 
professionals who took part were female (10 female, 3 male). The gender imbalance was more 
pronounced in the nursing participants, which reflects the workforce structure in this area. All the 
male healthcare professional participants took part in the focus group conducted at centre 1. The 
majority of participants self-identified as white British, with a mixture of other ethnicities. The 
focus group at centre 3 was the most homogenous, containing three white British women.  
In the groups for parents of children under the age of 13 years, there were 11 participants, the 
majority of whom were mothers. They were between 35 and 44 years old, all described 
themselves as White British and all were in committed relationships. They had between two and 
seven children of varying ages. In centres 1 and 3, all participants were employed. In centre 2, the 
majority of participants were not currently employed. Participants had a wide range of 
educational levels.  Their partners’ educational and employment levels were similar to their own. 
Seven participants were owner occupiers, with 4 participants renting their homes.  Both parents 
from one family participated, therefore there were ten affected children represented.  
The affected children were between 2 and 10 years old. Six children had ALL, two had brain 
tumours, and two had other solid tumours. These index children had experienced between two 
and 10 episodes of febrile neutropenia each. The majority of episodes were high risk. In centres 1 
and 2, almost all episodes were managed in the PTC; in centre 3 all were initially managed in a 
POSCU (Paediatric Oncology Shared Care Unit). Only one child had ever been admitted to a 
paediatric intensive care unit (PICU). The most common complication was a delay in the 
administration of the next course of chemotherapy. The duration of admissions for febrile 
neutropenia was between 2 and 19 days, with the median duration of admission being slightly 
longer at centre 2 than elsewhere. 
In the focus group for parents of children over the age of 13 years, there were 5 participants; 3 
mothers and 2 fathers. These participants were understandably older than in the other parent 
groups, being 41-53 years old. They all described themselves as White British. Three were from 
nuclear families with 2-3 children, one couple (both parents present) were a blended family with 
three children. There were a range of educational levels and the majority were employed. Their 
partners were of similar educational and employment levels. All owned their own house.  
The four index children were 13-16 years old. Two children had Hodgkin’s disease and two had 
ALL, one of whom had relapsed disease. Two children had minimal experience of febrile 
neutropenia (one or fewer low risk episodes, no high risk episodes). The other two children each 
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had 6-7 previous episodes of febrile neutropenia, the majority of which were high risk episodes. 
All episodes had been treated at the PTC, although two had presented to the local POSCU and 
then been transferred in to the PTC. No patient had ever been admitted to intensive care, but two 
course of chemotherapy had been delayed. The duration of past febrile neutropenia episodes was 
2 to 10 days, with the majority being 5-6 days.  
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Table 19 - Table of focus group composition 
Location Group Number of 
participants 
M:F 
ratio 
Age Ethnicity 
(self-defined) 
Composition notes 
Centre 1 Young 
people 
3 0:3 15-16 
years 
3 White British 2 participants with Hodgkin’s disease, one with ALL. One participant with no febrile 
neutropenia episodes, one with one low risk episode, one with 6 high risk episodes. 
All episodes treated at PTC (two episodes started at POSCU but transferred to PTC).  
No ICU admissions. One course of chemo delayed following high risk episode. 
Admissions 2-10 days (most 5-6 days). 
Centre 1 Parents of 
Under 13s 
3 0:3 36-43 
years 
3 White British All nuclear families with two children. 2 degree level education, one GCSE level. All 
employed. Partners same educational and employment. Two own house, one rents 
privately.  
Affected children aged 4-10 years. Two ALL, one medulloblastoma. Between 2-10 
episodes of FN; 0-8 high risk episodes each, 1-2 low risk episodes each. All managed 
at PTC. No ICU. One removal of line. One delayed course of chemo.  Admissions  2 - 
19 days (most 48-72 hours) 
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Table 20 - Table of focus group composition 
Centre 1 Parents of 
Over 13s 
5 2:3 41-53 
years 
All White 
British 
3 nuclear families with 2-3 children. One blended family (both parents present), with 
three children. One degree level education, one A Level, one ONC, two GCSE level. All 
employed except one who is semi-retired (to care for child). Partners same 
educational and employment levels. All own house, four with mortgage. Four have 
children who participated in young people’s group. 
Affected children 13-16 years old. 2 with Hodgkin’s disease, one with ALL, one with 
relapsed ALL. One patient with no febrile neutropenia episodes, one with one low 
risk episode, one with 6 high risk episodes, one with 7 high risk episodes and one low 
risk episode. All episodes treated at PTC (two episodes started at POSCU but 
transferred to PTC).  No ICU admissions. Two courses of chemo delayed following 
high risk episodes. Admissions 2-10 days (most 5-6 days). 
Centre 1 Healthcare 
Professionals 
7 3:4 30-51 
years 
6 White British, 
1 Chinese 
3 medical (SHO, registrar and consultant), 4 nursing (bands 5-7). 1-13 years at current 
grade. 1-24 years at current centre. 
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Table 21 - Table of focus group composition 
Centre 2 Parents of 
Under 13s 
5 1:4 35-44 
years 
All White 
British 
All nuclear families with 2-7 children. Two participants from same family. Three with 
degree level education, two with O levels. One employed, four homemakers/carers. 
Partners – one degree level education, one A levels, one HNC, two with O levels. 2 
employed, one self-employed, two homemakers/carers. Three own house (two with 
mortgage), two rent privately. 
Affected children 2-9 years old. Diseases relapsed Wilm’s tumour, ALL, osteosarcoma, 
ependymoma. 2-7 episodes of febrile neutropenia; 1-5 high risk episodes each, 0-2 
low risk episodes each. All but one managed in PTC. No ICU admissions. One course 
of chemo delayed. Admissions 2-14 days (median 4 days). 
Centre 2 Healthcare 
Professionals 
3 0:3 43-60 
years 
1 White British, 
1 Indian 
(British), 1 
Pakistani 
2 medical (registrar, consultant), 1 nursing. 7 months - 20 years at current grade. 7 
months - 28 years at current centre. 
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Table 22 - Table of focus group composition 
Centre 3 Parents of 
Under 13s 
3 0:3 36-45 
years 
All White 
British 
2 nuclear families with two children. One blended family with 7 children. One A level 
education, 2 O level. All employed. Partners same educational and employment 
levels. Two own house (with mortgage), one rents from Local Authority.  
Affected children 4-8 years old. All with ALL. 4-9 episodes of febrile neutropenia; 1-8 
high risk episodes each, 0-3 low risk episodes each. All in POSCU (one later 
transferred to PTC). One admission to PICU after high risk episode. 3 delayed courses 
of chemo after high risk episodes. Admissions 2-14 days (most 48-72hrs). 
Centre 3 Healthcare 
Professionals 
3 0:3 30-55 
years 
All White 
British 
1 medical, 2 nursing (band 7). 3-12 years at current grade. 5-12 years at current 
centre.  
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The participants in the young people’s group all had parents who had participated in the relevant 
focus group discussion. These young people were 15-16 years old, all female and all described 
themselves as White British. Two had Hodgkin’s disease and one had ALL. Two had minimal 
experience with febrile neutropenia and one had considerable experience with high risk disease.  
Further details, including family demographics, are discussed in the paragraph relating to their 
parents.  
Discussion of recruitment difficulties and implications for findings 
This study aimed to purposively sample participants from a broad range of ages, genders, 
ethnicities, socio-economic backgrounds, family structures, locations of home and care, and 
previous febrile neutropenia experiences. Although these aspirations were attained for some 
factors, including age, gender, location of care and previous febrile neutropenia experiences, the 
sample was limited in terms of ethnicity, socio-economic background and family structures. 
Within this section of the chapter and consistent with the reflexive nature of this research project, 
I reflect upon potential reasons for the recruitment challenges and what these may mean for the 
findings of the research as a whole. 
There are a number of reasons why these difficulties in recruitment may have occurred. First, the 
staff involved in recruiting to the study at each centre may have made judgements about which 
participants would be most likely to be interested in such a study, and therefore affected 
recruitment of certain groups through their choices of people to approach or their presentation of 
their research to these groups. One research nurse had raised this particular issue with me during 
one contact discussion, stating she was specifically approaching only participants who lived close 
to the location of the focus group discussion. At this point, I stressed the importance of having a 
wide variety of views present and therefore a desire for sample diversity, which she appeared to 
take on board. However, it is still possible that pre-conceived ideas about potential participants 
continued to play a part in the recruitment at this and the other centres. These challenges of 
using ‘gatekeepers’ to access participants have been described in the literature.(56) 
The second possible explanation for the lack of diversity in certain areas may be that particular 
groups of people chose not to take part in the study. This could be that potential participants are 
not interested in participating in research of any type, or are choosing not to participate in this 
study specifically. The parents who choose to participate in focus groups are most likely to be 
those who are actively involved in their child’s treatment, who are more likely to engage with 
treatment plans when discharged, and who want to contribute to improving future services. They 
may also be the participants who have strong opinions about the current care of children with 
febrile neutropenia and may be more likely to be the parents who are dissatisfied with the care 
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which is currently given, particularly as the information given to participants joining this study 
clearly states its intentions to consider ways to redesign services. The parents of children under 
the age of 13 at Centre 2 astutely identified the issues surrounding parent involvement in the 
following exchange of conversation:  
“4: yeah but what I’m saying is there’s parents that perhaps think well I can’t be 
bothered to go in 
5: them parents aren’t here are they? 
Rest: no 
5: that speaks for itself doesn’t it so?” (Centre 2, parents of under 13s) 
Population groups who are very busy, or time-poor, are likely to struggle to attend groups, even 
when they have an interest in the research area. This explains the given reasons for non-
attendance, with parents being busy caring for children and attending treatment, whilst 
professionals have significant clinical commitments. Linked to this, some parent and young people 
participants commented on the regularity of their attendance at hospital and a desire not to make 
any further trips in order to participate in the research. Unfortunately, attempting to hold groups 
which co-ordinated with their clinic visits would have been logistically impossible given that 
participants have appointments at different times.  
For the healthcare professionals group, participants of more junior grades might have felt less 
inclined to take part in the research, given that they are not used to being asked their opinions 
about care and how it should be changed. As conveying these kinds of opinions is usually the role 
of more senior healthcare professionals, social norms may have prevented junior professionals 
from attending discussions. I made specific attempts to prevent this by asking local contacts to 
approach junior colleagues and emphasise how important all opinions were in this work. Despite 
this, the group at Centre 3 consisted solely of senior professionals. 
The challenges for participants for whom English is not their first language, have already been 
discussed earlier in this chapter. This did not seem to be a problem within the groups, given that 
the majority of participants had English as their first language. Two healthcare professionals did 
not speak English as their first language, but used it extensively in their working lives and so did 
not appear to struggle with the content of the focus group discussions. However, other 
participants may have chosen not to participate because of their concerns about being unable to 
follow a discussion carried out in English.  
In the final point about the possible reasons for the recruitment difficulties, it is important to 
discuss what may have precluded holding the young people’s groups in centres 2 and 3. Along 
with the issues mentioned above, there were additional challenges obtaining teenage 
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participants. First, the numbers of teenagers diagnosed with cancer each year are thankfully 
small, but results in a small pool of potential participants to invite at each centre. Furthermore, 
teenagers tend to be particularly busy with school, exams and work, especially during 
maintenance therapies for their cancer. As this makes up a considerable portion of the population 
at risk of low risk febrile neutropenia, this had a dramatic impact on both willing participants and 
successful date setting for these groups. In addition, a number of teenagers who were 
approached to participate in the group stated that they would be prepared to take part in 
individual interviews about their thoughts and experiences but were reluctant to talk within the 
group setting. This was somewhat at odds with the rationale for selecting focus groups methods 
for this study discussed earlier in this chapter. 
Next I consider the potential implications of the difficulties in recruitment to the study. The aim of 
including varied groups of participants was to draw out broad similarities and differences from 
this diverse sample, instead of noting individual differences between participants. Some aspects 
of this aim were potentially compromised by the difficulties in the recruitment and these are 
primarily reflected in two areas.  
The first is that the voice of young people within the findings is less prominent than that of the 
parents and health care professionals. This is in part due to the smaller numbers of participants 
and the single focus group when compared to the other participant groups. This group were also 
relatively reserved in their discussions and required more prompting and encouragement to 
participate than the adult groups. The young people’s group was the shortest discussion within 
the study, lasting 45 minutes. When they did articulate their experiences and perceptions, the 
young people generally expressed views which were consistent with the parental groups, 
although often with less nuance and depth to the concepts. This may be due to the small size of 
this group, with less people to further the discussion, but may also represent different ways of 
considering the issues. Where the young people’s voice coincides with the parental views, I have 
aimed to highlight this within the presentation of the analysis. Where the young people’s 
experiences are at odds to their parents or the healthcare professionals’ perceptions of them, I 
have provided further discussion. Further work which could be done to investigate and represent 
the teenage voice in this area is discussed within Chapter 9.  
The second area to discuss in relation to the implications of the recruitment problems is the issue 
of diversity in family structure. It is known that compliance to home maintenance therapy for 
children with leukaemia is strongly associated with family status, where patients whose parents 
are not in stable partnerships are less likely to be compliant. (173) This is relevant to the issue of 
febrile neutropenia as this may also apply to administration of home antibiotics. Furthermore, 
these parents might have different preferences when it comes to the location of care – either 
 142 
 
preferring to stay in hospital where they may feel they have more support, or having more 
responsibilities at home that cannot be easily shared and therefore be much more keen on early 
discharge. As this study was unable to recruit from this group, it is difficult to be sure about these 
issues, although the included participants did discuss these issues. Their views are presented later 
in Chapter 7.   
Focus group discussions 
Each group aimed to include between 5 and 8 participants. After participant details had been 
given to me and they had confirmed their interest in the study, I began to identify potential dates 
for the focus group discussion. Once I had contacted all participants, the date which suited the 
most participants and which both I and the assistant moderator could attend was chosen as the 
date for the discussion. The process of identifying potential dates could take a number of 
telephone calls to participants and frequently took two to three weeks of chronological time. The 
date for a discussion was not set until at least 5 participants had agreed to attend on that date. 
Participants were then contacted to confirm the date and time of the focus group. Other 
participants who were recruited following date setting were invited to attend at this specific date 
and time.  
I contacted each participant a few days prior to the focus group to remind them of the date, time 
and location and to attempt to reduce the number of participants who did not attend. At the time 
of the focus group, if three or more participants attended then the discussion proceeded as 
planned. At all focus groups, at least one participant failed to attend, despite the efforts made to 
reduce the likelihood of this occurring. If fewer than three participants attended, the group was 
cancelled and rearranged for another date. This occurred on one occasion, with all the original 
participants also attending the second group.  
In one healthcare professional group, a participant arrived very late due to unexpected clinical 
work. Given that the discussion was well established by this point, including the introduction of 
the systematic review results, I felt that introducing a new member to the discussion at this point 
would be detrimental to the group. I therefore thanked the new participant for coming but asked 
that they not take part in the group at this point. They were very understanding of this and the 
group then continued from where it had been interrupted. 
Focus groups were held in private meeting rooms in a convenient location (see also Rapport 
building, engagement and participant experience section of this chapter) and at a convenient time 
for the participants.(168) Each focus group session lasted between 45 and 86 minutes (median 73 
minutes), with 30 minutes or so prior to starting the discussion used to allow participants to 
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review the information sheet, complete consent and data collection forms, and ask any questions 
about the study. Thus in total, most participants spent 90 minutes to two hours attending the 
group. 
I facilitated each focus group session. An assistant moderator, HH, who is also a junior doctor and 
a researcher, attended each group to provide additional practical support and also aimed to 
record data on ordering of speech and any non-verbal communication. An assistant researcher 
plays a key role in the performance of focus group studies. They facilitate the smooth running of 
the group by assisting with practical aspects such as group set-up and attendance to matters 
arising during a group.(168) In this study, this involved entertaining children who had been 
brought to two groups as families had struggled with child-care and taking consent from late-
comers to two groups. Assistant moderators also help through the recording of key information 
during the group so as to provide a backup in case of the loss of the digital recording and to help 
with the ordering of speech when transcribing from the recording.(167,168) Finally, they act as an 
observer within the group, noting non-verbal behaviour, participant responses and interactions. 
They can therefore help the primary researcher through de-briefing discussions to record initial 
responses to focus groups and identify key areas for discussion within the findings. 
The researchers performing or assisting in focus groups had an enhanced CRB check and the 
research complied with all guidance issued as part of the Government sponsored Vetting and 
Barring Scheme.(174)  
Researchers carried photographic identity cards at all times to reassure participants of the 
academic nature of the study. Policies of the University of York for the physical and emotional 
protection of researchers were followed throughout the study to ensure that the researcher and 
assistant were safe during each episode of field work. Mechanisms were in place for any difficult 
or distressing situations for researchers to be debriefed by Professor Karl Atkin and followed up as 
appropriate. Thankfully, no such situation occurred.  
All focus group discussions began with a reminder of the aims of the study, and with the setting of 
ground rules. The main ground rules for the study were to respect other participants and their 
opinions, and to keep confidential the things that were shared in the focus group. I also 
encouraged participants to talk freely, as the main aim of the study was to find out about their 
experiences, perceptions and the influences on decision that they make about febrile 
neutropenia. Finally, I used this time to restate the right to withdraw from the study up to two 
weeks following the focus group and gave the opportunity for participants to ask any outstanding 
questions.  
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Participants in the focus groups for healthcare professionals were reminded that the research 
team were only interested in their general views and would not be discussing the details of 
individual cases. It was clearly explained that if identifiable information was given about a patient 
then, on the first occasion, this part of the discussion would be interrupted and participants 
reminded of the need to keep patient information confidential. On the second occasion of 
providing identifiable information, the focus group discussion would be discontinued. 
Topic guides were prepared for the focus group discussions so as to provide structure to the 
‘guided conversations’.(175) The guides were informed by the findings of the syntheses of 
quantitative and qualitative studies described in Chapters 2 and 4 respectively. (144,176) 
Discussions with key stakeholders also aided in the development of the topic guides, which were 
reviewed by qualitative researchers and healthcare professionals from other centres in the UK 
who were therefore not eligible to be participants. The focus group topic guides are provided in 
Appendix 5.5. 
The introductory questions for groups of young people and parent participants focused on their 
understanding of febrile neutropenia and experience of treatment for previous episodes of febrile 
neutropenia. This provided an opportunity for participants to become comfortable speaking in the 
focus group environment and also allowed the moderator to introduce the idea of risk 
stratification of episodes and differences in current treatment strategies. It provided the data that 
allowed consideration of the influence of past experiences on future acceptance of early 
discharge, and was used as key information within the analysis. 
I then introduced the idea of different possible treatment strategies based upon those found 
within the literature of the systematic review within Chapter 3 (without providing the detailed 
evidence from the systematic review) and allowed participants time to discuss the various 
options. This allowed me to establish initial responses to a reduced therapy regime and then later 
identify the role of data in shaping and changing these responses, if this happened at all. 
The treatment failure, admission and safety rates were then brought into the discussion based on 
the information obtained through the meta-analysis in Chapter 3 and further discussion about 
preferences was encouraged.(144) I explored how participants responded to the data, both in 
their understanding and attitudes towards early discharge.  
The focus group discussion was then guided to the issue of outpatient treatment and I probed 
into the different factors involved in decision making about this option. In particular, I asked 
about the various issues identified by the qualitative synthesis in Chapter 4, being sure to note 
which issues were raised spontaneously by participants and which required prompting.(176) The 
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aims of this process were to provide as much clarity and depth to the data as possible and to 
allow the further consideration of the concepts seen within the Qualitative Synthesis.   
The questions following this then focused on the influence of other members of the family and of 
healthcare professionals on the perceptions of participants. This section of the focus group 
intended to explore the social and environmental influences on the decisions made about 
outpatient therapy, and to give more contextual data for the analysis of different preferences. 
Furthermore, this allowed me to investigate the nature of triadic decision making in this setting 
and the influence of the power balance within triads when making choices.  
Finally, participants were asked about how the specific aspects of an outpatient service could be 
designed so as to make it most acceptable to them. This allowed the consideration of how 
different issues could be resolved in the most acceptable way for participants.  
Meanwhile, the focus group discussions for health care professionals used a similar thread of 
discussions, adjusted so as to be more relevant to the health care professionals’ situation but still 
enabling the comparison and linking of accounts across groups (see topic guides in Appendix 5.5). 
I asked the healthcare professionals more in-depth questions about potential service design as 
this group were more likely to have experience of the design process and the specific service 
challenges in the regional and national arenas. This approach allowed comparisons of similar 
responses between the different participant groups, whilst also creating an environment that 
allows them to reflect on their professional experiences.  
Throughout the discussions, I used prompts and probes including phrases such as “go on…” or 
“anyone else want to say anything there?”. In one group, I asked: “can I get you all to expand a 
little bit more about the frustration thing… that’s a word that’s come up three times now… why?” 
(Centre 1, HCP focus group). This helped to provide more precise and elaborate data about why 
participants brought up certain points, or the meanings of the phrases they used. This encouraged 
participants to be more explicit about some of the points made within the group, in an attempt to 
improve the information received and ensure that the interpretation of vague comments was 
correct from the participants’ point of view. I also used these short interjections to ensure that all 
participants’ voices on a topic were noted, particularly when I felt that they might not agree with 
the responses given by others. For example, in one group for parents of under 13s, one 
participant who had previously been very involved in the group stayed quiet during the initial 
discussion about early discharge approaches when the other participants had been quite vocal 
about not wanting outpatient care. When I then directed the discussion to this participant, she 
spoke about how her opinions regarding the location of care had changed, and provided real 
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insight into her own thoughts and feelings, which were somewhat different to the rest of the 
group: 
“Mod: …so, you said you live 20 minutes away, does that mean you might say 
something different to these guys about what was on offer? 
3: probably I think circumstances have sort of changed my mind… last time we were 
supposed to have the focus group (note: focus group initially planned for a different 
date and poor attendance so rearranged for this session)I was dead cert on I think I 
should go home every time cos I only live 20 minutes away but then just being on the 
ward again last week and then I get a little bit nervous and then I think no I’d definitely 
prefer to stay so I think it’s the circumstances that changed my mind but you know when 
we had the last one I was convinced my answer was gonna be just send me home every 
time 
Mod: so what … what changed your mind? 
3: just remembering really how you feel uncertain when you do come in with a 
temperature… erm…. And then we often come in late at night so… although its 48 hours, 
it ends up being longer because the bloods have gone so late at night… erm… and I 
suppose the night’s scary as well isn’t it… when you get the temperature in the night… 
erm… so yeah… I think just the realisation of coming into hospital recently has probably 
made me slightly change my mind…” (Centre 3, mother of under 13) 
Rapport building, engagement and participant experience 
“Rapport refers to the sense of respect, trust and positive regard between research and 
study participants that enhances openness in information sharing.”(170) 
Developing rapport and engagement serves two main purposes in focus group discussion studies. 
The first is to improve the material collected to answer the research questions, as discussed in the 
above quote from Padgett. The second is to improve the participant experience such that they 
feel an important part of the research process, that their views are listened to and important, and 
that being a participant was a worthwhile experience.(167,168) Rapport is developed over time 
through the initial contacts with the participants through to the focus group itself and then the 
follow-up to the study.(170)  
There were a number of features of the groups in this study that helped to build rapport and 
create an atmosphere that encouraged participants to talk freely and provided interesting and 
illuminating data for the study. A main feature in building rapport was the fact that many 
participants already knew each other. As previously discussed, this was a purposeful design point 
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for healthcare professional groups. Although not planned, individuals also knew each other in a 
number of the parent and young people groups. It was not however unexpected as the number of 
families involved in paediatric haematology and oncology services is relatively small, and the 
eligibility criteria for the study limited participation to patients being treated at the same time. 
Participants had therefore met at previous clinic appointments, during admissions to the wards or 
through local social media groups. Within the study, all interactions between participants who 
already knew each other seemed to be positive events helping to both initiate small talk before 
the formal focus group discussion started and to put people at ease during the groups.  
Nonetheless, it should be recognised that there may be some disadvantages to convening groups 
where the participants know each other and move in similar social circles. Participants may feel 
less able to disclose negative opinions or behaviours which may not be socially acceptable to the 
group for fear of being judged by their contemporaries, or if anxious about other members of the 
focus group not maintaining confidentiality. Interestingly, this did not appear to be the case in this 
study as participants disclosed behaviours such as non-attendance with febrile neutropenia, even 
when other participants had voiced strong views that this was not something they approved of. 
Another feature which may have built rapport was the fact that some participants knew me and 
the assistant moderator. The influence of this on the data collected is discussed elsewhere, but 
this may have helped participants to discuss their experiences, in healthcare professional, parent 
and young people’s focus groups. Furthermore, their confidence that we would understand terms 
such as ‘port’ or ‘Hickman’ allowed them to talk freely about subjects without needing to 
frequently stop to clarify such phrases.  
There were other key points of study design that helped to develop rapport. As discussed in the 
recruitment and ethical issues sections of this chapter, the consent process took place over a 
series of discussions with participants, which allowed me to engage with them over the weeks 
prior to focus groups taking place. Another rapport building action was to pick a location which 
participants could easily locate, knew how to access and felt comfortable talking in. For 
healthcare professionals, this was a meeting room which they routinely used within their work, 
and thus could attend easily and felt relaxed in. The locations for parent groups were more varied 
and included clinic waiting rooms (at a time when the clinic was closed to patients), meeting 
rooms near the hospital wards and a local library. Each of these were locations that participants 
could easily find and where transport and parking arrangements were familiar. By reducing the 
preparation required to attend and through using known spaces, I aimed to reduce participants’ 
anxiety and increase the likelihood of attendance.  
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Once within the group setting, the task of completing the necessary paperwork provided a short 
period of time for small talk between participants and a chance for brief introductions. I then 
started each group with a brief round of introductions of each participant and, where it was a 
parent group, a chance to speak about their child. This, followed by a question about previous 
experiences of febrile neutropenia, allowed participants to become comfortable in answering 
simple discussion-starting questions within the group setting, thus developing rapport within the 
group that was not solely related to interactions with me.(167) I also included a short question to 
participants asking what febrile neutropenia is, to ensure that we were all using the same 
definition when discussing this topic. Other technical language used throughout the group was 
checked when participants introduced it, as were local issues, such as when names of specific 
people were used, I would ask about what their roles were. Throughout the group discussion, I 
aimed to use positive and encouraging language and open prompts to show that I was keen to 
hear and understand the experiences and perspectives of the participants, using phrases such as 
“why do you think that is?” 
The engagement of participants with the research topic was apparent. In each group, either 
during the discussion or following the point where recording stopped, the participants asked 
about the likely impact of this study, including how I thought things would change in the future, 
and the likely timing of the process. All participants were keen to receive the final findings of the 
study in writing. At the end of the focus groups, participants were very positive about the 
experiences: 
“Mod: …and can I double check would you like the results when they are available… 
3: yes 
1: yes definitely be interested in having the results 
Mod: it will take as I said at least six months but then I’ll happily send them to z 
(research nurse) and a (PI) and I’m sure I’ll be here presenting 
1: thank you that was lovely 
2: yeah thank you that was really interesting” (Centre 3, Healthcare professional group, 
doctor (3) and nurse (1+2) 
In the days and weeks following the discussions a number of participants also contacted me to 
encourage me in the work, or to discuss further the points which they had found particularly 
interesting within their group. Their feedback regarding the experience was particularly gratifying 
as I felt that the rapport I had developed with these participants meant they felt able to engage 
more deeply with the study itself and the complex issue of management of low risk febrile 
neutropenia.  
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Recording and transcribing focus group discussions 
An encrypted digital audio recording of each focus group was obtained with the permission of the 
participants. The recording was then transcribed and anonymised in order to allow for analysis. I 
transcribed all focus groups myself, within one week of the date of each group. This provided 
distinct benefits as I could more easily identify the speakers within the flow of the discussion and 
could remember many of the issues discussed. Furthermore, through reviewing the group again 
prior to the next discussion, I was able to consider the areas for further exploration in future 
groups, whilst also identifying areas for improvement in my own moderation skills.  
Alongside these benefits, there was also one particular challenge present in transcription that has 
already been discussed in the literature.(165) As focus groups include many people who may talk 
over each other, there were a small number of occasions where it was not possible to separate 
the various voices. Each of these occasions was short lived and generally short phrases within 
these episodes could be captured for the analysis.  
Following the initial transcription period, all transcripts were reviewed repeatedly whilst listening 
to the recording of the group to ensure the quality of transcription and to further familiarise 
myself with the data. Analysis notes were taken throughout this process as codes became clear 
and connections between and within groups began to form. 
A research journal was kept throughout the period of research. This included field notes and 
reflections made during and immediately after each of the focus group discussions. It also 
recorded the analytical points as they developed and documented the challenges involved in 
performing the work. For example, one section of the HCP group from Centre 1 was initially coded 
as ‘special’, however over time this then was recognised to be within the ‘roles’ code and was 
assimilated. The process of this was captured in the research journal as follows: 
“I’ve been thinking through the ‘special’ code for the Centre 1 HCPs + trying to figure out 
where it fits. Today, suddenly realised it’s about role negotiation – how we see ourselves 
as HCPs and how that then would need to change if we went to outpt care and began 
being ‘normal’. It also links in the parent issues from Centre 2 [HCP group] – at the 
moment we know our roles and parents’ roles but these would have to change + we’re 
not sure we trust parents to take on the roles that we think we are ‘special’ for doing. 
After chatting to [supervisor], realised it also links to experiences in other specialties 
that have already changed quite a lot eg diabetes - ?something more generalizable 
about how when systems change people need signposting to their new roles and help in 
reframing who they are and what they do. We need to actively address their concerns 
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about their own changing roles – not just purely focus on pts + families.” (Research 
journal, January 2016) 
Data from both the transcripts and the research journal were used to inform the research 
questions. 
Data handling and confidentiality 
Respect for the privacy of research participants and the confidentiality of their information is a 
key ethical principle in health services research, and is underpinned by various legal 
frameworks.(56,167) Practically, maintaining confidentiality involves consideration of issues which 
participants might consider to be private and then protecting these through restriction of access 
to this information or through the use of anonymising techniques, so as to ensure that the 
participant is not identifiable in any oral or written discussions of the research.(56,170)  
In this work, the data handling and confidentiality plans applied to three main aspects of the 
work. Firstly in the conduct of the focus groups themselves, where consideration was given to the 
maintenance of participant confidentiality and that of the patients of healthcare professionals. 
Secondly, in the storage and management of the digital audio recordings and transcripts, 
including transcription and anonymization techniques (of over 9 hours of recording and almost 
two hundred pages of transcript). Thirdly, in the presentations of the work, both orally and in this 
written thesis. Each of these three areas will now be explored more explicitly. 
The issue of confidentiality was discussed in the Participant Information Sheets and was a specific 
statement on signed consent and assent forms (see Appendix 5.3). Furthermore, it was 
emphasised at the beginning of each focus group that as I was keeping all their data confidential, 
it was also expected that participants respect other participants by keeping confidentiality and 
not discussing the comments of other participants outside of the focus group discussion.  
As discussed earlier in the Focus group discussions section of this chapter, in the discussions with 
healthcare professionals, there was also a potential for disclosure of patient information for those 
within the study, as well as patients not recruited to this work. Participant information sheets 
clearly stated that healthcare professionals should not discuss the details of cases where this 
might make the patient identifiable. This principle was then repeated at the beginning of the 
focus group discussions. If such a disclosure occurred, the research team would have interrupted 
the discussion, explained that this data would not be used for the research and reiterated the 
requirement that individual cases not be discussed. If the discussion persisted following this initial 
warning or a further disclosure was made, the researcher would call an end to the focus group 
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discussion at that point. Thankfully, this situation did not occur and all healthcare professional 
participants maintained patient confidentiality throughout the groups. 
Data were stored according to the laws of the Data Protection Act.(177) Participants’ identifiable 
information was at all times stored separately from the data produced from the focus groups. 
Digital audio recordings of focus groups were uploaded to a double password protected 
University computer immediately on return from the study site and accessed only by the research 
team.    
Except for their initial secure transfer, between the study site and the University of York, written 
material did not leave the University site and was stored in secured filing cabinets, in my office, to 
which only the research team have access. Only me and the supervisory team had access to 
written material, such as transcripts, generated by the project. Both transcripts and identifiable 
information were stored on University of York servers within encrypted, double password 
protected files. The passwords and associated electronic material were available to only myself 
and Professor Karl Atkin. The document linking study identification numbers with identifiable 
information was stored securely as for the transcripts and identifiable information. Audio files 
were deleted once they were transcribed. All other data will be kept by the University for five 
years.  This process was reviewed and monitored by the University of York, Department of Health 
Sciences' Data Protection Committee – using guidance available at www.york.ac.uk/records-
management/dp/policy/.   
At all stages of transcript analysis, data were anonymised using unique study identification 
numbers to refer to participants, so as to be able to follow consistent lines of discussion. For the 
purpose of the thesis and future publications, these unique study identification numbers were 
used to allow for ease of comparison. Care was taken throughout the writing of the thesis to 
make sure that participants were not identifiable by the demographic information given as this is 
a small community and some participant backgrounds were unique. Thus, for parents and young 
people diagnoses were only given as broad groups, for example Acute Lymphoblastic Leukaemia 
or Hodgkin’s disease, rather than to more precise information such as stage of treatment, as this 
might narrow down potential participants to too small a group. Similarly, for healthcare 
professionals, the demographics given are relatively broad (consultant or non-consultant grade 
for doctors, and junior or senior for nurses) so as to prevent the identification of participants 
within the study.  
Within presentations of data to both clinical and academic audiences, care was taken to ensure 
that both centres and participants were not identifiable, using techniques similar to those used 
within this thesis. After one presentation in which a number of audience members were study 
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participants, I later discussed privately with a couple of participants whether they felt that these 
methods had maintained their confidentiality. Positively, they stated that they could not identify 
which centre was their own centre, nor could they identify the other two centres within the 
study. Furthermore, they stated that although they recognised some of the issues discussed, this 
was more of a familiarity with codes and themes rather than being able to identify the speakers 
within the quotes. They clearly stated that they were happy with the way in which they had been 
kept anonymous in the presentation of the work.  
Analysis  
Qualitative analysis can take a number of forms, with the main focus being upon conveying the 
participants’ experience to the reader through a rigorous process involving the identification of 
key material and the in-depth interpretation of the findings in relation to the research problem 
and questions. This study used a constant comparison approach, when analysing the fieldwork 
material, in which repeated comparing of the different individuals and groups, allowed parallel 
and contrasting themes to be identified and explored. Various additional methods can be 
employed to increase the credibility of the resultant account and these will be discussed in the 
following section.(165–168) The main aim of this section is to transparently describe the analytical 
process undertaken in this study, including the rationale for the decision made and providing 
evidence of the analysis process within the appendices. 
The overlaying of descriptive and conceptual findings allows a more nuanced consideration of the 
issues discussed, providing both straight-forward clinical answers to questions about preferences 
as well as a deeper, more sociological reflection upon the underlying complexities of the decision 
making process. The explicit process of considering social and contextual information and 
providing “insightful interpretation”, also known as thick description, allows the reader to 
consider the application of the findings elsewhere and hence provides a degree of transferability 
to the work.(170,178) This is consistent with the pragmatic aims of the study. An example of 
where thick description was particularly helpful in the analysis was in the consideration of non-
attendance with febrile neutropenia, where detailed consideration of the role, experiences and 
previously expressed attitudes of different participants provided nuance to the interpretation of 
the data. 
The data obtained from the focus group discussions was analysed iteratively, using traditional 
methods with pen and paper. I had initially intended to use ATLAS.ti software to perform the 
analysis but given the risks of losing analytical notes and my own preference for paper-based 
analysis, I decided not to take this route.  
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When using the constant comparative approach, the recognition of patterning within the data 
requires rigorous and structured reading and reviewing of the date. As previously discussed, 
transcripts and field notes were read repeatedly to identify codes described within them. Each 
transcript was individually coded using a coloured key, for ease of identification of coded sections. 
Notes were taken around the transcript and on separate sheets to record key points and possible 
new codes. An example page of coded transcript is given in Appendix 5.9. At this intra-group stage 
of the analysis, particular care was taken to follow individual voices through the focus group so as 
to identify codes which occurred more frequently, or with different quality, dependent upon the 
characteristics of different individuals. An example of this is seen in the code negotiation within a 
spectrum of control where parents with more experience of the paediatric haematology and 
oncology service used different means to negotiate compared with those who had been in the 
service for a shorter period of time. 
Codes were specifically identified to give the findings about current experiences and preferences 
for future care within paediatric low risk febrile neutropenia services. Care was taken to identify 
the precise features of service design which participants particularly preferred or disliked, for 
example, the particular location of follow-up, or the frequency of contact between healthcare 
professionals and families at home. I also focused on the factors likely to play a role in these 
preferences, including the demographic and social backgrounds of each participant as well as 
their past experiences with febrile neutropenia. I also considered the role of the current service 
with which participants were associated so as to establish how this might also influence their 
preferences in the descriptive aspects of the findings. In the next stage of the analysis, each focus 
group discussion was analysed for codes and concepts in relation to other groups.This process 
was carried out comparing focus groups of each type of participant (healthcare professionals, 
parents of under 13s, parents of over 13s and young people) and then each centre. Codes were 
then linked through mapping for each group and encircling themes were identified (see Appendix 
5.10).    It was at this inter-group analytical stage that the voices of each group of participants 
were considered and the similarities and differences identified. Thus the data obtained specifically 
through the triangulation of centres and participant groups were explicitly considered and 
explored.  
These maps were then overlaid to provide a network through with the themes were compared 
(also provided in Appendix 5.10). This network shows the interlinking of the identified themes. 
This framework of overarching concepts is presented in the thesis as the line of argument. The 
analysis has been presented transparently so as to allow readers to follow a thread from data 
through to the final line of argument.  
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Within this phase, I explicitly looked for similarities and differences between the various locations 
and aimed to identify the possible reasons for these perspectives. I anticipated that the current 
methods of management in each location might exert an environmental influence on attitudes 
and opinions to early discharge. I hypothesised that participants in centres with longer current 
durations of admission might be more concerned about early discharge strategies than those at 
centres where discharge at around 48 hours is more common. This aspect of the analysis was 
somewhat complicated by the problems with centre recruitment which are discussed elsewhere 
in this chapter. However, although the included centres have similar timings of discharge 
according to their protocols, it became apparent that practice was sometimes different and 
therefore consideration of these issues became possible through the course of the data 
collection.  
Additionally, I aimed to identify relationships between the attitudes of different participant 
groups. As discussed earlier in this chapter, I was particularly interested in how the ideas and 
opinions of young people are similar or different to those of parents and healthcare professionals. 
The literature reveals that young people often have different opinions to the adults in their lives 
and may be willing to take greater risks for given potential benefits.(17–21) I was keen to see how 
this applies to low risk febrile neutropenia management and have attempted to present the voice 
of the young people about this aspect of their care, within the limitations I have already 
discussed. I also anticipated differences between families and the healthcare professionals caring 
for them.  
I then explored whether past experiences and education about febrile neutropenia contribute to 
differences in attitude towards early discharge. For example, whether healthcare professionals 
with experience of patients who are critically unwell with febrile neutropenia felt more anxious 
about potential early discharge. I aimed to investigate the role of the sense of professional 
responsibility or duty on the attitudes of healthcare professionals. 
Continuing my use of the constant comparison, I went on to compare my findings to the 
qualitative synthesis reported in Chapter 4, looking for points that confirmed or refuted concepts 
within the existing literature, and aimed to adjust and expand the model provided in the 
qualitative synthesis as one of the outputs of the qualitative study. I contextualised the findings of 
the study within the existing theoretical debates in this area described within the earlier chapters 
of this thesis and, where possible, located it within broader healthcare policy, including 
considering how these findings might impact on the implementation of current guidance from 
national bodies.(181,182) I aimed to provide both descriptive details of the service designs 
suggested by participants so as to depict the various strategies which might be most acceptable, 
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and also a theoretical exploration of the comments supporting these suggestions so as to allow 
greater understanding of the complexities involved in changing these services. 
Throughout the findings chapters, anonymised quotations have been used, with associated 
stimuli and numerical identification of speakers, to ensure that the voice of the participants is 
conveyed throughout the research.  
During the analysis and writing up process, I met with my supervisory team regularly to ensure 
agreement with the progress being made and discuss future directions of the work. I also 
presented preliminary analyses at both clinical and academic meetings so as to receive feedback 
on whether codes and themes resonated with those involved. This was a very positive process as 
audiences became actively involved in discussing the issues, and often raised analytical points that 
I had already described in my writing but had not shared within the presentations. The fact that 
these topics were evoked spontaneously reassured me that the analysis had appropriately 
captured these within my own consideration of the issues. The final framework and line of 
argument were also presented to both participants and peers for critical review, prior to 
submission for the award of a PhD.  
Methods used to enhance credibility 
Credibility describes the way in which the quality of qualitative work can be assessed to be 
‘believable’ and ‘trustworthy’ to participants and the readers of the work.(183) Within the 
relativist epistemology, the aim is to evidence a trustworthy and believable constructed truth, 
located within the context of culture and history, which can be contrasted with the positivist 
singular truth which is more often associated with quantitative works.(183) In other words, 
credibility can be used to describe how successful a piece of research is in capturing the lived 
experience of the research participants.(178) Multiple methods have been advised to improve the 
credibility of qualitative research.(178,184,185) Many of these have been employed within this 
study, including transparency of method, triangulation, case studies, quotations critical review of 
the work during production and using a reflexive process. The issues of triangulation, case studies 
and quotations are explored further within this section. The other methods listed (transparency, 
critical review and reflexivity) are evidenced elsewhere in this chapter.  
Triangulation describes the use of various data sources, methods and theories to provide multiple 
viewpoints on a research topic, so as to increase the credibility of a piece of research.(178) This 
study primarily uses the triangulation of data sources, through multiple key stakeholders and 
multiple centres to address the issue of early discharge in paediatric low risk febrile neutropenia. 
Through the comparison of data from different locations or different groups, it becomes possible 
 156 
 
to identify key or recurring themes between and within groups, along with features which may 
influence the different perspectives on these themes.(168)  
Having stated the benefits of identifying recurring themes in triangulation, the pure reliance on 
prevalence as a marker of qualitative importance or ‘truth’ is somewhat reductionist, as well as 
dependent on the ontological beliefs of the researcher as to what constitutes ‘truth’ and where it 
lies.(165,186) Pragmatically though, triangulation allows the exploration of the occurrence of 
themes and the identification of frequency without necessarily applying worth or ‘truth’ within 
these. Furthermore, by exploring the various perspectives, a deeper understanding of the 
research area is achieved and richer description allows appreciation of the nuances within the 
research field.(167) This use of data source triangulation clearly complements the multiple 
methods nature of the thesis, whereby various methods are applied to provide depth and greater 
understanding of the area of research, for example in attempting to understand the reasons for 
low levels of consent to studies of reduced therapy regimens. 
To provide further contributions to the credibility of this work, I have also employed a case study 
within the analytical design so as to ensure focus upon codes which appear infrequently, and 
upon the perspectives which specifically stand out as inconsistent with other aspects of the 
data.(186) Focusing on areas of maximum variation within the data aims to capture the diverse 
range of experiences of febrile neutropenia and is consistent with the qualitative paradigm, which 
contrasts with the aims of obtaining a representative sample in quantitative work.(56) The 
selection of case studies which are more extreme than the “normal” experience offers the ability 
to compare and contrast experiences and to consider the influence of different circumstances and 
characteristics on participants’ responses. Through exploring possible explanations for the 
different interpretations given by the case study family and the potential tensions arising from 
them, it was then possible to evaluate the themes previously identified within the findings, make 
adjustments to them and thus illuminate some of the more nuanced aspects of attitudes to febrile 
neutropenia care.(167)  
Quotations are used in qualitative work for a number of reasons, which I employ within this 
thesis, as a further means to enhance its credibility. Quotations provide the raw data to back up 
the findings reported to the reader. This degree of transparency lends credibility in itself and 
allows the reader to follow the researcher’s analytical processes. Quotes can work specifically in 
two distinct ways. The first is to evidence the typical responses given to a particular prompt or 
issue. In this situation, the quote chosen provides a representative sample of the findings of the 
work. In the second use of quotes, they can be used to illustrate the diversity within the 
participants. This occurs within this work within the discussions about shared care within the 
professional roles subtheme in Chapter 6. Where appropriate, I have provided quotations which 
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include participants conversing to highlight these areas where the response are typical or diverse 
and also to demonstrate the development of the conversations within the groups.(168)  
Reflexivity 
Reflexivity is the process in which the researcher reflects on how their own experiences, 
perceptions and beliefs influence the work being performed, along with locating the work within 
its broader social and political context.(185) The ways in which the researcher affects the process 
of research, the participants and the subsequent analysis are explicitly explored and transparently 
presented to the reader to allow them to draw their own conclusions as to the credibility, and 
quality, of the research as a whole. Furthermore, through giving clear justification about the 
decisions taken when doing the research, reflexivity aims to provide the reader with the 
underlying rationale for key judgement points. The presence of reflexivity throughout this thesis is 
intended to achieve these aims. The discussions surrounding recruitment difficulties as well as 
rapport building and engagement have already considered a number of topics relevant to 
reflexivity. I discuss some additional considerations here and will demonstrate further reflexivity 
within the findings and discussion in Chapters 6-8.  
Throughout the planning of this research, I considered the impact of myself as a researcher on the 
study itself. Specifically, as a paediatric registrar, I may have unintentionally influenced the 
expressed ideas of the participants. As a doctor, I hold a position of social influence which may be 
particularly felt by young people and parents who may have felt that there was a ‘right’ answer to 
some of the focus group questions. Furthermore, within the healthcare professional focus group 
discussions, there were numerous potential influences between myself and nursing colleagues, 
and with more senior medical colleagues. For this reason, each focus group began with a clear 
discussion that there is no ‘right’ answer and that, in this situation, I was working in the role of 
qualitative researcher and not as a junior doctor. 
In some ways, however, being a healthcare professional provided an advantage to the focus 
groups. I was able to follow the more technical aspects of the discussions without needing to 
interrupt participants to request the definitions of various technical words. This allowed aspects 
of the conversation to flow more smoothly than they might have done with a lay moderator.  
Given the relatively small number of people involved in the specialty of paediatric haematology 
and oncology, there was a potential that, in some focus group discussions, I might already know 
some participants in a professional manner either as their colleague or as their or their child’s 
doctor. Thus the importance of emphasising confidentiality was heightened. This was clearly 
outlined in the Participant Information Sheets and in the introduction to discussions. 
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Finally I recognised the potential influence of my own experiences of healthcare, as both 
professional and patient. Within the analysis, I aimed to consider all possible viewpoints, and 
acknowledge where some viewpoints differ from those I personally hold. I have aimed to present 
balanced findings that express each viewpoint without the influence of researcher attitudes and 
particularly focused on this where my own views or reactions to comments are strong. I believe 
that this reflexivity about my own impact on this research improves the credibility of my findings 
to the audience. Further reflections on the performance of the research are included in Chapter 8. 
Other ethical issues surrounding the research 
All researchers involved in this study had received formal training in ethics and clinical 
governance, e.g. Good Clinical Practice.  I completed a formal Level 7 qualification in Qualitative 
methods and also attended formal training in the performance of Focus Group research. Within 
my medical career, I have also received training in obtaining consent, advanced communication 
skills and child protection procedures. I thus brought certain skills and attributes to the 
performance of the study. My practice was closely supervised by all co-investigators of the study. 
Informed consent was sought from all participants. Within my role as a paediatric specialist 
trainee, I have been trained in gaining consent and have experience of gaining consent from 
young people and their families on a regular basis. In the case of participants under the age of 16, 
consent was sought from someone with parental responsibility, but the assent of the participant 
was also essential for entry into the study. This is consistent with current guidance for medical 
research involving children.(187) Sample consent and assent forms are included within the 
Appendix 5.3.  
For this study, the process of consent was actually through a series of discussions with 
participants, with the consent and assent forms providing written confirmation that the process 
covered each of the necessary points. The first discussions with participants were by the research 
nurses with the basic information about the study being given verbally and a copy of the 
information sheet being given to provide further details. Once participants had decided they were 
interested in the study and gave permission for me to be given their contact information, I 
telephoned them to go through the study in detail and to ensure that all points on the consent 
form had been covered. Following confirmation of the dates and times of the focus group, 
participants were contacted again to ensure that these details were given and to further check 
they were interested in participating. Many participants were also in contact via email between 
these set telephone discussions. On attendance at the focus group, I then had a further one-to-
one discussion with each participant and formally completed the consent and assent form with 
them as this was often the first time we had met in person. The signing of this form represented 
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the various discussions that we had had over the preceding weeks of conversation. This process 
made me feel particularly confident that participants had given informed consent to the research 
as they had numerous occasions to receive information and to ask questions, through a variety of 
formats, with each discussion covering the key points and then further tailored to meet the 
individual participant’s needs. Furthermore, these conversations prior to the focus group 
discussion allowed me to begin to build a personal rapport with the participants, setting the tone 
for the focus group to be interactive and therefore informative.  
Initially, there was to be no financial incentive to participate in this research. However, after the 
first substantial amendment advised by the Research Ethics Committee, participants were offered 
travel expenses, as per INVOLVE guidelines, such that they were not disadvantaged by 
participating.(188) Only one application for travel expenses was received; all other participants 
declined this offer. 
Following the challenges with recruitment to parent and young people groups, a second 
substantial amendment was approved to allow the provision of a £20 Amazon voucher to each 
parent and young person participant, and the placement of promotional posters around the 
involved departments (see Appendix 5.7). This is also consistent with INVOLVE guidelines and 
reflects the time commitment involved in participating in this research.(188) Participants who 
took part in focus group discussions prior to this amendment were contacted and offered the 
voucher in retrospect.  74% of the 19 participants eligible for the Amazon vouchers claimed for 
them. 
I felt it was particularly important to investigate the experiences and perceptions of young people 
within paediatric haematology and oncology services. The importance of listening to young 
people can be found in many places, from the United Nations Convention on the Rights of the 
Child (Article 12 respect for the views of the child ‘Every child has the right to say what they think 
in all matters affecting them, and to have their views taken seriously’) through to the Department 
of Health Documents ‘No decision about me, without me’ and ‘You’re welcome’, and is further 
explored in Chapter 2.(30–33) Thus, this study actively sought their opinions and attitudes. I have 
considerable experience in communicating with and working alongside young people, as has the 
assistant moderator, in our clinical roles as paediatric specialty trainees. I have completed formal 
training in communication with adolescents, along with the full curriculum of the RCPCH 
Adolescent Health Programme. This provided me with specific skills for running focus groups with 
young people. 
As this was a study involving young people, there was a potential for disclosure of safeguarding 
issues, although this was felt to be unlikely within a single focus group discussion. Nevertheless, 
 160 
 
this potential was mentioned in the relevant patient information sheet and was discussed at the 
beginning of the focus group discussions for young people. Both I and the assistant moderator 
have completed formal training in Child Protection and, as paediatric registrars, are familiar with 
the procedures to be followed in the event of a disclosure. Any concerns raised regarding 
safeguarding of children and young people were to be reported to the local lead for Safeguarding 
at the participant’s treating centre.  Thankfully this was not necessary. 
I recognised that discussions about possible variations in treatment for low risk febrile 
neutropenia might raise concerns from participants about previous episodes of febrile 
neutropenia. There may have been difficult memories for families who had experience of higher 
risk episodes, perhaps even with admission to critical care services. Furthermore, participants 
might also have been stimulated to ask questions about the future treatment of low risk febrile 
neutropenia in their centre. Opportunities to discuss this further were offered to all participants 
at the end of the focus group discussions. All medical queries raised by the participants during the 
research were to be redirected to their clinical care team, but did not occur.  
Meanwhile, I considered that healthcare professionals might question their current practice in 
febrile neutropenia. They were offered information about where they could obtain continuing 
professional education on the management of paediatric febrile neutropenia. Debriefing was 
offered to participants immediately after the focus group discussions and a telephone number 
was also provided in case they wished to discuss any further issues with the research.  
In regards to the performance of the study, in two centres, the support from the research team 
was excellent. There was regular contact between myself and the research nurses to 
communicate successes and challenges for both parties and enabling consistent progress on 
recruitment and organisation of the work. However, with the final centre, communication with 
the research team was more challenging and it was difficult to speak with the key individuals in a 
timely manner. This site also struggled more with recruitment and the practical aspects of 
organisation which were the responsibility of the study site, perhaps due to limited research 
nurse time. To compensate for these issues, I changed my own preferred communication style to 
one more suited to my link person and took on more of the organisational roles myself, including 
the preparation of focus group paperwork and the booking of rooms for the discussions to take 
place. These two actions seemed to mitigate some of the earlier problems, but required 
considerably more time working on this site’s preparation than others.  
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Funding 
All funding for the study was provided by Candlelighters children’s cancer charity (Registered 
Charity No: 1045077). My own salary was paid for by a Clinical Research Fellowship awarded by 
the charity in 2013. A second funding request was put in to Candlelighters to allow for the 
provision of travel expenses to participants and to provide the grant to each study site for the 
research nurse time involved in recruitment. This request was approved, and following the second 
major amendment was adjusted to allow this money to also be used for the provision of vouchers 
to parent and young person participants. Each study site received funding to recognise the 
research nurse time taken in supporting the study, informed by NHS pay scales and anticipating 
how much research nurse time would be involved. This money was paid as a block sum to the 
department involved at the completion of the study. All financial records for the study were kept 
by Candlelighters charity. Candlelighters have had no influence over the design, execution or 
analysis of the study.  
Summary 
Through this chapter I have described and explored the methodology adopted in the focus group 
discussion study. In response to the findings of the qualitative synthesis, the study aimed to 
explore the experiences and perceptions of patients, parents and healthcare professionals in 
regards to paediatric, low risk febrile neutropenia. I have described the process of recruitment, 
including the challenges involved, and have provided information on the participants included 
within the study. The conduct of the focus groups, including rapport building and use of topic 
guides that drew upon the results of the systematic review and meta-analyses reported in 
Chapter 3, have been explored  I have described the methods used to record and transcribe focus 
group discussions, and to handle, anonymise and store the collected material. I have provided a 
detailed account of the methods used in the analyses and of the approaches taken to increase the 
credibility of the thesis. This chapter therefore provides a foundation to understanding the study 
conduct and the way in which the findings presented in Chapters 6 and 7. 
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Chapter 6: Qualitative Study Findings - The quest for certainty, 
attaining mutual trust and sharing roles and responsibility 
Overview of findings 
The next two chapters detail the findings of the qualitative study, combining both thick 
description and deeper explanatory accounts of the data. The three emergent themes of the 
quest for certainty, attaining mutual trust and sharing roles and responsibility, and the potential 
for realised discretion are comprehensively explored within these chapters with supporting 
material provided throughout. Their interrelated nature is highlighted and I cross-reference the 
key recurring threads, exploring the themes from the perspectives of the different stakeholders.  
As this thesis aims to help inform service re-design I also draw attention to practical issues that 
emerged during discussions and which may help to improve the experiences of paediatric patients 
with low risk febrile neutropenia.  
When describing the findings of this work, I use the word participants to reflect patients, parents 
and healthcare professionals. Similarly, when I use ‘families’, this means both young people and 
parents. Where the findings are specific to a single group, I will describe the particular group I am 
referring to.  
In the following paragraphs, I provide a summary of the findings which introduces the key themes 
and provides a guide to the chapters to come. This overview of the major concepts aims to assist 
the reader in navigating the following, more detailed, account and seeks to demonstrate the main 
links between the themes so as to prepare the structure for the subsequent work. These findings 
have been split into two chapters for easier management of the extensive data. Each of the two 
chapters include two of key themes within the work, Chapter 6 relates to the quest for certainty 
and attaining mutual trust and sharing roles and responsibilities, whilst Chapter 7 covers the 
potential for realised discretion and the impact upon future service design.  
The quest for certainty began with understanding, expressing and negotiating risk, where personal 
experience often held greater value than statistical findings and occasional inconsistencies 
enabled emotional reactions to risk to be balanced with the evidence. The benefits of following 
strict protocols in an attempt to control this risk were recognised but their rigidity was resented 
given the need to consider the individuality of febrile neutropenic episodes. Alongside this theme, 
the multiplicity of parties involved in paediatric haematology and oncology services led to an 
acknowledgement that relationships could be complex and challenging. Attaining mutual trust 
and sharing roles and responsibility was seen as vital for participants when considering reduced 
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therapy strategies for the management of low risk febrile neutropenia. The different roles 
identified by participants are explored, including different professional groups, shared care units 
and parental roles in the care of febrile neutropenia. The contrasts in attitudes between 
participant groups and the different centres are considered. Participants discussed how roles and 
responsibilities would need to change if reduced therapy regimens were implemented; they 
considered the challenges this would pose and the vital role that mutual trust would play in 
successfully achieving outpatient care. 
In the following chapter, I explain how the integration of the quest for certainty and mutual trust 
was achieved after establishing the spectrum of control and negotiating key points so as to reach 
the potential for realised discretion. Participants expressed a need for discretion, or individualised 
care, in the management of low risk febrile neutropenia so as to be able to take into account 
personal preferences expressed in the quest for certainty. Recognising that the current control 
over decision making lies with the protocol and the healthcare professionals, families’ expressed 
their frustrations with the limitations placed upon them and discussed how they managed within 
the current system. I present the material surrounding non-attendance with febrile neutropenia 
as an example of when parents have control of decision making, judging the risks of the potential 
courses of action, and considering the different roles involved in their child’s care. The factors 
which might promote non-attendance with febrile neutropenia are explored and I consider the 
impact that reduced therapy regimes might have upon these dilemmas. The Impact upon future 
service design of these three key themes is explored throughout this chapter and in more detail 
within its own specific passage. I consider why certain groups might prefer specific options for the 
timing of discharge and route of administration of antibiotics, along with the follow-up choices 
that might made. I outline a specific case study in which the family’s preference differed from 
many of the other participants, and detail how this is consistent with the previously described 
themes and how it has informed and developed the work. Finally within these findings, I report 
the considerations of the participants about the low rates of consent seen in Chapter 3 so as to 
understand from the key stakeholders’ view what might have prevented families and clinicians 
from taking part in these reduced therapy studies.  
To support the findings and provide evidence of the analytical processes used, a sample of coded 
transcript and the progression of structural maps which eventually resulted in these findings are 
provided in Appendices 5.9 and 5.10. 
The quest for certainty 
The quest for certainty theme encapsulates the challenges of understanding, expressing and 
negotiating risk; articulating and interpreting protocols; and preferences for care. The discomfort 
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of the uncertainty involved in risk assessments is balanced against the certainty implied by 
current protocols. The perceived benefits and harms of inpatient care that participants have 
previously experienced inform their appraisals of future treatment strategies. The judgements 
made about these three main codes and the weight given to each of them varied between groups, 
and particularly between families and professionals. The tensions that arise from this are 
highlighted and explored throughout this section.  
Understanding, expressing and negotiating risk 
Conceptually, the subtheme of understanding, expressing and negotiating risk encapsulates a 
number of subthemes, including problems with risk stratification, emotional responses to risk, 
understanding statistical risks, illogicality and comparisons with risks in other situations.  
In all centres, even those where risk stratification is routinely used, healthcare professional 
participants struggled to cognitively separate different febrile neutropenia risk groups. Thus in 
each group, specific examples were used in which the child or young person described by the 
professional would not have met the criteria for inclusion within a low risk treatment strategy. 
This was usually identified, either by the participant giving the narrative or by another participant 
within the group. The misperceptions surrounding risk stratification demonstrated unfamiliarity 
with the tools used, and challenges in applying them to particular children. It also reveals that 
participants tend to think about children as having ‘febrile neutropenia, rather than low risk or 
high risk disease. This failure to cognitively differentiate between levels of risk impacts upon both 
perceived risks and potential future management strategies. 
“4: I think it’s just I’ve been here for an awful long time and that’s what we’ve done and 
I know it’s the small number of children that you can remember that just … that just do.. 
collapse within less than 8 hours… 
Mod: without giving us patient identifiable data, could you describe one? 
4: mm...oh God… erm… ermm… yeah probably the most vivid one was when I was over 
at [another hospital] … so I couldn’t even tell you the name of the patient... erm… but 
walked onto the ward having had a single fever at home... and within… within minutes 
we were resuscitating him…  
1: but he wouldn’t be low risk would he? 
4: he wouldn’t no but that’s the bit that I don’t know why but that’s the bit that sticks in 
my mind…” (Centre 1, nurse (4) and doctor (1)) 
It is not surprising therefore that the healthcare professional participants had quite emotional 
responses to the idea of early discharge, which generally evoked anxiety or fear. This was 
expressed physically in centre 1 when a participant shivered at the mention of outpatient 
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treatment (discharge at less than 8 hours). After this physical reaction, they went on to clearly 
express their anxieties about early discharge which related to past experiences of children 
deteriorating with febrile neutropenia, as described above. On three further occasions during that 
group, phrases relating to this participant shivering were used to identify emotional responses to 
aspects of early discharge that made the group feel uncomfortable: 
“1: it’s not like they won’t be febrile at home… they’d be going home febrile wouldn’t 
they (murmur of agreement) so then you’d have to work out what… 
4: [4] shivered again!!! (laughter)” (Centre 1, doctor (1) and nurse (4)) 
Interesting, laughter was also a common feature of the healthcare professional discussions. At 
times, this appeared to be a collegial – giving the impression of a group of colleagues enjoying a 
comfortable conversation about shared aspects of the work environment. At other times 
however, laughter was used as another example of a physical response to anxiety or a form of 
emotional release, to signify a point at which a participant was uncomfortable within the 
discussion or with the opinions that had just shared.  
In contrast to the health care professionals, parents and young people groups participants were 
unfamiliar with the concept of formal risk stratification, and were almost universally unaware that 
this was performed at all. To compensate for this, parents employed their own methods to 
establish the dangers posed by an episode of febrile neutropenia, encapsulated within the code 
‘well/not well’. Participants, particularly those with considerable experience of their child having 
febrile neutropenia, differentiated episodes into those where the child appeared unwell, was not 
their usual self, and caused the parents to worry, from those in which the child had a fever but 
their behaviour did not otherwise concern their parents. As such, the idea of being ‘well’ or 
‘unwell’ formed an instinctive risk stratification ‘tool’ which enabled the grouping of children into 
different risk categories. Participants envisaged that the management of these groups would be 
adapted according to the severity of ‘unwellness’.  
Parents spoke about how they felt they were generally the best judges of whether their child was 
well or unwell, and expressed concerns that professionals sometimes neglected to take these 
assessments into account, resulting in parents repeatedly presenting to the hospital: “we’re their 
mums so we can tell when our kids are just having a bit of an off moment or when there’s 
something quite serious” (Centre 3, parents of under 13s) Occasionally however, this confidence 
waned and parents doubted their ability to detect deterioration: “I think you know… nurses and 
doctors can spot things that parents can’t although you might think they look alright I think er…” 
(Centre 1, parents of under 13s). Professionals also alluded to the instinctive knowledge that 
parents have of their child, and that sometimes they also had an innate sense of when a child was 
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not fit for discharge: “I suppose being a nurse though you’d have the intuition to say don’t… 
[discharge]” (Centre 1, healthcare professionals). 
Interestingly, when formal risk stratification tools were introduced into the parents’ focus groups 
discussions, participants spoke about how clearly knowing whether their child was at low or high 
risk of significant complications from febrile neutropenia, facilitated their own decision making 
about preferred care.  
“2: I think it probably is… I mean I’ve seen b) with much higher temperatures than that 
and he’s again still been really alert and just respond very quickly to antibiotics and now 
that I know that you’ve said that he’s in a lower risk group then actually maybe I 
wouldn’t have panicked quite so much and thought you know… and if the option would 
have been there… I would have probably gone with it but not knowing that information 
and … and just being told 38 degrees he’s got to go in and …. And I just follow protocol… 
I follow the rules…” (Centre 1, parents of under 13s) 
This clear acceptance by parents of risk stratification as a concept, and their current use of a 
similar assessment strategy, suggests that increased communication of the level of a child’s risk 
may support shared decision making between families and healthcare professionals. 
Furthermore, this explicit stating of the level of risk for a child may also quieten some of the 
emotional responses that healthcare professionals have towards reduced therapy regimens for 
children with low risk febrile neutropenic episodes.  
Related to these risk stratification discussions, parent and young people participants sometimes 
struggled to differentiate between episodes of febrile neutropenia, and those of febrile non-
neutropenia. This issue became particularly apparent in the groups for teenagers and their 
parents. Here, one of the young people had never had an episode of febrile neutropenia, but had 
had a number of episodes of fever without neutropenia. Within the discussions, both the young 
person and their parent discussed these episodes as if they were experiences of febrile 
neutropenia. This lack of clarity about whether an episode is febrile neutropenia or not, raises 
similar issues to the healthcare professionals’ difficulties in separating high and low risk episodes, 
in that it leads to inappropriate assessments of the level of risk involved, and as such attitudes to 
certain management strategies may be modified.  
The challenge of deciphering the statistical evidence presented regarding the risks of different 
strategies was also evident within the healthcare professionals groups. In one group, 
misunderstandings about systematic review methodology, and confusion over statistical issues, 
such as power, led to mistrust of the evidence.  
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“Mod: … 2660 episodes of data, how much more would people need to be more 
confident in this number (points to treatment failure rate)? 
1: I think it would need quite a lot, cos we don’t know whether this is just from one 
centre… several centres 
Mod: lots of centres, lots of centres, 37…. 
1: is that international? 
Mod: yes it’s international around the world 
2: so if it’s all round the world?  
Mod: we analysed the differences between different countries and the countries don’t 
show differences 
2: right, so that’s not just the UK 
Mod: no 
2: so actually you could say it’s a small number if it’s… 
1: there’s the whole world... 
2: yeah couldn’t you? and how many within each study? That would be the other thing 
Mod: very variable, between 20 up to the biggest number is a few hundred. 
2: so you would be looking at the few hundred as being a more… study that you would 
want as opposed to 20, wouldn’t you? 
1: because if the numbers were high, people would be more convinced that this is real, I 
think if er… you know I’d see, for instance this is just an example, if you had 500,000 
episodes and then you saw this, you’d say yeah that’s it, this is what we need to go for 
(murmur of agreement from (2)) but two and a half thousand odd is not going to be 
convincing.” (Centre 2, doctor (1) and nurse (2)) 
Alongside this poor statistical literacy, in all healthcare professional groups, there were moments 
within the discussion where comments made seemed disconnected and were not consistent with 
other beliefs they held. For example, in Centre 2, one participant stated “but if you look at the 
0.1% risk [of PICU admission or death in low risk febrile neutropenia], it’s still high, in that group, 
because your range is between 0.03 to 0.3%, and you’ve got 0.1%”. Considering a 0.1% risk of 
PICU admission or death to be high seems unusual: in the field of paediatric haematology and 
oncology, 3% of children diagnosed with cancer die of infection and around 15% will die of 
progressive disease.(1,193) Certain aspects of interpreting risk seemed specific to early discharge 
and may link to the common anecdote that professionals find it more difficult to lose a child to 
treatment-related effects compared to the death of a child due to progressive disease as 
professionals feel more directly responsible for the death of a child due to side-effects of therapy, 
including neutropenic sepsis.  
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Discussion by professionals about their own decision making revealed and acknowledged tension 
between making judgements based on research evidence and individual emotional experience. 
This was concisely summarised by centre 1 participants at two points within their discussion: 
“4: yeah… it’s bad you know the more you say it sounds more like an irrational anxiety… 
2: but then that’s your experience isn’t it so it’s the … it’s the … it’s the experience that 
you’ve had over years versus what’s in a paper that someone’s telling you…” (Centre 1, 
nurse (4) and doctor (2)) 
“2: I think the interesting thing there for me [Mod] is that you’ve presented us with the 
evidence (laughter from others) which is by far and away saying that this is a safe thing 
to do… 
4: we’ve chosen to ignore it… 
2: but we’ve chosen to ignore it… so we’re practicing non-evidence based anecdotal 
medicine (ongoing laughter) but it’s what we’re comfortable with… 
Mod: ok… so what factors played the role in making that decision… 
2: non evidence based anecdotal… 
4: anxiety... 
(laughter and indiscernible mutterings)” (Centre 1, doctor (2) and nurse (4)) 
The emotional, anecdotal accounts of participants were a greater factor in their opinions 
regarding early discharge than the empirical evidence, despite their training and knowledge that 
this was inconsistent with evidence based medicine. Interestingly, in Centre 3, where there is 
greater shared care and fewer patients with low risk febrile neutropenia are managed in the 
primary treatment centre, professionals used fewer anecdotal accounts of patient deteriorations 
and appeared to have a less emotional, and more positive, response to suggestions of early 
discharge.   
One method that healthcare professional participants used in all centres both in an attempt to 
understand the risk statistics and to express the inconsistency of their discussions was to compare 
the risks in febrile neutropenia to other clinical situations, both within the context of other 
haematology and oncology conditions and within other specialties, particularly general 
paediatrics. When talking within their own specialty, participants highlighted the risks involved in 
the discharge of patients following VIDE.4  
“1: I mean if you’re that worried about infection you could argue that after every course 
of chemotherapy I don’t know on VIDE for example you might have a one in three, one 
                                                             
4 VIDE is an acronym for the four drugs used in a specific course of chemotherapy most commonly used for 
children and young people with a particular bone cancer. 
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in four chance of coming back in so if you’re really… whereas we’re saying these ones 
have got a less…. Lower chance than that so you should… you could argue that well we 
need to keep you in after every course of VIDE chemotherapy until your count recovers 
or something cos there’s a …. 
2: no… that’s what I’m trying to say like we don’t keep them in… 
4: except on this occasion you’ve probably got a lower chance of them coming back than 
on your initial discharge from your chemotherapy…” (Centre 1, doctors (1+2) and nurse 
(4))  
Meanwhile, when comparing to other settings, participants discussed how children with fever 
would be managed in general paediatrics, where they seemed comfortable with the concept of 
children being managed in a less intensive way.  
“3: (mumbles) I think my point, I was about to say was that sometimes you can get 
children who do have febrile neutropenia but they’re very coryzal, and you know they’re 
viral, they’ve been in general paediatrics and then you would’ve just sent them home 
with paracetamol and fluids but because they’ve got febrile neutropenia, they’re febrile, 
maybe a spike of 38.4 and their neutrophils are 0.5, you still have to treat them with 
antibiotics, it does…” (Centre 2, doctor) 
They discussed how children with febrile neutropenia (as a whole) are different from 
immunocompetent children, and therefore there are challenges in determining how closely the 
care of low risk febrile neutropenic children should resemble general paediatric care compared 
with that of children with high risk febrile neutropenia. 
The presence of a central venous catheter (“line”) was one of these differences for both parents 
and healthcare professionals. This was discussed in almost all groups, most frequently pertaining 
to their increased infection risks. However, healthcare professionals also spoke about how 
children with central venous line infections are frequently managed on an ambulatory basis, 
which is readily accepted by the paediatric haematology and oncology community. They drew 
attention to the illogical contrast between these two groups, and suggested that “line” services 
could be extended to children receiving outpatient care for febrile neutropenia.  
“1: … but the only other issue is when you look at when you’ve got a line infection you’re 
treating with teicoplanin5, they’re quite happy to come and go, come and go, come and 
go, and we’re quite happy to do that aren’t we?  
                                                             
5 Teicoplanin, often shortened to ‘teic’, is an antibiotic. 
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2: the community do them once they go on to daily teic, that’s not a problem but then 
they’re not necessarily pyrexial neutropenic all the time. 
1: no but we’ve assessed them, and then we’ve sent them out” (Centre 2, doctor (1) and 
nurse (2)) 
Finally, the professional participants were very clear about the extent of influence that healthcare 
staff should have over families’ perceptions of risk – each group commenting on this in one way 
or another. In Centre 3, the professionals spoke about the dilemma of how much influence should 
be exerted over families, clearly commenting on how far this influence should reach. In the 
following quote, when a group were discussing the issue of non-attendance following fever 
(which is further explored later in this chapter), a participant outlines their perception of the role 
of healthcare professionals in communicating risk to families.  
“…and then you have to try and put the frighteners on them and you have to gauge that 
right as to how… because I’ve had people saying oh I… oh I know … we’ve got four hours 
to wait… and I say well sometimes children deteriorate more rapidly than that….erm… 
but it’s really difficult to know quite how… how scary to be with them isn’t it?” (Centre 3, 
doctor) 
Throughout the understanding, expressing and negotiating risk code, it is clear that participants 
struggled with the uncertainty of risk. They sought the illusion of certainty, aiming to find security 
in the absolute, irrespective of the reality of its non-existence. This may be founded in limited 
understanding or familiarity with statistical concepts, with evidence showing that both laypeople 
and healthcare professionals frequently struggle with the basic concepts of statistical literacy 
related to risk.(194) However, the assessment of risk is not a purely technical act but instead a 
political and social construct. There are many underlying social, emotional and cultural elements 
to the desire for certainty, which will be explored within the discussions in Chapter 7.  
Articulating and interpreting protocols 
This subtheme captures the various concepts surrounding fixed protocols that were discussed 
within the focus groups. These lie between the need to assess risks in the previous section and 
then determine the preferences of individuals for care which are covered in the following section 
so as to make a judgement about suitable future care. The benefits of illusory certainty and 
challenges of having strict and limiting protocols, such as those outlined in Chapter 5, are 
explored within this section. There are clear links between the frustrations found here and the 
later discussions about the spectrum of control between key stakeholders and the need for 
discretion when applying protocols to individual participants.  
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It is worth noting during this section that all the documents referred to as protocols and discussed 
earlier in Chapter 5 of this thesis are in fact entitled guidelines. The choice of the words seems 
relevant here as guidelines suggest a degree of flexibility in their usage, whilst protocols are more 
formal and rigid. Participants during the focus group discussions used the word protocol almost 
exclusively and appeared to understand and use these documents as protocols. I have therefore 
used this terminology in this section.  
Healthcare professional participants in all groups spoke about problems with febrile neutropenia 
protocols, both their current versions and any future protocol suggestions. Participants struggled 
to remember the details of current protocols, frequently correcting each other on points such as 
temperature definitions or duration of admission. In particular, participants were very clear about 
the actions to be taken on the presentation of a child with febrile neutropenia, perhaps as a 
results of the promotion of “one hour to first dose of antibiotic” concepts, but then struggled to 
explain the later points of the process, usually requiring prompting to elucidate the timings of 
discharge and factors involved in deciding about this. Centre 3 referred to their protocol 
repeatedly, suggesting a culture in which reference to the document is expected; the other 
centres did not refer to these documents other than to state that shared care colleagues have 
copies of these.  
It is perhaps unsurprising then that parents had a more fluid approach to protocols. Although all 
four groups mentioned existence of the protocol, there were some areas where they were 
unclear about its instructions. In the Centre 3 group for parents of under 13s, parents noted 
recent changes in the definition of fever and of neutropenia. This made parents uneasy as the 
alterations had not been communicated to them in advance and instead were simply enacted on 
arrival in hospital with their child’s next episodes of febrile neutropenia. Through this parents 
expressed their wish to be informed of protocol changes, and treated as valid team members in 
their child’s care. 
Parents’ main concern regarding the protocol related to the issue of delayed discharge in current 
practice. Throughout the focus group discussions for parents of children under the age of 13, 
participants were clear that discharge from hospital rarely occurred at the point where it was 
theoretically possible due to the protocol. Parents distinguished between times when delays were 
appropriate due to the child’s ill health, which they were more than willing to tolerate, and those 
which they felt were in some way avoidable. Avoidable delays were those due to the timing of the 
child’s admission, side effects of treatment, delays in liaising between centres and setbacks in 
obtaining blood culture results, which I now expand upon.  
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Parents clearly voice their frustration about how services, and decision making, were conditional 
upon the timing of a child’s presentation with low risk febrile neutropenia. The staff present in the 
hospital out of normal working hours may not be as senior or as experienced in oncological 
management as those who provide routine services, and as such, parents recognised that they 
may make different judgements about the levels of risk involved or may not feel able to take on 
the responsibility of discharging a child with febrile neutropenia. Furthermore, certain laboratory 
services, particularly those relating to blood cultures, are often not available out of hours. This 
may therefore impact upon the time at which the child would be considered eligible for discharge, 
as protocols often require a negative blood culture result (at either 36 or 48 hours) before a child 
can be considered for discharge. If the blood culture process is not commenced until later in the 
child’s hospital stay, sometimes days later, for example if the child is admitted at the start of a 
long weekend with no laboratory service, this can result in substantial delays in decision-making. 
As discussed later in this theme, parents reported various side effects of antibiotic treatment, 
particularly diarrhoea, which result in increased healthcare needs and therefore delays a child’s 
discharge. Participants viewed these delays as avoidable as they considered that if the protocol 
were less rigid, then certain doses of antibiotics might be avoided in children with previous 
adverse effects. Finally, participants in Centre 3, which has a significant amount of shared care, 
participants reported irritation with delays which occurred when healthcare professionals in the 
POSCUs needed to contact the PTC for advice and these conversations took prolonged periods of 
time. This is evident in the following quote from the focus group discussion for parents of children 
under 13: 
“3:… you know and we love all the staff at [POSCU], you know we cannot fault them, 
they are really really nice but the other thing that you have is that they, you ask them a 
question and they go oh we’ll have to ask [PTC], and then we could be waiting 8 hours 
for the answer and then you might have a question on top of that answer and then 
you’re waiting another 8 hours… 
1: and in some cases they don’t, they actually wait until they do all their rounds before 
they phone [PTC] 
3: and you know it gets really frustrating…” (Centre 3, Parents of under 13s) 
Astutely, parents in a number of groups identified that the blood culture results were a 
particularly significant factor in professionals’ decision making in regards to discharge and that 
most protocols demanded a negative blood culture result before a child with low risk febrile 
neutropenia could be evaluated for discharge home. As such, when blood culture results were 
delayed at any point, parents became particularly dissatisfied as they had identified that this 
would then prevent them leaving hospital. This comment from Centre 3 demonstrates this point: 
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“1: then my frustration comes with the process and blood culturing and that, towards 
the end of a stay, is what just really really narks me, that we actually spend at least an 
extra day in because they don’t culture the bloods when you get in straight away, so if 
we were admitted on Monday at noon or after, they don’t start culturing the bloods 
until Tuesday at 9am…” (Centre 3, parent of under 13s) 
Thus, blood cultures symbolise the potential for parents to escape from the trap of hospital 
treatment for febrile neutropenia and delays in obtaining results capture parents’ greatest dislike 
of current services – apparently unnecessarily prolonged hospital stays with a well child. 
The healthcare professionals groups also acknowledged that blood cultures were important for 
current decision making about discharge but this was mostly referred to in passing, when 
referring to the requirements of the protocol. No healthcare professionals mentioned the 
challenges for patients and parents of waiting for delayed blood cultures, although one group 
alluded to their own frustrations with waiting. In Centre 1, the group discussed whether the 
duration of time waited before declaring a negative culture could or should be shortened: 
“2: but I think the other thing is... the main point of evidence that we would usually go 
on discharge apart from the patient themselves is the blood cultures and we wait for 48 
hours so I would probably like to know from the evidence that you’re presenting with us 
how many patients it would have made a difference between sending them home at 24 
hours and 48 hours from the blood cultures so do we just arbitrarily keep them in for 48 
hours because that’s what our standard practice is or can we…. Is there a… can we have 
some evidence that actually you could even send them home at 24 hours and just review 
the blood cultures after 24 hours cos the majority of cases aren’t going to grow anything 
after 24 hours… cos it’s not just about how the patient is it’s also about the 
investigations that we do…. 
3: doesn’t the 48 hours thing come from how long the machine takes to work cos I know 
some of the like… when I did neonates they said that there was like… NICE and 
everything its 36 hours cos normal … you know... machines take 36 but in this hospital or 
the Trust I think its 48 hours until you get the…. 
1: I thought it’s just historical … you’re just waiting for the bugs to produce whatever 
gas and that sets the alarm off isn’t it? 
2: yeah I think they survey…. There’s a more… more of a continuum of it now… 
1: I don’t think there’s any evidence… 
2: …whereas I think there used to be… they used to show in the machine at 48 hours 
they’d look at it… 
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6: so let’s say you get a blood culture, a child comes in at like midnight and the blood 
culture gets sent who... does someone deal with that in microbiology straight… when do 
they … 
3: probably at 9 in the morning 
6: that’s what I mean so that’s … so 48 hours isn’t 48 hours is it? 
2: no but I think the way… 
1: … cos it’s culturing as soon as you put it in the bottle… 
2: …yeah… 
6: does it? 
2: …yeah... as soon as you put it in the bottle, the way the new culture bottles work as 
soon as you put it in the bottle it starts culturing so it will be 24 hours… 
6: ok…. Right... so it doesn’t need to go in a special machine like…. 
2: no... it used to when we used to have the big glass bottles … I mean it used to have to 
go onto the machines then the culture start at the time it was put in…. 
6: …so it would be eight hours… 
2: but the new bottles I think they culture straight away…” (Centre 1, healthcare 
professionals, doctors (1, 2 +3) and nurse (6)) 
Linked to the issue of delayed blood culture results and the theme of attaining mutual trust and 
sharing role and responsibilities was a separate concern from families about a future early 
discharge strategy. Many had previous experiences of blood test results being lost or identified 
late, meaning parents did not trust that professionals would appropriately monitor test results 
when their child was not in hospital. In a number of groups, they asserted that, if their child was 
managed in the outpatient environment, then the results of all investigations should be 
communicated to them via telephone, regardless of any abnormalities.  
“1: I had a couple of occasions where I was told that erm… if you need to come back for 
some more blood tests we’ll be in touch with you, if you don’t hear from us, you’ll know 
everything’s ok, now I don’t particularly like that. 
[laugher from rest] 
4: you want to be told, you want to be rung no matter whether it’s good or bad, you to 
be told… 
1: I want to know somebody’s checked the results and just told me what it was 
5: see I don’t even like that for myself this you know, you know when they take your 
blood results… I want them to tell me either way…I don’t just want a phone call telling 
me oh yeah something’s wrong” (Centre 1, parents of over 13s) 
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Although the direction given by protocols provided reassurance to healthcare professionals, 
certain features of current protocols could be interpreted as constraining and strict, resulting in 
frustration for the professionals involved: 
“1: I think the other thing that makes it frustrating its very protocol driven innit?  
(2: (at the same time) yeah) 
1: I think people stick rigidly to 48 hours as though it’s a magic number and nobody can 
go home at 43 hours and etcetera…so I think it’s very very rigid err which is done for 
good reasons but I think if you dare to suggest that you veer from that you’re scorned 
upon…” (Centre 1, doctors)  
Throughout the study, both professionals and parents used language to describe the protocol 
requirements which implied an inability to deviate from them. The sense of the protocol 
controlling and limiting decisions was communicated throughout the protocol discussions: “you 
still have to treat them with antibiotics” (Centre 2, doctor).  This language is echoed in other areas 
of the transcripts which I examine later in the spectrum of control subtheme. 
Participants varied in how much flexibility they thought there should be within a protocol. Despite 
the frustrations of working within protocols, participants described risks of working outside the 
protocol, in particularly relating to receiving criticism from colleagues, with groups only briefly 
referring to the safety risks to patients of deviating from a protocol. Notably, they referred to the 
risks to patients of other professionals departing from the protocol but the risks of criticism refer 
to their own practice. This difference between their own practice and that of others is further 
discussed within the professional roles section of the chapter.  
The issue of flexibility in application of a protocol was particularly apparent when considering the 
role of appropriate clinical judgements. Participants asserted that the clinical assessment of a 
child should, at times, lead to appropriate deviation from the protocol. However, the general 
approach to protocol deviations varied from centre to centre. Centre 1 spoke of the importance 
of having a strict protocol with minimal deviations due to the multiple professionals involved in 
the care of children with febrile neutropenia (see role discussion in following paragraph) and were 
willing to accept a greater degree of frustration because of this. Meanwhile, centre 2 gave 
considerable weight to clinical reviews, with minimal references to protocols as a guiding feature; 
“personally I’m one of those individuals, I like to review and review and review so I think where you 
have got 14% treatment failure, if you’re able to review and review at appropriate times you may 
be able to also shorten the amount of time somebody has oral antibiotics…” (Centre 2, doctor) 
Combining these two approaches, professionals at centre 3 spoke about the integration of 
protocol and clinical judgement: 
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“1: like you’ve got the protocol there but actually if you know your patient… me and the 
consultant might make a decision on our patient that isn’t what the protocol says but 
we’re happy with that clinical decision” (Centre 3, nurse)  
Preferences for care 
Participants’ past experiences help to inform and find balance between the uncertainty of risks 
and the certainty of protocols and begin to demonstrate the need for discretion and the 
importance of individualised care for paediatric low risk febrile neutropenia. This subtheme 
explores how past experiences within current febrile neutropenia services impact upon attitudes 
to future care and the concept of hospital being a ‘safe’ place is debated. I examine how 
participants anticipated other key stakeholders’ thoughts and how accurate these expectations 
were. Although a number of issues discussed here had been identified in the Qualitative Synthesis 
of Chapter 4, many of these were explored in greater detail during the study and various new 
codes were iteratively ascertained. The potential explanations for these new codes are 
deliberated upon within this passage. 
Parents spoke in all focus groups about the difficulties they had experienced when their child had 
previously had febrile neutropenia, particularly the challenges of juggling many different demands 
besides responding to this episode of illness. As covered in the Qualitative Synthesis, they spoke 
about both practical and emotional issues. Practically, problems associated with travelling to and 
from the hospital featured in all focus groups, except the group for parents at Centre 3. 
Participants spoke of the tiring nature of travelling, particularly at night time or during the rush 
hour. The distance from the hospital where the febrile neutropenia would be treated played a key 
role in discussions about whether early discharge regimens would be accepted, with families 
living close to the treating hospital being more likely to accept outpatient care whilst those 
further away tended to feel that inpatient care might be preferable. Interestingly, the degree of 
shared care performed in the centre seemed to impact upon this issue. Participants in the centre 
where febrile neutropenia is treated in POSCUs, barely mentioned travelling as an issue, 
presumably because they already live close to their treating centres, whereas in centres where 
participants would travel to the PTC with febrile neutropenia, distance was a more significant 
concern, particularly if the journey would take over half an hour.  
Another practical issue mentioned in the Qualitative Synthesis was that of finances, related to 
travel, parking, hospital food and lost income. This issue was quite vividly described by some 
participants, including the loss of a self-run business, repossession of a car and the receipt of 
benefits such as free school meals. The magnitude of these financial concerns are unlikely to be 
purely from febrile neutropenia admissions, but instead reflect the acute-on-chronic nature of 
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febrile neutropenia, in which families are already under financial strain due to their child’s cancer 
diagnosis and then a further hospital admission adds additional burdens. Nevertheless, one focus 
group discussed how the unpredictable nature of febrile neutropenia episodes proved more 
problematic than scheduled attendances for review or chemotherapy as it did not allow them to 
plan other aspects of their lives, chiefly their work. 
The third issue related to prior experiences which parents found to be particularly influential was 
the psychological impact of admission to hospital upon their child. Participants spoke about how 
their children would become quiet, anxious or angry when their temperatures were checked at 
home and they anticipated they might need to travel to hospital. Parents related the ways in 
which febrile neutropenia episodes would feel inevitable once a child’s temperature had begun to 
rise, and how the interval between recognising a slight increase in temperature and recording a 
figure over the defined fever threshold was filled with trepidation about the impending excursion. 
Furthermore, parents shared how, once admitted, children became distressed by procedures, 
refused to eat or open their bowels, and would withdraw socially. Children would become upset 
about the social isolation from their friends and their siblings. Following discharge, psychological 
effects would continue for some time: 
“1: we’re definitely a more stressed family when he’s admitted…definitely… and it takes 
a long time for the family to get back on track, it’s not just he’s home and we’re all fine, 
you actually have to completely collapse and rebuild and that takes a couple of days… 
it’s a really bizarre explanation but it’s just like you are all on this adrenaline and 
what’ve we got to do to get by and where has everybody got to go and then you’re all 
home and you go ahhh and then you start to… just try and get back that routine… it’s 
not easy to get back that routine if there is a routine but… yeah… there is a 
psychological impact on it definitely…”(centre 3, parents of under 13s) 
Linked to the psychological impact on the affected child, parents spoke extensively about the 
impact on the child’s siblings. This included practical issues such as sleeping at other people’s 
houses (one young person spoke about their younger sibling having “this little suitcase” for when 
she was in hospital), eating in the hospital and the impact of lots of hospital visits. However, 
parents placed more intense emphasis upon the psychological impact on siblings. They spoke 
about split families, where one parent was in hospital with the affected child and the other at 
home with their siblings, with occasional ‘handovers’ of care. Some families discussed how they 
felt that the oncology ward was not suitable for siblings as so many children were so unwell. They 
voiced siblings’ needs to see professional counsellors or Community and Adolescent Mental 
Health Services as a marker of the severity of the impact of a family cancer diagnosis. Finally, 
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parents expressed guilt over the choices they needed to make when faced with the differing 
needs of their children: 
“3: …and then I start feeling guilty and I’m like, my other kids need me as well, obviously 
his health is one of the most important things but while I’m concentrating on his health, 
who’s concentrating on the others you know and it is. Horrible… 
2: oh it is… [sister] slipped in b)’s first year on treatment and she cut her eye here 
[indicates area between eyebrow and upper eyelid] and she needed to go to A+E and 
have it glued and b) was… they get so clingy don’t they and she was, it was a steroid 
week and she would scream if I left the room never mind the house and [sister] was 
crying, she was saying but you take b) to the hospital, don’t I matter as much 
1: why won’t you take me? 
2: so I did take [sister] to the hospital and left her (points at b) home screaming and 
[husband] said she screamed for like three, three and a half hours, cos when they’re on 
steroids they just don’t stop do they? And… but she was right, like, you can’t not put 
them first sometimes too… 
3: that’s it… horrible…” (Centre 3, parents of under 13s) 
Concerns about siblings’ needs were seen in all parental groups and expressed by all participants; 
however, parents with many other children seemed to find this particularly difficult. This 
appeared to influence their attitudes towards early discharge, with all but one parents of three or 
more children expressing a strong desire for outpatient care.  
Alongside the negative impact of repeated hospital admissions upon the relationships between 
siblings, and then between parents and their children, participants also spoke about how current 
services impact upon their relationships as couples. They talked about being frequently separated 
so as to provide childcare to different children, but also about how the affected child would often 
want to sleep with one parent even when at home. The parent who took on the role of primary 
carer during admissions often had a deeper relationship with the child when they returned home 
as well, and thus the other parent could feel rejected or ‘worthless’ . The negative impact upon 
relationships was prevalent in many of the focus group discussions. Although this effect of 
admission on family relationships had been discussed within the qualitative synthesis (Chapter 4), 
the intensity of these concerns was not as apparent as demonstrated in this study. This may again 
relate to the acute-on-chronic nature of the problem, such that frequent, intermittent and 
unpredictable admissions cause more distressing effects on families.  
When the professionals reflected on current febrile neutropenia services, they mostly spoke 
about the experiences of patients and families, with very few references to their own 
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perspectives. They mentioned each of the key issues mentioned above but provided less detail to 
the individual topics and did not identify more nuanced issues about the patient experience. 
“… so you have problems, like sibling problems, with the parents having to be in hospital 
all the time with their siblings, you get bad eating habits, you get rule changes, so many 
things, so many side effects of being in hospital… is my thoughts…” (Centre 3, nurse)  
When it came to their own perceptions of care, healthcare professionals appeared to project their 
feelings and emotions onto families. It seemed that within the groups, professionals described 
families feeling anxious or frustrated when perhaps these were their own views and feelings. 
There is a clear link here with the anxieties described in the understanding, expressing and 
negotiating risk code.  
“1: I still… I mean… It can be done, but I think the key issue is parents wanting to know 
what are the failure rates, what are the chances of… 
2: I think it's more the doctors disagreeing on what they want” (Centre 2, doctor (1) and 
nurse (2)) 
This situation, where healthcare professionals conveyed the thoughts and feelings of parents 
instead of their own, resulted in double silencing of both parents and professional voices. In the 
following quote the parents and family views are not appropriately heard, as they are being 
spoken by a proxy, and the healthcare professionals do not express their own experience, despite 
being explicitly asked. Thus the healthcare professionals’ voices are also masked.  
““Mod: … how do you feel as professionals responsible for these children when they’re in 
your care or the thought of them having that at home? So your feeling rather than the 
parents feeling 
6: erm… depends on how… what the... the timespan is of discharge… I think if they were 
going to do that they’d need… the families would need a lot of … would need support… I 
don’t think we could just say… right after eight hours...erm... we’ve given you piptazo 
we’ve sent you home you’re not going to hear from us again…they need support... it 
shouldn’t be up to the families then to ring us it’s a problem like many families… like we 
do say if there’s ever a problem any temperatures just ring us… I think there should be a 
phone call then put in place to them… 
4: I’ve found that the families that we send home that are extremely anxious about 
going home and don’t want to leave us cos they feel safe when you leave them for 48 
hours they realise that when you get home they are safe, they can carry on with getting 
along with what they did and when you actually see them, they’re fine and all those 
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anxieties that you saw 48 hours before have just completely disappeared, so I think it is 
… I think the anxieties are based on their experience … so if they go home and have an 
absolute awful time then next time they’re gonna have huge anxieties about going 
home but when they go home and have an alright time… they’ll be fine next time…” 
(Centre 1, nurses) 
In addition to the challenges previously discussed in the qualitative synthesis, and expanded upon 
through this study, eight further codes were identified. First, the professionals spoke clearly about 
how these are generally well children who are active, noisy and boisterous on a ward with other, 
much more significantly unwell children; “well they get in the way! Up and down the wards on 
bikes and cars and goodness knows what!!” (Centre 2, nurse) They therefore reported boredom 
and frustration over the process of an admission for low risk febrile neutropenia.  
“1: well the children are often quite well… they’ve just got a cough or a cold or 
something and their parents know they’re well. But they’re sat there in hospital wasting 
time when they could be at home... not wasting time but 
4: *laughing* 
1: but they … you know that they’re well… it’s frustrating  
4: (at the same time) it’s frustrating” (Centre 1, doctor (1) and nurse (4)) 
Parents expressed these feelings even more strongly. They spoke about feeling guilty for having 
their well child on the ward and were concerned about disturbing other children who were more 
unwell. Interestingly, this was not an issue which the young people raised, perhaps as two had 
minimal experience of febrile neutropenia and the other, who is discussed further in a later 
section of this chapter, enjoyed being in the hospital environment.  
The second new code is that of ‘hospital acquired infection’. This was a particular concern to 
parents, who spoke about the risks of wards or hospitals which were not clean. One exchange in 
centre 2’s group for parents of children under 13 years clearly summed up this issue: 
“1: and I’ve always worried about that, I mean I know it’s a very clean ward, the nurses 
are great, everyone washes their hands everything else but there’s floating around in 
the air… 
5: there’s people coming in though… 
1: there’s visitors… 
5: and some of them don’t look the healthiest do they? 
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1: there’s other children, absolutely…so for me as well, I think, surely at home where I 
can say, there’s just me, her brother and her dad, that’s it until she’s better, isn’t that 
better isolation than being on a ward with…” (Centre 2, parents of under 13s) 
Staff in two of the focus groups in this study also spoke about the risks of nosocomial infection. 
This feature had been notably absent in the Qualitative Synthesis.  
The third new code related to source isolation. Participants, both professionals and parents, 
commented on this in two distinct ways. The first links with the initial new code, in that well-
children who are the source isolated are usually even more bored or frustrated and therefore this 
can be a very unpleasant period of time for families. The second way in which source isolation 
was discussed relates to the following code – where source isolation beds are limited, staff can 
feel that these are unavailable to sicker patients when children with low risk febrile neutropenia 
are admitted to them. Parents were also acutely aware of this issue, expressing guilt for using 
resources which might otherwise be isolated to children considered to be more unwell. 
Staff expanded on the issue of bed pressure within the fourth new code relating to current 
experiences. Here they spoke about the intense challenges faced by health services, where the 
numbers of bed spaces are reduced and the costs of occupying a bed are high. Although 
mentioned in all groups, this seemed a particular issue in centre 2, perhaps related to the fact 
that this is a smaller centre that the other two centres and has a minimal shared care network. 
There, this issue was most often brought up by one particular participant who has a management 
role within the team and hence may be particularly aware of certain service pressures. 
“6: …maybe delay children for chemotherapy…need the beds… that’s I imagine 
frustrating… you can’t get other children in…  
Mod: so you’re describing service pressure as well? 
6: probably yeah… cos your beds are full aren’t they? They’re full of well… potentially 
well children who could have gone home” (Centre 1, nurse) 
The fifth code, discussed only by parents and young people, related to side effects of antibiotics 
and other treatments. Clear descriptions were given of the diarrhoea caused by antibiotics, which 
necessitated source isolation, and all its associated challenges, and might also cause the child to 
need intravenous fluids or total parenteral nutrition6, thus delaying their discharge from hospital. 
Parents voiced a clear preference for reduced amounts of antibiotics, particularly those given 
intravenously, so as to prevent these side effects. In addition, parents spoke about their concerns 
                                                             
6 Total Parenteral Nutrition (or TPN) is an intravenous solution which aims to provide a patient’s nutritional 
needs when these are not being met via the enteral route. It includes carbohydrates, fats, vitamins and 
electrolytes tailored to the individual patient’s needs. 
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regarding antibiotic resistance and how this might impact on their child in the future. This added 
further to their wish for reduced therapy. Perhaps importantly, these issues were not raised in the 
healthcare professional focus group discussions. This may be due to the differences in risk 
assessment by professionals and families, such that professionals feel the risks of a poor febrile 
neutropenia outcome outweigh the harms of side effects or antibiotic resistance.  
In the fifth code, healthcare professional participants in Centre 3 discussed the long-term impact 
of current febrile neutropenic care. They spoke about the psychological effects of being 
considered an ill child and how recurrent admissions contribute to a family adopting a sick role for 
their child. The professionals felt this had the potential to impact on a child’s future perceptions 
of their health. 
“… as a late effects nurse… the risk of repeated hospitalisations and family seeing their 
child as sick and continuing to do so after the… and never really recovering from that 
sick child mentality… I don’t know if that’s a bit strong… I see the late effect of that 
when you’ve still got families who haven’t been able to stop treating their child as a sick 
child right up until the child being in their early adulthood… I don’t know how you’d ever 
measure that to balance it against that 0.1% risk…” (Centre 3, nurse) 
Alongside these five codes which capture some of the more difficult aspects of previous 
experiences, three codes describing the benefits of inpatient care were also found. The most 
pervasive, which also ran as a subtle undercurrent through many sections of the discussions, was 
the concept that hospital is a safe place, where professionals looked after and cared for their 
child’s health, though focused mainly on the physical aspects of this. Despite the concerns about 
hospital acquired infections and about considerable psychological impact, parents clearly stated 
that hospital was the place they would prefer their child to be if they judged them to be unwell, 
through their own risk stratification. Parents and young people felt comforted by the presence of 
healthcare staff with whom they had good relationships and by the ritual of performing regular 
observations, although a couple of groups did highlight that many observations could be done at 
home. This feeling of safety and comfort may be accentuated by the benefits of relinquishing a 
degree of responsibility for their child and control over decision making for this brief period. 
These issues are discussed later in this chapter. The feeling of safety was also dependent upon the 
ward and the hospital in which the child was located, and this is again discussed further in the 
following theme.  
The second main positive code is that hospital can be fun. This was primarily brought up in the 
groups for young people and their parents. One family in particular spoke about enjoying the 
input of youth support co-ordinators and the various activities that are organised in the hospital. 
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The social element of hospital admission was certainly appreciated by this family. In one other 
group, for parents of under 13s, one parent mentioned how their child enjoyed the playroom in 
the hospital, and sometimes did not want to leave this space. However, this did not seem to play 
a major role in decision making and this parent was clear that they would still prefer a reduced 
therapy strategy for episodes of low risk febrile neutropenia.  
The final positive code relates to the relational benefits that children and young people gained 
from the undivided attention of a parent, who, at home, might be distracted by other siblings and 
by the hubbub of daily life.  
“4: I think that’s why d) liked being in hospital because it was one-to-one she just had 
me, she didn’t have to share me with anybody… 
5: yeah 
4: you know so I could run round after her and I didn’t have to worry about [other two 
daughters] or you [referring to husband], it was just me or her so I think she quite liked 
that… errr… you know that I wasn’t going to work or doing anything but 100% here for 
d)” (Centre 1, parents of over 13s) 
The potential reasons for why these new codes were not discussed in the qualitative synthesis 
data most likely relate to three key factors. The first is that a number of the problems, including 
the challenges of well children being kept in hospital, are very disease specific features. Therefore, 
as the qualitative synthesis included only one paper specific to febrile neutropenia, it is perhaps 
understandable that these points were not discussed.  
The second feature that may explain some of the findings is that these are patients and parents 
who have prolonged contact with healthcare services. They therefore become more perceptive 
about issues related to admissions and through repeated experiences have identified problems 
which are recurrent, compared to those which are ‘one-off’ negative aspects of care. Thus the 
population involved in these focus groups is likely to be more sensitive to the challenges of 
frequent hospital admissions. However, they have also developed deeper relationships with 
healthcare staff members and thus may benefit more from the positive influences of care on a 
ward which they know. Although this explanatory factor is not specifically disease related, it is 
associated with having a chronic disease involving regular contact with healthcare services and 
periodic admissions. As this was not the case with some of the studies included within the 
systematic review, this may explain why certain codes had not been previously identified.  
The final possible explanatory factor is that of the current healthcare climate within the UK, 
where austerity measures and staffing crises reduce the funding available and mean that the 
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limitations of inpatient services are more apparent to professionals than in the times and 
locations of the studies included in the qualitative synthesis. 
When participants discussed the preferences of other participant groups, there were often 
inaccuracies in the perceived desires of others. The most clearly apparent areas of imprecision 
were between the groups of young people and their parents. Here, parents were relatively certain 
that their children would prefer outpatient treatment regimens for low risk febrile neutropenia 
and just one teenager was predicted to be unsure about leaving hospital. However, when the 
young people themselves were questions, this one teenager was very clear that she would prefer 
to always remain in hospital, and another teenager voiced that she would probably also elect for a 
period of admission following a fever. In the end only one young person stated she would select a 
reduced therapy option. Meanwhile, the young people anticipated that their parents would all 
rather receive inpatient care, which was at odds to the parents’ stated preferences.  
It is unclear precisely why these conflicting opinions occurred. It may be that each group felt that 
they knew what the response of the other member(s) of their dyad or triad would give and thus 
adjusted their own expressed posture accordingly. This suggestion is supported by the fact that in 
each group, participants stated that they would take their parent or child’s opinions into account 
when deciding about future treatment options.  
“1: if my mum agreed with the doctors, then I’d just do what she said, cos they don’t 
like… when I’m saying something its normally cos it’s what I’d prefer, when my mum 
tells me to do something its what’s best for me… so… I’d probably whinge about having 
to staying in hospital but then… I’d just stay anyway. 
2: I don’t know… I don’t think I’d really… I think my mum would just do what’s right for 
me. Yeah” (Centre 3, Young people) 
Attaining mutual trust and sharing roles and responsibility 
In this theme, participants spoke of the different roles within febrile neutropenia services and 
how these would need to change if outpatient or early discharge schemes were implemented, 
how mutual trust, though already present in some ways, would need to be fostered and 
strengthened and how responsibility would need to be redistributed between groups. 
Encapsulated within this theme were the relationships between and within patients and families, 
the roles of various professional groups,  attitudes to shared care networks, external influences on 
services, the interactions between families and professionals, and  the challenges of attaining 
mutual trust and sharing responsibility. Links with other themes are explored and expanded.  
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Relationships within and between families 
The impact of current febrile neutropenia management strategies on relationships within families 
has already been discussed in the Preferences for care section of the previous theme. Participants 
also spoke about how relationships between families being treated by paediatric haematology 
and oncology services, influenced experiences and perceptions. Parent participants spoke about 
how they learnt about different methods of managing problems through discussing them with 
other parents, and learning about their attitudes towards different hospitals or trials. Parents in 
Centre 3 also talked about the support they got from social media networks in living with and 
understanding their child’s condition, particularly as the significant shared care network meant 
families were less connected geographically. Parents viewed these relationships in a positive, or at 
least informative, way but stated they gave most weight to professional opinions.  
In contrast, the healthcare professionals raised concerns about relationships between families. 
They felt that providing individualised care could be complicated by parents speaking to each 
other and being displeased because children were managed in different ways for the same 
condition, creating more work for professionals in explaining the rationale for different choices. 
This could potentially complicate the management of children who are perceived to have a single 
condition, reflecting participants’ struggles to separate the various risk groups within febrile 
neutropenia. Were discussions about risks and shared decision making to occur, then families 
could be supported to understand and accept the differences in care for febrile neutropenia. 
Professionals also spoke about how groups of parents could influence the attitudes of a whole 
centre’s population towards certain changes in practice and thus prevent introduction of new 
policies. This is discussed further in the interactions between families and professionals section.  
Professional roles 
Professional roles were clearly defined for all participants within the focus groups, with very few 
distinctions between professional, parent and young peoples’ voices in this area. Where there are 
differences, these are highlighted at the appropriate point.  The ways in which medical and 
nursing roles are currently set up for febrile neutropenia were quite explicit: 
“Mod: tell me about how you treat low risk febrile neutropenia in this hospital 
7: Well… they come through the door, they should s’pose get seen within an hour by the 
doctor  ...um... but in that time the nurse does her assessments, accesses the port, takes 
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bloods, um.. administers calpol if they’ve got a ‘PGD’7 or… bleeps the doctor then it goes 
from there.  
3: Usually the junior doctor arrives, prescribes the first dose of IV piptaz8...um... does the 
peripheral cultures if they’re necessary and sees the child and assesses for any focus of 
infection, assess whether it’s actually likely to be a line infection or whether it’s likely to 
be another form of infection, whether serious infection or not, and then we usually bleep 
our more senior doctors for a review if we’re not sure.” (Centre 1, nurse (7) and doctor 
(3))  
With regards to medical roles, there were very clear distinctions drawn between junior doctors 
and consultants. Throughout the study, junior doctors were discussed in either a functional way 
or an unfavourable tone. Junior doctors were considered to be less able to manage children 
appropriately, needing stricter protocols, and were often felt to be less confident in decision 
making. These negative comments appeared in all groups, but were most frequent in the 
healthcare professional group with the most junior doctors present, though these comments did 
not come from the junior doctors themselves. Similar comments came from the other groups of 
both parents and professionals.  
Comments on nursing roles were more variable. Predominantly, there was clear respect and 
recognition of the skills that both hospital and community nurses bring to febrile neutropenia 
services, both in supporting patients and in guiding medical staff. However, there were occasional 
undertones of negativity towards nursing contributions:  
“so you could do reviewing in two ways, you would either have clinical nurse specialists 
trained, and there are centres that are doing that, where they train them, they’re not 
actually doctors but they’re able to do assessments and things, erm… and they go in and 
they assess and feedback and assess and that works, but only to an extent….” (Centre 2, 
doctor) 
A further set of key healthcare professional roles and relationships related to shared care teams. 
As discussed in Chapter 5, the involved centres were purposively selected with some of the 
selection criteria relating to the amount of febrile neutropenia treated in shared care centres. 
Thus, Centres 1 and 2 had small shared care networks with few episodes of low risk febrile 
neutropenia being managed outside of the Primary Treatment Centres. However, Centre 3 has a 
very different structure, where almost all children with low risk febrile neutropenia are managed 
                                                             
7 A PGD, or Patient Group Direction, allows nursing staff to assess a patient’s need and administer 
prescription-only medicines, without an individual prescription from a doctor, provided that the patient and 
medication fall under those described within the PGD.  
8 ‘piptaz’ is a common shortening of the combination antibiotic piperacillin/tazobactam. 
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by shared care teams and the Primary Treatment Centre simply provide support through the 
provision of protocols and intermittent contact to provide advice on individual patient care. Given 
these differences in service design, it is perhaps unsurprising that the attitudes towards shared 
care and the anticipated roles to be played by colleagues in POSCUs differed. 
In Centres 1 and 2 healthcare professional groups, shared care units were only minimally 
discussed, and generally in a negative fashion. Both groups talked about how changes to services 
ought to be changed at the PTC prior to being rolled out across the shared care network. They did 
not discuss the involvement of shared care staff in developing future protocols and they did not 
clearly outline a role for these staff in any suggested outpatient service.  
“4: and then I suppose we have to think about are we then happy to make that policy 
general and include shared care hospitals and are we happy that… the same safety 
applies to the shared care centres… 
2: that would be a major concern for me… (laughter)… having taken phone calls from 
shared care centres… yeah… 
1: it’d be harder for them… I mean… we see I dunno ten a week or so… they see one 
every month sometimes don’t they… 
2: I would have thought this kind of thing had to be… done here first…” (Centre 1, nurse 
(4) and doctors (1+2)) 
Centre 3, however, generally spoke very positively of their shared care colleagues, and of the 
current services set up for children in their area. They did highlight particular challenges to the 
PTC including frequent requests for advice from POSCUs, which were sometimes felt to be 
inappropriate as they related to ‘general paediatric problems’, and the difficulties that arise when 
the local lead for paediatric oncology in the POSCU is unavailable and the team subsequently 
need significantly more support.  
“3: they’re sometimes encouraged to talk to the… by the local consultants apparently… 
2: again, you only have usually one lead consultant who is knowledgeable and the 
others… 
3: so one of the difficulties happens that I know that the people who hold the phone 
here have is people in the local hospitals where the child is, asking for us to make what 
is a clinical decision about when to stop the antibiotics and that’s quite difficult, I think… 
2: and also asking for just… asking questions that, with their paediatric hat on, they are 
able to answer…” (Centre 3, doctor (3) and nurse (2)) 
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When considering the design of future services, Centre 3 spoke about how shared care centres 
might easily adapt to an outpatient regime, and also shared how these changes would need to be 
communicated, highlighting some of the complications experienced when changing protocols in 
the past.  
The opinions of young people and parents about shared care generally echoed those of the 
healthcare professionals at each centre. Within Centres 1 and 2, shared care was spoken about 
disapprovingly. Parents spoke about how staff at shared care hospitals did not know their child, 
had less understanding of oncological issues, were unclean and their treatment was less effective 
than in the Primary Treatment Centres. One participant did highlight that they found it difficult to 
differentiate between the nursing and medical skills which might be considered as specialist to 
oncology and more generic skills, as demonstrated in the following quote: 
“4: cos nobody’s there to access her port9… 
5: nobody accesses ports there... 
4: nobody could do it… 
5: nobody could do it cos they’re all nervous about doing anything over there 
4: and they said something like the lady that could do ports was off for three days or it 
was… it was shocking 
5: which we found really odd but obviously when we’ve asked the nurses here… they 
said yeah we do ports all the time, said its nothing to us but when they’ve been other 
places then they’re asked to train people to access ports… so we though oh ok then it 
starts to make sense a bit… you sort of get in your mind-set a nurse is a nurse and a 
doctor’s a doctor and they’ll just get on and do it but obviously with specialisations and 
things you don’t think of these things, you just want your child to be dealt with don’t 
you… so… in the proper way but…” (Centre 1, parents of over 13s) 
Due to their concerns about care in the shared care units, parents in these centres preferred to 
travel to the PTC for treatment of febrile neutropenia, even though this increased the distance 
travelled and thus impacted poorly upon their current experience of care as demonstrated in the 
Quest for certainty theme, outlined above. 
                                                             
9  A Port-a-cath is an implantable central venous access device in which a small box, or ‘port’, is sited under 
the skin (usually on the anterior or lateral chest wall) and connected to a catheter within a large vein 
(usually the subclavian vein). This allows the administration of certain medications such as chemotherapy 
and easy access to blood samples. ‘Accessing’ the Port-a-cath involves placing a needle into the ‘port’ under 
aseptic conditions, and requires a degree of technical skill and training. Most staff working outside oncology 
units do not have this skill. 
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Meanwhile, in Centre 3, parents spoke differently of their care in POSCUs. They shared how they 
had formed relationships with the staff in the POSCUs and could identify the knowledgeable staff 
in the centres. Furthermore, parents spoke about how they helped to educate staff about 
oncology issues and took more responsibility for communicating about their child’s disease and in 
directing care. Generally, this seemed to be interpreted as a positive occurrence as parents took 
on this role of educators and became valid team members alongside the shared care staff. 
Participants did complain about delays when POSCU staff needed to liaise with the PTC, but at no 
point did the parent participants at Centre 3 voice a desire to have their child’s febrile 
neutropenia managed at the PTC itself. Issues of cleanliness or poor skills were not mentioned in 
Centre 3, other than one issue related to Port-a-cath access in which the deficiency was felt to be 
related to individuals rather than to the whole shared care team.  
Between the discourse about shared care and considerations of professional roles were 
discussions about the role of community nurses. These staff members were highlighted by all 
groups as particularly busy, if not overstretched, in the current demands upon them. Their skills 
both in sampling from central venous lines and, increasingly, in the assessment of children were 
recognised and highly valued by teams. Indeed, despite their current work pressures, all groups 
felt that community nurses should constitute key roles within an outpatient service. Their 
expertise in liaison between patients, families and treatment centres meant that they were 
recognised as having proficiencies which participants would like to be multiplied either through 
the employment of further community nurses or the development of these skills in other staff 
groups. 
“…Community nurses are by nature usually very experienced nurses and often of higher 
grades and by educating them and by them having the links with both primary 
treatment centres and… which they’re very used to doing I think that they’re very well 
able to support the family and to act as their advocate and to link in with the primary 
treatment centres…. And I think that you don’t want people who are just going in to do 
bloods and things, that is a really good time for education and so, maybe strengthening 
of community services in some way, so that it’s not just seen as a ‘I’ve got to do a job for 
the PTC’ more as a ‘I am part of the team that is helping to support, advocate and 
educate this family’.” (Centre 3, nurse) 
When discussing other professional roles, external influences upon clinicians were apparent 
throughout the healthcare professionals’ focus groups, though notably absent in the groups for 
parents and for teenagers. In two groups there were comments about the anticipated opinions of 
the participants’ colleagues, with Centre 2 appearing to be particularly anxious about the fact 
they may have conveyed perceptions that others would not approve of: 
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“so in the study will it say (centre name) feedback? Cos they’re probably all going to say 
“well we didn’t say that, we don’t agree with what you three have said”” (Centre 2, 
nurse) 
This highlights a concern (or perception) that other, more ‘powerful’ parties might not approve of 
what the participants have said; and a real worry about conflict and disagreement within the unit, 
particularly as this centre are currently undergoing significant changes of policy in this area. 
Interestingly, this centre, and this participant in particular, had already discussed disagreements 
as a prominent feature in febrile neutropenia discussions: 
“…but it is very controversial with the doctors, cos our consultants, there’s 
disagreements isn’t there on what we should do? And I know that’s probably 
throughout the UK as well, throughout the universe probably…” (Centre 2, nurse) 
The influence of parties outside the participants’ departments was also demonstrated, through 
discussions about managers’ opinions and relationships with other professionals.  For example, in 
regards to relationships with microbiologists, some aspects of the discussions were very positive 
(“…we have a very good relationship with the microbiologist and virologist here,” Centre 2, 
doctor), whilst others were less so (“cos a lot of the time when you ring the lab…they’ll usually say 
oh it won’t be positive but they won’t say for definite so….” Centre 1, doctor) 
A particular challenge to healthcare professionals involved in these groups related to how these 
roles and relationships would need to be negotiated if early discharge regimes were instigated. 
The change in activities of different professional groups, within departments, hospitals and shared 
care networks, as well as the increased responsibility of patients and families inevitably made 
healthcare professionals feel quite uncomfortable. This links to their wish to mitigate the risks to 
their patients wherever possible, as well as to their wish for discretion as to how much a child’s 
treatment they control, as in the earlier discussion of determinism.  
One particular professional, a doctor, described the difficulties of changing roles particularly well. 
This was captured within two key quotes; one, previously discussed in the methodology chapter, 
relates to the issue of role negotiation and professional identity, the second to whether outcomes 
are “written in the stars”. The first quote explores how paediatric oncology patients are 
considered “special” and different from children within other paediatric services. This transfers to 
the professionals’ identity in paediatric oncology and haematology, which defines this group as 
people who care for children who are “special”. Changing the manner in which these children are 
treated so as to be more like “normal” children then also brings the professionals’ identity into 
dispute. Recognising this dilemma illuminates the emotional reactions of participants to early 
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discharge options, and provides understanding as to why instigating change in this area has 
proved problematic. 
“really what you’re saying at this point is that in… to a certain respect… if they’re a low 
risk patient you would treat them pretty much the same as you do a general paediatric 
patient… and it’s about moving... that shift of your opinion that our patients are ‘special’ 
([4] laughs) or susceptible whereas actually what you’re saying is they’re... they’re not. 
And in which case, you’re moving away from the oncology kind of let’s protect 
everybody kind of approach to more of a general paediatrics approach of somethings 
really gotta be wrong in order for us to kind of worry about this child. So I don’t know... 
but I agree with [1] and [4] I think… I don’t know whether going from your 48 hours to 
immediate discharge…” (Centre 1, Doctor) 
The second key quote from this professional also relates to role identity. Here, the data from the 
systematic review stimulated the participant to consider how current febrile neutropenia 
strategies do not prevent all deaths in paediatric low risk disease. He calls into question the 
efficacy of professionals in this area, challenging the traditional roles of clinicians outlined in 
determinism as people who cure disease. Surprisingly, this realisation does not appear to cause 
an identity crisis, but instead is laughed at and provides a moment of levity within the group, 
followed by a period of quiet contemplation before the conversation moves on. This comment 
seemed to allow participants to recognise that the change in roles to one of lesser involvement 
might not have a negative effect on their patient, and permitted them to consider a reduced 
therapy regime with a little less anxiety. 
“but what you’re saying from that data is the ones who died, it didn’t really make any 
difference that we were already treating them... and that’s the thing isn’t it? Is whether 
we actually think that what we do makes a difference (laughter) or whether that that 
stuff that happens is already kind of written in the stars so to speak….” (Centre 1, 
Doctor) 
Interactions between families and professionals 
As well as the roles of professionals, the relationships between families and their healthcare 
professionals played a vital part in decisions about the management of low risk febrile 
neutropenia. The ways in which roles and responsibilities were currently assigned were 
acknowledged and the challenges of negotiating and redefining these relationships were 
delineated. 
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Parents expressed themselves as playing three key roles in the care of their children with febrile 
neutropenia. First, they spoke repeatedly about their responsibility to protect their children from 
acquiring infection and thus prevent them developing febrile neutropenia. Parents deliberated 
over difficult decisions including when to send their child to school and how much socialising to 
allow their child to engage with. They also discussed the influence of siblings on a child’s risk of 
infection and how to prevent the transfer of microbes between siblings and the affected child, 
including also limiting a sibling’s attendance at school during outbreaks of infections. Practically, 
parents would carry out routines and rituals to prevent infection, including using bleach to clean 
their houses or by insisting on frequent hand washing of both family members and visitors:  
“4: I bleached d)’s bedroom yeah… I became obsessed with… 
5: that’s what we… our two youngest, we got them a little bit obsessed with washing 
hands and things, we had the err… alcohol as you come in the door 
1: yeah well my husband insisted on that but nobody liked it 
5: and they… [youngest child] would literally take it when d)’s friends came, take it to 
the door like you can’t come in… 
4: [other child]’s gone the other way now, we have to … we have to try stop her washing 
her hands… 
5: we’ve got to be careful with her…” (Centre 1, parents of over 13s) 
Finally, parents recognised that they engaged in superstitious behaviours such as keeping a 
packed hospital bag in the boot of their cars in the belief that this would prevent admissions with 
febrile neutropenia. This may reflect a desire to take control over the situation and to feel as if 
they have a means to prevent their child’s febrile neutropenia. This links with the issues of control 
discussed later in Chapter 7. 
Secondly, parents identified their roles in performing many essential care tasks for their children. 
These included the management of nasogastric or gastrostomy tube feeding, the care of central 
venous line dressings and the administration of oral chemotherapeutic agents. Participants spoke 
about how these were vital to their child’s wellbeing and to the successful completion of their 
child’s treatment for cancer. However, parents felt that these tasks were often undervalued by 
healthcare professionals and seemed arbitrary in the degree of responsibility devolved. In the 
centre 2 group for parents of children under the age of 13, one participant shared that she felt if 
she was able to deliver oral chemotherapy to her child at home, then she would be happy to 
observe him with febrile neutropenia.   
“2: …they trust me to do that massive job, I think those sorts of things, you know, 
individually have to be considered… 
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5: definitely… 
2: so from that point of view I think I’m more than happy to take on that responsibility, 
I’m taking on so many others with it and…” (Centre 2, parents of under 13s) 
Finally, parents viewed their role to be to care for their child’s overall health, including the 
physical, psychological and social factors beyond their febrile neutropenia, as described in the 
Preferences for care subtheme of the Quest for certainty theme of the study. This responsibility to 
draw attention to the broader impact of admissions for febrile neutropenia and to represent the 
needs of other family members formed a central tenet of the parent role.  
In response to these considered roles, participants recognised marked variation in family attitudes 
to febrile neutropenia episodes which then translated into behaviours, with some being very 
anxious, others “playing it by the book” and doing as healthcare professionals instruct, and others 
with a relatively laisse-faire approach to fever in their children. Indeed, parent participants in 
centre 2 spoke very negatively about another parent who they perceived to have endangered 
their child through poor adherence to central line infection prevention advice.  
Interestingly none of these three parental roles were acknowledged within the healthcare 
professionals’ focus groups. In fact, professionals identified very few roles for parents within the 
management of low risk febrile neutropenia. They did discuss the issue of non-presentation of a 
child with a fever (which is discussed later within the Potential for realised discretion theme) and 
thus implied that a key part of the parental role is in conveying the child to hospital immediately 
upon the detection of fever.  
Another role that healthcare professionals assigned to parents was that of disrupting attempts to 
reduce therapy. Professionals anticipated that families might have a negative opinion of early 
discharge regimens and that parent groups could undermine service changes in this direction: 
“1: one of the things that they used to do in [other centre] is they’d look at the blood 
count and monocytes, if they were coming up then you know that within a day or so 
before they’re not gonna be neutropenic and it worked to a point, but again of course its 
parents, parent group get hold of it and say “oh this is happening, that’s happening, not 
happy with it”, you have then got to change your policy because you’re not going to get 
compliance, and that’s a key problem for a lot of these things” (Centre 2, doctor) 
Juxtaposing this, the only time parents spoke about what future services they thought 
professionals might choose, they considered that it was healthcare professionals who were 
disinclined to allow early discharge and who were likely to delay the introduction of reduced 
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therapy regimens, Parents were understanding of this level of caution on the behalf of 
professionals, recognising the degree of responsibility felt by them: 
 “2: well they’ve got a lot of responsibility 
4: it’s on their shoulders isn’t it if they discharge you 
2: and something happens 
Rest: yeah 
2: that’s a big deal really isn’t it? So it’s difficult for them… 
1: yeah I can imagine it is… it’s got to be…” (Centre 2, parents of under 13s) 
Within these groups, participants identified a need to change the current balance of roles, with 
each centre discussing how responsibility would have to be shared between professionals and 
families. Healthcare professional participants raised concerns that although they would be willing 
to share responsibility with families, families might be unwilling or untrustworthy at times. 
Further, professionals were worried that blame for any adverse outcomes would be assigned to 
them, despite this renegotiation of responsibility (see the quest for certainty theme). 
“2: … but I think it’s also a balance between we’re very paternalistic... we wanna look 
after our patients we don’t want them to die which is understandable but also parents 
and families understanding that if you want to do this kind of thing you actually have to 
take a bit of responsibility yourself and we’re saying that you know yes this is a low risk 
thing but there are still very occasional cases where it goes wrong so you have to 
make… I think we need to maybe move more to care agreements with patients than 
necessarily dictating what happens to them but there has to be a dual responsibility 
with us saying this is the evidence, this is what we think but if you’re willing to accept 
that risk then... you know… then we can do this management pathway… if that’s what 
people want to do… 
6: do you think a lot of our families would take that on board [2]? I know some would… 
but I know a lot… 
2: I don’t think they would… no...  
6: ...no… no… 
2: and I think ultimately at the end of the day if it went wrong it would come back to us 
as our responsibility but we’re kind of... that’s the healthcare system that we’re working 
in at the moment…people want choice but equally… 
3: …no responsibility with it….” (Centre 1, doctors (2+3) and nurses (6+7) 
The parental responses to possible increases in responsibility also varied. One parent in Centre 3 
voiced her concerns twice about taking on more of this:  
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“2: I guess the difficulty is that if they have a rule that says you know, you listen to the 
parents, if the parents say we want to take them home and then something happens, I 
guess, is that on the hospital, is that on the parents…erm… I don’t know” (centre 3, 
parents of over 13s) 
However, in centre 2, parents drew attention to how the role of parent to any child involves 
enormous responsibility and stated unambiguously that they felt primarily responsible for each of 
their children. This was also the group who had described the additional care tasks that they had 
already taken on for their child with cancer and who therefore felt that administering antibiotics 
and monitoring febrile neutropenia did not constitute a significant increase in the responsibility 
that they bore. 
Particularly mentioned within this subtheme of shared responsibilities were teenage patients and 
the challenges that they held for healthcare professionals. Throughout the material provided by 
healthcare professional groups, teenagers were viewed quite negatively, being felt to be most 
likely to be non-adherent to specific regimes and being unlikely to present with episodes of febrile 
neutropenia. In one group, the professionals spoke about how an early discharge regime might 
increase the likelihood of presenting to hospital following a fever. This links nicely to the 
discussions of non-attendance later in Chapter 7. 
“I think for the teenagers that is slightly easier cos I think they’re a lot more in control so 
if they’re not feeling very well they won’t tell anybody they’re got… they’re not feeling 
well they won’t have their temperatures taken and they have a temperature and they’ll 
be at home for an awful lot longer but if there’s the option there potentially coming for 
one dose of IV antibiotics and then orals maybe as an outpatient then that might make 
them a bit more compliant with telling someone they’re not feeling very well and having 
their temperature taken and getting in quicker 
(murmur of agreement from other participants)” (Centre 1, nurse) 
Mutual trust 
The concept of mutual trust runs through these discussions of roles and responsibility. In order to 
redistribute their roles and responsibilities, healthcare professionals would need to trust parents 
and/or other professional colleagues to undertake these additional features, whilst parents would 
need to trust that professionals continue to fulfil the remaining aspects of care. Through the focus 
groups, trust was discussed in various ways.  
For professionals, the degree of trust between groups appears dependent upon their knowledge 
of each other. Thus in centres where shared care is regularly practiced and thus professionals at 
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the PTC are more familiar with staff at the POSCUs there seemed to be increased trust in the 
POSCUs to be able to care for children with febrile neutropenia appropriately. Conversely, for 
centres with minimal shared care currently in situ, the trust in shared care to be able to manage 
this condition was less clear. This aspect of roles and responsibilities has already be discussed in 
depth earlier in the chapter.  
For parent and young people participants, the levels of trust they had in professionals was also 
dependent upon their familiarity with them. Thus participants who had regular contact with their 
shared care centres tended to trust the care they received there, whilst those who attended 
POSCUs infrequently were not so confident in the professionals there (see also the professional 
roles subtheme). Meanwhile, when participants were managed on a different ward within their 
usual hospital or were cared for by agency (temporary) staff, they also disliked this experience.  
When discussing their usual healthcare professionals, parents in certain groups, almost entirely in 
Centres 1 and 2, spoke about having complete trust: “…we trust them you know 100% so you just 
go by what they say so if they say well you’re here then you’re here you know because you just 
trust exactly what they say…” (Centre 1, parents of over 13s). Notwithstanding the statistical 
issues with this comment, this implies certainty in the trust which parents have in their child’s 
clinicians. Although the conviction of this certainty was undermined at other points in the groups, 
such as when parents spoke about being unable to trust professionals to follow-up on blood test 
results and act on them accordingly (as discussed in the quest for certainty theme), generally 
discussions were very positive about the trustworthiness of healthcare professionals.  
In contrast, healthcare professionals in these centres spoke rather negatively of the parents of the 
children they cared for (as discussed in the earlier subtheme about Interactions between families 
and professionals). Professionals struggled to believe that parents would appropriately present 
children for care, ensure the administration of medications and be able to identify any acute 
deterioration in their child at home. This may again relate to the issue of healthcare professionals 
feeling ‘special’, as allowing parents to manage children with a fever at home becomes akin to 
general paediatric management. This negotiation of the professional role seems not to be 
something which the participants were willing to consider. 
Meanwhile, in centre 3 where significant shared care occurred, trust was moderated, parents felt 
more responsible for their child’s care and placed less trust in healthcare professionals, often 
guiding them towards what they felt was more appropriate care. Similarly, professionals in the 
shared care units trusted families more to be in contact with them when appropriate and to be 
able to identify when their child became more unwell. 
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“1: I think they’re very good at phoning … well I can only speak for my patients really… 
but I think they’re very good at making contact and even if it’s… I mean I suppose I 
always educate my families that even if they… even if you think your child is unwell… 
and you know your child best and they haven’t got a temperature, you still need to call 
in and seek advice if you think something’s wrong… so it is a bit about education…” 
(Centre 3, healthcare professionals) 
The difference between centres, which appears at least partly dependent upon the degree of 
shared care, seems to correlate with the amount of control apportioned to parents. The polarity 
of trust in those centres where febrile neutropenia is managed in PTCs reflects the degree of 
control and responsibility given to parents of children with cancer. Meanwhile in shared care 
centres, where parents take on greater responsibility for educating staff, the amount of control 
they have over their child’s care increases and enhanced levels of mutual trust are also seen. It is 
unclear which is the causative feature of these differences – do centres which relinquish more 
control to families foster increased mutual trust, or do centres with more mutual trust tend to 
increase the amount of control that families have? 
Summary 
This chapter has explore the two themes of the quest for certainty and attaining mutual trust and 
sharing roles and responsibilities.  I have demonstrated how participants in all groups struggled 
with understanding, expressing and negotiating risk, the challenges in articulating and 
interpreting protocols and the various influences on preferences for care. Alongside this, I 
considered the relationships within and between families, professional roles, interactions 
between families and professionals and the mutual trust found between different stakeholders 
involved in the care of children and young people with febrile neutropenia. The next chapter will 
explore how these two themes come together through a process of negotiation to impact upon 
desires for future service design.
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Chapter 7: Qualitative Study Findings – The potential for realised 
discretion and the impact upon future service design 
Introduction 
This chapter continues in the presentation of the findings from the qualitative study. It intends to 
build upon the two key themes from Chapter 6. In the discussion of the potential for realised 
discretion I consider the differences between professionals and parents in the need for discretion 
and desire for individualised care. I then discuss the challenges of negotiation within a spectrum 
of control before going on to explore non-attendance with febrile neutropenia as an example of 
when the spectrum of control is altered and risks, roles and responsibilities also change. Following 
on from this, I explore how the three earlier themes impact upon participants’ desires for future 
service design, considering issues such as location of care and follow-up arrangements, before 
considering a particular case study as an example of how these themes might be applied. Finally, I 
present the participants’ views on the poor consent rates seen in the studies in Chapter 3, with a 
view to further understanding the potential reasons for these rates of decline. 
Potential for realised discretion 
Drawing together the previous themes of the quest for certainty and attaining mutual trust and 
sharing responsibility, this chapter explores how patients, parents and healthcare professionals 
make decisions about the selection of a treatment path when children present with febrile 
neutropenia. This theme specifically focuses on the codes which relate to the need for discretion, 
a desire for individualised care, utilisation of a spectrum of control and the process of negotiation. 
Here, I also present the data relating to non-attendance with febrile neutropenia as a worked 
example of how these issues interconnect.  
The need for discretion and individualised care 
The codes entitled need for discretion and individualised care were used by healthcare 
professionals and families respectively. These concepts are similar in the fact that they express 
the need to respond to the social setting of patients and their families, including their proximity to 
emergency care, their comprehension of febrile neutropenia and its treatment, their prior 
experiences of febrile neutropenia, and their opinions about early discharge for their child; “it’s a 
bit like one size doesn’t fit all does it?” (Centre 3, nurse). However, the two codes differ in the 
participants’ approaches to achieving these aims.  
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The need for discretion, used by healthcare professionals, encapsulates a desire to have a single 
over-arching protocol, where the management of children and young people with low risk febrile 
neutropenia is generally the same, but with small areas of flexibility to adapt to the specific 
situation. Furthermore, participants desired the ability to move away from the strict rigidity of the 
treatment protocol should they feel this was necessary without the risk of criticism from their 
colleagues. 
The amount of discretion in adherence to the protocol felt to be appropriate by participants was 
clearly dependent on a professional’s role and experience - those in shared care centres and 
junior doctors were deemed less appropriate to apply flexibility within the protocol (if at all) 
compared with consultants at the primary treatment centre: 
“…you’re gonna have people who don’t potentially know these patients or the protocols 
properly… what they’re doing… what you want them to do for that period of time 
when… you know... their consultants aren’t actually around to make the decisions as 
well….so it’s safer in that aspect…” (Centre 1, doctor) 
Meanwhile, when parents used the code individualised care they were communicating a desire 
for considerably more flexibility than the healthcare professionals suggest. Parents preferred that 
care be created to support the needs and choices of the individual child, and their family, without 
being constrained by a protocol. Instead options would be created with parents able to contribute 
at key decision points, such as timing of discharge and the nature of follow-up reviews for each 
individual episode.  
“5: definitely… and also… I can’t stress enough, its gotta be down to the individual 
parents… 
Rest: absolutely, yes 
5: you know I don’t think can be a full gone conclusion 
2: and all those things, like we were saying, how long it’s going to take to get here, if it… 
5: all the factors 
2: all of the factors need to be sort of listed… 
5: on a personal basis it’s got to be done hasn’t it” (Centre 2, parents of under 13s)  
The differences between the need for discretion and individualised care codes are understandable 
when the focus of participants is considered. Parents place emphasis on their own child and 
family, independent of any other, and thus express a desire for the care and service which would 
best meet that child’s need during individual episodes of febrile neutropenia. Professionals 
meanwhile are compelled to consider the care of all children with febrile neutropenia, and as 
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such a pre-specified pathway may increase the efficiency of care, reduce the cognitive workload 
associated with each presentation and allow consideration of resource requirements and 
distribution across a whole service. Thus professionals meet the conflict of caring for individual 
patients and population health.  
Negotiation within a spectrum of control 
These two codes of need for discretion and individualised care connect to the attaining mutual 
trust and sharing responsibility theme through the code of a spectrum of control. The need for the 
amount of control given to each party within decision making to be flexible was discussed by all 
participant groups, with the degree of control desired changing over time and dependent on the 
situation, as discussed through the preferences for care section of Chapter 6, and explored later in 
this chapter. Some families may not wish to have control over decision making and this will also 
be discussed further within this section. Professionals also spoke about the degree of control 
given to the protocol, which links strongly with their discussion of discretion in relation to the 
protocol, and which I will cover first before moving to shared control between families and 
professionals.  
Professionals within the focus groups expressed a desire to make their own judgements about a 
child’s treatment, yet also a wish to have the responsibility for the situation relieved, for example 
by decisions being made by the protocol. Relinquishing control to the protocol in certain aspects 
of treatment allowed professionals to avoid the risks of criticism by colleagues or the 
dissatisfaction of patients and families, although parent participants did recognise this technique 
and certainly were frustrated by the rigidity of attitudes towards the protocols. The position of 
individual healthcare professionals upon this spectrum of control derived from their own personal 
attitudes, affected by the clinical situation, their past experiences and the centre culture 
surrounding this matter.  
This feature of decision making, where a spectrum of control is desired, has been described within 
the literature and discussed in Chapter 2 in the decision making theories section, where some 
patients may wish to make all of their own healthcare decisions whilst others choose to relinquish 
this control to healthcare professionals, with many of these preferences actually being situation 
and mood dependent. Recognising this within healthcare professional decision making challenges 
the presumption that healthcare professionals and patients inherently make decisions in different 
ways. Although there are nuanced differences in decision making, many of the underlying 
features of clinical decision making may be similar.  
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Moving away from the influence of the protocol towards the spectrum of control between 
professionals and families, parents generally noted that there was minimal negotiation about the 
treatment of febrile neutropenia in current services: 
“1: would it really be our decision in the end? Wouldn’t be the hospital’s decision 
whether we should… whether they’re happy for us to go home and I’m sure both of us 
would say right great fine lets go home... yeah…” (Centre 1, parents of under 13s) 
This was seen across centres, with agreement between parents about their inability to influence 
the management of their child: 
“1: I don’t see that there’s any negotiation with them. 
3: no there isn’t” (Centre 3, parents of under 13s) 
Similar to the healthcare professional responses to the protocol, parents used passive language in 
which they and their child are the objects, rather than participants in the decision making process: 
“we were sent home on the Sunday morning and we had to come on Tuesday and have his bloods 
done“ (Centre 1, parents of under 13s) Whilst much of this language was used without comment, 
seeming to be accepting of the paternalistic nature of the decision making, one parent expressed 
her anger about the restriction of her influence: 
“…we go with what we’re told to go with, we don’t really, we don’t have any control of 
how our children are treated at all... you know I mean at one point I said to them, I 
wanted them to stop the 6MP10 and not give it to him because that is one of his worse 
chemos and I was like, he needs a break from it, but his bloods are fine so he’s got to 
have it so why can you decide when he can stop having it but I’m not allowed to… you 
know and they ended up having to stop it because the side effects just took over” 
(Centre 3, parents of under 13s) 
Other parents gave examples of related decisions about their children where they also felt 
frustrated with their lack of control and the perceived irrationality of the healthcare professionals. 
These seemed to particularly occur in relation to situations where professionals insisted that the 
child be completely well before discharge but the parent felt that the behavioural aspects of their 
health would only improve at home. Thus parents felt they were not being listened to and that 
they were trapped in the hospital because of these cyclical requirements over which they had no 
control: 
                                                             
10 6MP or mercaptopurine is a chemotherapeutic agent. 
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“3: Has this happened yet? Oh right then well I can’t let you go home then… but it will 
happen if you let him go home, he’ll poo when he’s goes home, he won’t poo in hospital 
either, you know he does…” (Centre 3, parents of under 13s) 
Elsewhere, parents expressed how they would need to consider the approach they took in 
attempting to negotiate with professionals, either through showing the evidence they had 
recorded of side effects or ‘presenting their reasons’ for wanting to take a different course to that 
suggested by professionals. Participants also discussed how the balance of the spectrum of 
control changed and developed over time. Initially, parents stated they had been anxious and 
unable to participate in decision making at the beginning of their child’s treatment for cancer. 
However, those participants who had had a long relationship with the service began to question 
the paternalistic system of decision making and instead began to contribute to discussions about 
appropriate courses of action: 
“3: … in the early stages the doctors said we just did it… I suppose now we’re more 
confident to discuss with the doctors rather than just accepting whatever you’re told to 
start with… its more open you know… we’ve been doing  it that long so if we’re not quite 
happy about anything or you know uncertain, is there another way of doing it? Can we 
go home? Can we do this?” (Centre 1, parents of over 13s) 
This may reflect a decrease in trust, or doubt, in healthcare professionals, but is perhaps more 
likely to represent growth in families’ understanding of risk, augmented by past experiences, and 
an increase of confidence in their own abilities, such that they are better able to discuss with 
professionals the options for individualised care for their child. 
When professionals spoke about the involvement of parents in decision making, some 
acknowledged this imbalance in the power distribution:  
“even though we think we give parents choice, I don’t think we do, we set boundaries of 
keeping them in for 48 hours or five days…” (Centre 1, healthcare professionals) 
However, they did express desires to increase care that was sensitive to families’ needs and 
negotiated between the involved parties:  
“2: I think if we’re saying that we’re working with our parents and children, as in child 
and family centred care, we should take their views on board, and if it’s that they want 
to be in, I think that we should use that as an opportunity to strengthen their 
understanding and educate them and work towards it… and work towards what they 
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would think would be acceptable so it may be increasing… getting another home visit 
in… I don’t know…” (Centre 3, healthcare professionals) 
When healthcare professional participants were asked about how they negotiate with teenagers, 
the responses remained paternalistic and very little control was granted to teenagers. One group 
spoke about professionals giving teenagers set criteria that they must meet to be allowed home, 
whereas another participant stated that parental opinions were more important than the 
teenagers when they disagreed with their healthcare professionals, thus reducing situations 
involving teenagers back to a dyadic relationship between parents and professionals.  
“Mod: what would your teenager’s parents say?  
1: “oh I don’t think he’ll manage, he won’t take it” will be the first thing, and then they 
say, “well, will you take it”, “yeah I will mum I will” so there will be this discourse 
between parents but eventually I think one has to listen to the parents because although 
they’re teenagers they are under the jurisdiction of paediatrics so you’d have to work 
with the parent and again it boils down to convincing the parents that oral antibiotics 
are a good thing.” (Centre 2, doctor) 
The young people themselves generally stated that they would ask questions about their options, 
in similar ways to their parents, when trying to negotiate. Others spoke about using their parents 
as mediators to the discussion, choosing to relinquish this control to them:  
“Mod: So, say the doctors were saying something and you didn’t quite agree with what 
they were saying, they were saying go home and you didn’t really want to, or they were 
saying stay in and you didn’t really want to, how would you tackle that?  
2: probably just tell my mum. 
Mod: and expect her to… 
2: talk to them about it. 
1: when I’ve been told to like stay and I want to go, I’ve always like been… I’ve always 
asked if there’s like, is there not another way…erm… and I get told no so I just do what 
the doctor says…” (Centre 1, Young people) 
Throughout this theme, the challenges of sharing control are appreciated.  Currently, the balance 
of power lies with the protocol and the professionals when deciding about treatment of children 
with febrile neutropenia, whilst parents and young people have minimal input to the care they 
receive. If parents were to be increasingly included within decision making, some of this control 
would be relinquished to them. In conjunction with this right to control comes the responsibility 
for any negative consequences of the decision taken. Parents may therefore become more aware 
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of the risks associated with the various options and the uncertainty involved in making choices 
which have previously been the domain of professionals. The variation in professionals’ 
willingness to surrender this control and parents willingness to accept it has already been 
discussed.    
Non-attendance with febrile neutropenia 
One facet of febrile neutropenia which was discussed in all the healthcare professional groups 
and two of the three groups for parents of under 13s was that of non-attendance when a child 
had a fever, which goes against current professional advice. Exploring this aspect of decision 
making seems essential as it allows the understanding of a situation where the process takes a 
different direction from that planned by service providers.  
Professionals’ responses to families who do not attend with febrile neutropenia were almost 
exclusively negative:  
“2: and as the treatment goes on, they… we have more families where we come across 
that…. We’ve….you know we visit weekly for the bloods and they’ve waited… they had a 
temperature the day before and they’ve waited because they know that they’re…. you 
know their words… they would know if their child was ill… 
3: and then you have to try and put the frighteners on them” (Centre 3, nurse (2) and 
doctor (3)) 
Meanwhile, parents spoke of these incidents in a more measured way. Some parents said they 
would always attend with a fever. Others, having considered the predominantly negative 
experiences of previous care, including the deleterious effects of admission on the social and 
psychological health of their child, along with their perceived risks from an episode of febrile 
neutropenia when their child appeared to be well, had previously decided to observe their child at 
home rather than immediately present them to the healthcare professionals. Indeed, one parent 
from Centre 2 spoke of the guilt she felt when she did bring her child to hospital in the following 
quote: 
“1: whereas I knew… there were times when I knew and there were times when I sat 
there, when they were putting her on antibiotics, thinking I wish I hadn’t come, I really 
wish I hadn’t come… because I’m going to be in here 48 hours, she’s not going to eat, 
she’s not going to drink, it’s probably going to end up being long… 
4: we’ll be in here a week 
5: it’s a week isn’t it? 
1: yeah” (Centre 2, parents of under 13s) 
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These parents were mostly those with prior experience of febrile neutropenia, who reported 
being dissatisfied with the duration of previous admissions and the impact which this had on their 
child and family. It is worth mentioning that the occurrence of these discussions reflects the good 
rapport and safe environment created within the focus groups for parents, where they felt they 
could discuss this relatively prohibited behaviour.  
The differences in assessing the risks of non-attendance and the relative harms of hospital 
admissions may well explain the challenges in negotiation between professionals and parents, as 
they come from different viewpoints about these issues. Professionals may have distorted 
opinions of the relative risks of this non-attendance, as they may be unaware of a number of 
episodes in which children are not brought to hospital following fever. This incorrect 
‘denominator’ for the risk means that they may then consider it to be a much more dangerous 
practice than the families who engage in it: 
 “1: I would like a study to be done on how many patients actually don’t come in when 
they’ve got a temperature and they’re neutropenic… 
1: and they’re ill? 
2: no, they’re not ill, they just get away with it. That would be quite interesting because I 
think… well there definitely are people who do that…” (Centre 2, nurse (2) and doctor (1) 
Furthermore, the issue of non-attendance also links to the need of healthcare professionals to 
feel in control and to have a voice in negotiating about a child’s care. As the decision about when 
a child is presented to hospital is usually taken primarily by the parents, professionals are 
excluded from this. It is one of the few aspects of febrile neutropenia care where parents can 
exercise control and influence their child’s care, as once admitted to febrile neutropenia services, 
parents can feel unable to escape from the protocol-driven pathway. If they do decide to attend 
hospital, parents are choosing to accept the benefits of a hospital admission but also the harms 
that come with it.  
An alternative way to view non-attendance with febrile neutropenia is instead as a self-instigated 
reduced therapy regime, where families have made an active decision about this choice. Through 
allowing outpatient treatment to be negotiated following presentation with FN, parents and 
young people may feel more comfortable with presenting for assessment, as the response is more 
likely to be graded to the child’s illness and there will be shared discussion of the different 
actions, rather than an immediate inpatient admission without negotiation. This is consistent with 
the findings presented in the Interactions between families and professionals subtheme in 
Chapter 6.  To healthcare professionals the introduction of the option for reduced therapy 
regimes provides the benefits of more patients attending following a fever, and therefore 
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increased likelihood of detecting children and young people with high risk febrile neutropenia. 
Beneficially, it could also allow the assessment of the numbers of patients who did not previously 
attend following fevers, and professionals might have more exposure to patients with low risk 
febrile neutropenia who have a favourable outcome, thus bringing their personal risk assessments 
more in line with that of patients and parents.  
Impact upon future service design 
Participants within this study had multiple views about possible future service designs for children 
with low risk febrile neutropenia. Some of the ideas given were consistent across all focus groups; 
others were more specific to individual groups. However, they can generally be categorised into 
the codes of the preferred timings of discharge, follow-up requirements, the presence of clear 
criteria and practical issues of space and personnel, to gain agreement from multiple groups prior 
to any change in service provision. Through this section I aim to demonstrate how these views are 
linked to the earlier findings of the study and are influenced by the quest for certainty, mutual 
trust, roles, responsibilities and the spectrum of control.  
Within the healthcare professional groups, each group had different overarching opinions about 
the timing of early discharge in low risk febrile neutropenia. The group from centre 2 were against 
early discharge as a potential future treatment strategy and the general attitude within this group 
is perhaps best summed up as “…putting the dampener on it, but I’m not so sure I can ever see it 
happening anyway” (centre 2, nurse).  
Meanwhile, the centre 1 group were willing to consider early discharge as a potential future 
option, but seemed hesitant about changing in the near future and anxious about the rate of 
change being too rapid. 
“1: I am certainly in favour of the very low risk ones bringing it down from 48 hours … 
but not saying send them home again in an hour if you’ve got blood results and 
everything and you… but … 
6: somewhere midway… 
1: somewhere… 8, 24… talk about sitting on the fence… but…” (Centre 1, doctor (1) and 
nurse (6)) 
In contrast, centre 3 healthcare professionals were keen on the possibility of an early discharge 
model, tending to focus more on the positive aspects of a reduced therapy regime than the other 
groups: “if you turn this on its head though... 86 children out of every hundred didn’t have to 
spend 48 hours in hospital and I think that’s good... that’s a wonderful achievement!” 
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The potential explanations for these differences between the healthcare professionals at the 
centres are multiple. As with all research, the findings may simply be a result of the particular 
structure of these specific groups, the individuals within them and the "snapshot" nature of focus 
groups as a methodology that records a specific place and date in time. However, there are other 
possible explanations which also appear credible, each of which relate to the specific cultural 
environment within which the participants operate. The positive attitude towards early discharge 
regimes of the healthcare professional focus group in centre 3 may relate to the fact that this 
centre already operates a significant shared care service. Therefore healthcare professionals are 
more familiar with relinquishing control over the care of patients to others and have established 
trusting relationships with parents and other professionals. They have experienced the risks and 
benefits of allowing a child to be cared for outside of the primary treatment centre. Furthermore, 
these healthcare professionals have already renegotiated their own roles in services for low risk 
febrile neutropenia to that of providing support to those administering the immediate care and 
giving advice remotely. Thus it can be seen that the change in practice for this group when 
redesigning their service to an early discharge regime would be smaller than for those in centres 1 
and 2. 
“2: so I don’t think necessarily the PTC would change because a lot of the low risk febrile 
neutropenics are being managed by shared care… what would need to change is the 
shared care centres and particularly the community services… yeah… and… where they’d 
come in for review, how that would happen and who would review them…. 
1: which mostly is set up anyway, isn’t it? Because all our shared care patients have 24 
hour access to the shared care centre and a pathway for being reviewed and not going 
through A+E…  
2: and I’m think I’m right in saying, all shared care centres… oncology children that go 
into a shared care centre have to be reviewed by a registrar or above so actually that’s 
a… that seems fairly safe even if you discharged early… to my mind…” (Centre 3, nurses) 
Parental attitudes to the timing of discharge were also quite diverse. First, participants were keen 
to stress the importance of the initial review at the hospital following a temperature. They felt 
comforted by the fact that their child had been reviewed by a doctor and had been thoroughly 
assessed, reflecting the parental assessment of roles and of their trust in the clinicians caring for 
their child. The hospital visit also allowed parents to discuss questions that they had and to ensure 
they understood the best ways to care for their child at home, as a means of defining their roles 
and responsibilities. Their opinions about what would constitute best care after this point were 
heterogeneous. One family were keen to stay in hospital and be treated by the current protocol – 
their experiences are discussed further in the case study later in this section. All other participants 
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were keen to reduce the duration of admissions for febrile neutropenia by varying degrees. Some 
parents, especially those at centre 2 but also some participants elsewhere and one of the young 
people, wished to be discharged immediately following the first review.  These families were 
generally those who had extensive experience of febrile neutropenia, whose children had been 
treated for cancer for some time. Other parents, and two of the young people, were a little more 
cautious and preferred to stay in hospital for the first 24 hours or so following a fever. This 
provided them with the reassurance that the child was not deteriorating and allowed review by a 
senior clinician prior to discharge. Finally, some parents voiced that the condition of their child, at 
the time of presentation would greatly influence their judgement about the timing of discharge. 
Thus, on some occasions, they might wish to go home immediately, whilst on other occasions 
they might prefer a brief admission. The right to use their parental acumen to make 
contemporaneous decisions was felt to be a vital part of individualised care. Thus it can be seen 
that parents had personalised responses to risk that were situation-dependent and that would 
then inform their choices about individualised care for their child. 
Significantly, parents’ views were more variable within centres. Where healthcare professionals 
tended to agree with each other within the groups, parents expressed a range of views. This may 
relate to the professional hierarchy, in which the views of the most high-ranking participants are 
assumed by the rest of the group, or may simply reflect that the professionals are pre-existing 
groups who are exposed to similar professional and cultural influences, and may thus be 
constrained in the choices that they identify. Furthermore, it also mirrors similar issues to those 
discussed in the need for discretion and individualised care subtheme, in which professionals 
preferred a single choice with small adaptations for each child, whilst parents wanted a more 
diverse range of options. 
Recognising the individuality of decision making, participants clearly stated that they thought 
some parents might make more cautious decisions than those recorded in the study, highlighting 
younger parents, single parents, parents of newly diagnosed children, those without transport 
and those living further from the hospital as groups who might be more guarded about outpatient 
regimes. Although it was not possible to capture the views of young and single parents within this 
research, the other assessments made captured key social influences on decision making that 
have already been discussed.  
“4: I mean to be honest, I suppose you’ve got young mums, single mums maybe that 
wouldn’t want to take them home because obviously  
1: their situation might not allow it” (Centre 2, parents of under 13s) 
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For parents, another key feature of future services was the route of administration of their child’s 
antibiotics. Whilst healthcare professionals barely mentioned this other than to note the increase 
in staff members required to administer intravenous antibiotics in the community, the route of 
antibiotics was a significant matter for parents. Linked with the previously discussed focus on 
central lines, a major consideration was the presence of absence of a central venous line. Those 
parents whose child did not have an indwelling line were keen to avoid intravenous antibiotics 
where possible and universally opted for oral antibiotics. For parents whose child had a line, they 
showed little preference between routes of administration. However, the issue of who 
administers intravenous antibiotics came to the fore. Some parents were willing to learn to 
administer the intravenous medications themselves, and saw this as a further extension of their 
role in performing care tasks. Others felt that this should not be their responsibility and preferred 
for community nurses to administer the antibiotics at home, though they appreciated the staff 
time and costs of this option. This demonstrates again, the preference of families for 
individualised care which best suits the needs of their child and their family and the need for a 
negotiation of roles should current services change. These issues had not been appreciated by 
professional participants.   
When thinking about the design of follow-up services following early discharge for febrile 
neutropenia, healthcare professional groups focused on two main models of care. The first was 
ambulatory care in which patients return to the hospital for regular review, with physical space 
and staff located within the hospital. This is consistent with more traditional healthcare service 
designs, but also has challenges as discussed in Chapter 4 where patients may struggle with the 
practicalities of attending the hospital frequently. At one point, healthcare professionals at centre 
2 discussed an even more traditional approach, where patients would stay at a “home from 
home” located close to the hospital for the duration of their episode. This desire reflects the risk- 
and change-averse nature of the group at this centre, along with a distrust of parents to re-
present their child in case of deterioration.  The second suggested service design was that of 
community based care, where after discharge, families were visited at home to administer 
antibiotics and monitor progress.  Participants in centre 1 discussed a model which bridged 
ambulatory and community based approaches through a “virtual ward”: 
“2: …where patients were still on your ward for 48 hours but they weren’t actually in 
and if there was a role for ambulatory antibiotics as in like almost home antibiotics 
ward for the service where … and they do this in certain adult services… where the 
antibiotics are administered at home rather than in hospital and at 48 hours when the 
cultures come back you could then discharge them off your virtual ward… 
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7: you know using the community team more which is why that…” (Centre 1, doctor (2) 
and nurse (7)) 
Most parents and young people leaned towards a more community based approach, with 
repeated visits to the hospital generally viewed negatively, although parents were happy to 
comply with these if necessary. This reflects the experiences of parents and young people in 
which hospital visits can be socially and psychologically disruptive for a child, as described in the 
preferences for care subtheme. The amount of community input felt to be appropriate varied 
from participant to participant though, which correlates well with the need for discretion and 
individualised care described earlier in this chapter:  
“3: if it was more at home, it would be useful to have some point of contact that you can 
ring, so that you’re gonna speak to somebody who knows what they’re talking about 
Mod: and would you want that to be just when you needed it, so you just ring when you 
want to talk about stuff, or would you want the staff to ring regularly? 
3: I don’t think there’s a black and white answer to that one cos some people would 
need the regular contact and some wouldn’t and for us, I think we’d prefer to get on 
with it, leave us to it, if we’re not sure we’ll ring up but other people wouldn’t like that 
so… 
5: I quite like the idea of a review… 
4: well I quite like the idea of the Macmillan nurse popping in… I know that’s all distance 
and... and time…” (Centre 1, Parents of over 13s) 
In regards to follow-up, all participant groups touched upon the issues of isolation noted in the 
qualitative synthesis and considered how this could be reduced. They spoke positively about the 
input of community services and about telephone calls (both staff making calls to the patient and 
an advice line for patients to call in to) as methods to support families who were discharged early. 
The issue of contacting families with blood culture and test results, discussed in the quest for 
certainty theme, was also relevant here as a feature which families felt strongly should be part of 
their follow-up and would provide them with confidence that they were being supported by the 
hospital in the care of their child. 
All participant groups spoke clearly about how, if patients were to be discharged early, families 
would need clear criteria for home management which should be consistently communicated, so 
as to establish their roles and responsibilities. For professionals, these criteria would 
predominantly relate to when a child needed to return to hospital, for example, with repeated 
fevers. For parents, meanwhile, the focus was somewhat broader. They did ask for clear criteria 
for reassessment, but also desired guidance about care of the child at home, including the rules 
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for social contact (eg school attendance, visits with friends) when receiving treatment for febrile 
neutropenia. Finally, parents spoke about the burden of medicines administration and how this 
demanded a lot of their attention. In the focus group for parents of over 13s, participants 
particularly spoke about the benefits of medication cards or applications to support accurate 
medication delivery at home. Healthcare professionals in Centre 2 also discussed the potential for 
at home monitoring of observations and the ability of applications to make these accessible to 
clinicians in the hospital environment.   
The benefits of having clear criteria for treatment at home are that they give the appearance of 
controlling risks and provide a similar illusion of certainty as that provided by protocols. They are 
also a formal way of negotiating responsibilities between parents and professionals and provide a 
gradual transfer of control compared with current care. Thus all stakeholders may feel able to 
accede to the introduction of early discharge regimens.   
A final concern about future services for healthcare professionals that was raised in Centre 3, 
perhaps due to their large shared care network, was the risk of deskilling professionals when they 
have reduced exposure to children with febrile neutropenia. The group discussed whether this 
was a reasonable fear to have and the factors which might mitigate against this. Future services 
should aim to modify this risk wherever possible rather than using this as a reason to prevent 
change to reduced therapy regimens. 
“2: yeah… my only concern would be… and I’m really for it… for as less time in the 
hospital the better… my only concern would be… for… erm… perhaps two concerns… 
reduce… for parents feeling isolated in being… not even having shared care centre now… 
now they’re literally on their own in the house… but that could be ameliorated to some 
degree by the support of community services and then the other thing is you will 
actually have reduced number of children in your shared care oncology centres and if 
they’re not visible… erm… then that need… people’s triggers to get trained in oncology 
would be less and you would have people who would have even less experience of 
oncology unless you’re shoving out some of your sicker children which seems to be the 
case anyway… like bone marrows and things which never used to come… 
3: I don’t think it’ll reduce that much you’ll still have people…won’t you… you’ll still have 
people… that aren’t low risk… 
2: a lot of the inpatient work at shared care for oncology is low risk febrile neutropenia 
1: is your low risk ALLs… 48 hours... 
3: but you do get lots of line infections... 
1: yeah true 
3: and they’ll still end up in… so I don’t think… I don’t think you’ll really  
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2: no… but the potential’s there” (Centre 3, nurses (1+2) and doctor (3) 
One factor which professionals felt would influence families’ assessment of future service design 
was the timing of change to a new protocol. Each centre’s group spoke about how the families 
who were treated during a change in febrile neutropenia policy might struggle with the reduction 
in admission time, but those families who came to the service after the policy change would be 
unlikely to have as many concerns about an early discharge strategy. Interestingly, no 
professionals acknowledged that they might also be included within this sentiment, with 
professionals who are established within the setting being more likely to struggle with a change in 
practice than those who come into the specialty at a later point.  
“Mod: what do you think families would think if you started doing outpatients?  
1: I think they’d be worried at first… 
2: they wouldn’t know anything different at the end… 
3: the new ones wouldn’t know any different, the ones in the transition would have to 
have their anxieties allayed wouldn’t they and there would be some people who 
wouldn’t wear it and some people who’d cheer…” (Centre 3, nurses (1+2) and doctor (3)) 
Notably, this issue of change over time was rarely discussed within the young people and parents’ 
groups, though the group for parents of over 13s at Centre 1 did mention it briefly. The neglect of 
this concept in other discussions may be simply an oversight on the part of participants, or may 
reflect parents being more willing to change current services or more adaptable to changes which 
are placed upon them, as discussed in the articulating and interpreting protocols subtheme of the 
quest for certainty theme.  
Finally, when discussing future services, healthcare professional participants spoke about the 
practical issues surrounding designing an outpatient or early discharge programme, and their 
main focuses were on the physical space required to allow this and the personnel needed to 
provide care, with participants generally feeling that more of both of these resources would be 
needed. These features were primarily discussed by Centre 1 and 2, with Centre 3 considering 
these issues as predominantly solved by their current shared care structure. The practical issue of 
personnel required for future care options is covered within the earlier professional roles 
subtheme of the attaining mutual trust and sharing responsibility theme. 
Case study: diversity in family perceptions impacts upon future service design 
preferences 
Though many participants had concerns about early discharge strategies and declared a wish for 
considered change without substantially increasing risks, there was one family who were 
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distinctive in their attitudes and opinions. The affected child of this family participated in the 
focus group for young people whilst both her parents attended the focus group for parents of 
over 13s. This family stated that they would prefer inpatient care for febrile neutropenia, that 
they enjoyed the time that they spent in hospital and that reduced therapy regimes would not be 
appealing to them. The possible rationale for these differences is explored within this section of 
the chapter, focused around the key threads of uncertainty, trust and control. I decided to 
specifically explore this case so as to better understand this more unusual perspective which 
represents maximum variation within the sample, considering the ways in which it informs the 
findings and provides more nuance to the analysis, as discussed earlier in Chapter 5. 
This family appeared to have different attitudes to the risks and harms of different locations of 
treatment for febrile neutropenic episodes. They were particularly risk averse, and this was 
enforced by struggling to understand some key concepts of the statistics of risk: 
“5: as soon as you started talking about percentages, erm… all that I think is I don’t care 
if its only 85% chance of coming in, I wanna come in now because there’s you know, a 
14, 15% chance that something might change and I get a bit… I get a bit erm…. I prefer 
to then just be in hospital… like before when you were saying it I was thinking, oh yeah, 
at home, we do this but then when you start saying that you know, there’s chances 
they’d need to come in, I think, just might as well be in…” (Centre 1, parents of over 13s) 
This heightened awareness of risk was balanced with a strong belief that hospital was safe and 
previously very positive experiences of being in hospital. Thus this family attempted to gain 
certainty through opting for inpatient care of febrile neutropenia. 
Furthermore, this family spoke about how their child struggled to trust them but she, and they, 
had complete trust in the healthcare professionals caring for her: 
“… she wouldn’t take our word or even though we knew… we had to ring up and she 
could speak to a doctor or a nurse on the ward because we didn’t know anything did 
we…we were useless. She needed them to be told… [laughs]” 
These polarised levels of trust, as discussed earlier in the chapter, may have been accentuated 
through high levels of PTC care and relatively low levels of family control in regards to febrile 
neutropenia. In fact, this family chose to relinquish their control about many decisions by allowing 
their child’s consultant to make decisions about treatment. This case therefore demonstrates an 
extreme example of the issues already discussed within this findings chapter. 
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Poor consent rates to studies 
For the final section of this chapter, I summarise the data in which participants were asked to 
consider the reasons why studies of reduced therapy regimens might have poor rates of consent. 
This section of the focus group discussions was intended to provide supplementary information to 
explain the poor recruitment to the studies included in the systematic review of Chapter 3. 
Although many of the findings already discussed relating to early discharge regimes were to be 
relevant to this decision, the decision making challenges for standard care and for trials were 
slightly different. Therefore, it is reasonable to examine this situation independently. 
There was a spectrum of responses from the participants when asked why they thought the 
consent rates to the studies had been relatively low. First, the healthcare professionals in Centre 2 
did not feel the consent rates for the studies were particularly poor and did not discuss reasons 
for patients to decline these kinds of study. The other focus group discussions pointed out a 
number of reasons why people may not be keen to be involved. Many of these mapped closely to 
the themes which feature strongly in the rest of this study.  
Participants spoke about how the risks of taking part in a study of early discharge may be 
perceived to be too large for patients to be happy with:  
“if you asked me that question and I thought that it was going to have some sort of 
effect on d) as in erm… she would be asked to go home because she’s part of the study 
then I would have probably said no because as I said, when you start talking about 
percentage things if its 2% that something could go wrong and its d), she stays in, you 
know and I would prefer to do that than take any sort of risk, I want to take out every 
type of risk. So if I thought you were asking me to go into a study where… erm… this 
person will stay in and d) will go home because she’s part of the study, erm… then I 
would’ve said no because again I would’ve just want you to go to what they already 
know and they already know and they’ve done for a long time…” (Centre 1, parents of 
over 13s) 
Accentuating this, the use of the word trial or study suggested to families that clinicians and 
researchers were unsure about the risks involved and increased the degree of uncertainty about a 
treatment: “…I want the trial to be when there’s nothing more you can do… and you know then 
you’d try anything…” (Centre 2, parents of under 13s). These attitudes towards trial participation 
have been well-described in the literature.(180–183) Interestingly though, they contrast with the 
healthcare professional views within this study, where the idea of additional research was very 
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acceptable, and often requested by participants. The potential reasons for this professional 
attitude are discussed in Chapter 9.  
Linked to the quest for certainty and consistent with the existing literature, participants also 
commented that they disliked the idea of randomisation of an episode of febrile neutropenia on 
arrival at the hospital. They spoke about how they would want to know what treatment to expect 
before they had arrived and desired a familiarity to the processes involved. The additional factors 
which correlate with the quest for certainty theme are that parents spoke about how the distance 
to travel to the hospital would influence their decision to take part, whilst healthcare 
professionals cited other studies of de-escalating therapy and stated that anxiety was the reason 
for reduced rates of consent.  
Alongside the issues of risk, participants also spoke about how relationships influenced choices to 
participate in studies and healthcare professionals acknowledged their own influence on parents’ 
choices. Parent participants spoke about their role in protecting their child and taking 
responsibility for decisions to enrol in research. A number of groups discussed how parents might 
feel guilty if they had enrolled their child in a reduced therapy study and then the child had had a 
bad experience. The parent might then have felt responsible for that outcome and therefore 
some families might choose not to enrol their child at the outset. However, participants also 
spoke about feeling guilt for refusing to participate in research because they appreciated the fact 
that other families had joined research projects in the past which were now benefitting their 
child.  
Finally, linked to the potential for realised discretion theme, one participant spoke about how they 
had relinquished the control of their decisions to enter another study to their child’s consultant as 
they felt that this was not a choice that they could make and because they trust her judgement 
(ultimately their child was not enrolled in the study). They proposed this might also be a reason 
for other families choosing not to take part in studies about the management of low risk febrile 
neutropenia.  
Summary 
This and the previous chapter have reported the findings of the focus group study. Chapter 6 
explored how the quest for certainty influences decisions made by key stakeholders in paediatric 
febrile neutropenia. The discomfort of the uncertainty involved in risk assessments is balanced 
against the certainty implied by current protocols. The perceived benefits and harms of inpatient 
care that participants have previously experienced inform their appraisals of future treatment 
strategies. In attaining mutual trust and sharing roles and relationships, participants described 
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how interactions between these stakeholders play a key role in shaping perceptions of care. They 
spoke of the different roles within febrile neutropenia services and how these would need to 
change if outpatient or early discharge schemes were implemented, how mutual trust, though 
already present in some ways, would need to be fostered and strengthened and how 
responsibility would need to be redistributed between groups. 
Chapter 7, details how having identified a need for discretion and a desire for individualised care, 
negotiating the spectrum of control allows achievement of the potential for realised discretion. I 
have discussed how non-attendance with febrile neutropenia is an example of where the 
prevailing model of professional control is disrupted and families use their own assessments of 
risk and mutual trust, along with their previous experiences, to make decisions about their child’s 
care. 
 In the final sections of this chapter I have explored the way the earlier themes might impact on 
re-designed future services, with a focus on individualising care for children and young people. I 
have described a case which addresses many of the issues identified within the analysis, 
particularly relating to attitudes to risk and trust.  I have also presented the participants views on 
the poor consent rates observed in the studies in Chapter 3 and how these relate to the 
remainder of the findings in the study. The following chapter will discuss these findings further, 
relating to them to the earlier literature explored in Chapters 3 and 4, considering the possible 
reasons for their occurrence and providing a reflexive account of the research process.   
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Chapter 8: Discussion of Qualitative Study Findings 
Introduction 
This chapter summarises the findings of the qualitative study and considers them in relation to 
the findings of the qualitative synthesis presented in Chapter 4. I outline possible explanations for 
the findings and the key threads that tie the themes together. The chapter continues with my 
reflexive considerations on the conduct of the study and the influences upon its findings. I 
conclude with a discussion of the strengths and limitations of the study. The implications of the 
findings upon policy and practice and the considerations for future research are discussed in the 
final conclusions chapter that follows. 
Review of findings 
This study involved 32 participants in 8 focus group discussions across three paediatric 
haematology and oncology centres in the UK and sought to identify factors involved in decision 
making about outpatient therapy in paediatric low risk febrile neutropenia. It identified three 
interrelated themes of the quest for certainty, attaining mutual trust and sharing roles and 
responsibilities and the potential for realised discretion. It then explored how these themes impact 
upon participants’ preferences for future service design aiming to inform those involved in 
structuring services of the potential impact of changes in care. 
Participants described a quest for certainty, in which they attempted to balance the uncertainty 
involved in understanding, expressing and negotiating risk with the illusion of certainty provided 
by strict protocols. Risks were assessed using both formal and informal stratification tools, 
overlaid with the emotional reactions to risk and experiences of risk within other situations. 
Understanding statistical expressions of risk proved challenging for patients, parents and 
healthcare professionals. Meanwhile, the benefits of certainty provided by protocols resulted in 
frustration at the strict constraints they mandated. The perceived benefits and harms of inpatient 
care that participants had previously experienced informed their appraisals of future treatment 
strategies and provided them with both more confidence in their risk assessments and a greater 
desire for flexibility within protocols. 
Alongside this quest for certainty, participants’ worked to attain mutual trust and share roles and 
responsibilities. They spoke about the relationships between families, professionals’ roles and the 
relationships between families and professionals. The benefits of good relationships and the 
challenges involved in maintaining these were discussed within the subtheme of mutual trust.   
Parents and young people generally had high levels of trust in professionals, though this was 
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dependent upon their familiarity with them, and this trust could be undermined by issues such as 
failing to follow-up on blood tests. Professionals meanwhile spoke negatively of parents and 
raised concerns about some families’ trustworthiness, though this response was more muted in 
the centre with increased shared care. Also within this theme, participants were clear about the 
difficulties in other relationships between groups, such as between the PTC and shared care units 
and with management. They discussed how these could impact negatively on experiences of 
febrile neutropenia. Furthermore, they acknowledged that roles and responsibilities would need 
to change to accommodate reduced therapy regimens; healthcare professionals would need to 
trust parents to undertake additional aspects of care, whilst parents would need to trust that 
professionals continue to fulfil the remaining tasks.   
These two themes of the quest for certainty and attaining mutual trust and sharing roles and 
responsibilities were drawn together through the need for discretion and individualised care. 
Participant groups used these concepts to speak differently about how care should be structured 
for children and young people. Professionals wanted a general protocol with the facility for 
discretional change based on the individual patient. However, families sought a more flexible 
approach designed around their child and family, without the need for specific protocols. Though 
both of these concepts suggest a more personalised treatment strategy than currently, they 
suggest different methods of achieving this goal. 
The process of negotiation was outlined and potential difficulties in redistributing responsibilities 
to families were voiced. The degree of control held by each party in decision making was explored 
and found to be unbalanced between families and healthcare professionals. The decision making 
involved in non-attendance with febrile neutropenia was considered as a counter example where 
control is reversed and families take the lead in managing their child’s care. The potential for 
realised discretion along this spectrum, and influenced by the two earlier themes, forms a key 
feature of this work. 
Finally, the means by which the three earlier themes come together to impact upon participants’ 
perceptions of future service designs are reported. The differences between key stakeholder 
groups have been described and the challenges in providing a service that satisfies everyone are 
considered. This theme begins to explore many of the more practical aspects of future services 
and attempts to inform those involved in designing these about the conflicting opinions between 
groups along with why these might occur. 
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Relation to the existing literature 
In this section I explore the ways in which the findings from the qualitative study mix with  the 
broader subject-specific literature which has been systematically and extensively explored within 
the qualitative synthesis described in Chapter 4. Locating this research within the existing 
narrative about early discharge enables identification of the similarities in this field, whilst also 
highlighting the areas where this thesis contributes new and informative material that extends 
and adds nuance and depth to the preceding works.  
Many of the key similarities and differences between the synthesis and the new data relate to 
practical logistics and social issues that have been outlined within the preferences for care sub-
theme in Chapter 6. There are additional features to address here. I also discuss how the study 
relates to the decision making theories discussed in Chapter 2, reviewing correlations with the 
psychological and sociological literature.  
Many of the key factors from the qualitative synthesis were confirmed and expanded upon within 
the qualitative study. The complexity of decision making has been described in detail in Chapter 6 
and a number of the influences confirmed, as I discuss further in the following paragraphs. The 
code relating to fear within the qualitative synthesis has become more nuanced in the qualitative 
study.(151,152,157) Although fear is described, the participants in the study spoke more clearly 
about anxieties and worry, reflecting a more complex emotional impact upon their perceptions of 
early discharge. Furthermore, the feature of timing also played a role. Consistent with the studies 
in the qualitative synthesis, participants clearly described the influence of timing of febrile 
neutropenia within a child’s treatment for cancer, and spoke about how previous experiences of 
febrile neutropenia had changed their views over time.(151) This study also adds the perspective 
of healthcare professional experiences, which was largely absent from the synthesis. 
The social and emotional impacts of an admission for febrile neutropenia were also identified but 
have been re-structured and greater weight given to the roles and relationships between families 
and healthcare professionals. This most likely reflects the long term nature of relationships 
between children with cancer and their families, and the healthcare professionals who care for 
them compared to some of the other conditions included in the synthesis. Thus the development 
of mutual trust within these relationships plays a greater role than in the settings included within 
the qualitative synthesis.  
The established nature of relationships between participants in this study also explains why the 
continuity of care code from the qualitative synthesis does not occur in the qualitative study. 
Participants in the study know that their care is generally provided by the same small team of 
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professionals and as such the concerns about being known to the professionals providing an early 
discharge service are diminished. Continuity of care within the population of this study seems to 
have been taken for granted by the participants.  
Elsewhere, the study adds to the synthesis in different ways. The subtheme of negotiation and a 
spectrum of control arose iteratively from the study. Its appearance is probably related to the 
prolonged nature of the relationships between these families and the professionals, as those with 
a longer duration of treatment became more aware of their lack of control and had an increasing 
desire to negotiate a change in care. Furthermore, the parents included in this study already carry 
a considerable care burden in relation to their child’s disease, and thus view themselves as having 
a greater role in the provision of treatment. As such, it can be seen that they may be more likely 
to want to be included in decision making than many of the families included within the studies in 
the qualitative synthesis.  
Compared to the Diorio et al study of parental preferences for treatment of paediatric febrile 
neutropenia included in the qualitative synthesis, the parents included in this study were 
generally more positive about reduced therapy regimens.(151) This may be due to a number of 
different factors. First, and perhaps most importantly, the Diorio et al study asked participants to 
choose between four potential service designs for low risk febrile neutropenia. The outpatient 
service design was therefore pre-specified with no opportunity for participants to discuss how 
they would ideally like their child to be treated. In my study, participants were asked to talk about 
how they would like febrile neutropenia services to be organised. This may have facilitated 
acceptance of outpatient care, but may also indicate that services need to be co-designed to 
satisfy patients and families. Indeed, if I had introduced a specific outpatient regime for 
discussion, I may have found similar responses to those of Diorio et al.  
Another factor that may have resulted in the different findings between this study and Diorio et al 
is in their current treatment regimens. Although Diorio et al do not give precise details of how 
children in their centre are managed for febrile neutropenia, their paper suggests that this is with 
inpatient treatment for over 48 hours, as they describe a 48 hour admission as an early discharge 
regime. For the centres in my study, 48 hours was considered to be a standard admission length 
rather than an early discharge option, so the participants may already have been used to a shorter 
stay in hospital. This observation lends support to the hypothesis that participants’ current 
duration of stay for febrile neutropenia may impact upon their perceptions of reduced therapy 
regimes, with gradual reductions in length of stay perhaps being more acceptable than larger 
changes. 
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On a slightly separate note, it is reassuring that Diorio et al also struggled to recruit parents of 
teenagers. This suggests that the problems that I had with this group are related to intrinsic 
factors within the lives of families with children of this age and in their experiences of treatment 
for cancer. Future studies may wish to consider alternative methods to capture the views of this 
group, perhaps through telephone or online interviews and focus groups. 
The issue of resilience discussed within the qualitative synthesis (Chapter 4) was less evident in 
this study. Although trust and confidence in healthcare professionals was a key theme in the 
study, participants spoke less about resources than had been identified in the qualitative 
synthesis. Financial pressures did play a role in the study findings but participants spoke little 
about their social and psychological resources, and where they did discuss them, they were 
framed differently to the synthesis. This may relate to the fact that all parent participants were in 
committed relationships and thus received social support from their partners.  
The absence of the resilience theme in the study may also reflect the fact that parents, in 
particular, were less likely to see early discharge as an adverse event, instead framing it as a 
potential tool to improve the adverse nature of an admission for febrile neutropenia. 
Alternatively, families may have already developed significant resilience during the period of their 
child’s diagnosis with cancer, and thus their perception of their need for increased resilience may 
have altered. This would be consistent with evidence in the study about the perceived risks of 
febrile neutropenia.  
To locate this research within some of the broader literature,  findings of this study echo, in some 
ways, the Health Belief Model described by Rosenstock, Hochbaum and Kegels described in 
Chapter 2.(74) I have found that the perceptions of risk and the patient’s known experiences of 
admissions for febrile neutropenia have an impact upon their opinions about early discharge. 
Although families of a child with low risk febrile neutropenia are unlikely to have had cues to 
action before their child’s diagnosis with cancer or from mainstream media outlets, they can be 
influenced by information from healthcare professionals and other parents within paediatric 
haematology and oncology services during the course of their child’s cancer treatment. 
Furthermore, my research has outlined the modifying factors of centre culture, past experience 
and personal preferences for control of decision making, when thinking about reduced therapy 
regimens.  Thus, the Health Belief Model captures some of the key features of the work I describe. 
However, it can be seen to be incomplete when applied to this study, as it does not capture the 
relational nature of decision making in chronic conditions, where trust between different 
stakeholders plays a vital part and where different roles and values must be negotiated before 
deciding upon an initial course of action. It also does not capture the influence of culture, 
including the direct pressure of protocols but also the more subtle normative values and 
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assumptions of society when making healthcare choices. Thus this thesis adds nuance and detail 
to the Health Belief Model when thinking about the management of low risk febrile neutropenia.  
Interpretation of the findings 
I will now discuss certain aspects of the study and potential explanations for the findings in detail. 
In particular, I will consider differences in focus, paternalism and determinism, and shared 
decision making.  
Differences in focus between families and healthcare professionals. 
Throughout the study, the differences in focus between families and healthcare professionals 
became apparent in a number of distinct ways. First, participants had different degrees of focus 
concerning health. Healthcare professionals had a limited focus on the physical health of a child 
during an episode of febrile neutropenia and almost entirely focused on the prevention of an 
intensive care admission or death of a child. Thus their focus for individual children was relatively 
narrow, though they had a broader focus on the number of families impacted, taking into account 
their service population and the variety of different patients with whom they come into contact. 
Parents meanwhile focused on the broader aspects of child health, including the side effects of 
possible interventions, social and emotional impacts and wider family health. However, parents 
mostly concentrated on their individual child. Though they did discuss how others might differ in 
their opinions and desires when considering future services, it was the optimum regimen for their 
child and family that was put forward most strongly. Thus it can be seen that the priorities and 
objectives for future care were different between families and healthcare professionals. As 
discussed within Chapter 6, this is understandable given the responsibilities of these two different 
groups.  
Linked to this difference in focus on health, another distinction came when participants discussed 
negative consequences of care. Throughout the focus group discussions, participants used ‘horror 
stories’ to illustrate the difficult and distressing aspects of being involved with children and young 
people with febrile neutropenia. ‘Horror stories’ have been described as a method which 
participants employ to demonstrate key points within focus group discussions, forming an 
important part of their narrative reconstruction and assuming symbolic meaning relative to their 
beliefs and priorities.(168) Horror stories should thus  be given significant thought by the 
researcher.(168) When considering the horror stories told by healthcare professionals within this 
study, they almost always discussed bad outcomes such as intensive care admission or death as 
their primary adverse experiences of febrile neutropenia. Meanwhile, parents focused much 
more upon their experiences of poor care, such as certain encounters at shared care centres, 
delayed identification of positive culture growth, difficult venous access issues and the failure of 
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professionals to identify what they perceived to be an unwell child. This again highlights the 
differences in consideration of health between the two groups, whilst emphasising the fact that 
many parents have no experience of death or intensive care admissions related to febrile 
neutropenia. Thus their perceptions of risk of these events were somewhat different to those of 
professionals who often do have experience of these due to high risk febrile neutropenic 
episodes. To young people and parents therefore, who experience more of the burdens of 
inpatient febrile neutropenia care, it is the failures to provide care focused on a holistic definition 
of health which play a significant role in their experience. 
It is important here to note that these differences in focus further inform the interpretation of the 
findings of the systematic review in Chapter 3. This review used outcomes that can be seen to 
more closely reflect the focus of healthcare professionals – intensive care, death and healthcare 
service usage, as opposed to those of the families receiving care. This reflects the common 
findings in the literature that traditionally studies (which eventually form part of systematic 
reviews) are designed by professionals to detect these outcomes and fail to take into account the 
experiences of care that families value more highly, meaning these outcomes are also hidden in 
secondary research. This qualitative study highlights, particularly in relation to the quest for 
certainty, the way in which stakeholders then weigh the information provided by the systematic 
review differently, based on their prior experiences and consideration of other benefits and 
harms. This indicates that study design should involve more public and patient involvement in the 
outcome setting stage, but also that the interpretation of quantitative research should involve 
discussions with patients and families so as to gain more insight into the different viewpoints on 
specific statistical findings. 
 
Figure 14 – Schematic comparison of family and healthcare professional narrative focus during 
an episode of febrile neutropenia, where the height of the bar represents the weight given to 
each timeframe within the episode 
Pre-hospital Admission Duration of stay 
Families 
Professional
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The final divergence in focus that was seen within this study was in the narrative weight given to 
each phase of a febrile neutropenia admission (Figure 14). Young people and their parents vividly 
described the period of time leading up to the presentation of a child with fever, including 
attempts to prevent infections, the emotional stress of anticipating a fever and the practical and 
logistical implications of attending the hospital. Following arrival at the hospital, they barely 
mentioned the assessment and admission of their child to their local centre, but then focused on 
the duration of the hospital admission and the interval between admission and discharge as a key 
feature of their experiences. In direct contrast to this, healthcare professionals said very little 
about the pre-hospital stage. Instead their narrative focused on the assessment of a child 
presenting with febrile neutropenia and the initial management of these patients. In each group, 
the healthcare professional groups did not review the management of the later phases of the 
admission until prompted. This waxing and waning of focus within an episode of febrile 
neutropenia is pictorially represented in Figure 14. Thus it can be seen that healthcare 
professionals may not consider the timing of discharge, or the changing of this, to be a particularly 
important issue in the management of febrile neutropenia. This may give further information, 
combined with that provided earlier in Chapter 6, to explain why this aspect of care has not been 
modified, despite the increasing evidence of safety and the potential benefits for patients. 
Through performing this study and then disseminating and promoting its results I hope to 
stimulate healthcare professionals to think more about this stage of febrile neutropenia care and 
to highlight the material available to them to facilitate future decision making.  
The influence of paternalism and determinism 
Historically, paternalism and determinism have shaped healthcare culture and both play key roles 
in illuminating why the key themes of certainty and control run through findings of this 
study.(194) In the deterministic worldview which was predominant in early medicine, the role of 
the physicians was to establish the definitive causes and treatments for disease. The clinician 
should and would strive to control each aspect of a patient’s health so as to have control over 
their outcomes.(194) This focused viewpoint does not allow for the uncertainty and risk that is 
inherent in contemporary medicine, where diagnostic tests are recognised to be fallible, risky 
behaviours do not necessarily result in harm and treatments may have high numbers that need to 
be treated so as to obtain individual patient benefit. Determinism inspires and promotes the 
creation of certainty, and thus where this cannot be achieved, the illusion of certainty can be 
considered a reasonable replacement as it provides a sense of control and reassurance within 
difficult situations. Understanding statistical risks and making decisions based upon them is not 
prioritised, instead: “The goal is certainty, rather than learning how to live with uncertainty”.(194) 
In low risk febrile neutropenia, as in all healthcare, there is no certainty. The data shown in 
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Chapter 3, and discussed within the focus groups, shows that there is low (but not no) risk of 
serious safety events, regardless of the location of care, with variable rates of treatment failure 
dependent upon the timing of discharge from hospital. Sharing these risks, acknowledging the 
uncertainty and engaging in shared decision making based on patient and healthcare professional 
agreed values, is a difficult but necessary step to improving patient care in this area.  
Historically, healthcare professionals, particularly physicians, were considered trustworthy and 
reliable. They could be depended upon to make the ‘right choice’ and deliver decisions about 
patients without significant discussion. Within this paternalistic paradigm and culture, patients 
were not informed of the risks and benefits of treatment options and would instead be told the 
‘correct’ choice of action. This was seen to be in the best interest of the patient, who was believed 
unlikely to have access to the specialist knowledge required for medical decision making. 
Although they did express certain frustrations about specific aspects of care, parents and 
particularly young people in this study appeared to be relatively accepting of their lack of control 
over febrile neutropenia decisions. This may link with the implicit amounts of control within their 
social roles. For example, young people may be used to having less control in negotiations with 
their parents or their teachers on a day to day basis, which then transfers to their acceptance of 
reduced control over healthcare decisions. Furthermore, for both them and their parents, the 
historically paternalistic culture associated with medicine means that they may be culturally 
influenced to relinquish more control in situations related to healthcare than in other areas of life. 
This may be even more prominent given their cancer diagnosis, which also conveys many social, 
emotional and cultural influences upon their responses and behaviours.  
Patient choice and shared decision making 
Issues relating to patient choice and decision making run throughout this thesis, and particularly 
through this qualitative study, and so I will discuss this further within this segment of the chapter.  
As has already been covered, some participants within the study did not want to take on the 
responsibilities associated with making their own choices about treatment of febrile neutropenia. 
Indeed one family had made an active choice to devolve decision making to the healthcare 
professionals. Other families were very keen to have a say in their child’s care, and wished to take 
more control for the decisions made when their children had febrile neutropenia. Although many 
of the potential personal reasons behind these choices are discussed in Chapter 7 there may also 
have been social and cultural influences upon this decision. Of note, the families participating in 
the qualitative study will generally have been exposed to the current healthcare narrative 
regarding patient choice, though this was not explicitly mentioned within the focus group 
discussions. Whilst it is not clear that this narrative made differences to individuals’ attitudes 
about who should make decisions about patients’ care, it may be that the balance between those 
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who wish to make decision and those who do not, on a societal level, may have been altered by 
the cultural and political background related to patient choice. Thus it may be that the proportion 
of families wishing to play an active role in decision making is increasing over time. Further issues 
related to patients choosing to let professionals make their healthcare decisions were discussed in 
Chapter 2, and will also be considered in the following sections about shared decision making in 
febrile neutropenia care. 
Shared decision making has been suggested as an appropriate next step in overcoming 
paternalism and determinism, recognising differences in focus and beginning to respect the rights 
of patients to have autonomy over their healthcare decisions.  
In contemporary medicine, shared decision making is becoming increasingly valued. With the 
current political climate prioritising the right for patient choice and involvement in their own 
healthcare and the ‘nothing about me without me’ agenda, shared decision making is a prominent 
feature throughout policy.(199) Indeed, the Department of Health’s policy document ‘Equity and 
excellence: Liberating the NHS’ outlines a strategy in which one of the first statements is that 
“Shared decision-making will become the norm”(200). Supporting shared decision making has also 
been included within the duties of a doctor outlined by the General Medical Council: 
“Work in partnership with patients. 
 Listen to, and respond to, their concerns and preferences. 
 Give patients the information they want or needs in a way they can understand. 
 Respect patients’ right to reach decisions with you about their treatment and care. 
 Support patients in caring for themselves to improve and maintain their 
health.”(59) 
There are numerous definitions of shared decision making in healthcare. However, the essential 
features of all consider sharing of information about treatment options, their potential risks and 
benefits, identifying the patient’s key values and priorities and then patient and professionals 
working together in partnership to select the most appropriate option for the individual, based on 
the best available evidence.(201) As discussed in Chapter 2, in the case of children and young 
people, this process is complicated by the presence of three parties. Many of the challenges of 
achieving true patient choice related to children have already been discussed and explored (see 
Chapter 2).  
Despite the political and cultural drives to increase shared decision making, it is often not fully 
optimised. In many cases, medical paternalism, including retaining power over information and 
control over treatment pathways, remains the predominant method of decision making.(87,202) 
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Elsewhere, professionals may feel that they engage in shared decision making, but research has 
found they often do not engage in discussions about patient values or providing accurate 
representations of options and risks to patients.(203) As such, patients still frequently report a 
desire to receive more information and to be more involved in decisions about their care.(204) 
This is exacerbated in paediatric decisions by the issues discussed in Chapter 2.  
It has been suggested that shared decision making is most suited to particular situations in which 
there is no clear evidence of the most appropriate course of action, and where the patient’s 
values or preferences might play a more important role in resolving this 
equipoise.(83,87,202,203) In low risk paediatric febrile neutropenia, this could now be considered 
to be the case for the decision about timing of discharge from hospital. Although previously there 
has not been sufficient data to support this as a ‘preference-sensitive’ decision, this thesis 
provides material suggesting that serious safety events are not obviously affected by the location 
of care and as such individualised judgements about other treatment failure features and patient 
preferences become more prominent. Furthermore, this thesis provides clarification on the rates 
of treatment failure at different discharge time points and may therefore assist in shared decision 
making by facilitating more accurate discussions of the associated risks of the various options. 
Specifically, there has been a drive to use shared decision making “where the balance of risks and 
benefits varies widely in different medical, social and health care situations”.(203) Given the 
findings reported in Chapter 6, it might be considered that patients’ social circumstances, along 
with the individual psychological impact of admission, might lead to a different balance of risks 
and benefits for each family. 
Finally, shared decision making is particularly useful for patients who are involved in increased 
numbers of healthcare decision and who have prolonged contact with services over time. Shared 
decision making provides a method for empowering and enabling patients, within partnerships 
with healthcare professionals involving mutual trust and autonomy.  In children and young people 
with cancer, shared decision making could be achieved through continuing discussions about the 
management of their febrile neutropenia. The priorities identified and skills developed through 
this situation can then be transferred to other healthcare decisions for these patients. 
I therefore argue that shared decision making for children and young people with low risk febrile 
neutropenia is the most appropriate approach for making decisions about timing of discharge. 
This would involve sharing risks with patients and their parents, discussing their priorities and 
values, including past experiences, before negotiating a decision about how to manage this 
episode of febrile neutropenia. It would facilitate a redistribution of control and appreciation of 
each other’s roles, responsibilities and areas of focus. Furthermore, this process would improve 
communication in general, allow young people to feel included in the process as much as they are 
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willing and able to, and might encourage clinicians to use the approach in similar decision making 
situations. I will discuss further how this might be achieved in Chapter 9. 
Before implementation can be planned, there are many challenges that stand in the way of 
implementing shared decision making which must be considered. These can include professionals 
not knowing the risks associated with various options, not understanding the statistics shared in 
the literature, or being unable or unwilling to communicate these. In addition to this, although 
they may be encouraged to discuss uncertainty with patients, professionals can feel that sharing 
their lack of certainty may jeopardise their patient’s trust, thus undermining the paternalistic 
nature of medicine.(87,205) In contrast to this, others have proposed that through sharing their 
lack of certainty, professionals may instead help to create a more balanced power dynamic with 
patients and thus allow a more equal balance in the decision making.(83)  
Following this discussion, patients, having been presented with the risks, may weigh these 
differently to the professional and autonomously choose the ‘wrong’ option.(87,194,206) Indeed, 
a number of studies have found that patients who are enabled through a shared decision making 
process to make choice about their healthcare, often reduce the amount of intervention that 
would have been suggested by clinicians. The lack of paternalistic control over such decisions can 
be disconcerting for clinicians and wrests some of their own sense of certainty from them through 
the unpredictable nature of patient choice, particularly when they feel that there is a ‘correct’ 
way to manage the situation.(87)  
For patients and families, concern about making the wrong choice is also prominent, as evidenced 
in this study. This concern was particularly strong for parents compared with patients, which 
reflects previous research that making decisions about your children is more stressful than making 
decisions for yourself.(84) Participants worried about the potential negative effects of particular 
choices and some were concerned about the increased accountability that would come with a 
choice for reduced therapy options. This expression of a Damoclean sword, in which the power to 
make decisions about their child’s care also came with the responsibility for any adverse 
outcomes, was more prominent for some participants than others.  
Another challenge to the implementation of shared decision making is that professionals may feel 
that they can assess which patients wish to participate in shared decision making and which might 
prefer a more paternalistic approach, therefore some participants might not be offered the 
opportunity to share decision making and are therefore prevented from accessing its benefits. 
Although the literature suggests that certain groups are more likely to want to participate in 
healthcare decision making, as discussed in Chapter 2, it is not possible to predict this with 
certainty. Certain factors can influence the desire for shared decision making and the most 
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relevant for this study is that of trust. Kraetschmer et al found that patients who show blind trust 
in their clinicians (defined as an average Trust-in Physician Scale score of 5.0) are more likely to be 
passive in their decision making, where as those with moderate to high levels of trust prefer a 
shared decision making approach.(207) This seems to fit with the findings of my study, particularly 
in the example of the outlier case, where complete trust resulted in a more passive approach to 
decision making. Meanwhile, most participants had high levels of trust in the healthcare 
professionals caring for them along with a desire to shared decision making about discharge in 
low risk febrile neutropenia. Furthermore, participants with increased knowledge about febrile 
neutropenia and increased experience of this condition tended to be more keen to be involved in 
decision making, which is also consistent with Kraetschmer et al’s findings.(208)  
Linked to the issue of patients’ trust in professionals, others have looked at how professionals’ 
trust in patients may impact upon shared decision making. Here, research shows that 
professionals who trust their patients and believe in their competence to understand and make 
decisions are more likely to engage in shared decision making.(208) This also seems to hold true in 
my study, in which Centre 3, who showed a more positive attitude to parents and their 
competence felt more willing to engage in discussions about early discharge. In Centre 2, where 
professionals spoke relatively negatively of the families in their care, there was less willingness to 
consider a change in practice.  
Although it is important to identify those patients who wish to be involved in shared decision 
making, it is also vital to recognise that involving all patients in shared decision making can have 
positive effects on a number of outcomes, regardless of preferences. Participation in shared 
decision making has been found to improve patients’ quality of life, increase knowledge, and 
reduce the degree of decisional conflict experienced.(206,209) Though few studies have found 
strict clinical benefits, this is perhaps not the aim of shared decision making, given that these are 
usually situations with equipoise.(210) Instead, it might be considered that patient and family 
centred outcomes are as important as purely clinical ones, linking with the differences in focus 
between professionals and families. 
Another challenge frequently discussed in the literature about shared decision making is the 
pressure of time.(201,202,205) In the UK, where there is a culture of efficiency and increasing 
demand on healthcare services, including paediatric haematology and oncology, any increase in 
the time taken to see a patient can be viewed negatively.(202) Professionals feel they struggle 
with current workloads and so adding anything which is perceived to increase their time demands 
may be avoided. In the case of febrile neutropenia, this pressure may be particularly acute as 
clinicians know that outcomes for children are improved if initial antibiotics are administered 
within 1 hour of presentation. If professionals feel that all aspects of discussion and decision 
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making need to be performed at once, then they may attempt to perform the quickest pathway 
possible, which is perceived to be paternalistic, protocol driven care. These time concerns can be 
addressed in two ways. First, the literature currently does not provide clear evidence of how 
much time is involved in facilitating shared decision making.(209) However, for decision aids 
(which will be discussed further in Chapter 9), a recent systematic review found that their 
introduction increases the duration of consultations by a median of 2.55 minutes (range 8 
minutes shorter to 23 minutes longer).(211) Having this information may help professionals to 
realise that shared decision making does not seem to greatly increase the time taken to make 
decisions. Furthermore, time spent in shared decision making discussions may be compensated by 
time saved on future discussions about care, or through inpatient treatment, should the family 
choose a reduced therapy option. Secondly, healthcare professionals in paediatric haematology 
and oncology could be encouraged to reduce some of the felt time pressure by uncoupling the 
decision to administer the initial dose of antibiotic and the decision about ongoing care of febrile 
neutropenia. In this way, the first decision would need to be made within 1 hour but the second 
decision could then take as much time as necessary to meet a shared choice. Methods to facilitate 
the second decision could be developed and will be discussed in the following chapter.   
Within this section, I have explored why shared decision making is now particularly important in 
discussions about low risk febrile neutropenia. I have discussed some of the challenges to 
introducing shared decision making to this condition, whilst relating these back to the findings 
shared in Chapter 6. There are a number of methods proposed to increase shared decision making 
in healthcare and these will be discussed in the following chapter, along with the other practice 
and policy implications of this work.   
Strengths and limitations 
This qualitative study has a number of key features which allow it to add to and develop the 
previous literature in this area. In particular, it involves new voices in the qualitative discussion of 
febrile neutropenia management. It provides data on the experiences and perceptions of young 
people, their parents and healthcare professionals involved in paediatric haematology and 
oncology services. Furthermore it facilitates a deeper consideration of the disease-specific factors 
relating to febrile neutropenia which influence stakeholders’ experiences and inform their 
decisions about future care.  
The inclusion of multiple centres within the study allows for an understanding of the impact of 
service design and centre culture upon the perceptions of management options. As such, I have 
been able to explore features which would not have been apparent had this study simply 
explored the experiences in a single centre.  This was facilitated by working in a country in which 
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there is considerable range in the provision of care for febrile neutropenia and through the 
recruitment of Centre 2 during its change in febrile neutropenia protocol.  Without doubt, the 
success of this study was made possible through the existence of a strong network of paediatric 
oncology and haematology services in the UK and more specifically through the availability of the 
regular febrile neutropenia audits performed by the Children’s Cancer and Leukaemia Group. 
(40,42) 
Another particular asset of this work lies in its reflexive approach. I hope that this provides for a 
transparent account of the work performed and enables the assessment of the credibility of this 
thesis. Through clearly explaining the decisions made within the design and execution of the 
study, I aim to allow the reader to assess the extent to which this relation of the findings captures 
the participant experience and provides possible underlying explanations for the data.  
Linked with this, the limitations of this study have been discussed openly and reflexively through 
the previous chapters. The majority of the challenges relate to the groups which proved difficult 
to recruit, including some demographic groups and those who have a limited ability to 
communicate in English. This reflects broader problems within the research community of 
engaging with participants from social disadvantaged groups and those from multi-cultural 
contexts.(165,168) In addition, like many other research projects, this study struggled to engage 
with the young people in its target population. The implications of these limitations have already 
been discussed extensively in Chapter 5 and I hope have been limited as far as possible by the 
active responses made to these challenges. These resulted in improvements in recruitment over 
time and thus have helped to reduce any shortcomings. Future studies with these populations 
may wish to integrate other methodologies, including interviews or online focus groups for those 
who do not wish to participate in face-to-face groups.  
A further limitation lies in the inclusion of only English centres. Despite my intentions to include 
centres elsewhere in the UK, this was limited by the small numbers of PTCs outside England and 
the purposive selection strategy discussed in Chapter 5. Given the strong networking between all 
centres across the UK through the Children’s Cancer and Leukaemia Group, the treatment 
strategies and ethos of these centres are unlikely to be vastly different from those included within 
this study. However, I recognise that health services have been devolved to other UK nations and 
thus the political management of healthcare is different in Scotland, Wales and Northern Ireland. 
Furthermore, particularly in Scotland, patients frequently have a long distance to travel for their 
treatment, exceeding that of most English centres. As this study found that the issue of duration 
of journey to the hospital did impact upon participants’ perceptions of care, those families living 
in particularly rural areas of Scotland may feel less comfortable with reduced therapy regimens 
and thus care should be taken when planning services for this population.  
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Finally, the small size of some of the focus groups may be considered a limitation by some 
academics as they may lead to relatively restricted discussions and the presence of particular 
character traits, such as shy participants or dominating participants, may have a more acute effect 
on the group.  However, for others, smaller groups of three to six participants have been 
purported by others to be beneficial in focus group discussions involving complex subjects, of 
which febrile neutropenia is certainly one, or in groups of experts, such as the healthcare 
professionals in this study.(165,166,212)  
Reflexivity 
The methodological decisions relating to the qualitative study have been explored and evaluated 
in Chapter 5 of this thesis, whilst the procedural influences on the work were highlighted where 
necessary in Chapters 6 and 7. This additional section therefore aims to specifically discuss the 
political and cultural setting of the research and my personal influences upon the work.  
Political and cultural reflexivity 
Culture is a complex and frequently ill-defined term, which generally refers to the shared values 
and behaviours of groups of people.(213) A single individual can be part of many cultures, with 
differing social expectations and practices, which each provide their own freedoms and 
constraints to thoughts and actions. There are a number of cultural influences upon this work, 
including the concepts of paternalism and determinism covered in the earlier sections of this 
chapter. Through considering these influences, I hope to not only locate the work within the 
broader debates but also provide an account of how these might influence the interpretation of 
the findings. 
Certain features of Western culture may have played a role in the development and 
interpretation of the study, such as societal attitudes to children, who hold a particular value but 
are also innately vulnerable and require protection by responsible adults.(214) Furthermore, this 
study takes place in a societal structure which values individuality and personal autonomy, thus 
collective decision making is unusual throughout people’s lives. This may explain some of the 
difficulties in coming to a shared decision, where individualisation is desired by families but 
achieved through a partnership process with professionals.     
More narrowly than this generic Western culture, the professional culture within the health 
service has become relatively risk averse. Where clinicians are concerned about the risk of 
litigation, the practice of defensive medicine is prevalent.(215,216) This culture may have 
contributed to the attitudes of healthcare professionals in this study by increasing their sensitivity 
 233 
 
to the risk of death or intensive care, increasing their sense of responsibility for these, and 
heightening their awareness of external scrutiny.  
Furthermore and speculating about other potential influences on participants, the discussions of 
the healthcare professionals in the focus group discussions at times mimicked culturally that of 
Lipsky’s ‘street-level bureaucrats’ where the volume of cases and limited resources require 
professionals to adapt their attitudes and behaviours so that they can provide a service within the 
constraints of a larger system, perhaps explaining the ‘need for discretion’ in professionals as a 
contrast to ‘individualised care.(217) As a result of this system, professionals are unable to 
provide the individualised service that they originally aspired to, and may change their stated 
beliefs so as to reduce the feeling of failure in the provision of the service that they are limited to. 
Furthermore, ‘street-level bureaucrats’ often seek more control over the people they work to 
serve so as to ensure that the system is not over-stretched. (217) This echoes with a number of 
the codes relating to the healthcare professionals, particularly the discussions about protocol 
constraints, individualised care and the spectrum of control within febrile neutropenia. Lipsky 
suggests three main methods for facilitating change in street-level bureaucracies: encouraging the 
autonomy of patients (clients), improving current practice, and equipping the bureaucrats with 
the skills to instigate change.(217) Some of these issues resonate with the discussions of shared 
decision making, practice implications and the education and training of professionals in the 
following chapter. Future studies may wish to intentionally and explicitly examine the role of 
healthcare professionals as ‘street-level bureaucrats’, in paediatric oncology services and 
elsewhere in child health.  
UK healthcare has also seen a rising emphasis on increasing quality of life for patients, with 
consideration of the negative impacts of treatment upon this. As such, small survival advantages 
of treatment may not be felt beneficial if accompanied by a significant reduction in the quality of 
life. This is relevant in the care of low risk febrile neutropenia, where the survival advantages of 
inpatient admission have not been identified but are unlikely to be large, given the data in 
Chapter 3. 
In addition to these general issues, I have already explored the cultural background to the 
physician’s role in this setting, within the earlier section on the influence of paternalism and 
determinism. The influence of the specific paediatric haematology and oncology culture in which 
patients and, by proxy, professionals are viewed as different or ‘special’, along with the influences 
of centre culture upon perceptions of early discharge, have been discussed within the findings 
chapter.   
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Personal influences 
Many of my influences on the study have been considered in the methodology (Chapter 6) and in 
my accounts of the participants’ responses to my role as doctor within the Professional roles 
subtheme of the findings. I noted two additional important features during the study. The first 
related to the negative comments about junior doctors, which are also described in the 
Professional roles subtheme. Here, I debated whether, as a junior doctor myself, I was sensitive to 
these comments, particularly given the political climate in the UK during the study (where junior 
doctors’ contract renegotiations had failed and doctors at my level of training were involved in 
industrial action). I therefore took great care to review the transcripts repeatedly to ensure this 
code had been accurately captured. I was reassured of this when the initial healthcare 
professional findings were presented to a clinical audience, as this code did appear to resonate 
with both senior and junior clinicians, who felt the narrative had been accurate to their 
experience.  
The second relates to my own experiences within paediatric haematology and oncology services. 
The main centre within which I have worked has a relatively positive approach to reduced therapy 
for febrile neutropenia. Their current protocol involves risk stratification and discharge at 48 
hours for low risk children. There is minimal shared care with other centres. Furthermore, this PTC 
does a relatively large amount of supportive care research and there have been frequent 
discussions within the team about febrile neutropenia management. On a personal note, I have 
experience of patients with febrile neutropenia, including my own ‘horror stories’ in which 
patients have died suddenly or been seriously unwell due to febrile neutropenia. Similarly, I have 
known many patients with low risk febrile neutropenia and their families, who have shared with 
me their frustrations of being in hospital with a ‘well’ child following a single temperature.  
Each of these features therefore could influence my own research as I might consider them to be 
the ‘normal’ with other factors being identified as aberrant. I was aware of this potential and took 
steps to reduce this effect. This took two main forms. First, through being aware of these 
potential biases, I was able to identify where these might impact and took care to examine areas 
which might be affected by my own experiences. I used an approach which looked specifically for 
issues which both agreed with and challenged my own experiences, and for each of these 
considered the potential reasons for this. Secondly, I had supervisory teams with different clinical 
and academic backgrounds who were involved within the analysis stage and provided honest 
critique of these issues where necessary. 
Finally, it is important to reflect upon the impact of this study upon me as a researcher. At times, 
the findings of this study caused me to feel anger or sadness, particularly relating to the impact of 
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febrile neutropenia admissions on children and their families. Occasionally, this resulted in a 
feeling of blame towards professionals’ for their choices, which could be felt to be due to poor 
judgement and based on minimal scientific evidence. Acknowledging this feeling, discussing and 
debriefing this with my supervisors enabled me to make substantial progress with the analysis. I 
recognise that professionals are making difficult decisions with what they feel to be the patients’ 
best interests at heart in challenging cultural settings and thus have aimed to accurately voice the 
professionals’ experiences and to represent their viewpoint alongside that of parents and young 
people. Through recounting the personal impact that the management of febrile neutropenia has 
on healthcare professionals, I hope to communicate the challenges that they encounter in 
treating this ‘simple’ problem.  
This experience has resulted in a change in my own professional practice, having questioned my 
own professional identity and role, through the performance and analysis of this research. 
Overall, I feel I am more aware of the importance of gaining families’ perspective, of my own 
personal influences in febrile neutropenia decisions and the value in sharing more information 
with families and working together to make choices which everyone is happy with, within the 
confines of the current centre protocol. Finally, I have an increased desire to discuss the findings 
of this research with the professional community so as to provide a voice to all parties and to 
raise awareness of previously hidden issues and to aim to impact policy and practice for the 
benefit of both families and professionals. 
Summary 
In this chapter I have summarised the findings of the multi-centre focus group discussion study, 
relating them to the findings from the other research projects undertaken as part of this thesis, 
and to the broader literature. I considered the differences in focus between parents and 
healthcare professionals in relation to health in general, and to the experience of an episode of 
febrile neutropenia specifically. I have also considered the influence of paternalism and 
determinism on medial culture and how this impacts upon decision making in low risk febrile 
neutropenia. Leading on from this, I have presented shared decision making as a way to improve 
communication surrounding febrile neutropenia, to balance the degree of control and to facilitate 
negotiation between families and healthcare professionals. I have concluded this discussion 
chapter with a reflexive section considering the political, cultural and personal influences on the 
study process and its findings. The following chapter combines these findings with those of the 
earlier chapters, summarising the thesis as a whole and identifying the implications of the work 
upon future research, policy and practice.  
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Chapter 9: Conclusions 
Introduction 
This final chapter aims to draw together the findings of the three phases of the thesis – the 
systematic review of reduced therapy regimens for paediatric low risk febrile neutropenia, the 
qualitative synthesis of experiences of early discharge, and the qualitative study exploring 
experiences and perceptions of early discharge in paediatric febrile neutropenia. I intend to 
demonstrate how the overarching aims of the thesis have been met through the sequence of 
three interlinking projects and to identify the future implications of these results for practice, 
policy and research. I will expand on the strengths and limitations of the thesis as a whole and will 
explicitly outline its original contributions to the literature in paediatric febrile neutropenia. 
Summary of thesis  
Febrile neutropenia is the commonest life-threatening complication of treatment of children with 
cancer.(1) Many episodes of febrile neutropenia will have no septic complications and these 
children will remain essentially well during the event. Previous research has identified various risk 
stratification tools, which help to identify these low risk episodes from those at higher risk of 
serious complications.(10) Current treatment in the UK for children with low risk febrile 
neutropenia varies but generally involves at least 48 hours in hospital and the administration of 
intravenous antibiotics.(40) Recent NICE guidelines advise consideration of outpatient antibiotic 
therapy for this group, which is at odds with current paediatric practice.(21)  
This thesis used a sequential mixed methods approach to undertake three consecutive phases 
utilising different research methodologies to further investigate important issues surrounding the 
reduction of therapy for children and young people with low risk febrile neutropenia.  In the first 
phase, I intended to systematically review the evidence for reduced therapy regimens and identify 
the safety, adequacy and treatment failure rates for these at different timings of reductions in 
therapy. I then planned to explore attitudes to early discharge regimes, through three different 
methods. First, through assessing the rates of consent to studies within the systematic review; 
second, through a qualitative synthesis of the primary studies in areas relating to paediatric 
febrile neutropenia (Phase 2); and finally through a focus group study involving young people, 
parents and professionals (Phase 3). I intended to establish the factors influencing decision 
making about outpatient therapy in febrile neutropenia and to establish the barriers and 
facilitators to this. I also aimed to compare the views of key personnel in these decisions and to 
consider how service provision could best reflect the views of these different stakeholders. The 
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research questions for different phases of the thesis were outlined in Chapter 1, Figure 2 and the 
findings in response to these are summarised within this chapter, Figure 15. 
Phase 1: Systematic review of reduced therapy regimens for children with low-
risk febrile neutropenia 
The systematic review of effectiveness for reduced therapy regimes is described in Chapter 3. In 
this review, I identified 37 different studies including 3205 episodes of paediatric low risk febrile 
neutropenia. Two deaths and two intensive care admissions occurred within these episodes, 
giving a proportion of severe safety events of 0.1% (95% CI 0.03-0.3%). There was no obvious 
association between occurrence and route or location of treatment. It was therefore essential to 
examine the treatment failure rates at different times of discharge. The meta-analysis found that 
14% (95% CI 9.7-19%) of episodes managed entirely with outpatient care resulted in treatment 
failure. Meanwhile, treatment failure occurred in 2.2% (95% CI 1.2-4.1%) of episodes managed 
with at least 48 hours of inpatient care. Although these data were from observational cohorts and 
therefore it is not appropriate to statistically compare these groups, the trend would seem 
clinically plausible. When considering consent rates to the studies included in the systematic 
review, 19.3% (range 1.3-30.1%) of patients failed to consent to enrolment, whilst 8.3-12% failed 
to confirm consent after enrolment. This rate of refusal was uncharacteristic in the context of 
children’s cancer, where high recruitment rates are generally seen.(143) Clinicians declined to 
enrol patients into studies at similar rates. This suggested that there are concerns within the 
paediatric haematology and oncology community about reduced therapy regimes, and justified 
the following two phases of the thesis. This review provided a robust and up-to-date summary of 
the evidence to inform the focus group participants’ discussions of risk in Phase 3, meaning that 
considerations were focused on realistic estimates of the outcomes of possible future service 
designs. 
Phase 2: Experiences of early discharge, with a focus on paediatric febrile 
neutropenia: a meta-ethnography 
The first step in exploring the nature of concerns about the acceptability of reduced therapy 
regimens was the conduct of the qualitative synthesis described in Chapter 4. This aimed to draw 
together the evidence relating to early discharge in paediatric febrile neutropenia, including data 
from studies of adult febrile neutropenia and other paediatric chronic conditions with life 
threatening consequences. In total, nine papers were included in the meta-ethnography, with 
varied participants and methods. This work found that early discharge involved complex and 
difficult decision making, influenced by fear, timing and resources. Participants struggled with 
practical aspects of reduced therapy regimes, particularly those relating to childcare, finances and 
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attendance at follow-up. They also experienced social and emotional problems, including 
isolation, relational and environmental challenges. Finally participants focused on the importance 
of receiving information and continuity of care, emphasising that increasing these would help to 
circumvent some of the difficulties they faced in accepting early discharge regimes. I proposed 
resilience as a theory that could draw together these interrelated themes and which was 
applicable to the evidence found in this review.  
However, the synthesis had specific challenges, mostly related to the literature available, with 
only one study that explored paediatric febrile neutropenia and minimal material on the 
experiences of young people and healthcare professionals. As these are key players in decision 
making about paediatric febrile neutropenia, I designed the third phase of the thesis to explicitly 
take these issues into account.  
Phase 3: A multi-centre focus group study of experiences and perceptions of early 
discharge in paediatric low-risk febrile neutropenia involving patients, parents 
and healthcare professionals 
The final phase of the thesis involved a multi-centre focus group study including young people, 
parents and healthcare professionals in discussions about potential treatment options for 
paediatric low risk febrile neutropenia. The systematic review and qualitative synthesis impacted 
upon the design, performance, analysis and interpretation of the qualitative study, showing 
mixing at many levels through the work. The study included 8 focus group discussions in three 
different centres, which were purposively selected from a large national survey for their 
differences in their service structure and febrile neutropenia management. In the findings 
(Chapters 6 and 7), I depict the three main interrelating themes, cross-referencing the recurrent 
threads and emphasising areas of agreement and contrast between the various groups. The 
nuanced nature of the decision making involved is explored in detail and practical issues that may 
help to improve the experiences of children and their families during an episode of febrile 
neutropenia are highlighted.  
The study found that the quest for certainty influences decisions made by key stakeholders in 
paediatric febrile neutropenia. The discomfort of the uncertainty involved in risk assessments is 
balanced against the certainty implied by current protocols. The perceived benefits and harms of 
inpatient care that participants have previously experienced inform their appraisals of future 
treatment strategies. In attaining mutual trust and sharing roles and relationships, participants 
described how interactions between these stakeholders play a key role in shaping perceptions of 
care. They spoke of the different roles within febrile neutropenia services and how these would 
need to change if outpatient or early discharge schemes were implemented, how mutual trust, 
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though already present in some ways, would need to be fostered and strengthened and how 
responsibility would need to be redistributed between groups. 
Having identified a need for discretion and a desire for individualised care, negotiation within a 
spectrum of control allows achievement of the potential for realised discretion. Non-attendance 
with febrile neutropenia is an example of when the spectrum of control is different and families 
use their own assessments of risk and mutual trust, along with their previous experiences, to 
make decisions about their child’s care. The earlier themes impact on desired future services in a 
number of ways, most of which aim to individualise care for children and young people. Their 
influence on preferred future services was demonstrated using one family as a case study. 
The findings highlighted the differences in focus between families and healthcare professionals, in 
relation to children’s health in general and to the experience of an episode of febrile neutropenia 
in particular. Furthermore, they enabled a deeper understanding of the qualitative literature 
explored in Chapter 4 – providing highlights of features which are disease specific, exploring how 
patients and professionals negotiate in these situations, and detailing the specific aspects of 
reduced therapy regimes which stakeholders desire. This phase also demonstrated how the 
statistics identified in phase 1 are interpreted and used by key stakeholders in different ways to 
assess risk, and how families in particular can view the harms of therapeutic options as different 
from those outcomes identified and used in the systematic review, as discussed in further detail 
within the section on Differences in focus between families and healthcare professionals in 
Chapter 3. This combining and translating between the different phases of the research gives a 
depth and richness to the thesis as a whole and provides a more nuanced consideration of the 
research problem. 
Overall, the findings suggest that introducing shared decision making could improve current 
paediatric low-risk febrile neutropenia services, which fits with the current NHS narrative of 
increasing patient choice. This process would be supported and facilitated by the good 
relationships that are already present within the paediatric haematology and oncology 
community.  
In summary, this thesis has defined the safety risks in low risk febrile neutropenia and the relative 
benefits of varied durations of hospital admission. The advantages of prolonged admissions are 
smaller than anticipated, particularly for serious safety events. The work has highlighted the 
previously underestimated harms of admission for febrile neutropenia and the paternalistic 
nature of decision making about febrile neutropenia care, along with the frustrations and 
challenges for all parties involved in caring for these children. This research justifies a 
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reassessment of the appropriateness of current treatment strategies for these children and their 
families and exploration of the potential to introduce shared decision making.  
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Phase 1: Systematic Review
• In children with low-risk febrile 
neutropenia:
•The rate of death or ICU admission is 
0.1% (CI 0.03-0.3%), with no obvious 
relationship to route of antibiotics or 
location of care.
•The rate of treatment failure is 14% 
(CI 9.7-19%) for entirely outpatient 
care and 2.2% (CI 1.2-4.1%) for those 
admitted for at least 48 hours.
•19.3% (range 1.3-30.1%) of patients 
failed to consent to enrolment; 8.3-
12% failed to confirm consent after 
enrolment. 
•Clinician declined to enrol patients 
at similar rates.
Phase 2: Meta-ethnography
•Decision making in early discharge is 
complex and difficult. This 
experience is influenced by various 
common factors, including fear, 
timing and resources. Within this 
decision making, we identified two 
distinct themes. First, families 
struggled with practical aspects 
associated with maintaining 
successful treatment regimens, 
namely childcare, finances and 
attendance at follow-up. Second, 
parents struggled with social and 
emotional issues raised by early 
discharge, including social isolation, 
relational and environmental issues.  
Linking these two themes, 
participants noted the importance of 
continuity of care and the need for 
information if they accepted early 
discharge. Participants described 
strategies that might circumvent 
some of the practical challenges 
faced and alleviate the feelings of 
isolation experienced.
Phase 3: Focus group study
•The quest for certainty requires 
balancing assessments of risk, 
the rigidity of protocols and 
prior experiences so as to 
assess the different treatment 
options.
•Attaining mutual trust and 
sharing roles and 
responsibilities is vital for good 
decision making. The various 
roles of different groups have 
been explored and the changes 
to these needed to facilitate 
early dischagre have been 
considered. 
•The need for discretion and 
individualised care are 
explained by the differing 
degrees of focus and priorities 
of families and professionals. 
Through negotiating the 
spectrum of control, shared 
decision making can be 
facilitated.
•All these factors influence 
individuals' preferences for  
potential future services 
designs, which are discussed in 
detail within the text. 
Figure 15 - Overview of thesis findings 
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Reflections on the use of mixed methods in the thesis 
I have described many of the specific reflections on each phase of the thesis within the relevant 
chapters. This section therefore aims to review the impact of certain decisions related to the design 
of the thesis as a whole. I will also reflect upon the original contributions of this thesis to the wider 
literature.  
The use of multiple methods within the thesis has allowed me to explore the complexity surrounding 
reduced therapy for febrile neutropenia. Instead of simply focusing on the strict clinical outcomes, I 
have also been able to ascertain a number of surrounding issues, including the concomitant social 
and psychological repercussions of each strategy, which provide richness and depth to the evidence. 
Through the inclusion of qualitative methods, the different perspectives upon the research problem 
are considered, and each key stakeholder is given a voice. This breadth of deliberation on the issues 
provides a unique and significant contribution to the pre-existing literature, and will allow for 
enhanced consultations regarding future service design in this area, which is complemented by the 
pragmatic nature of the research.  
However, as noted in Chapter 1, challenges can arise in mixed methods research when the 
underlying epistemological and ontological beliefs of quantitative and qualitative paradigms appear 
to conflict.(53) I hope to have managed these challenges within the thesis by adhering to a 
pragmatic approach, in which the best methods have been selected at each stage. This has been the 
focus of many discussions between myself and my supervisor team, and the thesis hopes to present 
work that is scientifically robust whilst still being accessible to those from either research paradigm, 
and most specifically to healthcare professionals work within this field. 
The three interwoven phases of the thesis contribute to the current debates in the area in a number 
of ways, and have built upon and informed each other in a manner consistent with the mixed 
methods paradigm. The systematic review demonstrated that reductions in therapy in paediatric low 
risk febrile neutropenia are associated with increased readmission rates, but do not increase the risk 
of serious adverse events. The risk of treatment failure seemed to be higher when reduced intensity 
therapies were used immediately after assessment, with lower rates observed when these were 
introduced after 48 hours. This exploration of the quantitative literature is more extensive than in 
previous works and has specifically considered the influence of timing on the outcomes of interest. It 
provides healthcare professionals and service commissioners with more precise and robust data to 
inform the design of future services. This review also explored the issue of failure to consent to 
reduced therapy trials, which has not previously been investigated in a systematic fashion.  
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The findings of the systematic review informed the qualitative synthesis which provides a unique 
exploration of the literature in order to understand the issues surrounding early discharge. This work 
highlighted the areas which had not yet been researched in relation to early discharge. In particular, 
the voices of children and young people, and healthcare professionals have been relatively under-
researched and there is minimal disease specific data relating to febrile neutropenia.  
The qualitative synthesis therefore stimulated a focused qualitative study that aimed to address 
these key limitations in the current literature and thus the study is able to make a number of 
contributions to the existing debates. The work has highlighted the previously underestimated 
harms of admission for febrile neutropenia and the paternalistic nature of decision making, along 
with the frustrations and challenges for all parties involved in caring for these children. It has aimed 
to provide both practical and conceptual information to the research problems outlined at the 
beginning of the thesis. It has advanced the understanding of attitudes to early discharge in febrile 
neutropenia and has underlined the importance of considering these alongside the quantitative data 
when considering the design of services for children and young people in the future. 
Relating the findings from the qualitative study back to the syntheses, the challenges of consenting 
to the studies included in the systematic review have been highlighted by this later phase of the 
work. More than this, the focus groups have highlighted the contrast between families and 
healthcare professionals in terms of their focus in relation to febrile neutropenia care and the way in 
which this impacts upon the systematic review findings have been discussed within Chapter 8. The 
interpretation of the statistics included in the systematic review by the participants of the qualitative 
study has shown the variation in opinions between individuals and stakeholder groups. Meanwhile, 
the study has also expanded upon and provided deeper insight into the qualitative synthesis, 
identifying both disease-specific aspects of reducing therapy in paediatric low risk febrile 
neutropenia, but also more generic insight into the experiences and perceptions of key stakeholders 
involved in caring for families of children with chronic diseases. This is also explored in more detail 
within Chapter 8. 
Implications on research, policy and practice 
Throughout this doctorate I have used a pragmatic approach, stimulated by and grounded in my 
own clinical practice to consider the particular issue of reduced therapies in the management of 
paediatric low risk febrile neutropenia in the future. I have demonstrated that although multiple 
methods and perspectives can add complexity, high quality clinical research can and should be 
combined with policy and practice considerations in order to advance the field of paediatric 
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haematology and oncology. Consistent with these underlying values of the thesis and with its aim to 
provide clinically informative and practically useful outcomes, this section will provide a practical 
account of the direct implications on research, practice and policy that result from this thesis so as to 
inform the next phases for development in the care of children and young people with low risk 
febrile neutropenia.  
I intend to outline the main areas for future work in terms of immediate, medium and long-term 
actions that may result in improved service design (see Box 9). This timeframe correlates relatively 
well with the extent of change or the volume of work required before they can be implemented. 
Some of the changes are comparatively straightforward and thus can be undertaken quickly and 
with minimal resources, whilst other improvements in practice are more significant and may take 
more time. Additionally, whilst a number of changes can be taken immediately on account of the 
current evidence, other factors may require further research before they can be implemented. 
Within this section, I will also consider how to accomplish these developments, specifically noting 
the research methods which may be employed in the future. The options I have chosen to discuss 
are not exclusive and consideration should be given as to the strengths and weaknesses of different 
combinations of strategies for progress in this area. Many of the immediate and medium term 
options will impact upon the long-term change and, if successful, will help to inform other decisions. 
I have drawn attention to the relationships between different options where these exist and have 
attempted to outline the potential benefits of different strategies. 
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Immediate implications 
The most important work to be done in the immediate period following the submission of this thesis 
is in the dissemination of its results. The systematic review has already been published, the 
qualitative synthesis submitted for publication, and many of the other key findings have been 
presented at local, national and international meetings.(144) This distribution of the work is vital to 
informing and educating healthcare professionals about the various issues surrounding the 
management of paediatric low risk febrile neutropenia, including the importance of differentiating 
between low and high risk episodes when talking and writing about febrile neutropenia. I hope to 
stimulate clinicians to think about both how they view low risk febrile neutropenia and the way they 
communicate about it to families. Furthermore, I plan to increase awareness of patients’ and 
families’ current experiences of hospital admissions for febrile neutropenia, particularly the 
difficulties they face and the accompanying adverse effects on the child’s physical, emotional and 
social health. I intend to highlight the current challenges in regards to protocols, control and 
negotiation and to explore with professionals the reasons that these occur. Many of the immediate 
actions from the thesis follow on from these points and are dependent upon this communication 
strategy. I believe that educating and empowering healthcare professionals to think and act 
Box 9 – Policy and practice implications  
Immediate 
 Dissemination of thesis findings 
 Education of healthcare professionals 
 Discussion of risk 
 Communication of all test results to parents  
 Implementation of current guidelines 
Medium term 
 Blood culture research  
 Development of decision aids for febrile neutropenia  
 Further febrile neutropenia research, including introduction of reduced therapy 
regimens 
 Ongoing development of shared care networks 
Long term 
 Culture changes regarding shared decision making, roles and responsibility 
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differently when treating a child with febrile neutropenia is as important as any enforced practice 
change.  
There are two main areas for education and immediate discussion. The first of these relates to the 
challenges of understanding risk. I discussed in Chapter 6 how statistical literacy among patients, 
parents and professionals was generally poor and that this is consistent with others’ findings within 
the literature.(194) As a result of this, specific time and effort is needed to communicate the risks of 
early discharge in low risk febrile neutropenia to professionals and then to facilitate them in 
communicating risk to patients. This will involve providing informative materials using natural 
frequencies as well as direct encouragement to participate in risk discussions. Practically, this might 
mean something as simple as including a question within febrile neutropenia treatment booklets 
which, after the completion of a risk stratification tool, asks “Have you discussed this risk level with 
the patient and their family?” and then requires the clinician to indicate a “Yes/No” response. This 
practice may have two benefits. The first is that the discussion informs, involves and empowers the 
family experiencing this febrile neutropenic episode. The second is that this encourages healthcare 
professionals to acknowledge the differences between patients with high risk and low risk episodes, 
thus engaging them in consideration of the variations in risk in this condition. 
The second main area for changing practice is in the disclosure of test results to parents. In the 
qualitative study, parents stated that the failure of professionals to inform them of their child’s test 
results, particularly blood cultures, was a negative aspect of their care. Through informing clinicians 
of the desire for this simple change and encouraging centres to establish pathways for this to occur, 
it may be possible to change behaviours and enhance the patient experience. In the longer term, 
centres may choose to use pre-existing tools such as PatientView11 to enable patients to access their 
own results in the community, thus allowing families to review their tests online and saving staff 
time in communicating simple results.(218) 
Alongside educational and dissemination plans, another immediate implication of this thesis is to 
encourage the application of current guidelines regarding paediatric febrile neutropenia. Poor 
compliance to NICE CG151 is evidenced within recent surveys and audits and may result in longer 
admissions for patients and confusing communications to families.(40,42) The qualitative study 
within this thesis also suggests that centres are not fully compliant with this guideline and that 
parents feel the delays in discharge that result from this have a detrimental effect on their child and 
                                                             
11 PatientView is an online tool which enables patients to view their personal health record, including 
information about their diagnoses, as well as up-to-date lists of their medications and real-time test results. It 
was first developed for patients with renal disease but is now available for a wide variety of conditions. 
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family. Obtaining a more comparable service throughout the UK may improve current febrile 
neutropenia outcomes, simply by conveying the benefits of previous research to those patients who 
are not currently exposed to such practices. Specifically, the introduction of risk stratification 
throughout all centres and a more evidence based approach to empirical antibiotic choice may 
reduce the healthcare burden for families without reducing the safety or efficacy of treatment 
strategies. Furthermore, consistency in local guidelines and practice may allow for clearer instruction 
to families moving between centres, greater understanding between professionals when discussing 
patient care, and a basic groundwork from which to build further changes and to develop further 
research.  
Medium term implications  
The majority of medium term implications of this work that I will discuss relate to potential further 
research. These, not surprisingly, include methods for introducing reduced therapy treatment 
regimens to the UK, alongside other suggestions for research into decision aids for patients and 
research about blood cultures (as one of the key influences of decision making in low risk febrile 
neutropenia). The final medium term implication I will discuss is that of the ongoing development of 
shared care networks.  
The first medium term area for progression from this thesis involves the implementation of 
strategies which offer reduced durations of hospitalisation for children with low risk febrile 
neutropenia in the UK. This thesis provides evidence supporting these options as both safe and 
efficacious in the management of such children. Some of the barriers and facilitators for 
stakeholders have been explored and as such it may be possible to design a service which is most 
acceptable to patients, families and healthcare professionals. Having said this, there are significant 
challenges facing the implementation of such changes. These include the need for networked 
implementation, which although clearly present within paediatric oncology for the delivery of 
treatment for malignancies is less well developed for the implementation of supportive care 
initiatives.  Furthermore, the anxieties of both staff and families will need to be addressed, most 
likely with phased introduction of changes and clear practical guidance, both in relation to patient 
eligibility and management of a patient on an outpatient low risk febrile neutropenia pathway.  
The introduction of some of these changes in practice may best be served using a quality 
improvement (QI) initiative. QI methods allow a structured approach to implementation, along with 
frequent reassessment of the progress made and the issues that arise. This rapid, focused 
methodology allows responsiveness to patient and staff experience, as well as to local factors QI 
may be particularly applicable to the problem of the management of low risk febrile neutropenia 
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given that this research has found that it is a complex issue where early discharge is safe but has 
varying rates of treatment failures, and where experiences and preferences vary by centre, between 
families and professionals and between individuals. As such an implementation model which 
involves regular review and reconsideration of best quality care may enable changes to be made to 
best suit the specific situation of a service. If these efforts were co-ordinated and findings were 
shared throughout centres, as well as prospectively documented and assessed, the benefits to all 
centres in the UK may be maximised within a relatively short time frame.  
However, this approach brings some challenges. First, the precise details of a strategy would need to 
be defined at least initially so as to provide a framework on which to work. This thesis can suggest 
basic structures of the various service options, but cannot give evidence for features beyond this. A 
centre would therefore have to agree on the most appropriate way forward. Secondly, QI projects 
require a strict methodology and careful planning and documentation so as to obtain the most 
helpful information and to allow the sharing of findings with other organisations.(219,220) This is 
likely to require significant personnel, time and resources to achieve in a meaningful manner, along 
with a clear institutional commitment to publication of results if they were to benefit patients in 
other locations. For many centres, there may not be the experience with these new methods to 
enable to the institution of such a large national project. 
The alternative to QI methodologies may be to perform further formal research to provide more 
detailed and comprehensive data. This option was requested by two of the three healthcare 
professional focus groups in the qualitative study and may therefore be the approach which is more 
familiar to by the paediatric haematology and oncology team. Before discussing potential future 
research methods, it is important to consider whether the request for further research reflects two 
additional issues for healthcare professionals. The first is that ‘needs further research’ is often a 
taught response to the question of ‘What next?’ for healthcare professionals. Within teaching about 
research for professional groups, this is a standard response to the discussion of original research 
and hence our participants may have been primed to reply in this way. Secondly, the request for 
further research may represent a delaying tactic for professionals. The knowledge that the design, 
funding and set-up for such a trial may take years, if achieved at all, means that professionals may 
choose consciously or unconsciously to ask for further research so as to postpone the 
implementation of a change. This is particularly likely if the change is one which professionals are 
anxious or unsure about, and thus a delay in implementation performs a role in relieving that anxiety 
and allows further time to consider the option and potentially to act to prevent its implementation 
at a later point. Acknowledging this anxiety and negotiating ways to alleviate it is likely to be more 
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productive both practically and emotionally than simply taking at face value the request for further 
research.  
However, performing additional research may bring unique benefits, beyond that of further data in 
this field. The introduction of research trials into supportive care may help to alleviate concerns by 
providing professionals with a framework of practice with which they are familiar and which is held 
in high esteem within the paediatric oncology community, as discussed in Chapter 7. Additionally, 
the performance of a trial may result in better adherence to proposed changes than that seen with a 
change in guidelines, as trials may limit, or at least require explanation, for deviation from the given 
protocol. Finally, the culture of trial performance in paediatric oncology has resulted in a quietly 
competitive attitude to recruitment, in which centres are able to review their own success in 
recruiting to certain studies, with the benefit of better trial recruitment and increased research data 
which provides more powerful evidence for the interventions being investigated. Utilising this 
culture may allow future febrile neutropenia research in the UK to be outstanding within this field. 
Should the performance of further research be felt appropriate, one option, which may be 
particularly successful is a multi-arm, multi-stage (MAMS) trial. This methodology allows the 
investigation of multiple experimental arms at one time against a single control arm and then the 
adaptation and progression of research questions and interventions as the initial data is gathered 
and analysed.(221) This provides a more rapid answer to multiple questions than running multiple 
individual RCTS, thus the MAMS approach forms an efficient approach to research areas like 
paediatric febrile neutropenia where there are a variety of different treatment options which should 
be considered. However, the MAMS approach requires considerable planning in regards to which 
interventions to trial first, the appropriate stopping rules for each research arm, complex statistical 
analyses required to assess multiple interventions at once and often substantial financial costs, all of 
which must be considered before embarking on such a project. 
Fortunately, MAMS trials are not a new concept in the field of paediatric oncology and many centres 
will be familiar with running trials such as the SIOPEN High Risk Neuroblastoma Study 
(Clinicaltrials.gov Identifier NCT01704716) and the BEACON-Neuroblastoma Trial (Clinicaltrials.gov 
Identifier NCT02308527). However, large scale supportive care trials are less well established within 
the UK and as such any further research may experience significant challenges in both set-up and 
recruitment. The MAMS approach allows researchers to introduce interventions that are more likely 
to be acceptable as initial stages. In paediatric febrile neutropenia, these might be the interventions 
advised by NICE guidelines or investigations of biomarkers for infection, whilst also allowing centres 
to set up the infrastructure for febrile neutropenia data collection and creating a positive culture 
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around supportive care research. Over time, as professionals become more comfortable with this 
then more complex randomisations could be introduced and it may be at this point that the 
challenging four way randomisation of both location of treatment and route of antibiotic 
administration could be achieved.  
Key clinical outcome measures in febrile neutropenia have been defined for some time and should 
be used.(222) Other issues which might also be addressed within the programme of research are the 
assessment of risk stratification tools, the timings of assessments (including follow-up), economic 
analyses of the interventions implemented and ongoing work into the experiences of the key 
stakeholders involved in paediatric haematology and oncology services.  
The number of participants required to provide conclusive data about each individual treatment 
option is likely to be large, when compared to the small paediatric haematology and oncology 
population.  Furthermore, a large clinical study of such a design would require significant funding, 
particularly in the initial period of set-up and liaison with study centres. However, this seems 
consistent with the National Institute for Health Research aims of providing well-designed research 
of tangible benefit to patients and families, with the potential to improve healthcare systems and be 
good stewards of healthcare costs.(223) An overarching study into the diagnosis, management and 
prognostic features of febrile neutropenia in children, whilst simultaneously increasing shared 
decision making, could arguably be seen to meet these aims and as such be eligible for many funding 
streams, along with the support of the Clinical Research Network Portfolio. 
Along with these larger studies of management of low risk febrile neutropenia, there are two other 
important areas for research in the medium term. The first group of research questions relates to 
the issue of blood cultures. As discussed in Chapter 6, parents within the focus group study spoke 
about blood cultures as being a key feature that they had identified in professionals’ decision making 
about early discharge and that delays in obtaining blood culture results caused significant 
frustrations for families. There are a number of possible solutions to be considered here. It may be 
important for certain centres to consider their current blood culture processes as these may be 
improved through faster arrival and processing at the laboratory to initiate  sample testing, or 
through more timely reporting of blood culture results. Elsewhere, service providers may wish to 
consider the economic impacts of earlier discharge throughout the hospital compared to employing 
additional microbiology staff overnight or at weekends. From a research point of view, one key 
question is whether the current time limit of 48 hours for a blood culture to be declared negative 
remains accurate. This test cut-off was defined at a time when blood culture techniques were less 
advanced than contemporary processes and as technology has developed, we may find that a 
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shorter time frame provides sufficient confidence in a negative blood culture. Given that blood 
culture results are such an important feature of febrile neutropenia decision making, shortening the 
time needed to obtain results may also allow for shorter admissions with febrile neutropenia.  
The second area for additional research lies in methods to aid decision making. Decision aids can 
facilitate shared decision making through providing a framework for discussions, including informing 
patients of accurate representations of risk, identifying treatment options and assisting in making a 
choice. They are intended to support in the process of shared decision making rather than replacing 
consultations between patients and professionals.(224) There has been broad and wide-ranging 
exploration of the use of decision aids in medicine, particularly for decisions about health screening 
and management of chronic conditions such as hypertension and hypercholesterolaemia.(119,205–
210) A recent Cochrane review found high quality evidence that decision aids can increase 
knowledge and reduce decisional conflict.(225) Furthermore, they can encourage increased shared 
decision making and understanding of risk. It should be noted however, that the use of decision aids 
does not necessarily result in patients making the desired choice of healthcare professionals.(206–
208) This has been discussed most extensively in relation to screening programmes, where decision 
aids can decrease the number of patients choosing to participate in screening, after being informed 
of the relative risks and benefits. For low risk febrile neutropenia, the results of introducing decision 
aids may be unclear. Some patients may choose to remain as inpatients receiving treatment similar 
to that currently provided, others may choose outpatient care. Ultimately however, it may be 
argued that the aim is not to increase the uptake of a particular option, but instead to facilitate 
discussions about difficult choices in which allowing the patient to select the choice most 
appropriate for their individual situation and their personal values is the key aim. 
As discussed in Chapter 2, decision making in paediatric populations can be even more complicated 
due to the triadic nature of the consultations. Decision aids and other support for shared decision 
making in children may need to be adapted to account for this and for the different developmental 
ages of the children and young people involved. According to a recent Cochrane review, there has 
been no research into decision aids for children with cancer.(228) Furthermore, in contemporary 
society “real-world clinical decision making is also mediated by technology and teamwork”(76). 
Therefore the decision aids may also take an electronic form, particularly given that children and 
young people are frequently very competent in using these forms of communication. Finally, 
discussions about febrile neutropenia decisions would need to be ongoing during episodes, as 
families may decide that after 24 hours a different treatment strategy is more appropriate, and 
between episodes, as they are influenced by prior experiences and by increasing knowledge about 
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their child’s cancer and febrile neutropenia itself. Decision aids will need to take this into account 
and be usable throughout a febrile neutropenia episode and should help to inform future decisions 
about febrile neutropenia care for that child or young person. 
Informed by all these issues, it may be that future research aims to develop a decision aid in the 
form of an app for children with low risk febrile neutropenia in which the healthcare professional, 
patient and family work together through the process of risk stratification. The risks of different 
treatment options would then be provided from the systematic review in Chapter 3 of this thesis, 
using natural frequencies for ease of understanding and tailored to different age groups. The app 
could then help guide discussions which identify values, priorities and parental skills, before helping 
the team come to a decision. Once a decision has been made, the team can then design a treatment 
plan (including follow up and stopping rules) and define their roles and responsibilities. Once at 
home, families could use the app to record symptoms, provide reminders for antibiotic 
administration and communicate with healthcare professionals in the hospital. Finally, such a 
programme could collect data on the process of decision making and the treatment of febrile 
neutropenia along with the outcomes achieved.  
This kind of decision aid and associated technological support may form part of future trials for 
febrile neutropenia and be assessed alongside the treatment strategies, as discussed earlier in this 
section. Given that decision aids can influence the choices made by patients and their families, it is 
important that they are well-designed to provide accurate information, without bias, using 
appropriate evidence to inform the individual patient and support their personal decisions.(224) The 
International Patient Decision Aids Standards (IPDAS) Collaboration have created a checklist of 
criteria assess the quality of patient decision aids.(224) These criteria may also be used as points to 
assist researchers in the development of high-quality future decision aids. Ultimately, the aim should 
be tools that inform both patients and clinicians, are easily accessible and that will be suitable for 
use within the time-pressured everyday practice of the NHS.(230) 
In the final suggested change for the medium term, centres may wish to dedicate time and effort to 
the ongoing development of shared care networks, so as to resolve some of the issues with shared 
care that were discussed in the qualitative study, including that POSCU staff did not know the 
patients, had poor understanding of oncological issues, provided less effective treatment and did not 
have specialty specific skills such as Port-a-cath access (see Chapter 6). Centres with minimal shared 
care input may find that the knowledge and skills of shared care professionals would benefit from 
increased investment and could then be kept at safe levels through the attendance of more children 
at the POSCUs instead of travelling directly to the PTC. Families would benefit from reduced travel 
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time, easier visiting from friends and family members, and developing relationships with these staff, 
therefore increasing mutual trust and confidence. As was seen in the qualitative study, those 
families who attend shared care centres with febrile neutropenia are more likely to take on an 
increased role in their child’s care and to feel in control of their child’s condition (see Chapter 7). 
Thus there are many potential benefits from increased shared care. However, I acknowledge the 
many concerns from centres where POSCU management of febrile neutropenia is unusual. This kind 
of change is likely to require increased time, resources and support in the early stages.  Any efforts 
to increase shared care involvement should recognise that the initial period of change may be the 
most challenging time for families and for professionals at both POSCUs and the PTC.  
Long term implications 
Long term, the findings of this thesis suggest that cultural changes are required to improve the care 
of children and young people with low risk febrile neutropenia. A move away from the traditional 
paternalism and determinism of medicine towards increased shared decision making would allow 
closer adherence to the values of contemporary healthcare. In order to achieve this, there is a need 
to consider how to establish a culture in which shared decision making is valued, professionals have 
the skills to support it and these are put into practice in everyday healthcare.(230) This change 
requires acknowledgement of the uncertainty involved in all areas of medicine, open communication 
of the thoughts and values of patients and healthcare professionals, the redistribution of 
responsibility and the provision of various options for care, which can be adapted to suit the 
individual. To achieve such an aim will require diverse and multi-level interventions within the 
complexity of current services and as such, this is likely to take a considerable period to instigate and 
then achieve.(231,232) However, I feel this should be the long term action that springs from the 
research presented in this thesis. 
A key feature in effecting culture change is that of engaging leaders and key influential figures within 
organisations at both local and national levels, so as to encourage the development of shared 
decision making practice and to champion the role of patients in making choices about healthcare on 
individual and collective levels.(230) These leaders should come from multi-disciplinary backgrounds 
and should also include patients and families in the discussions about service development in order 
to promote the values of service users in the organisation and to facilitate engagement.(230,231) 
These leaders should aim to inspire the community to understand why change is necessary and how 
it can be achieved. Through engaging many different members of staff in this endeavour to change 
the behaviours and underlying values of the community, leaders play a key role in developing 
cultural change. Furthermore, by encouraging colleagues to acknowledge the unspoken norms and 
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values that promote ongoing paternalism and determinism, including a failure to recognise parental 
roles or the belief that all non-attendance with febrile neutropenia is bad, leaders can stimulate 
their colleagues to question these assumptions and consider a change in practice.(233)  
There are a number of practical actions which could also facilitate cultural change in the paediatric 
haematology and oncology community. Centres will need to consider the specific challenges related 
to their service and how these might be addressed, just as the study participants did in their 
discussions of future service design. This may require changes in physical space, staffing and 
resources available to professionals. Equipping professionals with the communication skills to 
facilitate shared decision making will require provision of appropriate training resources and a 
prominence of this topic within undergraduate and postgraduate professional training, along with 
recognition of the importance and value of these skills within the professions.(86,206)Many of the 
actions set out in the previous two sections discussing immediate and medium term implications of 
this research, if achieved, will help the paediatric haematology and oncology community to move 
forward in these practical aspects to support cultural change and will mean that positive steps have 
already been taken to increase shared decision making with families.  
Summary 
Febrile neutropenia is a common complication of childhood cancer and its treatment. Over the last 
70 years there has been considerable progress in its management such that the majority of children 
will have no significant complications of its occurrence, but there are still improvements to be made. 
This thesis has examined whether the current treatment for febrile neutropenia could be reduced in 
those children for whom the risk of complications is low, with anticipated benefits for children, their 
families and the healthcare service. I used a sequential mixed methods approach to undertake three 
consecutive phases utilising different research methodologies to further investigate important issues 
surrounding the reduction of therapy for children and young people with low risk febrile 
neutropenia.   I performed two in-depth systematic reviews of the literature which provide detailed 
data on the safety and treatment failure rates when treatment is reduced at different time points, as 
well as an interpretive account of the experiences of early discharge, which I have related to 
paediatric febrile neutropenia. Drawing on both of these pieces of research I performed a multi-
centre study determining the experiences and perceptions of key stakeholders in febrile neutropenia 
care in the UK.  
These three interwoven phases of the thesis have demonstrated the challenges involved in 
developing these services. The significance of shared decision making in improving the experience of 
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all involved through sharing risks, developing mutual trust and negotiating control to achieve 
individualised treatment cannot be underestimated. This thesis has outlined aspirations for the 
future care of these children and young people and charted various actions to achieve these goals. 
Despite the complexity of options and opinions in this area, I believe that this thesis presents the 
paediatric haematology and oncology community with an imperative to act to deliver services that 
better suit the needs and desires of the population we serve.  
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Appendix A 
This Appendix includes all appendices related to chapter 3 of the thesis. 
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Appendix 3.1: Database search strategies 
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) <1946 to Present> 
was searched on 02/04/2014, using the OVID SP interface.  
1408 records were retrieved 
Key: 
/=index term (MeSH heading) 
*=truncation 
?= embedded truncation 
ti=title field 
ab=abstract 
tw= textword 
.ti,ab=terms were searched for in either title or abstract 
adj = terms adjacent to each other (same order) 
adj1 = terms within one word of each other (any order) 
adj2 = terms within two words of each other (any order) 
 
1     Agranulocytosis/ or neutropenia/ or leukopenia/ (26903) 
2     exp Fever/ or exp "Fever of Unknown Origin"/ or exp Body Temperature/ (103535) 
3     (1 and 2) or febrile neutropenia/ (2868) 
4     (febrile adj5 (neutropen* or granulocytop* or agranulocyto* or leukocytop??ni*)).ti,ab. (5241) 
5     ((fever or temperature or temp) adj5 (neutropen* or granulocytop* or agranulocyto* or 
leukocytop??ni*)).ti,ab. (2727) 
6     3 or 4 or 5 (8261) 
7     (antibiotic* or antimicrob* or anti-biotic* or anti-microb*).tw. (293708) 
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8     exp anti-bacterial agents/ (522999) 
9     exp beta-lactamases/ or exp beta-lactams/ (114490) 
10     exp penicillins/ or penicillin*.tw. (89738) 
11     tazobactam*.tw. (2549) 
12     ureidopenicillin*.tw. (203) 
13     exp ticarcillin/ or ticarcillin*.tw. (2002) 
14     exp piperacillin/ or piperacillin*.tw. (5122) 
15     exp quinolones/ or quinolone*.tw. (38463) 
16     exp ciprofloxacin/ or ciprofloxacin*.tw. (20215) 
17     exp ceftazidime/ or ceftazidime*.tw. (7133) 
18     meropenem*.tw. (3297) 
19     exp imipenem/ or imipenem*.tw. (8147) 
20     exp aztreonam/ or astreonam*.tw. (1269) 
21     exp aminoglycosides/ (126292) 
22     aminoglycoside*.tw. (14842) 
23     exp amikacin/ or amikacin*.tw. (7485) 
24     exp gentamicins/ or gentam?cin*.tw. (27182) 
25     exp tobramycin/ or tobram?cin*.tw. (6382) 
26     exp kanamycin/ or kanam?cin*.tw. (17391) 
27     exp netilmicin/ or netilm?cin*.tw. (1885) 
28     (beta-lactam* or beta?lactam*).tw. (30330) 
29     or/7-28 (762602) 
30     exp "length of stay"/ or exp patient admission/ or exp patient discharge/ or exp patient 
readmission/ or exp inpatients/ or exp outpatients/ (109775) 
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31     (discharge* or (length* adj2 stay*) or (duration* adj2 stay*) or admission* or readmission* or 
inpatient* or outpatient*).tw. (428579) 
32     30 or 31 (475681) 
33     29 or 32 (1211026) 
34     adolescent/ or exp child/ or exp infant/ or exp young adult/ (2972677) 
35     (newborn* or new-born* or baby* or babies or neonat* or infan* or kid or kids or toddler* or 
adoles* or teen* or boy* or girl* or junevil* or youth* or puber* or prepuber* or pubescen*or 
prepubescen* or pediatric* or paediatric* or young person* or young people or young adult* or 
child* or schoolchild* or schoolage* or school* or preschool*).tw. (1838751) 
36     34 or 35 (3514897) 
37     6 and 33 and 36 (1408) 
 
Cochrane Database of Systematic Reviews Issue 4 of 12, April 2014 was searched on 03/04/2014, 
using the Cochrane Library interface. 
367 records were retrieved from The Cochrane Library, of which 5 were from CDSR. 
Key: 
*=truncation 
ti=title field 
ab=abstract 
.ti,ab.=terms were searched for in either title or abstract 
near/1 = terms within one word of each other (any order) 
near/2 = terms within two words of each other (any order) 
next = terms are next to each other 
 
ID Search Hits 
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#1 MeSH descriptor: [Agranulocytosis] this term only 309 
#2 MeSH descriptor: [Neutropenia] this term only 1449 
#3 MeSH descriptor: [Leukopenia] this term only 514 
#4 {or #1-#3}  2101 
#5 MeSH descriptor: [Fever] this term only 1646 
#6 MeSH descriptor: [Fever of Unknown Origin] this term only 72 
#7 MeSH descriptor: [Body Temperature] explode all trees 3323 
#8 {or #5-#7}  4863 
#9 #4 and #8  522 
#10 MeSH descriptor: [Febrile Neutropenia] this term only 0 
#11 #9 or #10  522 
#12 ("febrile" near/5 (neutropen* or granulocytop* or agranulocyto* or leukocytop*ni*)):ti,ab 
 1176 
#13 (("fever" or "temperature" or "temp") near/5 (neutropen* or granulocytop* or 
agranulocyto* or leukocytop*ni*)):ti,ab  460 
#14 {or #11-#13}  1574 
#15 (antibiotic* or antimicrob* or anti-biotic* or anti-microb*):ti,ab  15148 
#16 MeSH descriptor: [Anti-Bacterial Agents] explode all trees 9158 
#17 MeSH descriptor: [beta-Lactamases] explode all trees 131 
#18 MeSH descriptor: [beta-Lactams] explode all trees 7776 
#19 MeSH descriptor: [Penicillins] explode all trees 4621 
#20 penicillin*:ti,ab  1799 
#21 tazobactam*:ti,ab  229 
#22 ureidopenicillin*:ti,ab  10 
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#23 MeSH descriptor: [Ticarcillin] explode all trees 147 
#24 ticarcillin*:ti,ab  215 
#25 MeSH descriptor: [Piperacillin] explode all trees 336 
#26 piperacillin*:ti,ab  520 
#27 MeSH descriptor: [Quinolones] explode all trees 3106 
#28 quinolone*:ti,ab  402 
#29 MeSH descriptor: [Ciprofloxacin] explode all trees 960 
#30 ciprofloxacin*:ti,ab  1488 
#31 MeSH descriptor: [Ceftazidime] explode all trees 404 
#32 ceftazidime*:ti,ab  692 
#33 meropenem*:ti,ab  197 
#34 MeSH descriptor: [Imipenem] explode all trees 262 
#35 imipenem*:ti,ab  410 
#36 MeSH descriptor: [Aztreonam] explode all trees 142 
#37 aztreonam*:ti,ab  221 
#38 MeSH descriptor: [Aminoglycosides] explode all trees 6668 
#39 aminoglycoside*:ti,ab  567 
#40 MeSH descriptor: [Amikacin] explode all trees 312 
#41 amikacin*:ti,ab  548 
#42 MeSH descriptor: [Gentamicins] explode all trees 1056 
#43 gentam*cin*:ti,ab  1374 
#44 MeSH descriptor: [Tobramycin] explode all trees 484 
#45 tobram*cin*:ti,ab  875 
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#46 MeSH descriptor: [Kanamycin] explode all trees 849 
#47 kanam*cin*:ti,ab  75 
#48 MeSH descriptor: [Netilmicin] explode all trees 149 
#49 netilm*cin*:ti,ab  243 
#50 beta-lactam* or beta*lactam*:ti,ab  1021 
#51 {or #15-#50}  31219 
#52 MeSH descriptor: [Length of Stay] explode all trees 6581 
#53 MeSH descriptor: [Patient Admission] explode all trees 564 
#54 MeSH descriptor: [Patient Discharge] explode all trees 1064 
#55 MeSH descriptor: [Patient Readmission] explode all trees 787 
#56 MeSH descriptor: [Inpatients] explode all trees 657 
#57 MeSH descriptor: [Outpatients] explode all trees 831 
#58 (discharge* or (length* near/2 stay*) or (duration* near/2 stay*) or admission* or 
readmission* or inpatient* or outpatient*):ti,ab  39686 
#59 {or #52-#58}  44114 
#60 #51 or #59  72787 
#61 MeSH descriptor: [Adolescent] explode all trees 76133 
#62 MeSH descriptor: [Child] explode all trees 78 
#63 MeSH descriptor: [Infant] explode all trees 13097 
#64 MeSH descriptor: [Young Adult] explode all trees 113 
#65 (newborn* or new-born* or baby* or "babies" or neonat* or infan* or "kid" or "kids" or 
toddler* or adoles* or teen* or boy* or girl* or junevil* or youth* or puber* or prepuber* or 
pubescen*or prepubescen* or pediatric* or paediatric* or ("young" next person*) or "young 
people" or ("young" next adult*) or child* or schoolchild* or schoolage* or school* or 
preschool*):ti,ab  91703 
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#66 {or #61-#65}  151768 
#67 #14 and #60 and #66  367 
 
CENTRAL (Issue 3 of 12 March 2014), Database of Abstracts of Reviews of Effects, DARE (Issue 1 of 4 
January 2014) and Health Technology Database, HTA (Issue 1 of 4, January 2014) were searched on 
03/04/2014, using the Cochrane Library interface. 
 
520 records were retrieved from The Cochrane Library, of which 415 were from CENTRAL, 20 were 
from DARE, 1 was from HTA and the remainder were from CDSR (and therefore discarded). 
Key: 
/=index term (MeSH heading) 
*=truncation 
?= embedded truncation 
ti=title field 
ab=abstract 
tw= textword 
.ti,ab=terms were searched for in either title or abstract 
 
#1 MeSH descriptor: [Agranulocytosis] this term only 309 
#2 MeSH descriptor: [Neutropenia] this term only 1449 
#3 MeSH descriptor: [Leukopenia] this term only 514 
#4 {or #1-#3}  2101 
#5 MeSH descriptor: [Fever] this term only 1646 
#6 MeSH descriptor: [Fever of Unknown Origin] this term only 72 
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#7 MeSH descriptor: [Body Temperature] explode all trees 3323 
#8 {or #5-#7}  4863 
#9 #4 and #8  522 
#10 MeSH descriptor: [Febrile Neutropenia] this term only 0 
#11 #9 or #10  522 
#12 ("febrile" near/5 (neutropen* or granulocytop* or agranulocyto* or leukocytop*ni*)) 
 1566 
#13 (("fever" or "temperature" or "temp") near/5 (neutropen* or granulocytop* or 
agranulocyto* or leukocytop*ni*))  643 
#14 {or #11-#13}  2000 
#15 (antibiotic* or antimicrob* or anti-biotic* or anti-microb*)  22059 
#16 MeSH descriptor: [Anti-Bacterial Agents] explode all trees 9158 
#17 MeSH descriptor: [beta-Lactamases] explode all trees 131 
#18 MeSH descriptor: [beta-Lactams] explode all trees 7776 
#19 MeSH descriptor: [Penicillins] explode all trees 4621 
#20 penicillin*  3272 
#21 tazobactam*  297 
#22 ureidopenicillin*  13 
#23 MeSH descriptor: [Ticarcillin] explode all trees 147 
#24 ticarcillin*  279 
#25 MeSH descriptor: [Piperacillin] explode all trees 336 
#26 piperacillin*  660 
#27 MeSH descriptor: [Quinolones] explode all trees 3106 
#28 quinolone*  1191 
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#29 MeSH descriptor: [Ciprofloxacin] explode all trees 960 
#30 ciprofloxacin*  1866 
#31 MeSH descriptor: [Ceftazidime] explode all trees 404 
#32 ceftazidime*  849 
#33 meropenem*  263 
#34 MeSH descriptor: [Imipenem] explode all trees 262 
#35 imipenem*  527 
#36 MeSH descriptor: [Aztreonam] explode all trees 142 
#37 aztreonam*  291 
#38 MeSH descriptor: [Aminoglycosides] explode all trees 6668 
#39 aminoglycoside*  836 
#40 MeSH descriptor: [Amikacin] explode all trees 312 
#41 amikacin*  680 
#42 MeSH descriptor: [Gentamicins] explode all trees 1056 
#43 gentam*cin*  1844 
#44 MeSH descriptor: [Tobramycin] explode all trees 484 
#45 tobram*cin*  1059 
#46 MeSH descriptor: [Kanamycin] explode all trees 849 
#47 kanam*cin*  194 
#48 MeSH descriptor: [Netilmicin] explode all trees 149 
#49 netilm*cin*  302 
#50 beta-lactam* or beta*lactam*  1022 
#51 {or #15-#50}  35898 
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#52 MeSH descriptor: [Length of Stay] explode all trees 6581 
#53 MeSH descriptor: [Patient Admission] explode all trees 564 
#54 MeSH descriptor: [Patient Discharge] explode all trees 1064 
#55 MeSH descriptor: [Patient Readmission] explode all trees 787 
#56 MeSH descriptor: [Inpatients] explode all trees 657 
#57 MeSH descriptor: [Outpatients] explode all trees 831 
#58 (discharge* or (length* near/2 stay*) or (duration* near/2 stay*) or admission* or 
readmission* or inpatient* or outpatient*)  54270 
#59 {or #52-#58}  54270 
#60 #51 or #59  85611 
#61 MeSH descriptor: [Adolescent] explode all trees 76133 
#62 MeSH descriptor: [Child] explode all trees 78 
#63 MeSH descriptor: [Infant] explode all trees 13097 
#64 MeSH descriptor: [Young Adult] explode all trees 113 
#65 (newborn* or new-born* or baby* or "babies" or neonat* or infan* or "kid" or "kids" or 
toddler* or adoles* or teen* or boy* or girl* or junevil* or youth* or puber* or prepuber* or 
pubescen*or prepubescen* or pediatric* or paediatric* or ("young" next person*) or "young 
people" or ("young" next adult*) or child* or schoolchild* or schoolage* or school* or preschool*) 
 228756 
#66 {or #61-#65}  228756 
#67 #14 and #60 and #66  520 
 
EMBASE <1974 to 2014 April 02> was searched on 03/04/2014, using the OVID SP interface.  
1327 records were retrieved 
Key: 
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Key: 
/ = indexing term (EMTREE heading) 
* = focussed EMTREE heading 
exp = exploded EMTREE heading 
* = truncation 
? = embedded truncation 
.ti,ab. = terms in either title or abstract fields 
.tw.= textword 
adj = terms adjacent to each other (same order) 
adj1 = terms within one word of each other (any order) 
adj2 = terms within two words of each other (any order) 
 
1     *Agranulocytosis/ or *neutropenia/ or *leukopenia/ (19402) 
2     *Fever/ or *pyrexia idiopathica/ or exp *Body Temperature/ (36896) 
3     (1 and 2) or *febrile neutropenia/ (3340) 
4     (febrile adj5 (neutropen* or granulocytop* or agranulocyto* or leukocytop??ni*)).ti,ab. (8453) 
5     ((fever or temperature or temp) adj5 (neutropen* or granulocytop* or agranulocyto* or 
leukocytop??ni*)).ti,ab. (3832) 
6     3 or 4 or 5 (12398) 
7     (antibiotic* or antimicrob* or anti-biotic* or anti-microb*).tw. (373110) 
8     exp *antiinfective agent/ (1071546) 
9     *beta lactamase/ or *beta lactam/ (9024) 
10     exp *penicillin derivative/ or penicillin*.tw. (126214) 
11     tazobactam*.tw. (4083) 
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12     ureidopenicillin*.tw. (242) 
13     *ticarcillin/ or ticarcillin*.tw. (4356) 
14     *piperacillin/ or piperacillin*.tw. (9280) 
15     *quinolone/ or quinolone*.tw. (13985) 
16     *ciprofloxacin/ or ciprofloxacin*.tw. (27190) 
17     *ceftazidime/ or ceftazidime*.tw. (11063) 
18     meropenem*.tw. (5362) 
19     *imipenem/ or imipenem*.tw. (11955) 
20     *aztreonam/ or astreonam*.tw. (2260) 
21     *aminoglycoside/ (3461) 
22     aminoglycoside*.tw. (17847) 
23     *amikacin/ or amikacin*.tw. (14248) 
24     *gentamicin/ or gentam?cin*.tw. (45689) 
25     *tobramycin/ or tobram?cin*.tw. (13380) 
26     *kanamycin/ or kanam?cin*.tw. (16149) 
27     *netilmicin/ or netilm?cin*.tw. (3859) 
28     (beta-lactam* or beta?lactam*).tw. (37408) 
29     or/7-28 (1288501) 
30     *"length of stay"/ or *hospital admission/ or *hospital discharge/ or *hospital readmission/ or 
exp *hospital patient/ or *outpatient/ (44885) 
31     (discharge* or (length* adj2 stay*) or (duration* adj2 stay*) or admission* or readmission* or 
inpatient* or outpatient*).tw. (595967) 
32     30 or 31 (609598) 
33     29 or 32 (1857828) 
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34     adolescent/ or exp child/ or exp infant/ or young adult/ (2668461) 
35     (newborn* or new-born* or baby* or babies or neonat* or infan* or kid or kids or toddler* or 
adoles* or teen* or boy* or girl* or junevil* or youth* or puber* or prepuber* or pubescen*or 
prepubescen* or pediatric* or paediatric* or young person* or young people or young adult* or 
child* or schoolchild* or schoolage* or school* or preschool*).tw. (2226295) 
36     34 or 35 (3421519) 
37     6 and 33 and 36 (1327) 
 
LILACS (Literatura Latino-Americana e do Caribe em Ciências da Saúde) - http://lilacs.bvsalud.org/en/ 
was searched on 11/04/2014 
 
Key: 
tw=. Text word 
$= truncation 
mh= index term 
 
To make the most of the interface, a number of different strategies were run, and duplicates 
removed from the final results. Overall, 450 different records were retrieved. 
 
Search 1: 
(tw:((febrile AND (neutropen$ or granulocytop$ or agranulocyto$ or leukocytop$)))) OR (tw:((fever 
AND (neutropen$ or granulocytop$ or agranulocyto$ or leukocytop$)))) OR (tw:((temperature AND 
(neutropen$ or granulocytop$ or agranulocyto$ or leukocytop$)))) OR (tw:((temp AND (neutropen$ 
or granulocytop$ or agranulocyto$ or leukocytop$)))) 
Retrieved 225 records 
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Search 2: 
((mh:(Agranulocytosis)) OR (mh:(neutropenia)) OR (mh:( leukopenia)) AND (mh:(Fever)) OR (mh:( 
"Fever of Unknown Origin")) OR (mh:( Body Temperature))) 
Retrieved 94 records 
 
Search 3: 
 ((C15.378.553.546) OR (C15.378.553.546.184) OR (C15.378.553.546.184.564) OR (Leucopenia) OR 
(Agranulocitosis) OR (Agranulocitose)) AND ((C23.888.119.344) OR (C23.888.119.344.345) OR 
(Fiebre) OR (Febre) OR (Fiebre de Origen Desconocido) OR (Febre de Causa Desconhecida)) 
Retrieved 246 records 
 
Search 4: 
 (C15.378.553.546.184.564.750) OR (Neutropenia Febril) 
Retrieved 135 records 
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Appendix 3.2: Data extraction form 
General Information 
Person performing data extraction: Choose an item. 
Date of data extraction: Click here to enter a date. 
Study title: Click here to enter text. 
Study Author, Year: Click here to enter text. 
Language: Choose an item. 
Country of origin: Click here to enter text. 
Source of funding: Choose an item. 
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Study Information 
Aim of study: Click here to enter text. 
Study design: Choose an item. 
Appropriate risk of bias tool completed: ☐ 
Inclusion criteria: Click here to enter text. 
Exclusion criteria: Click here to enter text. 
Definition of fever used: Click here to enter text. 
Definition of neutropenia used: Click here to enter text. 
Risk stratification tool/definition of low-risk: Click here to enter text. 
Timing of risk stratification: Click here to enter text. 
Details of randomisation/selection of cohorts: Click here to enter text. 
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Participants 
Number of participants: Click here to enter text. 
Number in each group: Click here to enter text. 
Number withdrawn: Click here to enter text. 
Number included in analysis: Click here to enter text. 
Age – provide details for each group: Click here to enter text. 
Gender – provide details for each group: Click here to enter text. 
Ethnicity (if given): Click here to enter text. 
Socio-economic status (if given): Click here to enter text. 
Disease(s): Click here to enter text. 
Are recruitment/refusal to consent numbers given? If so, please record details including, if given, number, distribution, reasons for declining: 
Click here to enter text. 
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Intervention 
Describe the intervention(s) (eg. how long inpatient, if outpatient how often reviewed and where, antibiotics used, route, time of change): 
Click here to enter text. 
 
 
 
 
 
 
Give details of control/routine care: 
Click here to enter text. 
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Outcomes: 
Definition of treatment failure used: Click here to enter text. 
 
Primary outcome(s): 
Click here to enter text. 
 
 
 
 
Secondary outcome(s): 
Click here to enter text. 
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Results: 
All data should be in unit numbers, not percentages or proportions 
Dichotomous outcomes 
Outcome Group 1 Group 2 Group 3 Notes 
Observed (n) Total (N) Observed (n) Total (N) Observed (n) Total (N) 
Click here to 
enter text. 
Click here to 
enter text. 
Click here to 
enter text. 
Click here to 
enter text. 
Click here to 
enter text. 
Click here to 
enter text. 
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Click here to 
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Click here to 
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Click here to 
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Click here to 
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enter text. 
Click here to 
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Click here to 
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Click here to 
enter text. 
Click here to 
enter text. 
Click here to enter text. 
Click here to 
enter text. 
Click here to 
enter text. 
Click here to 
enter text. 
Click here to 
enter text. 
Click here to 
enter text. 
Click here to 
enter text. 
Click here to 
enter text. 
Click here to enter text. 
 
  
 278 
 
Continuous outcomes 
Outcome Timing of 
outcome 
assessment 
Group 1 Group 2 Group 3 Notes 
Mean/ 
mean 
difference 
SD N Mean/ 
mean 
difference 
SD N Mean/ 
mean 
difference 
SD N  
Click here to 
enter text. 
Click here 
to enter 
text. 
Click here 
to enter 
text. 
Click 
here 
to 
enter 
text. 
Click 
here 
to 
enter 
text. 
Click here 
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here 
to 
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Click 
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to 
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Click here 
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to 
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Click here to enter text. 
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Click here to 
enter text. 
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Appendix 3.3: Reasons for study exclusion 
Study Reason for exclusion 
Acuna, 1987(234) Not intervention of interest 
Ahmed, 2007(235) Mixed risk groups 
Ammann, 2004(236) Correspondence 
Ammann, 2005(237) Review article 
Anak, 1989(238) Not intervention of interest 
Anoop, 2007(239) Correspondence 
Aquino, 1997a(240) Retrospective 
Aquino, 1997b(241) Retrospective 
Arceci, 2000(242) Editorial 
Barnes, 1988(243) Adult study 
Barsanti, 1988(244) Review article 
Bellesso, 2013(245) Review article 
Buchanan, 1992(246) Correspondence 
Chamberlain, 2005(247) Audit 
Cohen, 1995(248) Not intervention of interest 
Cornely, 1997(249) Mixed population 
De Pauw, 1997(250) Adult study 
Dominic, 2007(251) Adult study 
Escalante, 2004(252) Adult study 
Fink, 1989(253) Retrospective 
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Fleischhack, 1997(254) Not intervention of interest 
Freifeld, 1999(255) Mixed population 
Gala Peralta, 2006(256) Article describing interview 
Gaya, 1979(257) Adult study 
Girmenia, 2007(258) Adult study 
Hodgson-Viden, 2005(259) Retrospective 
Holdsworth, 1995(260) Not low risk patients 
Innes, 2003(261) Adult study 
Jaksic, 2006(262) Adult study 
Jin, 2010(263) Adult study 
Kaplan, 1991(264) Retrospective 
Karthaus, 1998(265) Mixed population 
Karthaus, 2000(266) Adult study 
Katz, 1993(267) Review article 
Kern, 1999(268) Mixed population 
Kern, 2013(269) Adult study 
Klastersky, 1977(270) Adult study 
Lee, 2010(271) Retrospective 
Lehrnbecher, 2002(272) Retrospective 
Lopez Hernandez, 2010(273) Mixed population 
Martino, 1992(274) Mixed population 
Maschmeyer, 1994(275) Adult study 
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Mullen, 1990 (276) Retrospective 
Mullen, 1998 (277) Conference abstract of full article already included 
Mullen, 1999 (48) Economic outcomes of study already included 
Mullen, 2001 (16) Review article 
Nenova, 2003 (278) Adult study 
Nijhuis, 2005 (30) Mixed population 
O'Connell, 1998 (279) Retrospective 
Oppenheim, 2000 (280) Review article 
Paganini, 2007 (281) Review article 
Patrick, 1999 (282) Review article 
Pennington, 1977 (283) Adult study 
Petrilli, 1989 (284) Not intervention of interest 
Pizzo, 1979 (285) <80% paediatric patients 
Pizzo, 1982 (286) <80% paediatric patients 
Preis, 1997 (287) Correspondence 
Rodriguez, 1973 (288) Adult study 
Rubenstein, 1993 (289) Adult study 
Rubin, 1989 (290) Correspondence 
Sahu, 1997 (291) Mixed risk groups 
Saini, 2007(292) Review article 
Santolaya, 1997 (293) Not studying outcome of interest 
Santolaya, 2001(294) Review article 
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Santos-Machado, 1999 (295) Retrospective 
Shemesh, 1998 (47) Retrospective 
Talcott, 1994 (296) Adult study 
Talcott, 2011 (297) Adult study 
Tomiak, 1994 (298) Adult study 
Tordecilla, 1994 (299) Not intervention of interest 
Villanueva, 2013 (300) Retrospective 
Wacker, 1997 (301) Not intervention of interest 
Willoughby, 1994 (302) Review article 
Wiwanitkit, 2010 (303) Correspondence 
Zubizarreta, 2002 (304) Correspondence 
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Appendix 3.4: Risk of bias tables 
Randomised Controlled Trials 
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Brack et al, 2012 (17) - - + + - - 
Cagol et al, 2009 (107) - - + + ? ? 
Gupta et al, 2009 (108) - ? + + - - 
Klaassen et al 2000 (109) - ? - - - - 
Mullen et al, 1999 (110) - - + + - - 
Orme et al, 2014 (111) - ? + + - - 
Paganini et al, 2003 (112) - - + + - - 
Paganini et al, 2001  
(113) 
- - + + - - 
Paganini et al, 2000 (114)  - - + + - - 
Petrilli et al, 2000  (115) ? ? + + - - 
Santolaya et al, 2004 
(116) 
? ? + + - - 
Shenep et al, 2001 (117) - ? + + - - 
Varan et al, 2005 (118) ? ? + + - - 
Key: - low risk of bias, ? unclear risk of bias,  + high risk of bias 
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Prospective Observational cohorts 
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Abbas et al, 2003 (119) - - - - - - 
Aquino et al, 2000 (120) - - - - - - 
Bash et al, 1994 (18) - - - - - - 
Dommett et al, 2009 (121) - - - - - ? 
Doyle et al, 1996 (122) - - - - - - 
Fernandez et al, 2012 (123) - - - - - - 
Kaplinsky et al, 1994 (124) - ? - - - - 
Karthaus et al, 2000 (125) - - - - - - 
Lau et al, 1994 (126) - - - - ? - 
Malik, 1997(127) - - - - - - 
Miedema et al, 2012 (128) - ? - ? - - 
Mustafa et al, 1996 (305) - - - - - - 
Paganini et al, 2001 (129) - ? - - - - 
Paganini, 2003 (131) - - - - - - 
Paganini, 2000 (130) - - - - - - 
Park et al, 2003 (132) ? - - - - - 
Petrilli et al, 2007 (133) - - - ? - - 
Phillips et al, 2006 (134) ? - - - - - 
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Preis et al, 1993 (135) ? - - ? - - 
Quezada et al, 2007 (136) - - ? ? ? - 
Sari et al, 2007 (137) - - - ? - - 
Shrestha et al, 2009 (138) - ? - - - - 
Tordecilla et al, 1998 (139) - ? ? ? - - 
Wiernikowski et al, 1991 (140) ? - - - - - 
Key: - low risk of bias, ? unclear risk of bias,  + high risk of bias 
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Appendix B 
This Appendix includes all appendices related to chapter 4 of the thesis. 
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Appendix 4.1: Database search strategy 
British Nursing Index (BNI) (ProQuest – http://search.proquest.com/) 
1994 to current 
Searched on 18/07/2014 
Retrieved 315 hits (after automatic de-duplication by BNI) 
 
Search Strategy (Febrile neutropenia OR early discharge):= 
Key: 
ti(terms) = searches terms in title field 
ab(terms) = searches terms in abstract field 
NEAR/1 = terms within one word of each other (any order) 
NEAR/2 = terms within two words of each other (any order) 
* = truncation – unlimited characters 
?? = two wild characters  
SU.EXACT = single indexing term  
SU.EXACT.EXPLODE = exploded indexing term  
 
(ti(early NEAR/2 discharge*) OR ab(early NEAR/2 discharge*) OR (SU.EXACT("Patients : 
Discharge") AND SU.EXACT("Patients : Admission"))) OR ((ti(febrile NEAR/5 (neutropen* OR 
granulocytop* OR agranulocyto* OR leukocytop??ni* OR leukocytop?ni*)) OR ab(febrile NEAR/5 
(neutropen* OR granulocytop* OR agranulocyto* OR leukocytop??ni* OR leukocytop?ni*))) OR 
(ti((fever OR temperature OR temp) NEAR/5 (neutropen* OR granulocytop* OR agranulocyto* OR 
leukocytop??ni*)) OR ab((fever OR temperature OR temp) NEAR/5 (neutropen* OR granulocytop* 
OR agranulocyto* OR leukocytop??ni*))) OR (SU.EXACT("Fever") AND SU.EXACT.EXPLODE("Blood 
and Blood Disorders"))) 
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CINAHL - Cumulative Index to Nursing & Allied Health Literature (EBSCO – 
http://www.ebscohost.com/) 
1981 - current 
Searched on 12/06/2014 
Retrieved 517 hits 
 
CINAHL (EBSCO) 
Key 
MH = indexing term (CINAHL heading) 
+ =exploded CINAHL heading 
* = truncation 
? = embedded truncation 
“   “ = phrase search 
ZT = publication type 
n1 = terms within one word of each other (any order) 
n2 = terms within two words of each other (any order) 
 
Search Strategy – ((febrile neutropenia AND early discharge) OR (children AND early discharge)): 
S25 S23 OR S24 Search modes - Boolean/Phrase Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced Search  
517 hits 
 
S24 S3 AND S22 Search modes - Boolean/Phrase Interface - EBSCOhost Research 
Databases  
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Search Screen - Advanced Search  
508 hits 
 
S23 S3 AND S17 Search modes - Boolean/Phrase Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced Search  
21 hits 
 
S22 S18 OR S19 OR S20 OR S21 Search modes - Boolean/Phrase Interface - EBSCOhost 
Research Databases  
Search Screen - Advanced Search  
745,047 hits 
 
S21 TI ( newborn* or new-born* or baby* or babies or neonat* or infan* or kid or kids or 
toddler* or adoles* or teen* or boy* or girl* or junevil* or youth* or puber* or prepuber* or 
pubescen*or prepubescen* or pediatric* or paediatric* or “young person*” or “young people” or 
“young adult*” or child* or schoolchild* or schoolage* or school* or preschool* ) OR AB ( 
newborn* or new-born* or baby* or babies or neonat* or infan* or kid or kids or toddler* or 
adoles* or teen* or boy* or girl* or junevil* or youth* or puber* or prepuber* or pubescen*or 
prepubescen* or pediatric* or paediatric* or “young person*” or “young people” or “young 
adult*” or child* or schoolchild* or schoolage* or school* or preschool* ) Search modes - 
Boolean/Phrase Interface - EBSCOhost Research Databases  
Search Screen - Advanced Search  
453,137 hits 
 
S20 (MH "Young Adult") Search modes - Boolean/Phrase Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced Search  
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89,795 hits 
 
S19 (MH "Adolescence+") Search modes - Boolean/Phrase Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced Search  
302,618 hits 
 
S18 (MH "Child+") Search modes - Boolean/Phrase Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced Search  
404,639 hits 
 
S17 S11 OR S16 Search modes - Boolean/Phrase Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced Search  
1,187 hits 
 
S16 S12 OR S13 OR S14 Search modes - Boolean/Phrase Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced Search  
1,041 hits 
 
S15 TI ( temp N5 (neutropen* or granulocytop* or agranulocyto* or leukocytopeni*) ) OR AB ( 
temp N5 (neutropen* or granulocytop* or agranulocyto* or leukocytopeni*) ) Search modes - 
Boolean/Phrase Interface - EBSCOhost Research Databases  
Search Screen - Advanced Search  
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0 hits 
 
S14 TI ( temperature N5 (neutropen* or granulocytop* or agranulocyto* or leukocytopeni*) ) 
OR AB ( temperature N5 (neutropen* or granulocytop* or agranulocyto* or leukocytopeni*) )
 Search modes - Boolean/Phrase Interface - EBSCOhost Research Databases  
Search Screen - Advanced Search  
2 hits 
 
S13 TI ( fever N5 (neutropen* or granulocytop* or agranulocyto* or leukocytopeni*) ) OR AB ( 
fever N5 (neutropen* or granulocytop* or agranulocyto* or leukocytopeni*) ) Search modes - 
Boolean/Phrase Interface - EBSCOhost Research Databases  
Search Screen - Advanced Search  
288 hits 
 
S12 TI ( febrile N5 (neutropen* or granulocytop* or agranulocyto* or leukocytopeni*) ) OR AB 
( febrile N5 (neutropen* or granulocytop* or agranulocyto* or leukocytopeni*) ) Search modes - 
Boolean/Phrase Interface - EBSCOhost Research Databases  
Search Screen - Advanced Search  
824 hits 
 
S11 S7 AND S10 Search modes - Boolean/Phrase Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced Search  
480 hits 
 
S10 S8 OR S9 Search modes - Boolean/Phrase Interface - EBSCOhost Research 
Databases  
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Search Screen - Advanced Search  
12,808 hits 
 
S9 (MH "Body Temperature+") Search modes - Boolean/Phrase Interface - EBSCOhost 
Research Databases  
Search Screen - Advanced Search  
6,820 hits 
 
S8 (MH "Fever+") Search modes - Boolean/Phrase Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced Search  
6,543 hits 
 
S7 S4 OR S5 OR S6 Search modes - Boolean/Phrase Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced Search  
2,901 hits 
 
S6 (MH "Agranulocytosis") Search modes - Boolean/Phrase Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced Search  
229 hits 
 
S5 (MH "Neutropenia") Search modes - Boolean/Phrase Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced Search  
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2,448 hits 
 
S4 (MH "Leukopenia") Search modes - Boolean/Phrase Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced Search  
319 hits 
 
S3 S1 OR S2 Search modes - Boolean/Phrase Interface - EBSCOhost Research 
Databases  
Search Screen - Advanced Search  
1,472 hits 
 
S2 TI early n2 discharge* OR AB early n2 discharge* Search modes - Boolean/Phrase
 Interface - EBSCOhost Research Databases  
Search Screen - Advanced Search  
1,064 hits 
 
S1 (MH "Early Patient Discharge") Search modes - Boolean/Phrase Interface - EBSCOhost 
Research Databases  
Search Screen - Advanced Search  
730 hits 
 
EMBASE: 
Febrile neutropenia and length of stay 
EMBASE <1974 to 2014 May 20> was searched on 21/05/2015, using the OVID SP interface.  
1326 records were retrieved 
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Early discharge and children 
EMBASE <1974 to 2014 July 22> was searched on 23/07/2015, using the OVID SP interface.  
778 records were retrieved 
 
Key: 
/ = indexing term (EMTREE heading) 
* = focussed EMTREE heading 
exp = exploded EMTREE heading 
* = truncation 
? = embedded truncation 
.ti,ab. = terms in either title or abstract fields 
.tw.= textword 
adj = terms adjacent to each other (same order) 
adj1 = terms within one word of each other (any order) 
adj2 = terms within two words of each other (any order) 
 
Strategy - Febrile neutropenia and length of stay: 
1     *Agranulocytosis/ or *neutropenia/ or *leukopenia/ (19460) 
2     *Fever/ or *pyrexia idiopathica/ or exp *Body Temperature/ (37027) 
3     (1 and 2) or *febrile neutropenia/ (3365) 
4     (febrile adj5 (neutropen* or granulocytop* or agranulocyto* or leukocytop??ni*)).ti,ab. 
(8603) 
5     ((fever or temperature or temp) adj5 (neutropen* or granulocytop* or agranulocyto* or 
leukocytop??ni*)).ti,ab. (3879) 
6     3 or 4 or 5 (12590) 
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7     *"length of stay"/ or *hospital admission/ or *hospital discharge/ or *hospital readmission/ or 
exp *hospital patient/ or *outpatient/ (45807) 
8     (discharge* or (length* adj2 stay*) or (duration* adj2 stay*) or admission* or readmission* or 
inpatient* or outpatient*).tw. (606089) 
9     7 or 8 (619909) 
10     6 and 9 (1326) 
 
Strategy - Early discharge and children: 
1     (early adj2 discharge*).ti,ab. (3877) 
2     *"length of stay"/ and *hospital discharge/ (302) 
3     or/1-2 (4096) 
4     (baby* or babies or infan* or kid or kids or toddler* or adoles* or teen* or boy* or girl* or 
junevil* or youth* or puber* or prepuber* or pubescen*or prepubescen* or pediatric* or 
paediatric* or young person* or young people or young adult* or child* or schoolchild* or 
schoolage* or school* or preschool*).tw. (2080868) 
5     *adolescent/ or exp *child/ or *infant/ or *young adult/ (201877) 
6     or/4-5 (2144190) 
7     3 and 6 (778) 
 
Medline: 
Febrile neutropenia and length of stay: 
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) <1946 to 
Present> was searched on 21/05/2014, using the OVID SP interface.  
882 records were retrieved 
Early discharge and children: 
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) <1946 to 
Present> was searched on 01/07/2014, using the OVID SP interface.  
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1850 records were retrieved 
 
Key: 
/=index term (MeSH heading) 
*=truncation 
?= embedded truncation 
ti=title field 
ab=abstract 
tw= textword 
.ti,ab=terms were searched for in either title or abstract 
adj = terms adjacent to each other (same order) 
adj1 = terms within one word of each other (any order) 
adj2 = terms within two words of each other (any order) 
 
Strategy - Febrile neutropenia and length of stay: 
1     Agranulocytosis/ or neutropenia/ or leukopenia/ (26987) 
2     exp Fever/ or exp "Fever of Unknown Origin"/ or exp Body Temperature/ (103894) 
3     (1 and 2) or febrile neutropenia/ (2887) 
4     (febrile adj5 (neutropen* or granulocytop* or agranulocyto* or leukocytop??ni*)).ti,ab. 
(5283) 
5     ((fever or temperature or temp) adj5 (neutropen* or granulocytop* or agranulocyto* or 
leukocytop??ni*)).ti,ab. (2742) 
6     3 or 4 or 5 (8323) 
7     exp "length of stay"/ or exp patient admission/ or exp patient discharge/ or exp patient 
readmission/ or exp inpatients/ or exp outpatients/ (110907) 
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8     (discharge* or (length* adj2 stay*) or (duration* adj2 stay*) or admission* or readmission* or 
inpatient* or outpatient*).tw. (433243) 
9     7 or 8 (480710) 
10     6 and 9 (882) 
 
Strategy - Early discharge and children: 
1     (early adj2 discharge*).ti,ab. (2808) 
2     "length of stay"/ and patient discharge/ (3610) 
3     patient discharge/ and Time Factors/ (2067) 
4     or/1-3 (7230) 
5     adolescent/ or exp child/ or infant/ or exp young adult/ (2748218) 
6     (baby* or babies or infan* or kid or kids or toddler* or adoles* or teen* or boy* or girl* or 
junevil* or youth* or puber* or prepuber* or pubescen*or prepubescen* or pediatric* or 
paediatric* or young person* or young people or young adult* or child* or schoolchild* or 
schoolage* or school* or preschool*).tw. (1703554) 
7     5 or 6 (3323001) 
8     4 and 7 (2008) 
9     8 (2008) 
10     limit 9 to english language (1850) 
11     10 (1850) 
12     limit 11 to yr="1950 -Current" (1850) 
 
PsycINFO (Ovid Online – http://www.ovid.com/) 1806 to July Week 1 2014 was searched on 
04/07/2014 
Retrieved 501 hits 
Key: 
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/ = indexing term  
$ = truncation 
? = embedded truncation 
md = methodology field 
.ti,ab. = terms in either title or abstract fields 
adj = terms adjacent to each other (same order) 
adj1 = terms within one word of each other (any order) 
adj2 = terms within two words of each other (any order) 
 
Search Strategy – (Early discharge AND child) OR febrile neutropenia: 
1     (early adj2 discharge*).ti,ab. (237) 
2     Hospital Discharge/ (1547) 
3     1 or 2 (1734) 
4     (baby* or babies or infan* or kid or kids or toddler* or adoles* or teen* or boy* or girl* or 
junevil* or youth* or puber* or prepuber* or pubescen*or prepubescen* or pediatric* or 
paediatric* or young person* or young people or young adult* or child* or schoolchild* or 
schoolage* or school* or preschool*).tw. (922624) 
5     3 and 4 (225) 
6     limit 3 to (100 childhood <birth to age 12 yrs> or 140 infancy <2 to 23 mo> or 160 preschool 
age <age 2 to 5 yrs> or 180 school age <age 6 to 12 yrs> or 200 adolescence <age 13 to 17 yrs> or 
320 young adulthood <age 18 to 29 yrs>) (409) 
7     5 or 6 (473) 
8     (febrile adj5 (neutropen* or granulocytop* or agranulocyto* or leukocytop??ni*)).ti,ab. (13) 
9     ((fever or temperature or temp) adj5 (neutropen* or granulocytop* or agranulocyto* or 
leukocytop??ni*)).ti,ab. (9) 
10     "febrile neutropenia".id. (6) 
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11     exp "Blood and Lymphatic Disorders"/ (3658) 
12     hyperthermia/ (813) 
13     11 and 12 (21) 
14     8 or 9 or 10 or 13 (39) 
15     7 or 14 (512) 
16     limit 15 to english language (501) 
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Appendix 4.2: Reasons for study exclusion 
Study Reason for exclusion 
Beguin et al, 2002 (306) Not primary research 
Belanger, 2001(307) Not patient group of interest 
Burke, 1999 (308) Review article 
Carpenter, 1998 (309) Neonatal 
Charles and Prystowsky, 1995 (310) Neonatal 
Finkelstein, 1980 (311) Not patient group of interest 
Flowers and Karten, 2013 (312) Commentary  
Forsander, 1995 (313) Quantitative 
Freifeld and Sepkowitz, 2011 (314) Commentary 
Gatford, 2004 (315) Not early discharge 
Graumlich et al, 2008 (316) Quantitative 
Gunnell  et al, 2000 (317) Not patient group of interest 
Jester and Hicks, 2003a (318) Not patient group of interest  
Jester and Hicks, 2003b (319) Not patient group of interest 
Jones, 2007 (320) Not patient group of interest 
Karthaus et al, 2000 (125) Quantitative 
Kibbler and Prentice, 1997 (321) Review article 
King, 1996 (322) Review article 
Krupski and Domm, 2014 (323) Commentary 
Lingaratnam et al, 2010 (324) Quantitative 
Luker et al, 2003 (325) Not patient group of interest 
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Margolan et al, 2004(326) Not early discharge 
Menahem et al, 1997 (327) Not early discharge 
Mendler et al, 1996 (328) Neonatal 
Meropol et al, 1994 (329) Quantitative 
Mikkelsen et al, 2008 (330) Not early discharge 
Moxley, 1977 (331) Not patient group of interest 
Mullen, 1998 (277) Quantitative 
Mullen, 2001 (16) Review article 
Orme et al, 2010 (332) Quantitative 
Ouvrier et al, 2006 (333) Correspondence 
Patrick and Shenep, 1999 (282) Review article 
Paulson, 1987 (334) Review article 
Pinto et al, 2010 (335) Qualitative synthesis 
Richards et al, 1998 (336) Quantitative 
Rolston et al, 1996 (337) Review article 
Rubenstein and Rolston, 1995 (338) Review article 
Silva and High, 1998 (339) Review article 
Slavin and Thursky, 2013 (340) Review article 
Svahn et al, 2004 (341) Quantitative 
Tice, 1998 (342) Review article 
Turley and Higgins, 1996 (343) Quantitative 
Uzark et al, 1994 (344) Quantitative 
Uzun and Anaissie, 1999 (345) Review article 
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Youngblut et al, 1994 (346) Quantitative 
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Appendix 4.3: Results of CLUSTER searches 
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Freund and Siegel, 
1986(152) No ? ? Yes ? Yes Yes No No ? No ? 
Fuji et al, 2013(153) No ? ? ? Yes Yes Yes No No Yes Yes Yes 
Hally et al, 
1977(154) No No ? ? ? ? ? No No ? ? Yes 
Sartain et al, 
2000(155) Yes Yes Yes Yes Yes Yes Yes No No Yes Yes Yes 
Sartain et al, 
2001(156)  No No ? ? Yes Yes Yes No No Yes ? Yes 
Smith and 
Daughtrey, 
2000(157) No ? ? ? Yes Yes Yes No No Yes Yes Yes 
Tatman et al, 
1992(150) No No ? ? ? ? ? No No Yes ? Yes 
While, 1992(158) ? No ? Yes ? ? Yes No ? Yes ? Yes 
? = Unclear
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Appendix C 
This Appendix includes all appendices related to chapter 5 of the thesis. 
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Appendix 5.1: Participant Information Sheets 
Young Person Participant Information Sheet 
Early discharge in paediatric febrile neutropenia: 
experiences and perceptions of young people, parents and healthcare professionals 
Young Person Participant Information Sheet 
Date: 30/11/15 
Version: 3 
 
Early discharge in paediatric febrile neutropenia: experiences and perceptions of young people, 
parents and healthcare professionals 
 
We would like to invite you to take part in the above named research study. Before you decide 
whether or not you would like to take part, we would like to tell you more about the study and 
about what being part of it would involve. If you would like to ask any questions about the study, 
we have provided details of who to contact at the end of this leaflet. 
What is the purpose of this study? 
Neutrophils are the commonest form of white blood cells and play an important role in the 
immune system. Treatment for cancer can result in low neutrophils, also known as neutropenia. 
This results in an increased risk of infection. When someone with neutropenia develops a 
temperature, this is called febrile neutropenia. Sometimes febrile neutropenia is very serious, but 
most of the time it does not cause any serious medical problems. We are working to look at the 
possibility of reducing the length of time that children and young people spend in hospital when 
we predict that they will not have serious problems from their febrile neutropenia.  
For this particular study, we are interested in hearing about what young people, their parents and 
their doctors and nurses, think about them spending less time in hospital. This information may 
then help to inform how we design services for children and young people who develop febrile 
neutropenia in the future.  
Who is doing the study?  
This study is being conducted as part of a PhD project by Dr Jessica Morgan from the University of 
York. Her work will be supervised by Professor Karl Atkin (also at University of York). There are 
further supervisory and advisory researchers involved in the work, as part of the university 
training procedures. All the researchers who contact you have been checked out by the Criminal 
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Records Bureau to ensure they are appropriately qualified to undertake research. This research 
has been funded by Candlelighters Childhood Cancer Charity (Registered Charity No: 1045077).  
Why have I been asked to participate? 
You have been asked to take part because we are interested in talking to young people, age 13 to 
18 years old, who have had treatment for cancer at some point within the last six months and 
who, if they developed febrile neutropenia, might be considered at low risk of serious 
complications. You are the people who are able to tell us about how you would prefer to be 
treated if this were to happen to you. We are also interested to talk to your parents and your 
doctors and nurses, because we know that that decisions about treatment are often made by 
taking into consideration all of these people’s opinions. We are going to ask these questions at 
groups at different hospitals around the UK as we think that people in different places, where the 
services are designed differently, might have different opinions about this problem. You will 
probably have been invited to take part because someone who looks after you felt that you were 
able to talk about what you think about this issue. 
Do I have to take part? 
No, this study is entirely voluntary. You can chose not to take part and this will not affect your 
treatment at all. If you decide to take part, you will be given this information sheet to keep and 
you will be asked to sign an assent form. Because of legal requirements, someone who has 
parental responsibility for you will also be asked to consent on your behalf. It is important that 
you both agree that you should take part in the study. After you have signed the consent and 
assent forms, you are still free to withdraw from the study at any time up to two weeks following 
the focus group discussion. If you withdraw from the study your quotations from the focus group 
will not be used in the analysis or any reports and publications. However, the rest of the 
information from the focus group (which relates to other participants’ quotations) will continue to 
be used.   You do not need to give a reason for withdrawing.  
What will be involved if I take part in this study? 
We would ask you to take part in a group discussion with between four and seven other young 
people, and led by a researcher. We would talk about your experiences of being treated for 
febrile neutropenia in the past - don’t worry if you have never had febrile neutropenia – we are 
specifically asking some people with no experience to the groups. We will then ask you about 
what you think about shorter hospital stays for febrile neutropenia. The discussion would take 
about 90 minutes and would be audio-recorded. We would choose people to try to reflect a range 
 310 
 
of possible opinions. The discussion will take place in or close to the hospital and the time will be 
selected to be convenient for as many participants as possible. 
What are the advantages of taking part? 
At the end of the work, when we have been able to look at all the discussions which will take 
place, we will provide you with a summary of our findings and the recommendations we make 
about improving future services.  
What are the disadvantages of taking part?  
Sometimes talking about your experiences can bring up some difficult memories. You may also 
start to think more about febrile neutropenia happening again in the future. People involved in 
your care will be available to talk to you about any questions you have about your own treatment 
after this study. 
Will I be paid to take part in this study?  
You will be offered a £20 Amazon voucher, provided by Candlelighters Children’s Cancer Charity, 
to recognise the time commitment involved in this study. If you chose to accept this, it will be sent 
to you following the focus group via email or post, depending on which you prefer.  
Candlelighters Children’s Cancer Charity have also given us funding to provide you with your 
travel expenses. This will be 45 pence per mile if you drive to the group discussion, or the price of 
a standard rate ticket for public transport. This will be sent to you following the focus group. 
 
Will the information obtained in the study be confidential? 
All information you give to us will be confidential. We will not tell anyone (including your family or 
the professionals who look after you) about what you share with us. The only exception to this is 
if you tell us things which we believe place you or other people at serious risk. If this happens, we 
are required to tell other people about it so as to protect you (or other people) from harm.  
The audio-recordings from the discussions will be listened to and everything that is said will be 
written down. This creates a document called a transcript. All information that is written or 
recorded will be kept in locked offices at the University of York. Only the research team will be 
able to see them. All the information you provide will have a code allocated to it and this will be 
stored separately from your personal details. No names will be used in the transcripts, our notes 
or any writing we do about this work. At the end of the study, the audio recordings will be erased. 
The data will be stored for five years, so that if the research needs to be checked or further 
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analysis needs to be done then this is available. At all times, all data will be treated in accordance 
with the current Data Protection Act.  
What will happen to the results of the study? 
The results of this study will be used in a number of ways. We will write a summary of the work 
for you to read and to know what was found from the research. Other members of the public will 
also be able to read this summary. The work will also be written as a full academic report for the 
PhD thesis of Dr Jessica Morgan. As well as this, it will also be submitted for publication in 
scientific journals. You can call members of the research team at any time to discuss the progress 
of the research.   
Who has reviewed this study? 
The plans for this study have been reviewed by the University of York Research Governance 
Committee, as well as an NHS Research Ethics Committee. The progress of the research will be 
monitored throughout by the University of York. 
 
Who do I contact in the event of a complaint? 
Please raise any difficulties or questions with Dr Jessica Morgan (01904) 321082 (8am to 5pm 
weekdays) email jem539@york.ac.uk or Professor Karl Atkin (01904) 321355 email 
karl.atkin@york.ac.uk.  If the research team are unable to give you a satisfactory answer, please 
contact Professor Lesley Stewart, (01904) 321093, email lesley.stewart@york.ac.uk. 
 
If you agree to take part, would like more information or have any questions or concerns about 
the study please contact Dr Jessica Morgan, Chief Investigator, Centre for Reviews and 
Dissemination, University of York, Tel 01904 321082, Email jem539@york.ac.uk   
 
Thank you for taking the time to read this information sheet. 
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Parent’s Information Sheet 
Early discharge in paediatric febrile neutropenia: 
experiences and perceptions of young people, parents and healthcare professionals 
Parent’s Information Sheet 
Date: 30/11/15 
Version: 3 
 
Early discharge in paediatric febrile neutropenia: experiences and perceptions of young people, 
parents and healthcare professionals 
 
We would like to invite you to consent for your child to take part in the above named research 
study. Before you decide whether or not you would like them to take part, we would like to tell 
you more about the study and about what your child being part of it would involve. If you would 
like to ask any questions about the study, we have provided details of who to contact at the end 
of this leaflet. 
What is the purpose of this study? 
Neutrophils are the commonest form of white blood cells and play an important role in the 
immune system. Treatment for cancer can result in low neutrophils, also known as neutropenia. 
This results in an increased risk of infection. When someone with neutropenia develops a 
temperature, this is called febrile neutropenia. Sometimes febrile neutropenia is very serious, but 
most of the time it does not cause any serious medical problems. We are working to look at the 
possibility of reducing the length of time that children and young people spend in hospital when 
we predict that they will not have serious problems from their febrile neutropenia. For this 
particular study, we are interested in hearing about what young people, their parents and their 
doctors and nurses, think about them spending less time in hospital. This information may then 
help to inform how we design services for children and young people who develop febrile 
neutropenia in the future.  
Who is doing the study?  
This study is being conducted as part of a PhD project by Dr Jessica Morgan from the University of 
York. Her work will be supervised by Professor Karl Atkin (also at University of York). There are 
further supervisory and advisory researchers involved in the work, as part of the university 
training procedures. All the researchers who contact you have been checked out by the Criminal 
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Records Bureau to ensure they are appropriately qualified to undertake research. This research 
has been funded by Candlelighters Childhood Cancer Charity (Registered Charity No: 1045077).  
Why has your child been asked to participate? 
Your child has been asked to take part because we are interested in talking to young people, age 
13 to 18 years old, who have had treatment for cancer at some point within the last six months 
and who, if they developed febrile neutropenia, might be considered at low risk of serious 
complications. These young people are the ones who are able to tell us about how they would 
prefer to be treated if this were to happen to them. We are also interested to talk to their parents 
and their doctors and nurses, because we know that that decisions about treatment are often 
made by taking into consideration all of these people’s opinions. (You may also have been asked 
to take part in this study yourself, in which care, you will receive another information sheet about 
your own participation.) We are going to ask these questions at groups at different hospitals 
around the UK as we think that people in different places, where the services are designed 
differently, might have different opinions about this problem. Your child will probably have been 
invited to take part because someone who looks after them felt that they were able to talk about 
what they think about this issue. 
Does my child have to take part? 
No, this study is entirely voluntary. You can chose for your child not to take part and this will not 
affect their treatment at all. If you decide to let them take part, you will be given this information 
sheet to keep and you will be asked to sign a consent form. We will also ask your child to sign a 
form stating that they would like to take part. It is important that you both agree whether your 
child should take part in the study. After you have signed the consent and assent forms, you are 
still free to withdraw your child from the study at any time up to two weeks following the focus 
group discussion. If you withdraw your child from the study their quotations from the focus group 
will not be used in the analysis or any reports and publications. However, the rest of the 
information from the focus group (which relates to other participants’ quotations) will continue to 
be used.  You do not need to give a reason for withdrawing.  
What will be involved if my child takes part in this study? 
We would ask your child to take part in a group discussion with between four and seven other 
young people, and led by a researcher. We would talk about their experiences of being treated for 
febrile neutropenia in the past - don’t worry if they have never had febrile neutropenia – we are 
specifically asking some people with no experience to the groups. We will then ask your child 
about what they think about shorter hospital stays for febrile neutropenia. The discussion would 
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take about 90 minutes and would be audio-recorded. We would choose people to try to reflect a 
range of possible opinions. The discussion will take place in or close to the hospital and the time 
will be selected to be convenient for as many participants as possible. 
What are the advantages of taking part? 
At the end of the work, when we have been able to look at all the discussions which will take 
place, we will provide you and your child with a summary of our findings and the 
recommendations we make about improving future services.  
What are the disadvantages of taking part?  
Sometimes talking about their experiences can bring up some difficult memories for your child. 
They may also start to think more about febrile neutropenia happening again in the future. People 
involved in your child’s care will be available to talk to you and your child about any questions you 
have about their treatment after this study. 
Will I be paid if my child takes part in this study?  
You will be offered a £20 Amazon voucher, provided by Candlelighters Children’s Cancer Charity, 
to recognise the time commitment involved in this study. If you chose to accept this, it will be sent 
to you following the focus group via email or post, depending on which you prefer.  
 
Candlelighters Children’s Cancer Charity have also given us funding to provide you with your 
travel expenses. This will be 45 pence per mile if you drive to the group discussion, or the price of 
a standard rate ticket for public transport. This will be sent to you following the focus group. 
Will the information obtained in the study be confidential? 
All information you and your child give to us will be confidential. We will not tell anyone (including 
yourself, your family or the professionals who look after your child) about what they chose to 
share with us in the discussion. The only exception to this is if your child tells us things which we 
believe place them or other people at serious risk. If this happens, we are required to tell the 
relevant authorities so as to protect them (or other people) from harm.  
The audio-recordings from the discussions will be listened to and everything that is said will be 
written down. This creates a document called a transcript. All information that is written or 
recorded will be kept in locked offices at the University of York. Only the research team will be 
able to see them. All the information you and your child provide will have a code allocated to it 
and this will be stored separately from your child’s personal details. No names will be used in the 
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transcripts, our notes or any writing we do about this work. At the end of the study, the audio 
recordings will be erased. The data will be stored for five years, so that if the research needs to be 
checked or further analysis needs to be done then this is available. At all times, all data will be 
treated in accordance with the current Data Protection Act.  
What will happen to the results of the study? 
The results of this study will be used in a number of ways. We will write a summary of the work 
for you and your child to read and to know what was found from the research. Other members of 
the public will also be able to read this summary. The work will also be written as a full academic 
report for the PhD thesis of Dr Jessica Morgan. As well as this, it will also be submitted for 
publication in scientific journals. You can call members of the research team at any time to discuss 
the progress of the research.   
Who has reviewed this study? 
The plans for this study have been reviewed by the University of York Research Governance 
Committee, as well as an NHS Research Ethics Committee. The progress of the research will be 
monitored throughout by the University of York. 
 
Who do I contact in the event of a complaint? 
Please raise any difficulties or questions with Dr Jessica Morgan (01904) 321082 (8am to 5pm 
weekdays) email jem539@york.ac.uk or Professor Karl Atkin (01904) 321355 email 
karl.atkin@york.ac.uk.  If the research team are unable to give you a satisfactory answer, please 
contact Professor Lesley Stewart, (01904) 321093, email lesley.stewart@york.ac.uk. 
 
If you agree to take part, would like more information or have any questions or concerns about 
the study please contact Dr Jessica Morgan, Chief Investigator, Centre for Reviews and 
Dissemination, University of York, Tel 01904 321082, Email jem539@york.ac.uk   
 
Thank you for taking the time to read this information sheet. 
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Adult Patient Participant Information Sheet 
Early discharge in paediatric febrile neutropenia: 
experiences and perceptions of young people, parents and healthcare professionals 
Adult Patient Participant Information Sheet 
Date: 30.11.15 
Version: 3 
 
Early discharge in paediatric febrile neutropenia: experiences and perceptions of young people, 
parents and healthcare professionals 
 
We would like to invite you to take part in the above named research study. Before you decide 
whether or not you would like to take part, we would like to tell you more about the study and 
about what being part of it would involve. If you would like to ask any questions about the study, 
we have provided details of who to contact at the end of this leaflet. 
What is the purpose of this study? 
Neutrophils are the commonest form of white blood cells and play an important role in the 
immune system. Treatment for cancer can result in low neutrophils, also known as neutropenia. 
This results in an increased risk of infection. When someone with neutropenia develops a 
temperature, this is called febrile neutropenia. Sometimes febrile neutropenia is very serious, but 
most of the time it does not cause any serious medical problems. We are working to look at the 
possibility of reducing the length of time that children and young people spend in hospital when 
we predict that they will not have serious problems from their febrile neutropenia.  
For this particular study, we are interested in hearing about what young people, their parents and 
their doctors and nurses, think about them spending less time in hospital. This information may 
then help to inform how we design services for children and young people who develop febrile 
neutropenia in the future.  
Who is doing the study?  
This study is being conducted as part of a PhD project by Dr Jessica Morgan from the University of 
York. Her work will be supervised by Professor Karl Atkin (also at University of York). There are 
further supervisory and advisory researchers involved in the work, as part of the university 
training procedures. All the researchers who contact you have been checked out by the Criminal 
Records Bureau to ensure they are appropriately qualified to undertake research. This research 
has been funded by Candlelighters Childhood Cancer Charity (Registered Charity No: 1045077).  
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Why have I been asked to participate? 
You have been asked to take part because we are interested in talking to young people, age 13 to 
18 years old, who have had treatment for cancer at some point within the last six months and 
who, if they developed febrile neutropenia, might be considered at low risk of serious 
complications. You are the people who are able to tell us about how you would prefer to be 
treated if this were to happen to you. We are also interested to talk to your parents and your 
doctors and nurses, because we know that that decisions about treatment are often made by 
taking into consideration all of these people’s opinions. We are going to ask these questions at 
groups at different hospitals around the UK as we think that people in different places, where the 
services are designed differently, might have different opinions about this problem. You will 
probably have been invited to take part because someone who looks after you felt that you were 
able to talk about what you think about this issue. 
Do I have to take part? 
No, this study is entirely voluntary. You can chose not to take part and this will not affect your 
treatment at all. If you decide to take part, you will be given this information sheet to keep and 
you will be asked to sign a consent form. After you have signed the consent form, you are still free 
to withdraw from the study at any time up to two weeks following the focus group discussion. If 
you withdraw from the study your quotations from the focus group will not be used in the 
analysis or any reports and publications. However, the rest of the information from the focus 
group (which relates to other participants’ quotations) will continue to be used.   You do not need 
to give a reason for withdrawing.  
What will be involved if I take part in this study? 
We would ask you to take part in a group discussion with between four and seven other young 
people, and led by a researcher. We would talk about your experiences of being treated for 
febrile neutropenia in the past - don’t worry if you have never had febrile neutropenia – we are 
specifically asking some people with no experience to the groups. We will then ask you about 
what you think about shorter hospital stays for febrile neutropenia. The discussion would take 
about 90 minutes and would be audio-recorded. We would choose people to try to reflect a range 
of possible opinions. The discussion will take place in or close to the hospital and the time will be 
selected to be convenient for as many participants as possible. 
What are the advantages of taking part? 
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At the end of the work, when we have been able to look at all the discussions which will take 
place, we will provide you with a summary of our findings and the recommendations we make 
about improving future services.  
What are the disadvantages of taking part?  
Sometimes talking about your experiences can bring up some difficult memories. You may also 
start to think more about febrile neutropenia happening again in the future. People involved in 
your care will be available to talk to you about any questions you have about your own treatment 
after this study. 
Will I be paid to take part in this study?  
You will be offered a £20 Amazon voucher, provided by Candlelighters Children’s Cancer Charity, 
to recognise the time commitment involved in this study. If you chose to accept this, it will be sent 
to you following the focus group via email or post, depending on which you prefer.  
Candlelighters Children’s Cancer Charity have also given us funding to provide you with your 
travel expenses. This will be 45 pence per mile if you drive to the group discussion, or the price of 
a standard rate ticket for public transport. This will be paid to you in cash on the day and we will 
need you to sign a receipt.  This will be sent to you following the focus group. 
 
Will the information obtained in the study be confidential? 
All information you give to us will be confidential. We will not tell anyone (including your family or 
the professionals who look after you) about what you share with us. The only exception to this is 
if you tell us things which we believe place you or other people at serious risk. If this happens, we 
are required to tell other people about it so as to protect you (or other people) from harm.  
The audio-recordings from the discussions will be listened to and everything that is said will be 
written down. This creates a document called a transcript. All information that is written or 
recorded will be kept in locked offices at the University of York. Only the research team will be 
able to see them. All the information you provide will have a code allocated to it and this will be 
stored separately from your personal details. No names will be used in the transcripts, our notes 
or any writing we do about this work. At the end of the study, the audio recordings will be erased. 
The data will be stored for five years, so that if the research needs to be checked or further 
analysis needs to be done then this is available. At all times, all data will be treated in accordance 
with the current Data Protection Act.  
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What will happen to the results of the study? 
The results of this study will be used in a number of ways. We will write a summary of the work 
for you to read and to know what was found from the research. Other members of the public will 
also be able to read this summary. The work will also be written as a full academic report for the 
PhD thesis of Dr Jessica Morgan. As well as this, it will also be submitted for publication in 
scientific journals. You can call members of the research team at any time to discuss the progress 
of the research.   
Who has reviewed this study? 
The plans for this study have been reviewed by the University of York Research Governance 
Committee, as well as an NHS Research Ethics Committee. The progress of the research will be 
monitored throughout by the University of York. 
 
Who do I contact in the event of a complaint? 
Please raise any difficulties or questions with Dr Jessica Morgan (01904) 321082 (8am to 5pm 
weekdays) email jem539@york.ac.uk or Professor Karl Atkin (01904) 321355 email 
karl.atkin@york.ac.uk.  If the research team are unable to give you a satisfactory answer, please 
contact Professor Lesley Stewart, (01904) 321093, email lesley.stewart@york.ac.uk. 
 
If you agree to take part, would like more information or have any questions or concerns about 
the study please contact Dr Jessica Morgan, Chief Investigator, Centre for Reviews and 
Dissemination, University of York, Tel 01904 321082, Email jem539@york.ac.uk   
 
Thank you for taking the time to read this information sheet. 
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Adult Participant Information Sheet 
 Early discharge in paediatric febrile neutropenia: 
 experiences and perceptions of young people, parents and healthcare 
professionals 
Adult Participant Information Sheet 
Date: 30/11/15 
Version: 3 
 
 Early discharge in paediatric febrile neutropenia: experiences and perceptions of young people, 
parents and healthcare professionals 
  
We would like to invite you to take part in the above named research study. Before you decide 
whether or not you would like to take part, we would like to tell you more about the study and 
about what being part of it would involve. If you would like to ask any questions about the study, 
we have provided details of who to contact at the end of this leaflet. 
What is the purpose of this study? 
Neutrophils are the commonest form of white blood cells and play an important role in the 
immune system. Treatment for cancer can result in low neutrophils, also known as neutropenia. 
This results in an increased risk of infection. When someone with neutropenia develops a 
temperature, this is called febrile neutropenia. Sometimes febrile neutropenia is very serious, but 
most of the time it does not cause any serious medical problems. We are working to look at the 
possibility of reducing the length of time that children and young people spend in hospital when 
we predict that they will not have serious problems from their febrile neutropenia. For this 
particular study, we are interested in hearing about what young people, their parents and their 
doctors and nurses, think about them spending less time in hospital. This information may then 
help to inform how we design services for children and young people who develop febrile 
neutropenia in the future.  
Who is doing the study?  
This study is being conducted as part of a PhD project by Dr Jessica Morgan from the University of 
York. Her work will be supervised by Professor Karl Atkin (also at University of York). There are 
further supervisory and advisory researchers involved in the work, as part of the university 
training procedures. All the researchers who contact you have been checked out by the Criminal 
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Records Bureau to ensure they are appropriately qualified to undertake research. This research 
has been funded by Candlelighters Childhood Cancer Charity (Registered Charity No: 1045077).  
Why have I been asked to participate? 
You have been asked to take part because you are the parent of a child or young person who has 
had treatment for cancer at some point within the last six months and who, if they developed 
febrile neutropenia, might be considered at low risk of serious complications. You are the people 
who are able to tell us about how you would prefer your child to be treated if this were to happen 
to them. We are also interested to talk to some young people and to doctors and nurses about 
this issue, because we know that that decisions about treatment are often made by taking into 
consideration all of these people’s opinions. We are going to ask our questions to groups at 
different hospitals around the UK as we think that people in different places, where the services 
are designed differently, might have different opinions about this problem. You will probably have 
been invited to take part because someone who looks after your child felt that you were able to 
talk about what you think about this issue. 
Do I have to take part? 
No, this study is entirely voluntary. You can chose not to take part and this will not affect your 
child’s treatment at all. If you decide to take part, you will be given this information sheet to keep 
and you will be asked to sign a consent form. After you have signed the consent form, you are still 
free to withdraw from the study at any time up to two weeks following the focus group 
discussion. If you withdraw from the study your quotations from the focus group will not be used 
in the analysis or any reports and publications. However, the rest of the information from the 
focus group (which relates to other participants’ quotations) will continue to be used.  You do not 
need to give a reason for withdrawing.  
What will be involved if I take part in this study? 
We would ask you to take part in a group discussion with between four and seven other people, 
and led by a researcher. We would talk about your experiences of your child being treated for 
febrile neutropenia in the past - don’t worry if your child has never had febrile neutropenia – we 
are specifically asking some people with no experience to the groups. We will then ask you about 
what you think about shorter hospital stays for febrile neutropenia. The discussion would take 
about 90 minutes and would be audio-recorded. We would choose people to try to reflect a range 
of possible opinions. The discussion will take place in or close to the hospital and the time will be 
selected to be convenient for as many participants as possible. 
What are the advantages of taking part? 
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At the end of the work, when we have been able to look at all the discussions which will take 
place, we will provide you with a summary of our findings and the recommendations we make 
about improving future services.  
What are the disadvantages of taking part?  
Sometimes talking about your experiences can bring up some difficult memories. You may also 
start to think more about febrile neutropenia happening again in the future. People involved in 
your child’s care will be available to talk to you about any questions you have about your child’s 
treatment after this study. 
Will I be paid to take part in this study?  
You will be offered a £20 Amazon voucher, provided by Candlelighters Children’s Cancer Charity, 
to recognise the time commitment involved in this study. If you chose to accept this, it will be sent 
to you following the focus group via email or post, depending on which you prefer.  
Candlelighters Children’s Cancer Charity have also given us funding to provide you with your 
travel expenses. This will be 45 pence per mile if you drive to the group discussion, or the price of 
a standard rate ticket for public transport.  This will be sent to you following the focus group. 
Will the information obtained in the study be confidential? 
All information you give to us will be confidential. We will not tell anyone (including your family or 
the professionals who look after your child) about what you share with us. The only exception to 
this is if you tell us things which we believe place you, your child or other people at serious risk. If 
this happens, we are required to tell the relevant authorities so as to protect you (or your child or 
other people) from harm.  
The audio-recordings from the discussions will be listened to and everything that is said will be 
written down. This creates a document called a transcript. All information that is written or 
recorded will be kept in locked offices at the University of York. Only the research team will be 
able to see them. All the information you provide will have a code allocated to it and this will be 
stored separately from your personal details. No names will be used in the transcripts, our notes 
or any writing we do about this work. At the end of the study, the audio recordings will be erased. 
The data will be stored for five years, so that if the research needs to be checked or further 
analysis needs to be done then this is available. At all times, all data will be treated in accordance 
with the current Data Protection Act.  
What will happen to the results of the study? 
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The results of this study will be used in a number of ways. We will write a summary of the work 
for you to read and to know what was found from the research. Other members of the public will 
also be able to read this summary. The work will also be written as a full academic report for the 
PhD thesis of Dr Jessica Morgan. As well as this, it will also be submitted for publication in 
scientific journals. You can call members of the research team at any time to discuss the progress 
of the research.   
Who has reviewed this study? 
The plans for this study have been reviewed by the University of York Research Governance 
Committee, as well as an NHS Research Ethics Committee. The progress of the research will be 
monitored throughout by the University of York. 
 
Who do I contact in the event of a complaint? 
Please raise any difficulties or questions with Dr Jessica Morgan (01904) 321082 (8am to 5pm 
weekdays) email jem539@york.ac.uk or Professor Karl Atkin (01904) 321355 email 
karl.atkin@york.ac.uk.  If the research team are unable to give you a satisfactory answer, please 
contact Professor Lesley Stewart, (01904) 321093, email lesley.stewart@york.ac.uk. 
 
If you agree to take part, would like more information or have any questions or concerns about 
the study please contact Dr Jessica Morgan, Chief Investigator, Centre for Reviews and 
Dissemination, University of York, Tel 01904 321082, Email jem539@york.ac.uk   
 
Thank you for taking the time to read this information sheet. 
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Healthcare Professional Participant Information Sheet 
Early discharge in paediatric febrile neutropenia: 
experiences and perceptions of young people, parents and healthcare professionals 
 
Healthcare Professional Participant Information Sheet 
Date: 27.5.15 
Version: 2 
 
Early discharge in paediatric febrile neutropenia: experiences and perceptions of young people, 
parents and healthcare professionals 
 
We would like to invite you to take part in the above named research study. Before you decide 
whether or not you would like to take part, we would like to tell you more about the study and 
about what being part of it would involve. If you would like to ask any questions about the study, 
we have provided details of who to contact at the end of this leaflet. 
What is the purpose of this study? 
We are researchers who are interested in the management of paediatric low risk febrile 
neutropenia. We are working to look at the possibility of reducing the length of time that children 
and young people spend in hospital with low risk febrile neutropenia. For this particular study, we 
are interested in hearing about what young people, their parents and their doctors and nurses, 
think about strategies involving outpatient therapy or early discharge from hospital. This 
information may then help to inform how services are designed for children and young people 
who develop febrile neutropenia in the future.  
Who is doing the study?  
This study is being conducted as part of a PhD project by Dr Jessica Morgan from the University of 
York. Her work will be supervised by Professor Karl Atkin (also at University of York). There are 
further supervisory and advisory researchers involved in the work, as part of the university 
training procedures. This research has been funded by Candlelighters Childhood Cancer Charity 
(Registered Charity No: 1045077).  
Why have I been asked to participate? 
You have been asked to take part because you are a healthcare professional involved in the care 
of children and young people with low risk febrile neutropenia. You are the people who are able 
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to tell us about how you feel patients and families should be treated. We are also interested to 
talk to patients who may develop low risk febrile neutropenia and their families, because we 
recognise that decisions about treatment are often made by taking into consideration all of these 
people’s opinions. This will be a multicentre study within the UK as we anticipate that where 
populations and services designs are different there might be different opinions about this issue. 
Do I have to take part? 
No, this study is entirely voluntary. If you decide to take part, you will be given this information 
sheet to keep and you will be asked to sign a consent form. After you have signed the consent 
form, you are still free to withdraw from the study at any time up to two weeks following the 
focus group discussion. If you withdraw from the study your quotations from the focus group will 
not be used in the analysis or any reports and publications. However, the rest of the information 
from the focus group (which relates to other participants’ quotations) will continue to be used. 
You do not need to give a reason for withdrawing.  
What will be involved if I take part in this study? 
We would ask you to take part in a group discussion with between four and seven healthcare 
professionals, and led by a researcher. We would talk about your experiences of treating febrile 
neutropenia and then about what you think about shorter hospital stays for febrile neutropenia. 
The discussion would take about 90 minutes and would be audio-recorded. We would choose 
people to try to reflect a range of possible opinions. The discussion will take place in or close to 
the hospital and the time will be selected to be convenient for as many participants as possible. 
You will not be required to travel away from your centre in order to take part. 
What are the advantages of taking part? 
At the end of the work, we will provide you with a summary of our findings and the 
recommendations we make about improving future services.  
What are the disadvantages of taking part?  
You might question your own practice, but you will be offered information about where you can 
obtain continuing professional education on the management of paediatric febrile neutropenia. 
Will I be paid to take part in this study?  
No, but we don’t want you to be disadvantaged by taking part. Candlelighters Children’s Cancer 
Charity have given us funding to provide you with your travel expenses. This will be 45 pence per 
 326 
 
mile if you drive to the group discussion, or the price of a standard rate ticket for public transport. 
This will be paid to you in cash on the day and we will need you to sign a receipt.   
Will the information obtained in the study be confidential? 
All information you give to us will be confidential.  It is important to note that the research team 
are only interested in your general views and that you should not discuss the details of individual 
cases where this may make the patient identifiable.  We will not tell anyone about what you share 
with us. The only exception to this is if you disclose information which we believe place you or 
other people at serious risk. If this happens, we are required to tell the relevant authorities so as 
to protect you (or other people) from harm.  
The audio-recordings from the discussions will be listened to and everything that is said will be 
written down. This creates a document called a transcript. All information that is written or 
recorded will be kept in locked offices at the University of York. Only the research team will be 
able to see them. All the information you provide will have a code allocated to it and this will be 
stored separately from your personal details. No names will be used in the transcripts, our notes 
or any writing we do about this work. At the end of the study, the audio recordings will be erased. 
The data will be stored for five years, so that if the research needs to be checked or further 
analysis needs to be done then this is available. At all times, all data will be treated in accordance 
with the current Data Protection Act.  
What will happen to the results of the study? 
The results of this study will be used in a number of ways. We will write a summary of the work 
for you to read and to know what was found from the research. Other participants and members 
of the public will also be able to read this summary. The work will also be written as a full 
academic report for the PhD thesis of Dr Jessica Morgan. As well as this, it will also be submitted 
for publication in scientific journals. We will look to present the results of the research at each 
study site. You can call members of the research team at any time to discuss the progress of the 
research.  
Who has reviewed this study? 
The plans for this study have been reviewed by the University of York Research Governance 
Committee, as well as an NHS Research Ethics Committee. The progress of the research will be 
monitored throughout by the University of York. 
 
Who do I contact in the event of a complaint? 
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Please raise any difficulties or questions with Dr Jessica Morgan (01904) 321082 (8am to 5pm 
weekdays) email jem539@york.ac.uk or Professor Karl Atkin (01904) 321355 email 
karl.atkin@york.ac.uk.  If the research team are unable to give you a satisfactory answer, please 
contact Professor Lesley Stewart, (01904) 321093, email lesley.stewart@york.ac.uk. 
 
If you agree to take part, would like more information or have any questions or concerns about 
the study please contact Dr Jessica Morgan, Chief Investigator, Centre for Reviews and 
Dissemination, University of York, Tel 01904 321082, Email jem539@york.ac.uk   
 
Thank you for taking the time to read this information sheet. 
 
  
 328 
 
Appendix 5.2: Invitation email to Healthcare Professionals 
Dear colleague,  
 
I am writing to inform you about a new research study opening at our centre, Early discharge in 
paediatric febrile neutropenia: experiences and perceptions of young people, parents and 
healthcare professionals. This study is being conducted with the University of York and will involve 
various focus group discussions about outpatient therapy and early discharge strategies for the 
management of paediatric low risk febrile neutropenia. I would like to offer you the chance to take 
part in the healthcare professionals’ focus group for our centre. The study team are keen to hear 
from doctors and nurses who have experience of caring for these parents. You could be acting in a 
junior or senior role and could be new to the service or have been here for a long time– as many 
different opinions as possible are wanted. I have attached the Healthcare Professionals’ Participant 
Information Sheet. If you would like more details or would like to take part in the study, please 
contact the Chief Investigator, Dr Jessica Morgan (01904) 321082. 
 
Best wishes 
 
Site specific coordinator 
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Appendix 5.3: Participant Consent and Assent forms 
Young Person Participant Assent Form 
Young Person Participant  
Assent Form 
Early discharge in paediatric febrile neutropenia:  
experiences and perceptions of young people, parents and healthcare professionals 
Date: 27/5/15 
Version: 2 
 
Chief Investigator: Dr Jessica Morgan 
Focus Group Moderator: Dr Jessica Morgan 
 
 
 
Please confirm 
agreement to 
the statements 
by putting your 
initials in the 
boxes below 
 
I have read and understood the participant information sheet: _____________ 
(Version) for the above study.  
 
 
 
I have had the opportunity to ask questions and discuss this study 
 
 
 
I have received satisfactory answers to all of my questions 
 
 
 
I have received enough information about the study 
 
 
I understand my participation in the study is voluntary and that I am free to withdraw 
from the study at any time up to two weeks following the focus group discussion 
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without having to give a reason for withdrawing and without affecting my medical care 
or legal rights. I understand that if I withdraw from the study my quotations from the 
focus group will not be used in the analysis or any reports and publications. However, 
the rest of the information from the focus group (which relates to other participants’ 
quotations) will continue to be used.    
 
 
I understand that the focus group that I am part of will be audio-recorded. 
 
 
 
I agree to respect the rights of other participants in the focus group and to maintain 
confidentiality of matters discussed within the focus group. 
 
 
I understand that sections of my medical notes and data collected during the study may 
be looked at by researchers, where it is relevant to this research.  I give permission for 
these individuals to have access to my records. 
 
 
I agree to my GP being informed of my participation in the study. 
 
 
I understand that any information I provide, including personal details, will be kept 
confidential, stored securely and only accessed by those carrying out the study. 
 
 
I understand that any information I give may be included in published documents but 
all information will be anonymised. 
 
 
I agree to take part in this study 
 
 
Participant Signature …………………………………………………………                       Date  
 
 331 
 
Name of Participant   
 
Researcher Signature ………………………………………………………..                       Date  
 
Name of Researcher 
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Parent Consent Form 
Parent Consent Form 
Early discharge in paediatric febrile neutropenia:  
experiences and perceptions of young people, parents and healthcare professionals 
Date: 27/5/15 
Version: 2 
 
Chief Investigator: Dr Jessica Morgan 
Focus Group Moderator: Dr Jessica Morgan 
 
 
 
Please confirm 
agreement to 
the statements 
by putting your 
initials in the 
boxes below 
 
I have read and understood the participant information sheet: _____________ 
(Version) for the above study.  
 
 
 
I have had the opportunity to ask questions and discuss this study 
 
 
 
I have received satisfactory answers to all of my questions 
 
 
 
I have received enough information about the study 
 
 
I understand my child’s participation in the study is voluntary and that I am free to 
withdraw them from the study at any time up to two weeks following the focus group 
discussion without having to give a reason for withdrawing and without affecting their 
medical care or our legal rights. I understand that if I withdraw my child from the study 
their quotations from the focus group will not be used in the analysis or any reports and 
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publications. However, the rest of the information from the focus group (which relates 
to other participants’ quotations) will continue to be used.    
 
I understand that the focus group that my child is part of will be audio-recorded. 
 
 
 
I will encourage my child to respect the rights of other participants in the focus group 
and to maintain confidentiality of matters discussed within the focus group. 
 
 
I understand that sections of my child’s medical notes and data collected during the 
study may be looked at by researchers, where it is relevant to this research.  I give 
permission for these individuals to have access to my child’s records. 
 
 
I agree to my child’s GP being informed of their participation in the study. 
 
 
I understand that any information I or my child provide, including personal details, will 
be kept confidential, stored securely and only accessed by those carrying out the study. 
 
 
I understand that any information I or my child give may be included in published 
documents but all information will be anonymised. 
 
 
I agree to my child taking part in this study 
 
 
Parent Signature …………………………………………………………                       Date  
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Name of Parent  
 
Name of Child 
 
Researcher Signature ………………………………………………………..                       Date  
 
Name of Researcher 
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Adult Patient Participant Consent Form 
Adult Patient Participant  
Consent Form 
Early discharge in paediatric febrile neutropenia:  
experiences and perceptions of young people, parents and healthcare professionals 
Date: 27/5/15 
Version: 2 
 
Chief Investigator: Dr Jessica Morgan 
Focus Group Moderator: Dr Jessica Morgan 
 
 
 
Please confirm 
agreement to 
the statements 
by putting your 
initials in the 
boxes below 
 
I have read and understood the participant information sheet: _____________ 
(Version) for the above study.  
 
 
 
I have had the opportunity to ask questions and discuss this study 
 
 
 
I have received satisfactory answers to all of my questions 
 
 
 
I have received enough information about the study 
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I understand my participation in the study is voluntary and that I am free to withdraw 
from the study at any time up to two weeks following the focus group discussion 
without having to give a reason for withdrawing and without affecting my medical care 
or legal rights. I understand that if I withdraw from the study my quotations from the 
focus group will not be used in the analysis or any reports and publications. However, 
the rest of the information from the focus group (which relates to other participants’ 
quotations) will continue to be used.    
 
 
 
I understand that the focus group that I am part of will be audio-recorded. 
 
 
 
I agree to respect the rights of other participants in the focus group and to maintain 
confidentiality of matters discussed within the focus group. 
 
 
I understand that sections of my medical notes and data collected during the study may 
be looked at by researchers, where it is relevant to this research.  I give permission for 
these individuals to have access to my records. 
 
 
I agree to my GP being informed of my participation in the study. 
 
 
I understand that any information I provide, including personal details, will be kept 
confidential, stored securely and only accessed by those carrying out the study. 
 
 
I understand that any information I give may be included in published documents but 
all information will be anonymised. 
 
 
I agree to take part in this study 
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Participant Signature …………………………………………………………                       Date  
 
Name of Participant   
 
Researcher Signature ………………………………………………………..                       Date  
 
Name of Researcher 
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Parent Participant Consent Form 
Parent Participant  
Consent Form 
Early discharge in paediatric febrile neutropenia:  
experiences and perceptions of young people, parents and healthcare professionals 
Date: 27/5/15 
Version: 2 
 
Chief Investigator: Dr Jessica Morgan 
Focus Group Moderator: Dr Jessica Morgan 
 
 
 
Please confirm 
agreement to 
the statements 
by putting your 
initials in the 
boxes below 
 
I have read and understood the participant information sheet: _____________ 
(Version) for the above study.  
 
 
 
I have had the opportunity to ask questions and discuss this study 
 
 
 
I have received satisfactory answers to all of my questions 
 
 
 
I have received enough information about the study 
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I understand my participation in the study is voluntary and that I am free to withdraw 
from the study at any time up to two weeks following the focus group discussion 
without having to give a reason for withdrawing and without affecting my medical care 
or legal rights. I understand that if I withdraw from the study my quotations from the 
focus group will not be used in the analysis or any reports and publications. However, 
the rest of the information from the focus group (which relates to other participants’ 
quotations) will continue to be used.    
 
 
 
I understand that the focus group that I am part of will be audio-recorded. 
 
 
 
I agree to respect the rights of other participants in the focus group and to maintain 
confidentiality of matters discussed within the focus group. 
 
 
I understand that sections of my child’s medical notes and data collected during the 
study may be looked at by researchers, where it is relevant to this research.  I give 
permission for these individuals to have access to my child’s records. 
 
 
I understand that any information I provide, including personal details, will be kept 
confidential, stored securely and only accessed by those carrying out the study. 
 
 
I understand that any information I give may be included in published documents but 
all information will be anonymised. 
 
 
I agree to take part in this study 
 
 
Participant Signature …………………………………………………………                       Date  
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Name of Participant   
 
Researcher Signature ………………………………………………………..                       Date  
 
Name of Researcher 
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Healthcare Professional Participant Consent Form 
Health Care Professional Participant  
Consent Form 
Early discharge in paediatric febrile neutropenia:  
experiences and perceptions of young people, parents and healthcare professionals 
Date: 27/5/15 
Version: 2 
 
Chief Investigator: Dr Jessica Morgan 
Focus Group Moderator: Dr Jessica Morgan 
 
 
 
Please confirm 
agreement to 
the statements 
by putting your 
initials in the 
boxes below 
 
I have read and understood the participant information sheet: _____________ 
(Version) for the above study.  
 
 
 
I have had the opportunity to ask questions and discuss this study 
 
 
 
I have received satisfactory answers to all of my questions 
 
 
 
I have received enough information about the study 
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I understand my participation in the study is voluntary and that I am free to withdraw 
from the study at any time up to two weeks following the focus group discussion 
without having to give a reason for withdrawing and without affecting my legal rights. I 
understand that if I withdraw from the study my quotations from the focus group will 
not be used in the analysis or any reports and publications. However, the rest of the 
information from the focus group (which relates to other participants’ quotations) will 
continue to be used.    
 
I understand that the focus group that I am part of will be audio-recorded. 
 
 
 
I agree to respect the rights of other participants in the focus group and to maintain 
confidentiality of matters discussed within the focus group. 
 
 
I understand that any information I provide, including personal details, will be kept 
confidential, stored securely and only accessed by those carrying out the study. 
 
 
I understand that any information I give may be included in published documents but 
all information will be anonymised. 
 
 
I agree to take part in this study 
 
 
Participant Signature …………………………………………………………                       Date  
 
Name of Participant   
 
Researcher Signature ………………………………………………………..                       Date  
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Name of Researcher 
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Appendix 5.4: Participant Basic Data Collection forms 
Young Person Basic Data Collection Form 
Young person basic data collection form 
Participant to complete 
Name:  
 
Age (years):  
 
Gender: Male ☐ 
Female ☐ 
Ethnicity: White British ☐ 
White Irish ☐ 
White, other European ☐ 
Any other White Background ☐ 
Indian ☐ 
Pakistani ☐ 
Bangladeshi ☐ 
Any other Asian Background ☐ 
Black Caribbean ☐ 
Black African ☐ 
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Any other Black background ☐ 
Chinese ☐ 
Mixed White and Black Caribbean ☐ 
Mixed White and Black African ☐ 
Mixed White and Asian ☐ 
Any other mixed background ☐ 
Other (please state) ☐ 
Address:  
 
 
 
 
Who I live with most often (please tell us your 
relationship to them and their age, if under 18 
years) 
You do not have to give their names if you do 
not want to. 
eg, mum, stepfather, sister (16), half-brother 
(10), grandmother (mum’s mum) 
 
 
 
 
 
 
 
Other important people in my immediate 
family who I don’t live with all the time 
eg. dad, sister (12) 
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Mother’s highest level of educational 
qualification 
Degree or higher degree ☐ 
A levels or Highers ☐ 
HNC/HND ☐ 
ONC/BTEX ☐ 
O level or GCSE equivalent (Grade A-C) ☐ 
O level or GCSE equivalent (Grade D-G) ☐ 
No formal qualifications ☐ 
Still studying ☐ 
Other (give details) ☐ 
Father’s highest level of educational 
qualification 
Degree or higher degree ☐ 
A levels or Highers ☐ 
HNC/HND ☐ 
ONC/BTEX ☐ 
O level or GCSE equivalent (Grade A-C) ☐ 
O level or GCSE equivalent (Grade D-G) ☐ 
 347 
 
No formal qualifications ☐ 
Still studying ☐ 
Other (give details) ☐ 
Mother’s occupation  
 
Father’s occupation  
 
Which best describes your family’s living 
arrangements 
Own house (outright) ☐ 
Own house (mortgage) ☐ 
Rent from Local Authority/Housing 
Association ☐ 
Rent privately ☐ 
Other (eg. living with family and friends) ☐ 
Your GP (if you agree to us informing them 
that you are taking part in this study) 
 
 
 
 
Is anyone else in your family taking part in this 
study? If so, please give their name and their 
relationship to you. 
 
 
Local team to complete: 
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Study site  
 
Diagnosis  
 
Date of initial diagnosis  
 
Treatment regimen  
 
Current/most recent course of treatment  
Previous episodes of febrile neutropenia 
(please give for each – dates, high or low risk episode, location of treatment (PTC/POSCU), 
treatment received, duration of admission, complications arising (eg PICU admission, removal of 
central line, delay in further treatment, etc) 
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Parent Participant Basic Data Collection Form 
Parent participant basic data collection form 
Participant to complete 
Name:  
 
Age (years):  
 
Gender: Male ☐ 
Female ☐ 
Ethnicity: White British ☐ 
White Irish ☐ 
White, other European ☐ 
Any other White Background ☐ 
Indian ☐ 
Pakistani ☐ 
Bangladeshi ☐ 
Any other Asian Background ☐ 
Black Caribbean ☐ 
Black African ☐ 
Any other Black background ☐ 
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Chinese ☐ 
Mixed White and Black Caribbean ☐ 
Mixed White and Black African ☐ 
Mixed White and Asian ☐ 
Any other mixed background ☐ 
Other (please state) ☐ 
Address:  
 
 
 
 
You have been asked to participate in this 
study because one of your children is at risk of 
low risk febrile neutropenia. Please could you 
tell us how old this child is(in years) 
 
Who I live with most often (please tell us your 
relationship to them and their age, if under 18 
years) 
You do not have to give their names if you do 
not want to. 
eg, Husband/wife, daughter (12), step son (9), 
mother  
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Other important people in my immediate 
family who I don’t live with all the time 
eg. son (17) 
 
 
 
 
 
 
 
What is your highest level of educational 
qualification 
Degree or higher degree ☐ 
A levels or Highers ☐ 
HNC/HND ☐ 
ONC/BTEX ☐ 
O level or GCSE equivalent (Grade A-C) ☐ 
O level or GCSE equivalent (Grade D-G) ☐ 
No formal qualifications ☐ 
Still studying ☐ 
Other (give details) ☐ 
What is your child’s other parent’s highest 
level of educational qualification 
Degree or higher degree ☐ 
A levels or Highers ☐ 
HNC/HND ☐ 
ONC/BTEX ☐ 
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O level or GCSE equivalent (Grade A-C) ☐ 
O level or GCSE equivalent (Grade D-G) ☐ 
No formal qualifications ☐ 
Still studying ☐ 
Other (give details) ☐ 
Your occupation  
 
Your child’s other parent’s occupation  
 
Which best describes your family’s living 
arrangements 
Own house (outright) ☐ 
Own house (mortgage) ☐ 
Rent from Local Authority/Housing 
Association ☐ 
Rent privately ☐ 
Other (eg. living with family and friends) ☐ 
Is anyone else in your family taking part in this 
study? If so, please give their name and their 
relationship to you. 
 
 
Local team to complete the following information about your child: 
Study site  
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Diagnosis  
 
Date of initial diagnosis  
 
Treatment regimen  
 
Current/most recent course of treatment  
 
Previous episodes of febrile neutropenia 
(please give for each – dates, high or low risk episode, location of treatment (PTC/POSCU), 
treatment received, duration of admission, complications arising (eg PICU admission, removal of 
central line, delay in further treatment, etc) 
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Healthcare Professional Basic Data Collection Form 
Healthcare professional basic data collection form 
Participant to complete 
Study site  
 
Name:  
 
Age (years):  
 
Gender: Male ☐ 
Female ☐ 
Ethnicity: White British ☐ 
White Irish ☐ 
White, other European ☐ 
Any other White Background ☐ 
Indian ☐ 
Pakistani ☐ 
Bangladeshi ☐ 
Any other Asian Background ☐ 
Black Caribbean ☐ 
Black African ☐ 
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Any other Black background ☐ 
Chinese ☐ 
Mixed White and Black Caribbean ☐ 
Mixed White and Black African ☐ 
Mixed White and Asian ☐ 
Any other mixed background ☐ 
Other (please state) ☐ 
Your profession Doctor 
- General Paediatrics ☐ 
- Oncology ☐ 
- Haematology ☐ 
- Infectious Diseases /Microbiology ☐ 
Nurse 
Your Grade (eg. consultant, staff nurse)  
 
Time spent at current grade (years)  
 
Time spent at current centre (years)  
Note: this may include time spent at a 
different grade 
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Appendix 5.5: Topic Guides 
Focus group topic guides 
Summary Topic Guide for Focus Group Discussions with young people and parent participants 
All focus groups will begin with a reminder of the aims of the study, verbal confirmation of 
consent, the restating of the right to withdraw from the study up to two weeks following the 
focus group discussion and the opportunity for participants to ask any outstanding questions.  
Introductory questions 
1. What do you understand about febrile neutropenia? 
 Do you know anything about how to decide if someone has low risk or high risk febrile 
neutropenia? 
2. Have you ever had an episode of febrile neutropenia? Can you tell me about it/them? 
 What is the treatment like in your hospital? 
 What were the best things about the episode of treatment? What were the worst? 
Why? 
Explanation of current research and different possible treatment strategies.  
3. What do you think about these different options? If they were all offered at your hospital, 
which would you pick and why? 
It would be good to talk more about outpatient treatment of febrile neutropenia. 
4. Tell me more about what you think of this option. Would you want it for you/your child?  
5. Can you tell me a bit about how you decided if you would or wouldn’t? What factors 
played a part in your decision making? How important was each factor? 
 If not mentioned, ask about: practical issues (eg transport, distance from hospital, 
finances, care of other children), emotional/social issues (eg. wanting to be 
together as a family, fear of going home, feeling of not being able to cope at 
home), trust in health care professionals 
6. How would what your family/child feel influence your decision? What do you think they 
would say about outpatient care? If disagreements occurred, how should these be 
negotiated? 
7. How would what your doctor/nurse feel influence your decision? What do you think they 
would say about outpatient care? If disagreements occurred, how should these be 
negotiated? 
Introduce evidence about failure to consent rates. 
8. Why do you think this might be? 
9. Do you want to say more about the questions we just discussed in the light of this 
research? 
Service design  
10. How do you think an outpatient febrile neutropenia service could be designed to make 
you most happy with it?  
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 If not mentioned discuss: when go home, route of antibiotics, how followed up 
(home/clinic), what symptoms would be tolerated at home (eg repeated fever) 
Any other issues/questions/comments? 
All medical queries raised by the participants during the focus group discussions will be 
redirected to their clinical care team. Debriefing will be offered to participants immediately 
after the focus group discussions and a telephone number (Dr Jessica Morgan, Tel 01904 
321082) will also be provided in case they wish to discuss any further issues with the research.  
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Summary Topic Guide for Focus Group Discussions with health care professionals 
All focus groups will begin with a reminder of the aims of the study, verbal confirmation of 
consent, the restating of the right to withdraw from the study up to two weeks following the 
focus group discussion and the opportunity for participants to ask any outstanding questions. 
Participants in the focus groups for healthcare professionals will be reminded that the research 
team are only interested in their general views and will not be discussing the details of individual 
cases. 
Introductory questions 
1. What is your role in looking after children with low risk febrile neutropenia? 
2. Tell me about the treatment of low risk febrile neutropenia in your hospital? 
3. What sort of issues develop when caring for patients with low risk febrile neutropenia? 
Explanation of current research and different possible treatment strategies.  
4. What do you think about these different options? Which one(s) do you think it is 
appropriate to offer to your patients? 
It would be good to talk more about outpatient treatment of febrile neutropenia. 
5. Tell me more about what you think of this option. Would you want it for your patients?  
6. Can you tell me a bit about how you decided if you would or wouldn’t? What factors 
played a part in your decision making? How important was each factor? 
 If not mentioned, ask about: practical issues (eg transport, distance from hospital, 
finances, care of other children), emotional/social issues (eg. wanting to be 
together as a family, fear of going home, feeling of not being able to cope at 
home), trust in health care professionals 
7. How would what the family/child feel influence your decision? What do you think they 
would say about outpatient care? If disagreements occurred, how should these be 
negotiated? 
Introduce evidence about failure to consent rates. 
8. Why do you think this might be? 
9. Do you want to say more about the questions we just discussed in the light of this 
research? 
Service design  
10. How do you think an outpatient febrile neutropenia service could be designed to make 
you most happy with it?  
 If not mentioned discuss: when go home, route of antibiotics, how followed up 
(home/clinic), what symptoms would be tolerated at home (eg repeated fever) 
11. How does the design of the healthcare service as a whole influence how services could be 
delivered?  
12. Who makes decisions about these kinds of changes? What do you think they would 
think/say? 
Any other issues/questions/comments? 
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Debriefing will be offered to participants immediately after the focus group discussions and a 
telephone number (Dr Jessica Morgan, Tel 01904 321082) will also be provided in case they 
wish to discuss any further issues with the research. 
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Appendix 5.6: Information Letter for General Practitioners  
Dear Doctor, 
 
This letter is to inform you that your patient, ________ (name, DOB, address) has agreed to take 
part in a research study, Early discharge in paediatric febrile neutropenia: experiences and 
perceptions of young people, parents and healthcare professionals. This study is being conducted 
by the University of York along with your local paediatric haematology and oncology service at 
______ (centre). Your patient will be taking part in a single focus group discussion around 
outpatient therapy and early discharge strategies for the management of paediatric low risk febrile 
neutropenia. Your patient has been invited as they are: a young person at risk of low risk febrile 
neutropenia/the parent of a child or young adult with low risk febrile neutropenia. 
 
If you have any questions about this research, or would like to know more about the study, please 
contact Dr Jessica Morgan, (01904) 321082, jem539@york.ac.uk. 
 
Yours sincerely, 
 
 
Dr Jessica Morgan 
Clinical Research Fellow 
Centre for Reviews and Dissemination 
University of York 
York 
YO10 5DD 
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Appendix 5.7: Promotional Poster 
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Participants wanted! 
Can you help? 
 
We have a research study open in this centre to find out what you think about how to 
treat temperatures in children and young people with cancer. 
You might be able to take part if you are a:  
 
 
 
 
 
 
 
 
 
 
What does the study involve?  
Coming to a focus group discussion for about 
90 mins and talking with people about your 
experiences and what you think we can do to 
make this better. You’ll get a £20 Amazon 
voucher for taking part, as well as travel 
expenses and refreshments. 
 
If you want to take part or have some questions about this research, please contact the research 
nurses …. or the lead researcher, Jess Morgan, 01904 321082, jem539@york.ac.uk 
PATIENT 
Aged 13 – 18 years old 
Have had chemotherapy or 
radiotherapy in the last six 
months 
Have a solid tumour (not 
NHL) OR have ALL on 
maintenance therapy 
Have not had a bone 
marrow transplant 
 
OR 
PARENT 
Your child is 1-18 years old 
Your child has had 
chemotherapy or 
radiotherapy in the last six 
months 
Your child has a solid 
tumour (not NHL) OR has 
ALL on maintenance therapy 
Your child has not had a 
bone marrow transplant 
 
Study site logo here 
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Appendix 5.8: Research Ethics Committee Approvals 
(taken from PDF letters) 
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NRES Committee Yorkshire & The Humber - Leeds West 
Room 001, Jarrow Business Centre 
Rolling Mill Road 
Jarrow 
Tyne and Wear 
NE32 3DT 
Telephone: 0191 4283548 
18 May 2015 
Dr Jessica Morgan 
Centre for Reviews and Dissemination 
University of York 
York 
YO10 5DD 
Dear Dr Morgan 
Study title: Early discharge in paediatric febrile neutropenia: 
experiences and perceptions of young people, parents 
and healthcare professionals 
15/YH/0208 
142973 
REC reference: 
IRAS project ID: 
The Research Ethics Committee reviewed the above application at the meeting held on 08 
May 2015. Thank you for attending to discuss the application. 
We plan to publish your research summary wording for the above study on the HRA website, 
together with your contact details. Publication will be no earlier than three months from the 
date of this favourable opinion letter. The expectation is that this information will be published 
for all studies that receive an ethical opinion but should you wish to provide a substitute 
contact point, wish to make a request to defer, or require further information, please contact 
the REC Manager Miss Christie Ord, nrescommittee.yorkandhumber-leedswest@nhs.net. 
Under very limited circumstances (e.g. for student research which has received an 
unfavourable opinion), it may be possible to grant an exemption to the publication of the study. 
Ethical opinion 
The members of the Committee present gave a favourable ethical opinion of the above 
research on the basis described in the application form, protocol and supporting 
documentation, subject to the conditions specified below. 
Conditions of the favourable opinion 
The favourable opinion is subject to the following conditions being met prior to the start of the 
study. 
Management permission or approval must be obtained from each host organisation prior to  
the start of the study at the site concerned.  
Management permission (“R&D approval”) should be sought from all NHS organisations 
involved in the study in accordance with NHS research governance arrangements. 
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Guidance on applying for NHS permission for research is available in the Integrated Research 
Application System or at http://www.rdforum.nhs.uk. 
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites (“participant identification centre”), guidance should be sought 
from the R&D office on the information it requires to give permission for this activity. 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation. 
Sponsors are not required to notify the Committee of approvals from host organisations. 
Registration of Clinical Trials 
All clinical trials (defined as the first four categories on the IRAS filter page) must be registered 
on a publically accessible database. This should be before the first participant is recruited but 
no later than 6 weeks after recruitment of the first participant. 
There is no requirement to separately notify the REC but you should do so at the earliest 
opportunity e.g. when submitting an amendment. We will audit the registration details as part 
of the annual progress reporting process. 
To ensure transparency in research, we strongly recommend that all research is registered but 
for non-clinical trials this is not currently mandatory. 
If a sponsor wishes to request a deferral for study registration within the required timeframe, 
they should contact hra.studyregistration@nhs.net. The expectation is that all clinical trials will 
be registered, however, in exceptional circumstances non registration may be permissible with 
prior agreement from NRES. Guidance on where to register is provided on the HRA website. 
It is the responsibility of the sponsor to ensure that all the conditions are complied with 
before the start of the study or its initiation at a particular site (as applicable). 
Ethical review of research sites 
NHS Sites 
The favourable opinion applies to all NHS sites taking part in the study taking part in the study, 
subject to management permission being obtained from the NHS/HSC R&D office prior to the 
start of the study (see “Conditions of the favourable opinion” below). 
Summary of discussion at the meeting 
Other ethical issues were raised and resolved in preliminary discussion before your 
attendance at the meeting. 
Ethical issues raised by the Committee in private discussion, together with responses 
given by the researcher when invited into the meeting 
Social or scientific value; scientific design and conduct of the study 
The Committee congratulated the applicant on her use of patient and public involvement and 
thanked her for submitting a good application. 
The REC queried whether the patient and public involvement group included younger 
children. 
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You confirmed that the youngest child was 11 and a half and stated that it was beneficial to 
have their views even though the age range was higher than this. You added that a 15 and a 
17 year old had also reviewed the documentation and that all feedback had been 
incorporated. 
The Committee noted that you intended to moderate the focus groups solely and queried 
whether it would be feasible to share these responsibilities with another individual to allow for 
better management of the groups. 
You explained that you had to consider this when designing your project and stated that you 
would consider getting support if someone was willing to help. 
The Committee advised that a medical student or psychology student would be grateful for the 
research experience and that this would be a good place to canvas for help. The REC stated 
that additional support may be particularly useful if a problem arose within a focus group as it 
would enable the group to run with limited disruptions. 
You confirmed that you would consider this advice. 
Recruitment arrangements and access to health information, and fair participant 
selection  
The Committee noted that the applicant would allow one week for individuals to consider 
consenting and stated that this may be problematic as the children may forget or be difficult to 
re-contact. Members advised that if children expressed an interest, the applicant could 
suggest and agree a time and day to telephone the children to give them further information. 
You thanked the Committee for this advice and confirmed that you would do this. 
The Committee queried whether travel expenses would be reimbursed. 
You confirmed that there was no allowance for this within her grant currently but that you 
would be applying for a further grant to allow for this. 
The Committee accepted this response and noted that this should be submitted to the REC as 
a substantial amendment. 
Members queried whether the applicant was confident that younger children would remain in 
the study and not lose interest. 
You accepted that this may be a concern but explained that you had structured the interviews 
to allow movement between topics and to keep attention. You explained that you had received 
independent advice on the suitability of the study information for the target population. 
Suitability of supporting information  
The Committee queried whether the topic guide had been piloted. 
You confirmed that it had not as the target population was quite small and you did not want 
ruin your project by ultimately piloting the topic guide on the individuals that you may recruit. 
You confirmed that your PPI group had seen the topic guide. 
Informed consent process and the adequacy and completeness of participant 
information  
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Document  Version Date  
Evidence of Sponsor insurance or indemnity (non NHS 
Sponsors only) 
  
GP/consultant information sheets or letters [Information letter 
for General Practitioners] 
  
Interview schedules or topic guides for participants [Focus group topic 
guides] 
 
Letter from funder [Funding Letter]  1 24 March 2015  
Letter from sponsor  1 30 January 2015 
Letters of invitation to participant [Invitation email to 
Healthcare Practitioners] 
  
Other [K. Atkin CV]  1 19 February 2015 
Other [R. Phillips CV]  1 18 February 2015 
Other [Responses to Research Governance Committee 
Decision Letter] 
  
Other [Young Person basic data collection form]  1 30 March 2015  
Other [Parent participant basic data collection form]  1 30 March 2015  
Other [Healthcare professional basic data collection form]  1 30 March 2015  
Participant consent form [Young Person Participant Assent Form] 1 18 February 2015 
Participant consent form [Parent Consent Form]  1 18 February 2015 
Participant consent form [Adult Patient Participant Consent Form] 1 18 February 2015 
Participant consent form [Parent Participant Consent Form]  1 18 February 2015 
Participant consent form [Healthcare Professional Participant 
Consent Form] 
  
Participant information sheet (PIS) [Young Person Participant 
Information Sheet] 
  
Participant information sheet (PIS) [Parent's Information Sheet]  1 28 October 2014 
Participant information sheet (PIS) [Adult Patient Participant 
Information Sheet] 
  
Participant information sheet (PIS) [Adult Participant 
Information Sheet] 
  
Participant information sheet (PIS) [Healthcare Professional 
Participant Information Sheet] 
  
REC Application Form [REC_Form_13042015]   13 April 2015  
Referee's report or other scientific critique report [University of 
York Research Governance Committee Decision Letter] 
  
Research protocol or project proposal [Protocol]  1 30 March 2015  
Summary CV for Chief Investigator (CI) [Jessica Morgan CV]  1 30 March 2015  
 
  
  
 
  
 
  
  
  
  
  
 
The REC advised that the applicant should protect her data by setting a time limit for 
withdrawal of date and suggested that she make clear to participants that they would have up 
to 2 weeks after the focus group to withdraw their data. 
You confirmed that you would do this. 
Independent review 
The Committee commended the applicant on the independent reviews obtained. 
You left the meeting. 
Approved documents 
The documents reviewed and approved at the meeting were: 
1 30 January 2015 
1 30 March 2015 
1 30 March 2015 
1 30 March 2015 
30 March 2015 
1 18 February 2015 
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Summary CV for supervisor (student research) 
Membership of the Committee 
The members of the Ethics Committee who were present at the meeting are listed on the 
attached sheet. 
After ethical review 
Reporting requirements 
The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
Notifying substantial amendments 
Adding new sites and investigators 
Notification of serious breaches of the 
protocol Progress and safety reports 
Notifying the end of the study 
The HRA website also provides guidance on these topics, which is updated in the light of 
changes in reporting requirements or procedures. 
User Feedback 
The Health Research Authority is continually striving to provide a high quality service to all 
applicants and sponsors. You are invited to give your view of the service you have received 
and the application procedure. If you wish to make your views known please use the feedback 
form available on the HRA website: http://www.hra.nhs.uk/about-the-hra/governance/quality-
assurance/ 
HRA Training 
We are pleased to welcome researchers and R&D staff at our training days – see details at 
http://www.hra.nhs.uk/hra-training/ 
15/YH/0208 Please quote this number on all correspondence 
With the Committee’s best wishes for the success of this project. 
Yours sincerely 
pp 
 
 
Dr Sheila E. Fisher 
Chair 
E-mail: nrescommittee.yorkandhumber-leedswest@nhs.net 
Enclosures: List of names and professions of members who were present at the 
meeting and those who submitted written comments 
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Document  Version  Date  
 Minor 
Amendment 
1 
 
 
  
 
NRES Committee Yorkshire & The Humber - Leeds West 
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Research protocol or project proposal 
Statement of compliance 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK. 
15/YH/0208: Please quote this number on all correspondence 
Yours sincerely 
 
 
 
Kirstie Penman 
REC Assistant 
Email: nrescommittee.yorkandhumber-leedswest@nhs.net 
Copy to: Mr Mohammed Khan, Leeds Teaching Hospitals NHS Trust 
Sue Final, University of York 
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NRES Committee Yorkshire & The Humber - Leeds West 
Room 001, Jarrow Business Centre 
Rolling Mill Road 
Jarrow 
Tyne and Wear 
NE32 3DT 
Tel: 0191 428 3444 
22 June 2015 
Dr Jessica Morgan 
Centre for Reviews and Dissemination 
University of York 
York 
YO10 5DD 
Dear Dr Morgan 
Study title: Early discharge in paediatric febrile neutropenia: 
experiences and perceptions of young people, parents and 
healthcare professionals 
REC reference: 15/YH/0208 
Amendment number: Substantial Amendment 1 
Amendment date: 08 June 2015 
IRAS project ID: 142973 
The above amendment was reviewed by the Sub-Committee in correspondence. 
Summary of amendment 
This amendment was submitted following the advice given from the Committee to offer 
travel expenses to participants. This would be paid at a rate of 45p per mile if the participant 
was to drive to the research site or the cost of a standard ticket for public transport as 
advised by INVOLVE guidelines. This would be paid in cash by the Chief Investigator as the 
participant arrived for the focus group discussion. All payments would be recorded on the 
receipt and would be kept on file for the duration of the study. 
The study team had also obtained funding for the research nurse time spent on the project. 
This will be paid as a block sum of £550 to the department involved at completion of the 
study. 
Ethical opinion 
The members of the Committee taking part in the review gave a favourable ethical opinion 
of the amendment on the basis described in the notice of amendment form and supporting 
documentation. 
Approved documents 
The documents reviewed and approved at the meeting were: 
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Document  Version  Date  
Notice of Substantial Amendment (non-CTIMP)  1 08 June 2015  
Other [Focus Group Topic Guides]  2 27 May 2015  
Participant consent form [Adult Patient Participant Consent Form] 1 18 February 2015 
Participant consent form [Health Care Professional 
Participant Consent Form] 
  
Participant consent form [Parent Consent Form]  2 27 May 2015  
Participant consent form [Parent Participant Consent Form]  2 27 May 2015  
Participant consent form [Young Person Participant Assent Form] 2 27 May 2015  
Participant information sheet (PIS) [Adult Participant 
Information Sheet] 
  
Participant information sheet (PIS) [Adult Patient Participant    
Information Sheet ]      
Participant information sheet (PIS) [Healthcare 
Professional Participant Information Sheet ] 
  
Participant information sheet (PIS) [Parent's Information Sheet]  2 27 May 2015  
Participant information sheet (PIS) [Young Person Participant    
Information Sheet]       
Research protocol or project proposal  2 27 May 2015  
 
  
  
  
  
  
  
 
Membership of the Committee 
The members of the Committee who took part in the review are listed on the attached 
sheet. 
R&D approval 
All investigators and research collaborators in the NHS should notify the R&D office for the 
relevant NHS care organisation of this amendment and check whether it affects R&D 
approval of the research. 
Statement of compliance 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK. 
We are pleased to welcome researchers and R & D staff at our NRES committee members’ 
training days – see details at http://www.hra.nhs.uk/hra-training/ 
15/YH/0208: Please quote this number on all correspondence 
Yours sincerely 
pp 
 
Mr Anthony Warnock-Smith 
Alternate Vice-Chair 
E-mail: nrescommittee.yorkandhumber-leedswest@nhs.net 
2 27 May 2015 
2 27 May 2015 
2 27 May 2015 
2 27 May 2015 
2 27 May 2015 
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Document  Version  Date  
Copies of advertisement materials for research 
participants [Promotional Poster] 
  
Notice of Substantial Amendment (non-CTIMP)  SA2  30 November 2015 
Participant information sheet (PIS) [Adult Participant 
Information Sheet] 
  
Participant information sheet (PIS) [Adult Patient Participant 
Information Sheet] 
  
 
  
  
  
 
Yorkshire & The Humber - Leeds West Research Ethics Committee 
Room 001, Jarrow Business Centre 
Rolling Mill Road 
Jarrow 
Tyne and Wear 
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Participant information sheet (PIS) [Parents Information Sheet]  3  30 November 2015 
Participant information sheet (PIS) [Young Person Participant    
Information Sheet]  
Research protocol or project proposal   30 November 2015 
 
  
  
 
Membership of the Committee 
The members of the Committee who took part in the review are listed on the attached 
sheet. 
R&D approval 
All investigators and research collaborators in the NHS should notify the R&D office for the 
relevant NHS care organisation of this amendment and check whether it affects R&D 
approval of the research. 
Statement of compliance 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK. 
We are pleased to welcome researchers and R & D staff at our NRES committee members’ 
training days – see details at http://www.hra.nhs.uk/hra-training/ 
15/YH/0208: Please quote this number on all correspondence 
Yours sincerely 
pp 
  
Dr Sheila E. Fisher 
Chair 
E-mail: nrescommittee.yorkandhumber-leedswest@nhs.net 
Enclosures: List of names and professions of members who took part in the 
review 
Copy to: Mr Mohammed Khan, Leeds Teaching Hospitals NHS Trust 
Ms Sue Final, University of York 
3 30 November 2015 
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Appendix 5.9: Samples of Coded Transcripts 
The following two pages provide a sample of transcript from the focus group discussions for 
parents of under 13s at Centre 2 and then the healthcare professionals at Centre 1. 
(taken from PDFs) 
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Appendix 5.10: Mapping of themes 
The following pages show the conceptual maps of the work for the groups of participants and 
then for the overarching findings (taken from PDFs). They demonstrate the development of the 
connections and cross-referencing and evidence how the analysis changed over time. 
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